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 Biomeasure collection in surveys has increased substantially in the last two decades, but 
little focus has been given to the recurrent nature of this collection in longitudinal panel surveys. 
The purpose of this dissertation is to explore various sources of biomeasure non-observation in a 
population-based longitudinal survey, identify predictors of missingness, ascertain if bias results 
from these different sources, and address approaches to imputation for this kind of data. These 
studies utilize interview, biomeasure, and interviewer data from the Health and Retirement Study 
(HRS) encompassing the 2006 through 2014 cycles. 
The first study defines and investigates five primary sources of non-observation for 
longitudinal biomeasure collection: mortality, nonresponse/attrition, health-related and non-
health-related ineligibility, and biomeasure non-consent. The first component of this study 
examines the common sociodemographic and health predictors of the five non-observation 
sources for dried blood spot (DBS) collection in HRS. After controlling for natural panel losses 
due to mortality, significant predictors of non-observation (nonresponse, ineligibility, and 
biomeasure non-consent) are respondent race/ethnicity, chronic conditions, physical activity, and 
cognitive functioning. The second component examines the successive impacts each of the five 
non-observation sources has on the final observed distributions of the five DBS biomarkers. 
Most DBS biomarkers see little change in their distributions after controlling for censoring due 
to mortality. Cystatin C and HbA1c see significant changes when excluding health-related 
ineligible respondents and wave nonrespondents, respectively. 
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 The second study builds on previous biomeasure consent work (e.g., Sakshaug, Couper, 
& Ofstedal, 2010) by looking specifically at the second biomeasure consent request for both 
DBS and physical measurements (PM) separately. This analysis expands past work by looking at 
recent changes in physical and mental health, a wider array of wave- and mode-specific survey 
resistance measures, interviewer continuity, and reason for non-consent to see how each of these 
impact consent to PM and DBS conditional on previous biomeasure consent behavior. Recent 
health changes such as increased number of functional limitations or less frequent physical 
activity reduce the likelihood of future consent to PM and DBS, but only for previous consenters. 
Interviewer continuity appears to reduce the likelihood of future consent to DBS for previous 
non-consenters, but also for future consent to PM for previous consenters. Using survey 
resistance measures from the prior face-to-face wave of data collection lead to better predictions 
of consent than survey resistance measures from the most recent telephone wave.  
 The third study compares three different applications of sequential regression 
multivariate imputation (SRMI) for the imputation of longitudinal biomarker data. This study 
also looks at the effects of imputing for all biomeasure eligible cases instead of only biomeasure 
consenting respondents. Focusing on two biomarker outcomes (Cystatin C and C-reactive 
protein), each approach is evaluated using multiple univariate and multivariate analyses to 
observe shifts in estimates, reduction in variability, and recovery of statistical information. The 
results are generally mixed as to which SRMI approach is best for longitudinal biomarker data. 
Imputing all biomeasure eligible cases does result in noticeable changes for Cystatin C with large 







Over the last two decades, the collection of biomeasures has increased substantially in 
surveys (Beebe, 2007; Sakshaug, 2013; Sakshaug, Ofstedal, Guyer, & Beebe, 2015). 
Biomeasures collectively refer to any kind of physical or biological measurement or sample 
(Jaszczak, Lundeen, & Smith, 2009; Sakshaug et al., 2015), including but not limited to 
anthropometric measures (e.g., height/weight, waist-to-hip ratio), physical performance measures 
(grip strength, spirometry), and biological material including blood (dried blood spot, whole 
blood draw), saliva (passive drool, oral swab), and urine.  
The driving force behind the collection of biomeasures in population-based social 
research is to understand the interaction of human behavior (social science) and biological forces 
(Harris, Gruenewald, & Seeman, 2007; see also Finch, Vaupel, & Kinsella, 2001; Weinstein, 
Vaupel, & Wachter, 2007). Weinstein and Willis (2001) provide four key uses and benefits of 
collecting biomeasures in conjunction with traditional, self-reported survey data (see also 
Sakshaug, Ofstedal, Guyer, & Beebe, 2015): (1) obtaining population-representative data from 
nonclinical samples; (2) the ability to calibrate self-reports with self-reported measures of health 
and disease; (3) the ability to explore and better define the causal connections between health 
and social research; and (4) the ability to link genetic information with surveys.  
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While each of these four uses has an important role in research, the third benefit – 
explore causal connections – is the only one that is strongly dependent on the collection and use 
of longitudinal data (Crimmins & Seeman, 2001). Repeated collection of biomeasures in large-
scale, population-based surveys has been on-going on for over a decade, but few investigations 
have been made into the issues related to non-observation associated with recurrent collection of 
biomeasures in a longitudinal context. 
The purpose of this dissertation is to explore various forms of biomeasure non-
observation in population-based longitudinal surveys, to identify various sources of missingness 
along with its predictors, to ascertain the biases incurred in biomeasures by these different 
missing data mechanisms, and investigate how to best address missingness for analyses directly 
and indirectly focused on those more causal connections between human behavior and biological 
forces. 
1.1 Methods of biomeasure collection in population-based longitudinal surveys 
There are a wide variety of surveys that collect biomeasures and each conducts that 
collection in different and distinctive ways. Harris, Gruenewald, and Seeman (2007) and 
Sakshaug et al. (2015) both discuss a variety of community and population-based studies that 
collect biomeasures. A number of studies are highlighted to illustrate differences in how the 
biomeasures are collected. 
The largest and most prominent of these studies is the National Health and Nutrition 
Examination Survey (NHANES) (Johnson, Dohrmann, Burt, & Mohadjer, 2014). NHANES 
serves many as a gold standard for population health statistics in the United States, especially in 
relation to biomeasure-related factors. NHANES collects a wide range of biomeasures through 
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the use of a Mobile Examination Center (MEC) which houses all of the necessary equipment to 
collect biomeasures under identical conditions at every survey location. NHANES has been able 
to maintain over a 90% examination rate from 1999 to 2016 for those households interviewed. 
While there is no question related to the quantity and quality of data NHANES collects, such a 
detailed and expansive collection of data is expensive. In addition, such a collection requires a 
large and well-trained medical operation involving trained doctors, nurses, and expensive 
medical equipment. For social research surveys, achieving this level of biomeasure collection 
and quality is virtually unattainable. NHANES is a repeated cross-sectional study as opposed to a 
panel study and thus does not collect data repeatedly for the same group of individuals. A 
simplification of the MEC model is to make use of local established health clinics similar to the 
Irish Longitudinal Study on Ageing (TILDA; Cronin et al., 2013) or the Midlife in the United 
States study (MIDUS; Love et al., 2010). However, coordination for a large-scale national panel 
study across all participants could prove a daunting task. 
A middle ground approach employed by some surveys, particularly of those using nurses 
for biomeasure data collection, are the English Longitudinal Study of Ageing (ELSA; Marmot & 
Steptoe, 2007), Understanding Society (UKLHS; McFall, Booker, Burton, & Conolly, 2012), the 
Irish Longitudinal Study on Ageing (TILDA; Cronin et al., 2013), the 1999 National Long Term 
Care Survey (NLTCS; Research Triangle International, 2002), and a pilot for the UK 
Millennium Cohort Study (Calderwood, Rose, Ring, & McArdle, 2014). This approach allows 
for the benefit of having a medically trained nurse perform the collection of select biomeasures 
in the respondent’s home including whole blood draws. This reduces respondent burden by 
removing unnecessary travel, but does necessitate a secondary visit from the original interview 
with a third party. The combined consent rate to the nurse visit with the biomeasure consent rate 
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produce a much smaller sample of final cases for these studies. For example, of the eligible 
respondents in Wave 2 of Understanding Society, 74% agreed to participate in the nurse visit and 
only 77% of those agreed to venipuncture resulting in only about 57% of the eligible sample with 
available biomeasures for analysis (McFall et al., 2012). 
A fairly inexpensive alternative to collect biomeasures viable in any survey mode is the 
mail-back approach. Here participants self-collect the biological material (e.g., dried blood spot, 
saliva) and mail the sample back to the study team. This has proven somewhat successful for a 
variety of different studies including the 2003 HRS Diabetes Mailout Study (65% return rate; 
Heisler et al., 2007) and the Wisconsin Longitudinal Study (54% return rate; Dykema, DiLoreto, 
Croes, Garbarski, & Beach, 2017). However, the overall success of this approach is highly 
dependent on the sampled population, the original survey mode, and the nature of the greater 
study itself (Gatny, Couper, & Axinn, 2013). Self-collection also limits what types of 
biomeasures can be collected, usually restricted to those deemed minimally invasive (Lindau & 
McDade, 2007). 
A large remainder of population-based surveys today that collect biomeasures use non-
medically trained field interviewers to perform a majority of this collection. These studies 
include the Health and Retirement Study (HRS; Weir, 2008; Guyer, Ofstedal, Lessof, Cox, & 
Jürges, 2009); the National Social Life, Health, and Aging Project (NSHAP; Jaszczak et al., 
2009; O’Doherty et al., 2014); the National Longitudinal Study of Adolescent to Adult Health 
(Add Health; Harris, 2013); the Survey of Health, Ageing and Retirement in Europe (SHARE; 
Weiss, Sakshaug, & Börsch-Supan, 2019; Korbmacher, 2014); and a pilot study for 
Understanding Society (UKLHS; McFall, Conolly, & Burton, 2014). This collection is more 
economically feasible for most studies rather than other large-scale operations or requiring travel 
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to a collection center. Anthropometrics, dried blood spots (DBS), and saliva are all minimally 
invasive collections that are routinely completed in this setting (Lindau & McDade, 2007). The 
interviewer can perform the collection of these biomeasures during the survey interview. The 
collection procedures are for the most part cognitively simple and low risk and the corresponding 
samples are easily transportable and stored.  
Collection of biomeasures using non-medically trained field interviewers has proved to 
be generally quite effective. In general, the consent rates for physical measurements, DBS, and 
various saliva-based collections see average rates around or above 85% (see Jaszczak et al., 
2009; Crimmins et al., 2013; Jaszczak et al., 2014; Crimmins et al., 2015; Weiss et al., 2019). 
Notable exceptions to these high rates are vaginal swab samples from NSHAP at 74% (Jaszczak 
et al., 2014) – understandable given the overly sensitive and intrusive nature of the collection – 
and the DBS collection in SHARE ranging from 34.6% in Greece to 83.5% in Denmark during 
Wave 6 (Weiss et al., 2019). Overall, these consent rates are strongly encouraging for studies 
considering whether to include biomeasures. 
The major disadvantage of this form of collection, similar to the mail-back approach, is 
that these procedures are minimally invasive. A simple example is the difference in collecting 
DBS versus whole blood via venipuncture. Blood serum or plasma contains a vast array of health 
biomarkers making it a gold standard in health research. DBS restricts you to a limited number 
of assays and excludes the study of some analytes because of the requirement for larger volumes 
of blood (Lindau & McDade, 2007). DBS assay values are strongly correlated with whole blood 
levels on a number of biomarkers including HbA1c, Cystatin C, and C-reactive protein, but not 
as strongly with others such as lipid levels (Crimmins et al., 2014). In addition, there are 
differences in scale making direct comparisons problematic. 
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With the context of these various forms of biomeasure collection in mind, this 
dissertation focuses on longitudinal panel studies using non-medically trained field interviewers 
to collect biomeasures recurrently. 
1.2 Overview 
This dissertation examines the sources, predictors, and treatment of non-observation in 
recurrently collected biomeasures in longitudinal panel surveys using non-medically trained field 
interviewers for biomeasure collection. Non-observation from wave to wave can be attributed to 
a number of sources including, but not limited to, mortality, attrition, ineligibility, and consent. 
Each of these mechanisms are impacted by different factors (e.g., declining health, respondent-
interviewer interaction) and could influence multiple mechanisms. Understanding the interplay 
between factors associated with obtaining a biomeasure and the bias incurred in the biomarker 
outcome by different forms of non-observation helps to balance the benefit or harm of potential 
interventions. 
Chapter 2 investigates a variety of non-observation mechanisms in relation to recurrent 
collection of DBS samples. The first part of the study examines the common sociodemographic 
and health predictors of each non-observation mechanism on DBS collection and looks for 
patterns across mechanisms. The second half of the chapter examines the successive impacts of 
these mechanisms on the distributions of five DBS biomarkers. 
While there are many sources of non-observation for biomeasure data, consent is one of 
the more direct forms of non-observation as the respondent makes an explicit decision in relation 
to the collection of the measure. Biomeasure consent has received some attention in recent years 
(e.g., Sakshaug et al., 2010; Korbmacher, 2014), but has always focused on cross-sectional 
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consent. Collection of biomeasure data in a longitudinal panel survey means that previous 
experiences and interactions can have a meaningful impact on decisions in a future wave. The 
role of changing health, interviewer continuity, and previous consent choices all play a role in 
whether biomeasure data will be collected in subsequent waves. 
Chapter 3 reviews known predictors associated with single wave biomeasure consent and 
postulates factors related to the longitudinal nature of the biomeasure collection. The analyses 
explore the role of recent physical and mental health changes for the respondent, reluctance by 
wave and mode, and interviewer continuity as factors impacting future consent to physical 
measurements and DBS samples conditional on previous biomeasure consent behavior.  
Understanding the sources of non-observation in biomeasures is important for making 
future design decisions, but there is always the inevitability that biomeasure data will not always 
be available for all cases. This loss in precision and potential for bias can be potentially mitigated 
by recovering statistical information through imputation. Depending on the imputation approach, 
imputation models can harness the power of historical observations of biomarker values to better 
inform imputed values. 
Chapter 4 investigates three different approaches using sequential regression multivariate 
imputation (SRMI) to impute missing biomeasure data. The cross-sectional approach ignores the 
longitudinal nature of the collection. The sequential approach uses only past waves of interview 
and biomeasure data for the imputation model. The wide approach includes all available waves 
of data collection, past and future, to inform the imputation model. Focusing on two DBS 
biomarker outcomes, each imputation approach is evaluated using multiple univariate and 
8 
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Understanding the Impact of Sequential Non-observation Sources on Longitudinal Panel 
Study Biomeasures  
2.1 Introduction 
There are many sources of non-observation that impact biomeasures collected in a 
longitudinal panel study. Each source is an opportunity to lose respondents and systematically 
bias the final distribution of key biomarker outcomes. While consent to biomeasure collection is 
often typically the first and likely the most salient given the direct relationship to biomeasure 
missingness, the numerous non-observation sources preceding consent can potentially be just as, 
if not more, troublesome. These additional sources include mortality, unit nonresponse, and 
operational eligibility. 
Each of these non-observation sources are impacted by different factors and some factors 
may effect multiple sources. If these effects are consistent across sources, the cumulative effect 
can bias population estimates. When considering a possible intervention to address a single form 
of non-observation, it is important to understand how addressing one source of non-observation 
could have an adverse effect on other sources of non-observation if they are not independent 
mechanisms. In order to balance the benefit and harm of a potential intervention decision on 
obtaining a biomeasure estimate with as little bias as possible, the interplay between the impact 
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of obtaining the outcome itself and the bias caused by the different sources of non-observation 
on the outcome must be understood.  
The purpose of this chapter is to examine the competing risks and associated bias from 
each source of non-observation. There are two overarching goals: identifying covariates 
associated with the propensity of removal at each source of non-observation and measuring the 
cumulative effect of sequential sources of non-observation on bias in biomeasure estimates. 
2.2 Non-observation sources 
Errors of non-observation refer to anything that excludes eligible respondents or sample 
records (Lavrakas, 2008). Sampling, coverage, and nonresponse error are all forms of non-
observation in the total survey error framework (Groves, Fowler, Couper, Lepkowski, Singer, & 
Tourangeau, 2009). This survey error framework can also be associated with the Heckman 
concept of sample selection bias popularized in the late 1970s, where nonrandom participant 
self-selection or nonrandom researcher decisions alter sample composition (Heckman, 1979).  
“Nonrandom self-selection by the participant” is nonresponse error in the survey 
framework. In the context of panel studies, it is referred to as attrition. This notion includes a 
participant’s conscious decision to not participate (e.g., hard refusal) as well as a possibly 
unconscious decision to not participate (e.g., unavailable or inaccessible). More commonly 
consent or permission to collect data would fall into this participant self-selection problem.  
“Nonrandom decisions by a researcher” is not discussed as often in the literature, as it is 
commonly an assumption or a feature of the research design. In the context of biomeasure 
collection, though, researchers can make administrative decisions – practical or theoretical, 
subjective or objective – about who is considered eligible to provide biomeasures. For example, 
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a common administration decision is based on age, including for instance only those younger 
than 65 years old. But the decision may also appear as a medical safety criterion (those not 
taking an anticoagulant, or blood thinner) or a survey design-based criterion (a particular mode 
of data collection). The impact of these less often considered dimensions of non-observation are 
also examined. 
In a longitudinal panel survey the sources include mortality, unit nonresponse, eligibility, 
and consent. Multiple factors can have an effect on the source and the size of bias in biomeasure 
estimates. 
2.2.1 Mortality 
Mortality is a natural source of non-observation or censoring especially for an aging 
population. Given the strong relationship between health and mortality (e.g., Idler & Benyamini, 
1997), and the relationship of biomeasures to health, it is an important non-observation source to 
understand in the longitudinal survey. The relationship between health and mortality is a well-
studied relationship for many populations (e.g., Hurd & McGarry, 1995; Luo, Hawkley, Waite, 
& Cacioppo, 2012). Mortality removes subjects from the sample and so it is important to capture 
when considering sources of non-observation. Death does attenuate many sources of longitudinal 
bias. 
However, mortality does not result in biased estimates, because estimates are for the 
population of the living unless mortality is not captured for all eligible sample members. 
Accuracy of mortality ascertainment can be problematic with both false positives (i.e., reported 
deceased but available) and false negatives (believed alive but deceased) resulting in biased 
findings, especially as it relates to mortality as an outcome. This is most often the case with long-
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term unit nonrespondents where mortality may not be systematically observed. Longitudinal 
studies of aging need accurate sources of information or the ability to verify informant reports of 
mortality. For example, the Health and Retirement Study (HRS) documents mortality through 
two primary sources: 1) deaths reported during attempts at subsequent wave interviews resulting 
in an exit interview with next-of-kin and 2) the National Death Index. Over 95% of deaths are 
reported in both sources. HRS retains those lost to attrition for mortality observation and overall 
has found the mortality ascertainment is accurate and representative (Weir, 2016). 
2.2.2 Unit nonresponse 
Survey response generally has two distinct mechanisms: contact and cooperation (or in 
other words, non-contact and refusal) (Groves & Couper, 1998). Contact relates to the ability to 
find or locate (or relocate) the participant, while cooperation is the process of convincing the 
participant to participate and is conditional on contact. Lepkowski and Couper (2002) further 
divide contact in the context of panel studies into location and contact (see also Amaya & 
Harring, 2017). Many studies have shown that these mechanisms are generally different in both 
cross-sectional and panel studies (Groves & Couper, 1998; Lepkowski & Couper, 2002; Olson, 
2006; Olson, Smyth, & Wood, 2012; Amaya & Harring, 2017). In panel studies, a single wave of 
nonresponse following the initial wave (also known as attrition) can occur due to noncontact or a 
lack of cooperation for any given wave. Attrition is a permanent state of nonresponse since a 
participant is never found again or requests to be removed from the panel permanently.  
Survey nonresponse and panel attrition are well documented in the literature and a full 
discussion is not necessary here. Some key predictors of nonresponse and attrition in face-to-face 
panel surveys include impediments to entry (Groves & Couper, 1998), employment status 
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(Groves & Couper, 1998; Lepkowski & Couper, 2002), housing tenure (Groves & Couper, 
1998), urbanicity (Groves & Couper, 1998), civic engagement (Groves, Singer, & Corning, 
2000), social integration (Lepkowski & Couper, 2002; Amaya & Harring, 2017), and previous 
survey enjoyment (Laurie, Smith, & Scott, 1999; Lepkowski & Couper, 2002; Olsen, 2005). In 
addition, surveys of older adult populations are likely to see nonresponse predictors like age, 
cognitive impairment, and physical limitations (Kelfve, Thorslund, & Lennartsson, 2013). While 
there are clear relationships with the nonresponse mechanism, it is unclear how these factors 
might influence estimated biomarker values. 
2.2.3 Operational eligibility 
A source of non-observation preceding consent is eligibility. A respondent may not have 
a particular attribute (e.g., questions regarding pregnancy are not asked of men) or may have 
characteristics that exclude subjects through study protocols. This latter form of eligibility is 
sometimes referred to as operational eligibility. It is not discussed often in the literature, though 
it is a major concern for survey practitioners and research teams. Often operational eligibility 
involves screening (identifying and excluding) selected respondents from participating on the 
basis of some characteristic in order to protect respondents or minimize risk to them. This may 
include location constraints, respondent limitations, survey conditions, or external factors.  
This concept can also be linked to following ethical practices in line with the Belmont 
Report and its principle of beneficence (National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research, 1978): (1) do no harm and (2) maximize 
possible benefits while minimizing possible harms. In biomeasure research it would be 
inappropriate and unsafe to ask a participant receiving anticoagulants (blood thinners) to provide 
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a blood sample due to increased risk of uncontrolled bleeding and perhaps even death. Similarly, 
one would not ask a respondent in a wheelchair to perform a walking test, exposing them to the 
risk of falls. Operational eligibility does not mean that a study participant does not have the 
desired attribute or that the measure could not feasibly be obtained given appropriate safeguards, 
controls, and conditions. In many cases, it is a necessary form of censoring that could induce bias 
in estimates.  
The researcher essentially redefines the population of interest by specifying that only a 
particular subset of all potential subjects is to be examined. Conclusions can only be made in 
relation to the redefined population to ensure that conclusions are not extrapolated to populations 
other than those studied. However, the exclusion of respondents whose levels of biomeasures are 
related to the outcomes of interest generates a systematic and potentially sizable bias in 
biomeasure estimates toward (most likely) healthier outcomes. 
In the context of an in-person, non-medically trained interviewer biomeasure collection, 
there are multiple forms of operational eligibility that exempt individuals from participating in 
biomeasure collection. Four forms of operational eligibility are explored here: (1) using a proxy 
respondent, (2) living in a nursing home, (3) completing collection in an out-of-scope survey 
mode, and (4) incomplete or partial interviews. These are not mutually exclusive states; a 
respondent could belong to any (or all) of these states.  
Study protocol may require data collection from a proxy informant to complete the 
survey interview. Most often, this is due to the respondent being too ill or disabled, cognitively 
or physically, to complete the survey on their own (Moore, 1988; Nelson, Longstreth Jr, 
Koepsell, & van Belle, 1990; Weir, Faul, & Langa, 2011). In some cases, a proxy respondent 
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may be used because interviewers are unable to contact the respondent and, in accordance with 
survey protocols, the research team seeks out a knowledgeable proxy (e.g., spouse, parent, adult 
child) to provide the relevant information (Moore, 1988; Cobb, 2018). Proxy respondents are 
allowed for some surveys to increase response rates and reduce data collection costs (Weir et al., 
2011; Cobb, 2018). However, proxies can also increase measurement error depending on the 
proxy’s familiarity with the selected respondent’s characteristics (Cobb, 2018). 
Switching from self to proxy interviews in a panel study of older adults is associated with 
age and declining physical and mental health (Weir et al., 2011). Cognition, physical limitations, 
and age-related chronic conditions are highly correlated with health status. As a result, proxy 
data collection may lead to bias toward healthier levels of some biomarker values. 
A second form of operational eligibility is living in nursing homes or other 
institutionalized facilities. Their placement in such a facility suggests an inability to complete 
daily or routine tasks due to diminishing physical and/or mental health. Depending on the 
condition of the respondent, these individuals may choose or even require that a proxy responds 
in their place. Given the respondent is being closely monitored due to their compromised mental 
and/or physical health, it is a sensible and necessary precaution to avoid collecting biomeasures 
as these individuals are at increased risk for injury and complications related to the collection 
procedures and may be inappropriately allowed or coerced to participate, compromised by an 
impaired cognitive state. In addition to safety, most facilities would not allow biomeasure 
collection by research study personnel, especially with non-medically trained interviewers. 
Again, cognition measures and physical limitations should be highly correlated covariates 
(Kelfve et al., 2013). These concerns are heightened by great disparities in placement into 
nursing home across racial groups (Stevens, Owen, Roth, Clay, Bartolucci, & Haley, 2004). 
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One factor related to declines in cognition ultimately resulting in the need for a proxy or 
placement in a nursing home is education. Higher education is generally attributed as a 
protective factor against cognitive decline, showing a decreased risk of dementia or Alzheimer’s 
disease (Stern et al., 1994; Cobb et al., 1995; Ott et al., 1995; Karp et al., 2004; Rapp et al., 
2013). However, higher education is also associated with steeper cognitive decline once 
diagnosed with dementia or Alzheimer’s disease (Stern, Albert, Tang, & Tsai, 1999; Wilson et 
al., 2004; Scarmeas, Albert, Manly, & Stern, 2006; Rapp et al., 2013). This more rapid decline 
may be related to delayed detection and onset of clinical symptoms (Stern et al., 1994). More 
education could manifest as either a positive effect denoting the protective aspect of education or 
as a negative effect denoting the rapid decline following onset. Similar to proxy status, the 
exclusion of nursing home respondents is also likely to bias biomarker estimates toward healthier 
levels. 
The third form of ineligibility is response in a survey mode other than one where 
biomeasure collection can occur. This specifically occurs in a multi-mode survey where 
biomeasure collection can only occur in a single or a subset of modes. For purposes of in-person, 
non-medically trained interviewer biomeasure collection, this would be any mode other than 
face-to-face (FTF). For example, the Health and Retirement Study (HRS) since 2006 has 
alternated between FTF and computer-assisted telephone interviews (CATI) every two year 
survey wave in order to reduce burden on respondents (Fisher & Ryan, 2018). Respondents are 
only eligible to provide biomeasures when they participate in a FTF wave. As such, interviewers 
cannot conduct any of the biomeasure collections if a respondent assigned to complete a FTF 
interview is responding via CATI. Other biomeasure collection studies which utilize a mail-back, 
self-collection approach for simple, non-invasive collections (e.g., Gatny, Couper, & Axinn, 
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2013; Dykema, DiLoreto, Croes, Garbarski, & Beach, 2017) may not observe this mode impact 
as acutely, depending on specific collection protocols by mode. 
The decision to participate in a mode other than one assigned may be due in part to a 
number of factors. Smyth, Olson, and Millar (2014) suggest four reasons why a respondent may 
choose one mode over another: (1) familiarity with and access to the mode, (2) physical and 
cognitive demands of the mode, (3) self-presentation, and (4) personal safety concerns. All of 
these reasons are relevant in interviewer biomeasure collection in a longitudinal panel study. A 
FTF survey requires that the respondent be physically present and available when the interviewer 
makes contact. Factors like employment status and barriers to entry then influence the choice of 
survey mode (Groves & Couper, 1998; Tourangeau, 2004), though some of this choice may 
ultimately be due to the interviewer and not the respondent. Though FTF and CATI collections 
are both interviewer administered modes, the CATI interview for some respondents could prove 
to be more convenient and less cognitively demanding as it increases the social distance between 
the respondent and the interviewer. Interviews may be shortened, removing social pressures of 
FTF interaction, and ensuring one’s personal safety and wellbeing (Groves, 1990; Schwarz, 
Strack, Hippler, & Bishop, 1991; Holbrook, Green, & Krosnick, 2003). Health related factors 
(e.g., chronic diseases, physical limitations) could account for some reasons to opt for a different 
mode, though there are potentially more factors related to the respondent and their living 
situation which may have more leverage in that decision.  
The fourth and final eligibility form is a partial interview (i.e., survey breakoff) and do 
not receive the biomeasure module. This is most likely to occur if biomeasure collection occurs 
near or at the end of the interview. Studies like HRS (Weir, 2008) and the National Social Life, 
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Health, and Aging Project (NSHAP) (O’Doherty et al., 2014) attempt to avoid this problem by 
placing the biomeasure collection in the middle of the interview.  
The general nonresponse framework established by Groves and Couper (1998) is useful 
for examining survey breakoffs (e.g., Peytchev, 2009; McGonagle, 2013). The framework 
repeatedly examines the respondent’s motivations, desire, and ability to complete the survey as 
each new question is presented. Survey characteristics like the questionnaire content and length 
certainly play a role in this decision. Situational factors related to the respondent characteristics 
or the respondent-interviewer interaction could also lead a respondent to breakoff prematurely. It 
is possible that in surveys of older adults that health-related factors related to things like physical 
or mental exhaustion could play a role in continuing the survey. The choice to prematurely halt 
the survey as opposed to choosing not answer a question (i.e., item nonresponse) could be due to 
increasing cognitive burden comprehending questions, difficulty retrieving relevant information, 
and making appropriate judgments necessary to respond accurately (Loosveldt, Pickery, & 
Billiet, 2002; Yan & Curtin, 2010; see also Tourangeau, Rips, & Rasinski, 2000; Beatty & 
Herrmann, 2002). 
While this overview of eligibility exclusions has tried to generally link different forms of 
ineligibility with health conditions (both physical and mental), there are a number of other 
factors that could result in exclusion under any of these situations. The connection between 
eligibility and overall health is important, because sample selection bias due to health yields 
systematic differences in health measure estimates, particularly biomeasures of interest. 
These non-observation sources are not successive in nature, generating additional levels 
of missingness. In order for these states to be more useful in understanding the systematic loss of 
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data, it is necessary to classify each state as taking precedence over another. For example, while 
presence in a nursing home temporally precedes whether or not a subject (or proxy) respond to 
the survey, a nursing home respondent can provide data while a nonrespondent cannot. From a 
data perspective, nonresponse determines data presence, while nursing home residency does not. 
These issues are discussed further in reference to specific analyses conducted in this paper in 
Section 2.3.2.   
2.2.4 Biomeasure consent 
Biomeasure collection requires secondary consent from the respondent in addition to the 
consent to conduct the survey interview due to the invasive nature of collection (Weir, 2008; 
Jaszczak et al., 2009). Consent is the direct form of non-observation for biomeasures since the 
respondent must make a conscious decision to participate in the collection of biomeasures. Other 
mechanisms discussed above were indirect, since they involve survey participation generally. 
A number of common sociodemographic factors have not been found to be significant 
predictors of biomeasure consent, including age, gender, and education (Gavrilova & Lindau, 
2009; Sakshaug, Couper, & Ofstedal, 2010; Korbmacher, 2014). African Americans have been 
found to be less likely to consent to biomeasure collection (Gavrilova & Lindau, 2009), though 
this is not always a strong association (Sakshaug et al., 2010). Dykema and colleagues’ (2017) 
found that more religious persons, as measured by weekly church attendance, are less likely to 
participate in biomeasure collection. However, after controlling for sociodemographic, health, 
and other factors, weekly church attendance led to higher rates of consent than those who did not 
attend or attended infrequently.  
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In general, healthier individuals are more likely to consent to biomeasure collection. 
More functional limitations (physical functioning where one needs assistance) as well as 
difficulty performing daily activities correspond to lower rates of biomeasure consent (Sakshaug 
et al., 2010; Korbmacher, 2014). Chronic conditions like diabetes are associated with higher 
levels of biomeasure consent, especially with dried blood spot assays (Sakshaug et al., 2010; 
Korbmacher, 2014). McClain et al. (2015) found higher levels of a word recall measure of 
cognition resulted in greater rates of consent to physical measurements (e.g., blood pressure, 
height, weight).  
2.2.5 Research questions 
The first research goal is to identify covariates associated with the propensity of 
participating in each eligibility state (living, response, biomeasure eligible, and consent) in 
opposition to the sources of non-observation (mortality, nonresponse, biomeasure ineligibility, 
and non-consent). Interest is in determining whether there are consistent sets of predictors that 
could result in a cumulative bias for key biomarker estimates. Existing research suggests that 
cognitive impairment, physical limitations, and chronic conditions are likely candidates for a 
survey of older adults. Thus, the first research question is: 
(1) Are there common covariate predictors between each source of between-wave 
non-observation that could result in a bias for biomeasure estimates? 
Individual respondent or household characteristics need to be examined, as well as 
potentially powerful predictors like knowing a respondent’s previous eligibility state when 
predicting their future eligibility state. For example, a respondent who fails to complete the 
interview in one wave may be less likely to respond in the next wave (Watson & Wooden, 2009). 
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An older respondent experiencing increasing physical or cognitive difficulty and refusing 
biomeasure collection could be more likely to need a proxy interview, be admitted into a nursing 
home, or be deceased in a future wave. These considerations lead to a second research question: 
(2) Does a previous source of non-observation predict a future eligibility state 
conditional on known covariate predictors of that future state? 
The second research goal of measuring the effect of the sequential sources of non-
observation bias on biomeasure outcomes focuses on the biomeasures themselves as they relate 
to each source of non-observation. While one might expect nonresponse or non-consent to 
represent major sources of non-observation for biomeasures, non-random associations of 
eligibility and health outcomes with consent could also be a source of systematic bias in 
biomarker estimates. Thus, two additional research questions posed are: 
(3) What is the size of the bias of each non-observation source on biomeasure 
estimates, and which source results in the largest bias? 
(4) How does the size of non-observation bias due to ineligibility compare to 
nonresponse or non-consent? 
2.3 Methods 
2.3.1 Data 
The HRS (Health and Retirement Study) is sponsored by the National Institute on Aging 
(grant number NIA U01AG009740) and is conducted by the Institute for Social Research (ISR) 
at the University of Michigan. HRS is a longitudinal survey of adults over the age of 50 living in 
the United States that collects various measures related to health, medical care, employment, 
income, and cognition. HRS began in 1992 with a cohort of preretirement-aged individuals born 
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between 1931 and 1941. New birth cohorts are enrolled every 6 years (e.g., 1998, 2004, 2010) to 
refresh the sample at younger ages (see Figure 2-1). The HRS conducts about 20,000 interviews 
every 2 years with response rates between 65 and 85 percent in the baseline wave and between 
85 and 95 percent in follow-up waves. 
In 2006, HRS began alternating respondents between face-to-face and telephone 
interviews, with a random half sample of the full panel being assigned to each mode (see Figure 
2-2). Every two years each half-sample switches to the other mode1. In face-to-face interviews, 
noninstitutionalized, non-proxy respondents are asked to provide measures of physical 
                                               
1 Respondents over the age of 80 alternate between FTF and E-FTF interviews unless they specifically request a 
telephone interview. 
Figure 2-1. Longitudinal cohort design of the Health and Retirement Study. Adapted from 
Figure A-4 of "The Health and Retirement Study: Aging in the 21st Century: Challenges and 
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functioning (i.e., blood pressure, hand grip strength, a walking test, height, weight, etc.), a one-
time saliva sample (for DNA extraction and storage), and a dried blood spot assay (for measuring 
Hemoglobin A1c, cholesterol, and other biochemical measures.). Saliva and blood samples have 
different collection, storage, and analysis procedures. Respondents are given three consent forms 
for each of the biomeasure components. HRS refers to this face-to-face interview with 
biomeasure collection and self-administered questionnaire on psychosocial topics as the 
enhanced face-to-face (E-FTF) interview.  
This study uses the 2006, 2010, and 2014 E-FTF waves of HRS. Biomeasure eligible 
respondents to the 2006 wave are included (n = 7,954). Analyses focus on biomarkers collected 
from the dried blood spot (DBS) assays in 2006. All respondent-level data was obtained from the 
HRS Public Release data available at http://hrsonline.isr.umich.edu/index.php?p=avail. 
Biomarker data, denoted as sensitive health data, were obtained through an application process 
(see http://hrsonline.isr.umich.edu/index.php?p=healthdat for details).
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Figure 2-2. HRS alternating wave design highlighting biomeasure collection. Each row represents a random half-sample in the 
alternating survey mode design. Colored boxes represent data used for the analyses in this chapter. Gray boxes are not included in this 
analysis. 
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2.3.2 Disentangling eligibility states 
In order to better disentangle the reasoning behind a biomeasure ineligible state and 
reduce the number of possible non-observation sources, one has to understand whether the 
reason for a respondent’s ineligibility is related to their health or other circumstances. Health-
related reasons would be more likely to cause bias in biomarker estimates.  
Reasons for ineligibility can be examined by reviewing interviewer observations from the 
HRS 2010 interview of those who were biomeasure eligible in 2006. HRS interviewers were 
asked on up to two separate occasions to assess the mental or physical state of the respondent 
relative to ability to respond. For proxy interview respondents, interviewers were asked item 
MA011, “Do you have reason to think that [FIRST NAME] would have difficulty completing 
this interview because of cognitive limitations?” Response options include “No reason to think” 
this, “the respondent may have some cognitive limitations”, and “the respondent has cognitive 
limitations that prevent him/her from being interviewed.” While these reasons are all related to 
the mental condition of the selected respondent, and not physical condition, the latter two 
responses are considered health reasons for purposes of this analysis. After the interview is 
complete, the interviewer answers item M011: “Did the (respondent have/informant report that 
the respondent has/proxy report that the respondent has) any of the following impairments 
making it difficult to respond?” Response options that deal with more permanent physical or 
mental health issues include “mentally handicapped”, “hard of hearing”, “physically 
handicapped”, and “speech impediment”. Other potential, non-health related responses include 
“poor spoken English”, “under the influence of alcohol or drugs”, and “some other impairment”. 
While being under the influence of alcohol or drugs is a temporary physical/mental condition, it 
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is not indicative of a permanent state of compromised health. “Some other impairment” is too 
vague for categorization as health-related or not.  
 For those classified as ineligible in 2010 (n = 699), 42.2% were classified as ineligible 
due to health-related reasons (see Table 2-1). Of all proxy respondents (41.8% of ineligible 
respondents), over 82% were recorded as having health problems that made them ineligible. Of 
nursing home respondents (23.0% of ineligible respondents), 84.5% were recorded as having 
health-related problems. Among CATI respondents (80.3% of ineligible respondents), nearly 
36% had health problems related to their response. However after excluding telephone 
respondents who used a proxy or were in a nursing home (nearly 50% of the total ineligible 
sample), there are only 9.3% with health-related impairments. The number of partial interviews 
is less than 10 cases, and most were proxy interviews. That is, proxy interview and nursing home 
respondents primarily identify health reasons for their biomeasure ineligibility, while CATI non-
nursing home and CATI self-respondents primarily do not identify health reasons for 
ineligibility. 
  
Table 2-1. Interviewer reported physical or mental difficulties for HRS 2010 biomeasure 
















Health reason 42.2% 82.2% 84.5% 36.5% 9.3% 
Not health reason 57.8% 17.8% 15.5% 63.5% 90.7% 
      
Sample size 699 292 161 561 347 
% of total sample 100.0 41.8 23.0 80.3 49.6 
Note. Reason for ineligibility in 2010 is based off of MA011 and M011 asked of the interviewer. 
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For operational eligibility, any or all of the non-observation sources can apply to a 
respondent. For example, a nursing home respondent could have a proxy respondent who 
completes the interview over the phone even though the respondent is assigned to E-FTF for a 
particular wave.  In order for these states to be useful and interpretable in these analyses, a 
hierarchy of mutually exclusive eligibility states was established.   
Sixty-eight percent of nursing home respondents use a proxy respondent while of all 
proxy respondents only 38% live in a nursing home. Thus, nursing home status is strongly 
influenced by the need for a proxy. Two exploratory logistic regression models (see Appendix 
A) predicting nursing home response and proxy response found a number of similarities in the 
demographic and health predictors for each non-observation source, including age, education, 
cognition, and physical activity. The largest differences are in home ownership and current work 
status with nursing home respondents less likely to own a home or currently hold a job. Given 
the relationship between these two sources of non-observation and the health-related reasons for 
each, proxy and nursing home interviews are considered as a single source of non-
observation associated with health-related issues.  
After excluding the proxy and nursing home interviews, the majority of the remaining 
biomeasure ineligible respondents completed CATI interviews and do not cite health-related 
issues as an impairment to response. The small remainder of ineligible respondents are survey 
breakoffs. Those who chose CATI over E-FTF and those who did not complete the interview are 
linked to increased survey resistance generally. Breakoff interviews are grouped with CATI 
respondents as a single source of non-observation associated with survey resistance and not 
health-related concerns. 
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Lastly, location, contact, and cooperation are usually modeled and examined separately 
for nonresponse (see Lepkowski & Couper, 2002). Due to small sample sizes, location, contact, 
and cooperation are considered as non-observation due to nonresponse. The analyses that 




(3) Proxy/nursing home respondent (i.e., health ineligible respondent), 
(4) Telephone/partial complete respondent (i.e., non-health ineligible respondent), and 
(5) Biomeasure non-consenting respondent. 
Including biomeasure consenting respondents, a total of six eligibility outcomes are considered 
(see Figure 2-3). Conversely, there are nested eligibility states representing the mathematical 
complements of the five non-observation sources above (i.e., living, respondent, non-nursing 













































































































Figure 2-3. Sources of non-observation and eligibility states for HRS 2006 biomeasure eligible 
respondents in HRS 2010. This figure illustrates the relationship between successive sources of 
non-observation and final eligibility states for biomeasure collection in HRS 2010 and the impact 
on observable data. The right-hand side depicts the interview and biomeasure data available for 
each eligibility state. Eligibility state sizes are not reflective of actual proportions per non-
observation source.  
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2.3.3 Part 1 – Sources of non-observation propensity model 
The two research questions related to the sources of non-observation, a continuation ratio 
ordinal multinomial regression model (Fullerton & Xu, 2016), also known more simply as the 
continuation ratio logit model (Agresti, 2002) or the sequential logit model (Tutz, 1991), will be 
applied simultaneously to each of the successive non-observation source. The continuation ratio 
model is equivalent to conditional logistic regression models used in previous studies (e.g., 
Lepkowski & Couper, 2002; Olson, 2006) when the covariate set for each conditional model is 
the same.  
Given known covariate differences across some of the non-observation models (e.g., 
Lepkowski & Couper, 2002; Olson, 2006), the non-parallel slopes continuation ratio model will 
be used. Covariance matrices are estimated assuming no covariance between models allowing 
for statistical testing of slopes across non-observation models. In addition, the parallel slopes 
assumption can be tested to assess whether a constrained or unconstrained partial model might be 
appropriate (Fullerton & Xu, 2016).  
The non-parallel slopes continuation ratio model can be written as 
 log�𝜋𝜋𝑗𝑗+1+⋯+𝜋𝜋𝐽𝐽
𝜋𝜋𝑗𝑗
� = 𝑿𝑿𝜷𝜷�𝒋𝒋 , 𝑗𝑗 = 1, … , 𝐽𝐽 − 1 (2.1) 
where �𝜋𝜋1, … ,𝜋𝜋𝐽𝐽� denotes the response probabilities of each non-observation source plus consent 
(i.e., eligibility outcomes) satisfying ∑ 𝜋𝜋𝑗𝑗𝑗𝑗 = 1, 𝑗𝑗 represents each of the eligibility outcomes 
(mortality, nonresponse, proxy/nursing home, biomeasure ineligible, non-consenters, and 
consenters), 𝑿𝑿 denotes the matrix of regressors, and 𝜷𝜷�𝒋𝒋 denotes the estimated regression 
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parameter vectors for the 𝐽𝐽-1 models. Expanding this model into its five sub-models, the 

































Two separate sets of models are considered here: a two-wave model predicting the 
second wave of biomeasure collection (i.e., 2010) and a three-wave model predicting the third 
biomeasure collection (2014).  
The base two-wave model is 
 log�𝜋𝜋𝑗𝑗+1,10+⋯+𝜋𝜋𝐽𝐽,10
𝜋𝜋𝑗𝑗,10
� = 𝒁𝒁𝜸𝜸�𝑗𝑗 + 𝑿𝑿𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎 (2.2) 
where �𝜋𝜋1,10, … ,𝜋𝜋𝐽𝐽,10� denotes the response probabilities to the six eligibility outcomes in HRS 
2010, 𝒁𝒁 denote a time-independent covariate matrix, 𝜸𝜸�𝒋𝒋 denotes the estimated regression 
parameter vectors of the time-independent covariates, 𝑿𝑿𝟎𝟎𝟎𝟎 denotes the matrix of wave-specific 
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HRS 2006 covariates, and 𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎 denotes regression parameter vectors of the wave-specific 
covariates from HRS 2006.  
To capture the impact of the previous wave eligibility outcome, an expanded version of 
model 2.2 is 
 log�𝜋𝜋𝑗𝑗+1,10+⋯+𝜋𝜋𝐽𝐽,10
𝜋𝜋𝑗𝑗,10
� = 𝒁𝒁𝜸𝜸�𝑗𝑗 + 𝑿𝑿𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎 + 𝑾𝑾𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟎𝟎𝟎𝟎 (2.3) 
where 𝑾𝑾𝟎𝟎𝟎𝟎 denotes previous wave non-observation source and 𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟎𝟎𝟎𝟎 denotes estimated 
regression parameters of previous wave non-observation source. Thus, model 2.2 is nested 
within model 2.3. For the two-wave model, because the sample is restricted to those who were 
biomeasure eligible in 2006, the only previous wave eligibility outcome available is whether they 
have consented to DBS collection.  




� = 𝒁𝒁𝜸𝜸�𝑗𝑗 + 𝑿𝑿𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎 + 𝑿𝑿𝟏𝟏𝟎𝟎𝜷𝜷�𝒋𝒋,𝟏𝟏𝟎𝟎 (2.4) 
where �𝜋𝜋1,14, … ,𝜋𝜋𝐽𝐽,14� denotes the response probabilities to the six eligibility outcomes in HRS 
2014, 𝑿𝑿𝟏𝟏𝟎𝟎 denotes a matrix of wave-specific covariates from HRS 2010, and 𝜷𝜷�𝒋𝒋,𝟏𝟏𝟎𝟎 denotes the 
estimated regression parameters of the wave-specific covariates from 2010. Model 2.4 is nested 
within an expanded model including eligibility states from 2010: 
 log�𝜋𝜋𝑗𝑗+1,14+⋯+𝜋𝜋𝐽𝐽,14
𝜋𝜋𝑗𝑗,14
� = 𝒁𝒁𝜸𝜸�𝑗𝑗 + 𝑿𝑿𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎 + 𝑿𝑿𝟏𝟏𝟎𝟎𝜷𝜷�𝒋𝒋,𝟏𝟏𝟎𝟎 + 𝑾𝑾𝟎𝟎𝟎𝟎𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟎𝟎𝟎𝟎 + 𝑾𝑾𝟏𝟏𝟎𝟎𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟏𝟏𝟎𝟎(2.5) 
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where 𝑾𝑾𝟏𝟏𝟎𝟎 denotes previous wave non-observation source in 2010 and 𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟏𝟏𝟎𝟎 denotes the 
estimated regression parameters of previous wave non-observation source for 2010. Model 2.5 
requires that cases deceased in 2010 that are part of model 2.4 be excluded from the model 2.5 
sample estimation. Thus, model 2.4 is subset to cases that allows it to be nested within model 
2.5. 
The sample used in the two-wave model is all age-eligible and biomeasure eligible 
respondents from 2006 HRS (n = 7,954), while the three-wave model is further reduced 
following the exclusion of those deceased in 2010 (n = 6,990). In order to confirm the non-
parallel slopes assumption in the above models, a formal parallel slope test for variable k across 
the j = 5 continuation ratio logit sub-models will be conducted: 
 𝐻𝐻0:  𝛽𝛽1,𝑘𝑘 = 𝛽𝛽2,𝑘𝑘 = 𝛽𝛽3,𝑘𝑘 = 𝛽𝛽4,𝑘𝑘 = 𝛽𝛽5,𝑘𝑘 (2.6) 
where 𝛽𝛽𝑗𝑗,𝑘𝑘  is a regression parameter from 𝜸𝜸�𝒋𝒋,𝜷𝜷�𝒋𝒋,𝟎𝟎𝟎𝟎,𝜷𝜷�𝒋𝒋,𝟏𝟏𝟎𝟎,𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟎𝟎𝟎𝟎, or 𝜷𝜷�𝒋𝒋,𝑾𝑾,𝟏𝟏𝟎𝟎 in sub-model j 
corresponding to covariate k. The parallel slope test is a Wald chi-square test with 𝑗𝑗-1, or 4, 
degrees of freedom. Failing to reject this hypothesis suggests the possibility of simplification of 
the analytic models, although such simplification could lead to an overfitted model.  
Demographic predictor variables included in the above models are age (continuous), 
gender, education (less than high school, high school graduate, some college, college graduate), 
race/ethnicity crossed by language of interview (non-Hispanic other, non-Hispanic black, 
Hispanics interviewed in English, and Hispanics interviewed in Spanish), current employment 
status, and religious service attendance (at least once a week vs. less than once a week). 
38 
In addition to individual sociodemographic variables, a number of household 
characteristics are included in the model, including whether the home is owned, if there are 
impediments to entry (based an interviewer observation), whether the respondent lives in a rural 
area, and if there is another eligible HRS participant in the household. These household variables 
are dichotomies and are included as factors associated primarily with contact and cooperation in 
nonresponse models. When impediments to entry was missing, previous values  
In relation to cognition and health, a variety of measures are included to capture mental 
and physical ailments and limitations. To measure cognitive functioning, two indices were 
created based on constructed variables developed by the HRS Health Working Group (Ofstedal, 
Fisher, & Herzog, 2005; Fisher, Hassan, Faul, Rodgers, & Weir, 2017). The first index measures 
memory through two word recall tasks including 10 immediate word recall items and 10 delayed 
word recall items totaling to a maximum score of 20. The second index measures the 
respondent’s overall mental status assessing knowledge, language, and orientation, and is 
comprised of three cognitive measures which combine the results from a test to count backwards 
from 20 (score of 2), eight naming tasks (each with a score of 1), and a five-stage subtraction 
task known as the Serial 7’s test (each stage with a score of 1). This combination of three 
measures results in an index with a maximum score of 15. In the event the respondent was not 
asked to complete the naming tasks, the most recent score available was used to calculate the 
mental status score. 
To measure physical health and wellness, self-rated health (four levels, combining fair 
and poor), mild vigorous activity (at least once a week, one to three times a month, or hardly 
ever/never), a functional limitation index, and a chronic disease index are included as covariates 
in the model. The functional limitation index is the summation of three separate scales: the six 
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item basic activities of daily living (BADL) (Katz et al., 1963), the seven item instrumental 
activities of daily living (IADL) (Lawton & Brody, 1969), and the 10-point NAGI impairment 
scale (Nagi, 1976). (Additional details about the inclusion of these measures in HRS is available 
in Fonda and Herzog (2004)). With each item in the three scales categorized as dichotomous 
responses, the functional limitation index has a maximum score of 23. The chronic disease index 
was the sum of indicators for hypertension, coronary heart disease, stroke, diabetes, cancer, 
arthritis, and lung disease resulting in a maximum score of seven. The list of chronic diseases 
used in the index was based on available variables presented in Ward et al. (2012). 
 To indicate change in the three-wave models from initial wave observations, covariate 
differences were added for whether the condition or state began or ended. For indices like word 
recall, mental status, functional limitations, and chronic diseases this is simply the difference 
between 2006 and 2010 values, with a positive value meaning the value increased (e.g., number 
of functional limitations increased). For the remaining health measures (e.g., self-rated health 
and mild vigorous activity), an indicator for whether the condition improved (e.g., fair/poor self-
rated health to good), or worsened (e.g., one to three times a month mild vigorous activity to 
hardly ever/never) was included where “no change” is the reference category. For the household 
measures (e.g., impediments, urbanicity), an indicator for each change was included. 
The final indicator in the two-wave model is previous DBS non-consent coded as 1 = 
non-consent. For the three-wave model, the 2006 DBS non-consent is included in addition to 
four non-observation source indicators for 2010: nonrespondent, nursing home or proxy 
respondent, biomeasure ineligible respondent, and non-consent.  
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For the two-wave continuation ratio logit model, there are up to 24 predictors in the 
model. The corresponding Bonferroni correction for a single sub-model or the parallel slope tests 
is α = 0.05/24 = 0.0021. For the three-wave continuation ratio logit model, there are up to 47 
predictors in the model resulting in a corresponding Bonferroni correction of α = 0.05/47 = 
0.0011. 
 Item missingness was less than 5% for most variables2 and was imputed by the nearest-
neighbor hot deck approach using the R package ‘HotDeckImputation’ (Joenssen, 2015). 
2.3.4 Part 2 – Bias evaluation across eligibility states  
 The second part of the analysis focuses on bias in biomarker estimates across the sources 
of non-observation. DBS biomarkers with the following characteristics are considered 
(Crimmins et al., 2013): 
(1) Glycosylated hemoglobin (HbA1c) – an indicator of blood glucose, or blood sugar, levels 
over a longer period of time (approximately 120 days) commonly used to measure the 
level of control for diabetics, or as a screening tool for diabetes 
(2) High-Density-Lipoprotein cholesterol (HDL) – an indicator of lipid levels related to 
“good cholesterol” 
(3) Total cholesterol – an indicator of overall lipid levels 
(4) C-reactive protein (CRP) – an indicator of systemic inflammation within the body related 
to infections, inflammatory diseases, and injury 
(5) Cystatin C – an indicator of kidney functioning and healthy aging. 
                                               
2 Impediment to entry had approximately 17% item missingness due to nonresponse from the interviewer. Using 
household move data in conjunction with data available from adjacent waves, impediment to entry was able to be 
logically imputed for a majority of cases and item nonresponse was reduced to under 5% for 2006.   
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Distributions of these five DBS biomarker measures from the 2006 HRS will be 
examined as cases for each 2010 non-observation source are deleted. The distribution of the 
surviving sample is the population of interest, serving as the primary sample, although the 
change in distributions due to mortality are examined as well. 
Analysis will compare percentiles (1st, 5th, 10th, 25th (Q1), 50th (median), 75th (Q3), 90th, 
95th, and 99th), means, and a proportion of those with high or at risk levels (see Table 2-2) for 
each of the five biomeasures. NHANES adjusted values based on whole blood values are the 
HRS recommended values for analysis (Crimmins et al., 2013, 2015).  
The 2006 biomeasure weights, and stratum and cluster variables, are used to estimate 
population values. The biomarker weight is the product of the core respondent weight3 and a 
nonresponse adjustment based on a propensity model predicting the probability of completing 
the biomeasure portion of the interview. The nonresponse propensity model uses predictors 
including age, sex, race/ethnicity, education, marital or partner status, and health factors 
(including self-rated health, number of physical limitations, hypertension, heart conditions, 
myocardial infarction, angina, congestive heart failure or stroke). The biomeasure nonresponse 
                                               
3 The core respondent weight is the product of the inverse of the probabilities of selecting a household and the 
individual respondent within households. A second post-stratification adjustment is also used, based on the 
American Community Survey, for differential nonresponse for the HRS survey based on age, gender, race/ethnicity, 
and geography. For more details on the creation of this weight, see Ofstedal, Weir, Chen, and Wagner (2011). 
Table 2-2. Dried blood spot biomarker thresholds for high or at risk levels 
Dried blood spot biomarker High/At risk level 
Glycosylated Hemoglobin (HbA1c) >= 6.4% 
HDL cholesterol < 40 mg/dL 
Total cholesterol >= 240 mg/dL 
C-Reactive Protein (CRP) >= 3.0 ug/mL 
Cystatin C > 1.55 mg/L 
Note. Thresholds consistent with those defined by Crimmins et al. (2013). 
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adjusted weights are post-stratified by age, gender, and race of the HRS sample (Crimmins et al., 
2013). 
Bias, after an initial adjustment for mortality, for each non-observation source is 
estimated as follows:  
 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 𝑎𝑎𝑎𝑎𝑗𝑗𝑂𝑂𝑎𝑎𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎𝑂𝑂 𝑓𝑓𝑂𝑂𝑓𝑓 𝑂𝑂𝑂𝑂𝑓𝑓𝑂𝑂𝑎𝑎𝑚𝑚𝑚𝑚𝑂𝑂𝑚𝑚(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐴𝐴𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑆𝑆𝑎𝑎𝑏𝑏𝑝𝑝𝑖𝑖𝑠𝑠  (2.7) 
 𝑁𝑁𝑂𝑂𝑎𝑎𝑓𝑓𝑂𝑂𝑎𝑎𝑁𝑁𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑅𝑅𝑠𝑠𝑠𝑠𝑝𝑝 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐴𝐴𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠  (2.8) 
 𝑃𝑃𝑓𝑓𝑂𝑂𝑃𝑃𝑚𝑚/𝑎𝑎𝑂𝑂𝑓𝑓𝑎𝑎𝑚𝑚𝑎𝑎𝑛𝑛 ℎ𝑂𝑂𝑂𝑂𝑂𝑂 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑆𝑆𝑠𝑠𝑖𝑖𝑠𝑠𝑅𝑅 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑅𝑅𝑠𝑠𝑠𝑠𝑝𝑝 (2.9) 
 𝑇𝑇𝑂𝑂𝑚𝑚𝑂𝑂𝑁𝑁ℎ𝑂𝑂𝑎𝑎𝑂𝑂/𝐷𝐷𝑓𝑓𝑂𝑂𝑁𝑁𝑂𝑂𝑂𝑂𝑂𝑂 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐸𝐸𝑖𝑖𝑠𝑠𝑖𝑖 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑆𝑆𝑠𝑠𝑖𝑖𝑠𝑠𝑅𝑅  (2.10) 
 𝑁𝑁𝑂𝑂𝑎𝑎 − 𝑂𝑂𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂𝑎𝑎𝑂𝑂 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐶𝐶𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐸𝐸𝑖𝑖𝑠𝑠𝑖𝑖  (2.11) 
where 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑆𝑆𝑎𝑎𝑏𝑏𝑝𝑝𝑖𝑖𝑠𝑠  is the full 2006 sample distribution estimate (mean or proportion) for the 
selected biomarker, 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐴𝐴𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠  is the 2006 biomarker estimate for those still alive in 2010, 
𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑅𝑅𝑠𝑠𝑠𝑠𝑝𝑝  is the 2006 biomarker estimate for those who responding to HRS in 2010, 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑆𝑆𝑠𝑠𝑖𝑖𝑠𝑠𝑅𝑅  is 
the biomarker estimate for non-nursing home, self-respondents in 2010, 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐸𝐸𝑖𝑖𝑠𝑠𝑖𝑖  is the estimate 
for the biomeasure eligible respondents in 2010, and 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐶𝐶𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 is the estimate of those who 
consented to biomeasure collection in 2010.  
Total bias due to all sources of non-observation (i.e., the sum of bias estimates in 
expressions (2.8) through (2.11) above) is of interest if the individual level changes are small: 
 𝑇𝑇𝑂𝑂𝑂𝑂𝑎𝑎𝑚𝑚 𝑎𝑎𝑂𝑂𝑎𝑎-𝑂𝑂𝑏𝑏𝑎𝑎𝑂𝑂𝑓𝑓𝑜𝑜𝑎𝑎𝑂𝑂𝑚𝑚𝑂𝑂𝑎𝑎 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐶𝐶𝑐𝑐𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐴𝐴𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠  (2.12) 
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Operational eligibility is the sum of two components. An overall operational eligibility 
bias is also estimated to compare to overall nonresponse and non-consent: 
 𝑂𝑂𝑁𝑁𝑂𝑂𝑓𝑓𝑎𝑎𝑂𝑂𝑚𝑚𝑂𝑂𝑎𝑎𝑎𝑎𝑚𝑚 𝑂𝑂𝑚𝑚𝑚𝑚𝑛𝑛𝑚𝑚𝑏𝑏𝑚𝑚𝑚𝑚𝑚𝑚𝑂𝑂𝑚𝑚 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) = 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝐸𝐸𝑖𝑖𝑠𝑠𝑖𝑖 − 𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵,𝑅𝑅𝑠𝑠𝑠𝑠𝑝𝑝 (2.13) 
The relative bias is also examined:  
 𝑅𝑅𝑂𝑂𝑚𝑚𝑎𝑎𝑂𝑂𝑚𝑚𝑜𝑜𝑂𝑂 𝑏𝑏𝑚𝑚𝑎𝑎𝑎𝑎(𝑚𝑚�𝐵𝐵𝐵𝐵𝐵𝐵) =
𝑝𝑝�𝐵𝐵𝐵𝐵𝐵𝐵,(𝑗𝑗+1)−𝑝𝑝�𝐵𝐵𝐵𝐵𝐵𝐵,𝑗𝑗
𝑝𝑝�𝐵𝐵𝐵𝐵𝐵𝐵,𝑗𝑗
   
where j is the “full” sample estimate and j+1 is the estimate of the desired subset. 
There are a total of 35 bias estimates for means as well as for proportions. A Bonferroni 
correction is used for all 70 estimates: α = 0.05/70 = 0.000714.  
Table 2-3 shows the analytic sample sizes in the biomarker bias evaluations. Four of the 
DBS biomarkers have observations available for over 90 percent of the total consenting sample. 
Loss in sample is due to insufficient or improperly collected specimens. For HDL, though, only 
available for 76 percent of the total sample is available.  
These bias estimates assume that biomarkers remain, on average, constant over time, 
ignoring aging, natural human variation, improvements or declines in physical health due to 
dietary, activity, or lifestyle changes, differences in collection and storage, and differences 
between laboratories used4. It is difficult to disentangle changes due to declines in health or 
laboratories used (Crimmins et al., 2014). In addition, some differences in Cystatin C and CRP 
may be of imputations in 2006 due to values too low for detection (Crimmins et al., 2013). This 
assumption of constancy across waves is examined further in Section 2.5.5. 
                                               
4 For dried blood spots, Biosafe Laboratories and the University of Vermont were used in 2006 and Heritage 
Laboratories and the University of Washington were used in 2010 (Crimmins et al., 2015). 
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2.4 Results Part 1 – Sources of non-observation propensity models  
This section focuses on the transitions from one source of non-observation to another 
from wave to wave. Section 2.4.1 reviews the basic eligibility outcome transition probabilities 
from 2006 to 2010, 2010 to 2014, and 2010 to 2014 conditional on 2006. Section 2.4.2 examines 
the two-year continuation ratio models that predict 2010 eligibility states based on respondent 
and household level sociodemographics and respondent health measures. These models also 
expand to include consent status from 2006. Section 2.4.3 examines the three-year continuation 
ratio models building on the results of Section 2.4.2 including the addition of household and 
health change measures and expanding the non-observation source indicators to include 2010. 


















DBS consenters 6,570 5,833 5,581 5,321 5,068 4,669 
Total sample1 6,203 5,537 5,309 5,062 4,817 4,447 
% of consenters 94.4 94.9 95.1 95.1 95.0 95.2 
       
HbA1c 6,101 5,445 5,218 4,976 4,735 4,374 
% of total sample 98.4 98.3 98.3 98.3 98.3 98.4 
HDL 4,708 4,209 4,042 3,861 3,673 3,392 
% of total sample 75.9 76.0 76.1 76.3 76.3 76.3 
Total Cholesterol 5,796 5,181 4,969 4,745 4,517 4,173 
% of total sample 93.4 93.6 93.6 93.7 93.8 93.8 
CRP 5,817 5,200 4,988 4,761 4,530 4,188 
% of total sample 93.8 93.9 94.0 94.1 94.0 94.2 
Cystatin C 5,724 5,121 4,911 4,685 4,454 4,120 
% of total sample 92.3 92.5 92.5 92.6 92.5 92.6 
Note. DBS = dried blood spot. 
1 Total is for sample with a non-zero biomeasure weight. Loss from the full set of consenters is due to 
insufficient or improperly collected specimens. 2 Sample sizes here are off compared to those reported in 
Crimmins et al. (2013) due to a match error between core interview data and biomeasure data. 
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2.4.1 Eligibility outcome transition 
 Table 2-4 displays the unweighted transition counts and probabilities for HRS 2006 
biomeasure eligible respondents to 2010 for the six sources of non-observation. These results 
show that a quarter of the original 2006 biomeasure eligible sample is lost to mortality, 
nonresponse, and ineligibility. Over 12% of the 2006 biomeasure eligible sample did not survive 
to the next E-FTF wave.  
There are large transition differences from 2006 and 2010 depending on whether the 
respondent consented or not to the dried blood spot (DBS) collection (see also Figure 2-4). 
Focusing on 2006 consenters, almost a quarter of respondents were not biomeasure eligible in 
2010 with nearly half of those cases having died before 2010 data collection, accounting for 
11.2% of 2006 consenters overall. Nearly 38% of 2006 non-consenters were ineligible in 2010 
 
Figure 2-4. HRS 2010 eligibility outcome transition probabilities by 2006 dried blood spot 
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with just less than half of those ineligible cases having died before 2010. Comparing non-
consenters to consenters, there are nearly doubled rates of nonresponse (8.2% vs. 3.8%) and out-
of-mode ineligibility (7.4% vs. 3.8%). Previous consenters who remained biomeasure eligible in 
2010 overwhelming consented at 92.1% while 57.6% of eligible non-consenters chose to consent 
in 2010 (36% of total non-consenters). 
Considering the transition from 2010 to 2014 for these same biomeasure eligible 
respondents in 2006, there are continued differences in non-observation source trajectories (see 
Table 2-5 and Figure 2-5). HRS 2010 consenters and non-consenters had similar transitions to 
those who consented in 2006 showing similar percentages across years. There is a greater 
proportion of biomeasure ineligible (i.e., CATI respondent or breakoff) who remain ineligible 
(13.8%) or whom are likely to be nonrespondents (16.9%). Fifty-four percent of those who were 
biomeasure ineligible in 2010 were eligible in 2014 with 85% consenting to biomeasure 
collection. Nursing home and proxy respondents are most likely to be deceased before the next 
E-FTF wave (54.7%) with over a quarter maintaining their nursing home/proxy state (27.5%). 
Less than 10% become eligible in 2014, though nearly 85% do consent to biomeasure collection 
if they are eligible. The majority of 2010 nonrespondents remain nonrespondents into 2014 
(56.4%). Nearly 14% of 2010 nonrespondents return in 2014 and provide consent to collection 
biomeasures (84.7% of eligible cases).
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Table 2-4. HRS 2010 eligibility outcome transition counts and probabilities by 2006 dried blood spot consent status 
 2010 Eligibility Outcome  
2006 DBS Status Mortality Nonresponse Nursing home/Proxy Ineligible Non-consent Consent Total 
Consent 737 252 260 253 399 4,669 6,570 
% of Total 11.2 3.8 4.0 3.8 6.1 71.1 82.6 
% of Total | Alive - 4.3 4.5 4.3 6.8 80.0  
% of Total | Eligible - - - - 7.9 92.1  
Non-consent 227 113 82 103 364 495 1,384 
% of Total 16.4 8.2 5.9 7.4 26.3 35.8 17.4 
% of Total | Alive - 9.8 7.1 8.9 31.5 42.8  
% of Total | Eligible - - - - 42.4 57.6  
Total 964 365 342 356 763 5,164 7,954 
% of Total 12.1 4.6 4.3 4.5 9.6 64.9 100.0 
% of Total | Alive - 5.2 4.9 5.1 10.9 73.9  
% of Total | Eligible - - - - 12.9 87.1  
Note. This only includes biomeasure eligible respondents from HRS 2006. Eligibility outcome columns include row percentages. Total column 
includes column percentages. DBS = dried blood spot.  
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Table 2-5. HRS 2014 eligibility outcome transition counts and probabilities by 2010 eligibility outcome  
 2014 Eligibility Outcome  
2010 Eligibility Outcome Mortality Nonresponse Nursing home/Proxy Ineligible Non-consent Consent Total 
Consent 593 229 164 160 157 3,861 5,164 
% of Total 11.5 4.4 3.2 3.1 3.0 74.8 64.9 
% of Total | Alive - 5.0 3.6 3.5 3.4 84.5  
% of Total | Eligible - - - - 3.9 96.1  
Non-consent 113 66 34 28 216 306 763 
% of Total 14.8 8.7 4.5 3.7 28.3 40.1 9.6 
% of Total | Alive - 10.2 5.2 4.3 33.2 47.1  
% of Total | Eligible - - - - 41.4 58.6  
Ineligible 40 60 13 49 29 165 356 
% of Total 11.2 16.9 3.7 13.8 8.1 46.3 4.5 
% of Total | Alive - 19.0 4.1 15.5 9.2 52.2  
% of Total | Eligible - - - - 14.9 85.1  
Nursing home/Proxy 187 28 94 1 5 27 342 
% of Total 54.7 8.2 27.5 0.3 1.5 7.9 4.3 
% of Total | Alive - 18.1 60.6 0.6 3.2 17.4  
% of Total | Eligible - - - - 15.6 84.4  
Nonresponse 53 206 26 21 9 50 365 
% of Total 14.5 56.4 7.1 5.8 2.5 13.7 4.6 
% of Total | Alive - 66.0 8.3 6.7 2.9 16.0  
% of Total | Eligible - - - - 15.3 84.7  
Mortality 964 - - - - - 964 
% of Total 100.0 - - - - - 12.1 
% of Total | Alive - - - - - -  
% of Total | Eligible - - - - - -  
Total 1,950 589 331 259 416 4,409 7,954 
% of Total 24.5 7.4 4.2 3.3 5.2 55.4 100.0 
% of Total | Alive - 9.8 5.5 4.3 6.9 73.4  
% of Total | Eligible - - - - 8.6 91.4  
Note. This only includes biomeasure eligible respondents from HRS 2006. Eligibility outcome columns include row percentages. Total column includes 
column percentages. 
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Respondents who were biomeasure ineligible in 2010 differed greatly by their 2006 
consent status (see Table 2-6 and Figure 2-6). Those who consented in 2006 saw 60% who were 
biomeasure eligible in 2014 following their intervening wave of ineligibility with 90.7% 
consenting (54.2% of total) while only 41% of non-consenters became biomeasure eligible after 
their temporary ineligibility with only 67% consenting (27.2% of total). Non-consenters from 
2006 were also more likely to remain ineligible in 2014 (19.4% vs 11.5%) or be a nonrespondent 
in 2014 (22.3% vs 14.6%). Eligibility state transitions for nursing home and proxy respondents 
shows little to no difference conditional on 2006 consent status with the majority not likely to 
survive into 2014 (55%) followed by maintaining their proxy/nursing home state (~27%). 
 
Figure 2-5. HRS 2014 eligibility outcome transition probabilities by HRS 2010 eligibility 
outcome. This only includes biomeasure eligible respondents from HRS 2006. The 964 
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Those who consented in 2006 but failed to respond in 2010 were most likely to not 
respond again in 2014 (54.8%) with a similar effect for those who did not consent in 2006 
(60.2%). Of the 2010 nonrespondents, only 17.9% who consented previously were biomeasure 
eligible in 2014 while only 12.4% of those who did not consent in 2006 were eligible. Of those 
eligible in 2014, previous consenters consented to biomeasure collection at 93.3% while previous 
non-consenters consented at only 57.1%. 
 
Figure 2-6. HRS 2014 eligibility outcome transition probabilities by HRS 2006 dried blood 
spot consent status and HRS 2010 eligibility outcome. This only includes biomeasure eligible 
respondents from HRS 2006. The 964 respondents deceased before 2010 are excluded. 
Columns are clustered by 2010 state to compare conditioned on 2006 consent status. DBS = 

































Table 2-6. HRS 2014 eligibility outcome transition counts and probabilities by 2006 DBS consent status and 2010 eligibility outcome 
  2014 Eligibility Outcome 
2006 DBS Status 2010 Eligibility Outcome Mortality Nonresponse Nursing home/Proxy Ineligible Non-consent Consent 
Consent 
Consent 529 208 147 145 102 3,538 
% of Total 11.3 4.5 3.2 3.1 2.2 75.8 
Non-consent 66 33 21 14 58 207 
% of Total 16.5 8.3 5.3 3.5 14.5 51.9 
Ineligible 26 37 9 29 15 137 
% of Total 10.3 14.6 3.6 11.5 5.9 54.2 
Nursing home/Proxy 142 20 73 1 3 21 
% of Total 54.6 7.7 28.1 0.4 1.2 8.1 
Nonresponse 33 138 23 13 3 42 
% of Total 13.1 54.8 9.1 5.2 1.2 16.7 
Mortality 737 - - - - - 
% of Total 100 - - - - - 
Non-consent 
Consent 64 21 17 15 56 323 
% of Total 12.9 4.2 3.4 3 11.3 65.1 
Non-consent 47 33 13 14 158 99 
% of Total 12.9 9.1 3.6 3.8 43.4 27.2 
Ineligible 14 23 4 20 14 28 
% of Total 13.6 22.3 3.9 19.4 13.6 27.2 
Nursing home/Proxy 45 8 21 0 2 6 
% of Total 54.9 9.8 25.6 0 2.4 7.3 
Nonresponse 20 68 3 8 6 8 
% of Total 17.7 60.2 2.7 7.1 5.3 7.1 
Mortality 227 - - - - - 
% of Total 100 - - - - - 
Note. This only includes biomeasure eligible respondents from HRS 2006. Eligibility outcome columns include row percentages. DBS = dried blood spot.
52 
2.4.2 Two-wave continuation ratio model 
This section examines the respondent- and household-level demographics, respondent 
health measures, and previous consent status predicting 2010 eligibility state. Table 2-7a displays 
all five of the nested models, only examining demographics and health measures. Near the end of 
the section, the predictors expand to include the previous wave source of non-observation: non-
consent. The full model is shown in Table 2-7b. Results deemed statistically significant are 
defined using a Bonferroni adjusted critical value for an overall critical value of 0.05. Results 
presented that are an exception to this rule are noted, but may be considered insufficiently 
conservative as a test criteria to assess the null hypothesis. 
 The first of the five models examines predictors related to mortality. Age and death are 
unsurprisingly related with older respondents less likely to survive to the next E-FTF wave. 
Females have almost 1.6 times the odds of survival between E-FTF waves over males. Compared 
to the non-Hispanic other race/ethnic group, non-Hispanic blacks and Hispanics interviewed in 
Spanish both have higher odds of survival, though not significant given the Bonferroni 
correction. Those employed at the previous wave as well as those who attend church weekly are 
also more likely to survive. Household characteristics like impediments to entry, owning a home, 
and living in a rural area all have no relationship with mortality when holding all other individual 
and household characteristics equal. As expected, a major driver of mortality is one’s physical 
and mental health. Respondents with higher word recall and mental status scores are significantly 
more likely to survive. Self-rated health, as documented previously, shows a strong relationship 
with those rating themselves as “good” having half the odds of survival over “excellent” and 
those rating themselves as “fair” or “poor” with nearly one-third the odds of survival over 
“excellent.” Individuals who are hardly ever or never active, as measured by mildly vigorous 
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activity, are less likely to survive as well as those with an increased number of functional 
limitations and chronic conditions. 
 In terms of wave nonresponse, very few respondent demographic and household 
characteristics are found to be significant predictors in these models at the Bonferroni adjusted 
critical value. Respondents with higher cognitive scores and larger numbers of chronic 
conditions both are more likely to respond. It is unclear how the lack of significant covariates 
may be related to the combining of contact and cooperation. 
 For predicting self-respondents not living in a nursing home, older respondents are more 
likely to have a nursing home or proxy interview. This is the only model where education is 
found to be predictive with those with higher education more likely to be a nursing home or 
proxy-respondent, consistent with the finding that higher education results in a quicker decline 
once diagnosed with dementia or Alzheimer’s Disease (e.g., Stern et al., 1999) which are not 
included in this model. However, this effect is not significant with the Bonferroni correction. 
Non-Hispanic black respondents have nearly twice the odds of being a non-nursing home, self-
respondent over non-Hispanic other respondents which shows consistency with the findings of 
Stevens et al. (2004). Respondents with higher cognition scores are more likely to be self-
respondents not in a nursing home. Those who rated themselves as “fair” or “poor” on self-rated 
health had 0.55 times the odds of being a self-respondent not in a nursing home, but only at α = 
0.05. Both limited mildly vigorous activity (1-3 times/month) and no mildly vigorous activity are 
associated with lower rates of self-response outside of a nursing home (OR = 0.51 and OR = 
0.65, respectively), though the latter is only significant at the 0.05 alpha level. Functional 
limitations and chronic conditions had no effect on this outcome holding all other demographic 
and health variables constant. 
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 Demographic and household characteristics seem to have few associations with being a 
biomeasure eligible respondent after removing nursing home and proxy respondents. Non-
Hispanic blacks who have 1.63 times the odds of being biomeasure eligible over non-Hispanic 
other while Spanish interviewed Hispanics had 0.58 time the odds over non-Hispanic other, both 
at only α = 0.05. More frequent church attenders have 1.46 times the odds of being biomeasure 
eligible than less frequent church attenders. Respondents who rated themselves “good” on self-
rated health had a lower odds of being biomeasure eligible compared to those who rated 
themselves “excellent” at α = 0.05 (OR = 0.60). A non-significant effect for those rated “fair” or 
“poor” may be due partially to the sample loss from earlier sources (i.e., mortality, proxy/nursing 
home) with those who rated themselves “fair/poor”. 
 Finally for the consent model, both non-Hispanics black respondents and Hispanic 
respondents interviewed in English have about 0.70 times the odds of consenting compared to 
non-Hispanic other respondents – a reversal from the strong positive effects seen in the previous 
models for non-Hispanic blacks. However, these effects are not significant when accounting for 
the multiple-comparisons. Weekly church attendance is also a predictor of consent at α = 0.05 
with those attending at least once a week having 1.25 times the odds over those who do not 
attend frequently or at all. No household characteristics seem related to consent. In relation to 
physical and mental health, those with higher mental status scores are more likely to consent, 
with no effect from word recall. Respondents who exercise very little if at all are less likely to 
consent to DBS over those who perform mildly vigorous activity at least once per week (OR = 
0.67). Each additional chronic condition also leads to 1.10 times the odds of consenting, 
potentially aided in particular from those whom are diabetic. However, these last two effects are 
weak given the multiple-comparison correction. 
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 Reviewing the five models with the previous consent status added (see Table 2-7b), 
consent refusal adds nothing significant to the mortality model and does not result in substantive 
changes in the previous interpretation of the respondent and household characteristics. In the 
nonresponse model, previous DBS non-consenters had 0.42 times the odds of responding in the 
current wave compared to those who had consented reflecting the earlier observation from the 
transition matrices showing non-consent as a strong indicator of future nonresponse. The 
addition of the non-consent indicator made little substantive change in the odds ratios for this 
model. 
 For the self-response model, previous DBS non-consent resulted in 0.69 times the odds of 
self-response, non-nursing home response over those who did consent previously, but not 
significant at the 0.0021 level. For the biomeasure eligibility model, non-consent results in 0.40 
times the odds of being a biomeasure eligible respondent in the subsequent E-FTF wave. The 
only notable change in the odds ratios is weekly religious service attendance, which is no longer 
significant using the Bonferroni adjustment, holding previous DBS consent constant. 
 Unsurprisingly the inclusion of previous DBS consent is significant in predicting future 
DBS consent. Previous consent refusals result in nearly 0.12 times the odds of consenting in 
2010 compared to previous consenters or, conversely, previous consenters have over eight times 
the odds of consenting over non-consenters. Looking at the demographic and health variables, a 
number of coefficients and standard errors change with the inclusion of previous non-consent 
given the strong correlated nature of the new variables and the outcome. The significant effect of 
chronic conditions is no longer present. More minor shifts in parameter estimates are seen for 
non-Hispanic blacks, church attendance, mental status score, and little/no mildly vigorous 
activity. 
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 The final evaluation of the two-year model is assessing the assumption of parallel slopes. 
Most of the variables that were significant predictors of multiple eligibility states had some 
evidence that the assumption of parallel slopes was violated (e.g., age, non-Hispanic black, 
cognition, chronic conditions). For age, there is a consistent negative effect (i.e., odds ratios less 
than 1) supporting the notion that biomeasure samples are less representative of the oldest of 
older adults. This pattern also matches with the cognitive measures, which are highly associated 
with age, which indicate an over representation of the most cognitively robust respondents. Self-
rated health also does this to a limited extent consistently removing the poorest in self-rated 
health. For non-Hispanic Blacks there is a consistent positive effect across the first four models 
until the final consent model where there is a negative effect though the parallel slopes test is not 
significant given the multiple-comparisons correction. This breakdown suggest that subsequent 
sources of non-observation may over-represent non-Hispanic blacks and that while they may be 
less likely to consent to DBS collection, this effect may not be as detrimental as it first appears. 
Current employment, mildly vigorous activity, and functional limitations also see weak 
violations of the parallel slopes assumption, but only a single model contains a significant odds 
ratio – employment and functional limitations in the mortality model and physical activity (1-3 
times per month) for the nursing home, proxy-respondent model. 
 When including the previous sources of non-observation, there are some minor changes 
to the parallel slope assumptions in terms of level of statistical significance. Previous consent 
refusal appears as significantly deviating from the parallel slopes assumption with the 
significance across the five models strongly in the negative direction given differing degrees of 
reduced odds ratios in particular for the response, biomeasure eligibility, and consent models. 
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Table 2-7a. Continuation ratio logit model odds ratios predicting sequential 2010 eligibility states based on 2006 respondent and 
household characteristics 
  Alive vs. Deceased 
Respondent vs. 
Non-respondent 











Respondent characteristics       
Age (years) 0.94 (0.004)**** 1.00 (0.007)  0.93 (0.007)**** 1.01 (0.008)  1.00 (0.005)  **** 
Female 1.58 (0.137)**** 0.96 (0.114)  1.11 (0.154)  0.86 (0.104)  0.98 (0.085)  *** 
Education (ref: less than HS)       
High school 0.97 (0.091)  1.01 (0.152)  0.68 (0.104)* 1.13 (0.174)  0.98 (0.105)    
Some college 1.14 (0.286)  0.69 (0.185)  0.59 (0.217)  1.21 (0.364)  1.29 (0.291)    
College graduate 1.03 (0.137)  0.83 (0.153)  0.64 (0.139)* 0.92 (0.173)  0.88 (0.120)    
Race/ethnicity (ref: Non-Hispanic Other)      
Non-Hispanic black 1.44 (0.172)** 1.27 (0.224)  2.02 (0.389)**** 1.63 (0.325)* 0.72 (0.084)** **** 
Hispanic (English interview) 1.17 (0.238)  1.07 (0.292)  0.66 (0.174)  0.96 (0.264)  0.69 (0.128)*   
Hispanic (Spanish interview) 1.78 (0.360)** 0.89 (0.236)  1.42 (0.426)  0.58 (0.146)* 1.44 (0.361)  ** 
Currently employed 1.55 (0.205)*** 1.15 (0.160)  1.04 (0.200)  0.83 (0.111)  1.20 (0.118)  * 
Attends church at least 1/wk 1.39 (0.114)**** 1.02 (0.116)  1.07 (0.136)  1.46 (0.174)*** 1.25 (0.103)**   
Household characteristics       
Impediments to entry 1.14 (0.138)  1.35 (0.271)  1.34 (0.270)  0.92 (0.165)  0.91 (0.118)    
Own home 1.21 (0.119)  0.87 (0.140)  1.11 (0.178)  1.27 (0.191)  0.95 (0.107)    
Rural 1.18 (0.103)  1.31 (0.169)* 1.13 (0.156)  0.96 (0.119)  0.96 (0.085)    
Another eligible HH member 1.25 (0.113)* 1.07 (0.138)  0.94 (0.136)  1.00 (0.132)  1.13 (0.105)    
Cognition and health       
Word recall score 1.08 (0.015)**** 1.05 (0.021)* 1.20 (0.027)**** 1.01 (0.021)  0.98 (0.014)  **** 
Mental status score 1.05 (0.016)*** 1.08 (0.024)*** 1.22 (0.029)**** 1.04 (0.026)  1.06 (0.019)** **** 
Self-rated health (ref: Excellent)       
     Very good 0.79 (0.171)  0.92 (0.166)  0.81 (0.221)  0.72 (0.144)  0.97 (0.132)    
     Good 0.50 (0.104)*** 1.00 (0.191)  0.82 (0.225)  0.60 (0.124)* 0.91 (0.129)    
     Fair/Poor 0.36 (0.077)**** 0.81 (0.177)  0.55 (0.158)* 0.80 (0.196)  0.92 (0.151)  ** 
Mildly vigorous activity (ref: At least 1/wk)      
     1-3 times/month 1.14 (0.173)  0.92 (0.200)  0.51 (0.102)*** 1.21 (0.307)  0.77 (0.118)  * 
     Hardly ever/never 0.55 (0.057)**** 0.97 (0.213)  0.65 (0.117)* 0.93 (0.208)  0.67 (0.099)**   
No. of functional limitations 0.96 (0.010)**** 1.03 (0.021)  0.99 (0.018)  0.99 (0.020)  0.98 (0.013)  * 
No. of chronic conditions 0.88 (0.028)**** 1.18 (0.061)*** 0.97 (0.050)  1.09 (0.057)  1.10 (0.040)** **** 
Note. The parallel slopes test is a Wald chi-square test with 4 degrees of freedom. HS = high school. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Recommended Bonferroni correction is α = 0.0021 and are bolded.  
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Table 2-7b. Continuation ratio logit model odds ratios predicting sequential 2010 eligibility states based on 2006 respondent and 
household characteristics and 2006 dried blood spot consent status 
  Alive vs. Deceased 
Respondent vs. 
Non-respondent 











Respondent characteristics       
Age (years) 0.94 (0.004)**** 1.00 (0.007)  0.93 (0.007)**** 1.01 (0.008)  0.99 (0.006)  **** 
Female 1.58 (0.137)**** 0.94 (0.113)  1.09 (0.152)  0.84 (0.103)  0.91 (0.085)  **** 
Education (ref: less than HS)       
High school 0.97 (0.092)  1.02 (0.154)  0.68 (0.104)* 1.13 (0.175)  1.02 (0.118)    
Some college 1.15 (0.287)  0.71 (0.190)  0.59 (0.214)  1.20 (0.365)  1.47 (0.355)    
College graduate 1.04 (0.138)  0.85 (0.158)  0.64 (0.139)* 0.93 (0.177)  0.94 (0.137)    
Race/ethnicity (ref: Non-Hispanic Other)      
Non-Hispanic black 1.45 (0.173)** 1.37 (0.244)  2.05 (0.395)**** 1.78 (0.358)** 0.88 (0.111)  ** 
Hispanic (English interview) 1.18 (0.239)  1.09 (0.300)  0.67 (0.178)  0.96 (0.263)  0.66 (0.132)*   
Hispanic (Spanish interview) 1.79 (0.365)** 0.90 (0.239)  1.45 (0.440)  0.56 (0.142)* 1.46 (0.387)  ** 
Currently employed 1.55 (0.204)*** 1.13 (0.157)  1.03 (0.198)  0.79 (0.107)  1.10 (0.116)  * 
Attends church at least 1/wk 1.38 (0.113)**** 0.99 (0.113)  1.06 (0.135)  1.44 (0.173)** 1.23 (0.109)*   
Household characteristics       
Impediments to entry 1.14 (0.139)  1.41 (0.285)  1.38 (0.279)  0.95 (0.171)  1.00 (0.140)    
Own home 1.21 (0.119)  0.88 (0.142)  1.11 (0.179)  1.30 (0.196)  1.00 (0.121)    
Rural 1.17 (0.103)  1.30 (0.168)* 1.13 (0.157)  0.93 (0.117)  0.90 (0.085)    
Another eligible HH member 1.24 (0.112)* 1.04 (0.135)  0.93 (0.135)  0.97 (0.129)  1.08 (0.107)    
Cognition and health       
Word recall score 1.08 (0.015)**** 1.05 (0.021)* 1.20 (0.027)**** 1.01 (0.021)  0.98 (0.015)  **** 
Mental status score 1.05 (0.016)** 1.07 (0.024)*** 1.22 (0.029)**** 1.04 (0.026)  1.05 (0.020)* **** 
Self-rated health (ref: Excellent)       
     Very good 0.79 (0.172)  0.92 (0.168)  0.81 (0.222)  0.73 (0.147)  1.00 (0.145)    
     Good 0.50 (0.105)*** 1.01 (0.195)  0.82 (0.225)  0.62 (0.127)* 0.95 (0.144)    
     Fair/Poor 0.36 (0.077)**** 0.83 (0.184)  0.56 (0.161)* 0.83 (0.205)  1.03 (0.182)  ** 
Mildly vigorous activity (ref: At least 1/wk)      
     1-3 times/month 1.15 (0.175)  0.97 (0.213)  0.51 (0.103)*** 1.26 (0.321)  0.84 (0.139)  * 
     Hardly ever/never 0.55 (0.058)**** 1.02 (0.224)  0.66 (0.119)* 0.98 (0.222)  0.71 (0.114)* * 
No. of functional limitations 0.96 (0.010)**** 1.03 (0.021)  0.99 (0.018)  1.00 (0.020)  0.99 (0.015)  * 
No. of chronic conditions 0.87 (0.028)**** 1.17 (0.061)** 0.97 (0.050)  1.08 (0.056)  1.08 (0.042)* **** 
Previous non-observation source       
DBS consent refusal 0.85 (0.081)  0.42 (0.051)**** 0.69 (0.102)* 0.40 (0.050)**** 0.12 (0.011)**** **** 
Note. The parallel slopes test is a Wald chi-square test with 4 degrees of freedom. HS = high school. DBS = dried blood spot. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Recommended Bonferroni correction is α = 0.0021 and are bolded. 
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2.4.3 Three-wave continuation ratio model 
 This section expands the earlier analyses to look at predicting the third wave E-FTF 
eligibility state for collecting biomeasures. Two nested models are tested here. The first 
examines the relationship between the five eligibility states and wave one characteristics 
including respondent demographics, household characteristics, and cognitive and physical health 
as well as the change indicators for those characteristics (Table 2-8a). The full model includes 
the non-observation source indicators for the first (non-consent vs. consent) and the second wave 
(nonrespondent, nursing home or proxy respondent, biomeasure ineligible, non-consent; see 
Table 2-8b). Again, results deemed statistically significant are defined using a Bonferroni 
adjusted critical value, but results of interest that may not conservative enough to test the null 
hypothesis are noted. 
 There are a number of similarities between the demographic characteristics in the two-
wave model and three-wave model for mortality including significant odds ratios for age, gender, 
Hispanic ethnicity, religious activity, as well as cognitive and physical health measures. Effects 
for non-Hispanics blacks and current employment are not seen in the three-wave model. While 
non-Hispanic black respondents were significantly more likely to survive from 2006 to 2010, this 
effect is not present for 2014. However the odds ratio for Hispanics interviewed in either English 
or Spanish increases dramatically (1.17 to 1.93 for English interviewed Hispanics and 1.78 to 
2.78 for Spanish interviewed Hispanics) suggesting that Hispanic respondents are significantly 
more likely to survive into the third E-FTF wave than non-Hispanic other respondents.  
 Adding to these already significant health and cognition predictors, many of the change 
measures and indicators are also significant. Both change in word recall and mental status have 
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coefficients nearly identical to their baseline counterparts suggesting that the change in these 
cognition scores does not have a differential effect on predicting mortality, though the latter is 
only significant at α = 0.05. Both self-rated health change indicators have effects on predicting 
E-FTF wave three mortality with a decline in self-rated health resulting in about 0.60 times the 
odds of survival (significant with the Bonferroni adjustment) and an improved rating resulting in 
1.35 times the odds of survival controlling for baseline self-rated health (only significant at a 
0.05 alpha level). Respondents who increased their mildly vigorous activity between 2006 and 
2010 were unexpectedly less likely to survive into 2014 having 0.55 times the odds of surviving 
compared to those with no change in activity, while those who decreased their level of activity 
saw no significant change in their odds of survival. An increase in the number of functional 
limitations has a similar effect as the baseline level of functional limitations (OR = 0.92), but a 
similar effect is not seen for change in the number of chronic conditions. Changes in household 
characteristics seemed to have no effect on predicting mortality into the third E-FTF wave.  
After introducing the non-observation sources from the previous two waves into the 
three-wave model (see Table 2-8b), there are minor shifts in the odds ratios of the respondent 
and household characteristics for the mortality model. The two-wave model showed previous 
non-consent as a significant predictor of mortality. With the 2010 non-observation sources, 
nonrespondents have half the odds of being alive compared to previous DBS consenters and 
proxy- or nursing home respondents have 0.43 times the odds of survival compared to previous 
consenters (an effect clearly observed in Figure 2-5).  
 Considering the three-wave model for nonresponse, those with some college have half 
the odds of responding in the third E-FTF wave compared to those with less than a high school 
education. There is no difference for high school graduates or college graduates. Non-Hispanic 
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black respondents have 1.52 times the odds of responding, but not accounting for the Bonferroni 
correction at 0.0011. No baseline household characteristics are significant in the three-wave 
response model, but a couple of household change indicators are at the 0.05 level. While 
changing residence alone had no impact on response, the introduction of an impediment to entry 
led to increased odds of obtaining an interview. However, this effect disappears with the addition 
of wave two non-observation sources in the model, reducing the odds ratio from 2.48 to 1.65. 
Similarly the end of employment in the second E-FTF wave also increases the odds of obtaining 
an interview (OR = 1.65) though this effect also disappears with the addition of wave two 
sources of non-observation (OR = 0.98).  
 Those with more chronic conditions are more likely to respond as in the two-wave model. 
The remaining health factors are only significant at the 0.05 level. The mental status score has an 
effect on predicting survey response, with each additional point of the scale resulting in 1.06 
times the odds of responding. Unlike the two-wave model, there is no effect on response from 
the baseline word recall score. Respondents with the lowest baseline self-rated health were less 
likely to respond compared to those with “excellent” self-rated health. Those who exhibit less 
frequent (1-3 times/month) baseline mildly vigorous activity are also less likely to respond (OR 
= 0.52). However, all of these effects completely (or nearly) disappear with the addition of wave 
two sources of non-observation. The two-wave models had self-rated health, mildly vigorous 
activity, and chronic conditions strongly associated with the nonresponse and nursing 
home/proxy states and may explain the removal of these effects with the introduction of the 
wave two sources of non-observation. Many of the physical health change indicators are 
positively associated with response in this three-wave model. Both declining and improving self-
rated health seem to result in odds ratios greater than 1 as does both declining and increasing 
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activity levels. An increase in the number of chronic conditions has a higher odds ratio than the 
baseline level. But like previous variables in the three-wave response model, all of these effects 
disappear or are reduced with the inclusion of wave two sources of non-observation. 
 Focusing on the non-observation sources related to response, nonrespondents in the most 
recent wave had only 0.03 the odds responding in the current wave compared to previous 
consenters holding all other demographic, household, and health factors constant. This translates 
into previous nonrespondents having over 37 times the odds of remaining a nonrespondent in the 
future wave compared to those who consented to DBS in the previous wave. This pattern is 
consistent with previous research and with what was seen in the eligibility outcome evaluation 
(see Figure 2-5). Both forms of biomeasure ineligibility (health-related and non-health-related) 
have about a quarter the odds of responding compared to previous consenters. Previous wave 
non-consenters had half the odds of responding compared to previous DBS consenters, holding 
all else constant. 
 The transition from the two-wave model to the three-wave model did little to change 
many of the significant effects for the non-nursing home, self-response model in relation to 
demographic and household characteristics. Age and education all maintained similar 
coefficients to the two-wave model though effects of race/ethnicity, specifically for non-Hispanic 
blacks, reduced from an odds of 2.02 to 1.57 of being a self-respondent not living in a nursing 
home. While the three-year model does show females are more likely to need a proxy-respondent 
or be in a nursing home, this effect is weak and ultimately removed with the introduction of the 
previous non-observation source indicators. Another temporary but weak effect is having another 
eligible study member in the household, but again dissipates with the inclusion of non-
observation sources. 
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 Cognition continues to play a large role in the proxy/nursing home eligibility at E-FTF 
wave three. Both coefficients are very similar to their two-wave counterparts with higher 
baseline word recall and mental status scores resulting in higher chances of being a non-nursing 
home, self-respondent. The change in both cognition scores between wave one and two have 
similar magnitudes to their baseline counterparts. For physical health, no mildly vigorous activity 
and the number of functional limitations each display reduced odds in completing a non-nursing 
home self-respondent interview, though these effects disappear with the inclusion of non-
observation sources.  
 Nonrespondents in the previous wave have less than 0.10 odds of being a self-respondent 
not living in a nursing home compared to previous consenters. Nursing home or proxy-
respondent in the previous wave had 0.02 odds of switching their status in the next wave 
compared to previous consenters (Figure 2-5). Previous wave non-health-related ineligibility and 
refusal to DBS collection have no effect on this state. 
 Non-observation related to telephone interview or partial interviews again show few 
significant predictors. Age increases the odds of a biomeasure eligible interview, but only at the 
0.05 level. The number of baseline chronic conditions at the initial E-FTF has a positive effect on 
completing a biomeasure eligible interview at the third E-FTF wave (α = 0.05) though there 
seems to be no relationship with a change in the number of chronic conditions from wave one to 
wave two.  
 Previous nonrespondents have one-tenth the odds of being biomeasure eligible in the 
upcoming wave relative to previous DBS consenters. Previous biomeasure ineligibility due to 
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non-health factors has 0.17 odds of being eligible in the third wave relative to previous DBS 
consenters. 
 College graduates have only half the odds of wave 3 consenting to DBS collection 
compared to those who did not complete high school. While the two-wave model suggested an 
effect for active churchgoers, the three-wave model does not show a significant effect though the 
odds ratio remains the same. Non-Hispanic black respondents have about 0.60 odds of 
consenting in the third wave compared to other non-Hispanic respondents before the inclusion of 
previous non-observation source measures. Baseline rural respondents are significantly more 
likely to consent to DBS collection than urban respondents when controlling for previous source 
of non-observation (OR = 1.56). Respondents who no longer owned their home between 2006 
and 2010 had 0.62 times the odds of consenting to DBS in 2014, but the standard error greatly 
increases with the non-observation sources removing the small effect at α = 0.05. The number of 
chronic conditions increases the odds of DBS consent in the three-wave-model (OR = 1.24) 
though the effect is weakened when previous wave non-observation source indicators are 
included (OR = 1.16). Mental status score and little to no mildly vigorous activity also see 
temporary weak significant effects before the inclusion of previous wave non-observation source 
indicators. 
 Like in the two-wave model, consent to DBS collection in 2006 has a large effect on 
consent in 2014. Consent refusal in 2006 has 0.17 odds of consent in 2014 while consent refusal 
in 2010 has 0.10 odds compared to previous consenters. Nonresponse and non-health-related 
ineligibility in the previous wave all result in reduced odds of consent with each having a similar 
0.30 odds compared to previous consenters, though the former is not significant with the 
multiple-comparisons adjustment. 
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Table 2-8a. Three-wave continuation ratio logit model odds ratios predicting sequential 2014 eligibility states based on 2006 and 

















Respondent characteristics       
Age (years) 0.93 (0.005)**** 0.99 (0.007)  0.93 (0.008)**** 1.02 (0.010)* 1.00 (0.008)  **** 
Female 1.61 (0.149)**** 1.16 (0.117)  0.73 (0.112)* 0.88 (0.130)  1.00 (0.119)  **** 
Education (ref: less than HS)       
High school 0.93 (0.095)  0.98 (0.125)  0.68 (0.114)* 1.08 (0.198)  0.69 (0.113)*   
Some college 0.73 (0.163)  0.50 (0.103)*** 0.87 (0.374)  2.11 (0.895)  1.03 (0.327)  * 
College graduate 0.98 (0.135)  0.91 (0.144)  0.55 (0.123)** 1.15 (0.266)  0.49 (0.093)**** ** 
Race/ethnicity (ref: Non-Hispanic Other)      
Non-Hispanic black 1.24 (0.151)  1.52 (0.239)** 1.57 (0.303)* 1.37 (0.305)  0.62 (0.094)*** *** 
Hispanic (English interview) 1.93 (0.469)** 1.04 (0.228)  1.17 (0.367)  1.61 (0.608)  0.88 (0.229)    
Hispanic (Spanish interview) 2.78 (0.659)**** 0.96 (0.218)  1.65 (0.539)  0.79 (0.252)  2.06 (0.804)  ** 
Currently employed 1.23 (0.198)  1.07 (0.135)  0.91 (0.218)  0.81 (0.143)  1.19 (0.179)    
Attends church at least 1/wk 1.19 (0.099)* 1.05 (0.098)  1.04 (0.135)  1.19 (0.164)  1.23 (0.137)    
Baseline household characteristics       
Impediments to entry 1.08 (0.163)  0.99 (0.171)  1.32 (0.335)  1.02 (0.283)  1.00 (0.208)    
Own home 1.22 (0.144)  1.14 (0.162)  1.29 (0.243)  0.91 (0.198)  0.87 (0.155)    
Rural 0.99 (0.090)  0.88 (0.088)  1.07 (0.156)  0.80 (0.114)  1.56 (0.206)*** ** 
Another eligible HH member 0.99 (0.099)  1.22 (0.134)  0.72 (0.116)* 1.27 (0.202)  1.05 (0.136)    
Baseline cognition and health       
Word recall score 1.11 (0.019)**** 1.03 (0.020)  1.18 (0.033)**** 1.01 (0.029)  1.00 (0.023)  **** 
Mental status score 1.04 (0.020)* 1.06 (0.023)** 1.19 (0.035)**** 1.03 (0.035)  1.06 (0.029)* ** 
Self-rated health (ref: Excellent)       
     Very good 0.72 (0.130)  0.93 (0.138)  1.27 (0.328)  0.71 (0.159)  0.76 (0.134)    
     Good 0.58 (0.107)** 0.80 (0.131)  0.68 (0.176)  0.66 (0.166)  0.77 (0.154)    
     Fair/Poor 0.37 (0.077)**** 0.66 (0.135)* 0.77 (0.239)  0.54 (0.171)  0.67 (0.170)    
Mildly vigorous activity (ref: At least 1/wk)      
     1-3 times/month 1.00 (0.167)  0.52 (0.111)** 0.63 (0.166)  1.02 (0.406)  0.72 (0.184)    
     Hardly ever/never 0.49 (0.071)**** 0.78 (0.176)  0.54 (0.139)* 1.48 (0.666)  0.55 (0.142)*   
No. of functional limitations 0.94 (0.013)**** 1.03 (0.019)  0.95 (0.021)* 1.01 (0.028)  0.96 (0.020)  ** 
No. of chronic conditions 0.87 (0.031)**** 1.22 (0.055)**** 1.02 (0.060)  1.22 (0.084)** 1.24 (0.068)**** **** 
     (continued) 
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Table 2-8a. Three-wave continuation ratio logit model odds ratios predicting sequential 2014 eligibility states based on 2006 and 

















Change in household characteristics       
Change in current work (ref: baseline)       
Now currently working 1.40 (0.538)  1.88 (0.667)  0.89 (0.432)  1.29 (0.561)  1.06 (0.339)    
No longer working 0.69 (0.131)  1.65 (0.287)** 1.12 (0.329)  1.39 (0.295)  1.05 (0.187)  * 
Moved residences 1.15 (0.325)  2.02 (0.877)  0.61 (0.220)  0.78 (0.325)  0.86 (0.306)    
Change impediment (ref: baseline)       
New impediment 0.93 (0.186)  2.48 (0.922)* 0.74 (0.225)  1.20 (0.486)  1.05 (0.303)    
No longer impediment 1.34 (0.365)  1.16 (0.370)  0.93 (0.393)  1.02 (0.481)  1.03 (0.363)    
Change rural (ref: baseline)       
Move to rural residence 1.67 (0.661)  2.84 (2.077)  0.75 (0.349)  0.45 (0.206)  1.42 (0.763)    
Move to urban residence 1.22 (0.481)  0.63 (0.254)  0.65 (0.351)  3.01 (3.094)  3.81 (3.909)    
Change home ownership (ref: baseline)       
Now own home 1.24 (0.299)  1.63 (0.536)  0.71 (0.237)  1.19 (0.516)  1.21 (0.442)    
No longer own home 0.83 (0.138)  1.00 (0.236)  0.83 (0.219)  0.86 (0.266)  0.62 (0.145)*   
Change in HH member status (ref: baseline)      
Now living w/ eligible HH member 0.93 (0.379)  0.97 (0.380)  4.07 (4.370)  2.21 (1.619)  2.33 (1.416)    
No longer living w/ HH member 1.06 (0.169)  0.81 (0.147)  1.39 (0.356)  0.88 (0.236)  1.22 (0.288)    
Change in cognition and health       
Change in word recall score 1.11 (0.018)**** 1.01 (0.018)  1.11 (0.028)**** 1.05 (0.027)  1.00 (0.021)  **** 
Change in mental status score 1.04 (0.021)* 1.02 (0.027)  1.17 (0.037)**** 1.06 (0.043)  1.05 (0.034)  * 
Change in self-rated health (ref: baseline)      
     Declined 0.59 (0.064)**** 1.50 (0.190)*** 0.74 (0.128)  0.96 (0.164)  0.85 (0.112)  **** 
     Improved 1.35 (0.157)* 1.69 (0.224)**** 0.91 (0.156)  0.97 (0.174)  1.15 (0.180)  * 
Change in mildly vigorous activity (ref: baseline)      
     Declined 1.03 (0.186)  2.33 (0.614)*** 1.94 (0.650)* 0.96 (0.419)  1.32 (0.369)    
     Improved 0.55 (0.054)**** 2.01 (0.336)**** 0.42 (0.064)**** 1.27 (0.287)  0.89 (0.144)  **** 
Change in no. functional limitations 0.92 (0.011)**** 1.04 (0.021)  0.93 (0.019)**** 1.00 (0.028)  0.98 (0.021)  **** 
Change in no. chronic conditions 0.95 (0.046)  1.42 (0.095)**** 1.15 (0.092)  1.08 (0.102)  1.06 (0.079)  *** 
Note. The parallel slopes test is a Wald chi-square test with 4 degrees of freedom. HS = high school. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Recommended Bonferroni correction is α = 0.0011 and are bolded.  
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Table 2-8b. Three-wave continuation ratio logit model odds ratios predicting sequential 2014 eligibility states based on 2006 and 

















Respondent characteristics       
Age (years) 0.93 (0.005)**** 1.00 (0.007)  0.93 (0.009)**** 1.02 (0.011)* 0.99 (0.009)  **** 
Female 1.65 (0.153)**** 1.14 (0.128)  0.72 (0.120)  0.90 (0.136)  0.95 (0.132)  **** 
Education (ref: less than HS)       
High school 0.96 (0.097)  0.98 (0.138)  0.69 (0.129)* 1.04 (0.198)  0.74 (0.139)    
Some college 0.76 (0.170)  0.49 (0.113)** 1.01 (0.482)  2.11 (0.915)  1.20 (0.437)  * 
College graduate 1.04 (0.144)  0.98 (0.170)  0.60 (0.148)* 1.19 (0.281)  0.48 (0.107)*** * 
Race/ethnicity (ref: Non-Hispanic Other)      
Non-Hispanic black 1.18 (0.146)  1.57 (0.272)** 1.50 (0.326)  1.41 (0.324)  0.76 (0.137)  * 
Hispanic (English interview) 2.00 (0.490)** 1.18 (0.293)  1.51 (0.547)  1.86 (0.724)  1.07 (0.317)    
Hispanic (Spanish interview) 2.73 (0.653)**** 1.05 (0.273)  1.46 (0.517)  1.00 (0.336)  2.08 (0.865)  * 
Currently employed 1.28 (0.208)  1.19 (0.171)  1.05 (0.271)  0.85 (0.155)  1.01 (0.177)    
Attends church at least 1/wk 1.19 (0.100)* 0.99 (0.105)  1.04 (0.152)  1.14 (0.161)  1.18 (0.153)    
Baseline household characteristics       
Impediments to entry 1.08 (0.164)  0.97 (0.189)  1.26 (0.351)  1.01 (0.285)  1.27 (0.311)    
Own home 1.26 (0.150)  1.09 (0.173)  1.49 (0.306)  0.87 (0.192)  0.96 (0.198)    
Rural 0.98 (0.089)  0.80 (0.090)  1.05 (0.169)  0.79 (0.116)  1.61 (0.246)** ** 
Another eligible HH member 0.98 (0.099)  1.28 (0.158)* 0.73 (0.129)  1.33 (0.216)  0.85 (0.131)  * 
Baseline cognition and health       
Word recall score 1.09 (0.019)**** 1.02 (0.021)  1.15 (0.035)**** 1.00 (0.029)  1.00 (0.026)  *** 
Mental status score 1.02 (0.020)  1.02 (0.024)  1.15 (0.037)**** 1.01 (0.036)  1.06 (0.034)  * 
Self-rated health (ref: Excellent)       
     Very good 0.72 (0.131)  0.97 (0.162)  1.26 (0.349)  0.73 (0.167)  0.91 (0.187)    
     Good 0.57 (0.107)** 0.90 (0.166)  0.66 (0.186)  0.69 (0.176)  0.95 (0.218)    
     Fair/Poor 0.37 (0.078)**** 0.74 (0.171)  0.87 (0.291)  0.56 (0.179)  0.89 (0.262)    
Mildly vigorous activity (ref: At least 1/wk)      
     1-3 times/month 1.10 (0.187)  0.81 (0.201)  0.78 (0.232)  1.11 (0.444)  1.17 (0.351)    
     Hardly ever/never 0.53 (0.079)**** 1.26 (0.322)  1.01 (0.307)  1.76 (0.832)  0.69 (0.212)  ** 
No. of functional limitations 0.95 (0.013)**** 1.03 (0.021)  0.96 (0.024)  1.01 (0.029)  0.97 (0.023)  * 
No. of chronic conditions 0.86 (0.031)**** 1.11 (0.056)* 0.99 (0.066)  1.20 (0.086)* 1.16 (0.074)* **** 
     (continued) 
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Table 2-8b. Three-wave continuation ratio logit model odds ratios predicting sequential 2014 eligibility states based on 2006 and 


















Change in household characteristics       
Change in current work (ref: baseline)       
Now currently working 1.32 (0.509)  1.17 (0.426)  0.78 (0.402)  1.17 (0.514)  0.82 (0.306)    
No longer working 0.64 (0.122)* 0.98 (0.181)  0.80 (0.251)  1.29 (0.282)  1.13 (0.237)    
Moved residences 1.24 (0.362)  1.76 (0.780)  0.57 (0.240)  0.79 (0.333)  0.94 (0.390)    
Change impediment (ref: baseline)       
New impediment 0.93 (0.188)  1.65 (0.619)  0.73 (0.247)  0.96 (0.390)  0.83 (0.277)    
No longer impediment 1.31 (0.361)  0.81 (0.272)  1.20 (0.616)  0.99 (0.476)  0.74 (0.301)    
Change rural (ref: baseline)       
Move to rural residence 1.72 (0.686)  2.59 (1.908)  0.85 (0.467)  0.47 (0.224)  1.19 (0.701)    
Move to urban residence 1.27 (0.510)  0.49 (0.200)  0.86 (0.546)  2.74 (2.841)  2.24 (2.348)    
Change home ownership (ref: baseline)       
Now own home 1.50 (0.377)  1.37 (0.468)  1.28 (0.530)  1.14 (0.505)  1.87 (0.785)    
No longer own home 0.83 (0.140)  0.78 (0.189)  0.72 (0.215)  0.93 (0.299)  0.63 (0.174)    
Change in HH member status (ref: baseline)      
Now living w/ eligible HH member 0.88 (0.362)  0.65 (0.259)  2.31 (2.411)  2.20 (1.632)  1.82 (1.231)    
No longer living w/ HH member 1.08 (0.176)  0.58 (0.108)** 1.94 (0.629)* 0.84 (0.229)  1.35 (0.370)  ** 
Change in cognition and health       
Change in word recall score 1.11 (0.018)**** 1.03 (0.021)  1.11 (0.031)**** 1.05 (0.027)* 0.99 (0.024)  *** 
Change in mental status score 1.04 (0.021)* 1.04 (0.032)  1.23 (0.046)**** 1.07 (0.045)  1.06 (0.039)  ** 
Change in self-rated health (ref: baseline)      
     Declined 0.57 (0.064)**** 0.88 (0.124)  0.74 (0.144)  0.88 (0.156)  0.90 (0.139)    
     Improved 1.32 (0.157)* 0.86 (0.125)  0.92 (0.178)  0.84 (0.156)  1.10 (0.199)    
Change in mildly vigorous activity (ref: baseline)      
     Declined 0.91 (0.167)  0.96 (0.275)  1.20 (0.441)  0.74 (0.335)  1.34 (0.446)    
     Improved 0.57 (0.058)**** 1.48 (0.262)* 0.45 (0.076)**** 1.23 (0.284)  0.88 (0.163)  **** 
Change in no. functional limitations 0.93 (0.012)**** 1.01 (0.022)  0.97 (0.023)  0.99 (0.029)  0.97 (0.024)  * 
Change in no. chronic conditions 0.92 (0.045)  1.15 (0.086)  1.02 (0.092)  1.05 (0.103)  1.01 (0.086)    
     (continued) 
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Table 2-8b. Three-wave continuation ratio logit model odds ratios predicting sequential 2014 eligibility states based on 2006 and 

















Wave 1 non-observation source       
DBS consent refusal 0.96 (0.105)  0.80 (0.101)  1.07 (0.207)  0.71 (0.125)  0.17 (0.022)**** **** 
Wave 2 non-observation source (ref: DBS consent)      
Nonrespondent 0.52 (0.098)*** 0.03 (0.004)**** 0.07 (0.021)**** 0.10 (0.031)**** 0.30 (0.123)** **** 
Non-nursing home/proxy respondent 0.43 (0.067)**** 0.24 (0.058)**** 0.02 (0.005)**** 1.44 (1.499)  0.33 (0.187)  **** 
Biomeasure ineligible respondent 0.98 (0.194)  0.23 (0.038)**** 0.66 (0.213)  0.17 (0.033)**** 0.27 (0.063)**** **** 
DBS consent refusal 0.88 (0.116)  0.50 (0.079)**** 0.67 (0.151)  0.87 (0.198)  0.10 (0.014)**** **** 
Note. The parallel slopes test is a Wald chi-square test with 4 degrees of freedom. HS = high school. DBS = dried blood spot. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Recommended Bonferroni correction is α = 0.0011 and are bolded. 
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2.5 Results Part 2 – Bias evaluation across eligibility states 
With a better understanding of the factors that predict various eligibility states, this paper 
now shifts focus to the impact that each source of non-observation has on the biomarker 
outcomes. Section 2.5.1 will look at the overall distribution of each biomarker outcome based on 
key percentiles. Section 2.5.2 will look at the difference in means across each eligibility state 
followed by the difference in high or at risk proportions in Section 2.5.3. An evaluation of 
potential confounding factors follows in Section 2.5.4. Finally, in Section 2.5.5 some of the 
assumptions from these analyses are evaluated. 
2.5.1 Distributional changes 
Looking first at the weighted percentiles for each biomarker outcome, the percentiles 
examined change very little for each eligibility state (see Table 2-9). Change is primarily 
observed in the higher percentiles, especially in the 90th, 95th, and 99th percentiles where those 
values were pulled closer to the median though there is limited substantive difference. This is 
more likely to impact the at risk proportions for the outcomes (the one exception being HDL 
which has a left tail at risk value). Cystatin C saw some of the largest changes with the upper 
percentiles of (1.50, 1.76, 2.74) for the full sample shifting down to (1.43, 1.63, 2.28) for the 
living sample, and finally down to (1.37, 1.63, 2.21) for the consenting sample. CRP saw a 
similar drop for mortality, but minimal change in the following states. Only two biomarkers saw 
the median value shift across the successive sources of non-observation: total cholesterol and 
CRP.  
These changes suggest that means and proportions are most likely to shrink as the 
extreme values in the upper tails are removed. Figures 2-7a through 2-7e also show how there is 
very little movement in the distributions with the most notable (though small) changes in 
Cystatin C and CRP consistent with the numerical evaluation.  
71 
Table 2-9. Percentiles of five dried blood spot assays by 2010 eligibility state 






(Q3) 90th 95th 99th 
HbA1c          
Full sample 4.65 4.88 4.99 5.22 5.57 6.03 6.72 7.53 10.18 
Alive in 2010 4.65 4.88 4.99 5.22 5.57 6.03 6.61 7.30 9.95 
Respondent in 2010 4.65 4.88 4.99 5.22 5.57 6.03 6.61 7.30 9.95 
Self-R in 2010 4.65 4.88 4.99 5.22 5.57 6.03 6.61 7.30 9.95 
BioElig-R in 2010 4.65 4.88 4.99 5.22 5.57 6.03 6.61 7.30 10.16 
Consent 2010 4.65 4.88 4.99 5.22 5.57 6.03 6.61 7.18 9.95 
HDL          
Full sample 25.28 32.00 35.36 42.20 52.16 64.48 76.80 84.64 98.08 
Alive in 2010 26.40 32.00 35.36 43.20 52.16 64.48 77.92 84.64 98.08 
Respondent in 2010 26.40 32.00 35.36 43.20 52.16 64.48 77.92 84.64 98.08 
Self-R in 2010 26.40 32.00 35.36 43.20 52.16 65.60 77.92 84.64 98.08 
BioElig-R in 2010 26.40 32.00 35.36 43.20 52.16 65.60 77.92 85.76 98.08 
Consent 2010 26.40 32.00 35.36 43.20 52.16 65.60 77.92 85.76 98.08 
Total cholesterol          
Full sample 126.56 142.16 151.53 171.30 198.35 229.56 262.86 282.63 306.56 
Alive in 2010 126.56 143.20 153.61 172.34 200.43 230.61 263.90 283.67 306.56 
Respondent in 2010 126.56 142.16 153.61 172.34 199.39 230.61 263.90 283.67 306.56 
Self-R in 2010 126.56 142.16 153.61 172.34 199.39 230.61 263.90 283.67 306.56 
BioElig-R in 2010 126.56 142.16 152.83 172.34 200.43 230.61 264.94 283.67 306.56 
Consent 2010 127.60 143.20 153.61 172.34 200.43 230.61 264.94 283.67 306.56 
CRP          
Full sample 0.11 0.26 0.41 0.91 1.97 4.82 10.02 15.95 41.32 
Alive in 2010 0.11 0.25 0.41 0.88 1.89 4.55 9.44 14.72 37.66 
Respondent in 2010 0.11 0.25 0.41 0.88 1.89 4.55 9.44 14.85 37.66 
Self-R in 2010 0.11 0.26 0.41 0.88 1.89 4.55 9.44 14.85 36.51 
BioElig-R in 2010 0.11 0.25 0.41 0.88 1.89 4.55 9.48 14.85 37.71 
Consent 2010 0.11 0.25 0.41 0.88 1.86 4.46 9.44 14.56 36.39 
Cystatin C          
Full sample 0.52 0.65 0.71 0.84 0.97 1.17 1.50 1.76 2.74 
Alive in 2010 0.52 0.65 0.71 0.84 0.97 1.17 1.43 1.63 2.28 
Respondent in 2010 0.52 0.65 0.71 0.84 0.97 1.17 1.43 1.63 2.28 
Self-R in 2010 0.52 0.65 0.71 0.84 0.97 1.11 1.37 1.63 2.24 
BioElig-R in 2010 0.52 0.65 0.71 0.84 0.97 1.11 1.37 1.63 2.21 
Consent 2010 0.52 0.65 0.71 0.84 0.97 1.11 1.37 1.63 2.21 
Note. NHANES adjusted biomarker values are reported. Corresponding sample sizes are included in Table 2-3. 
“Self-R” refers to non-nursing home, self-respondent. “BioElig-R” refers to biomeasure eligible. 
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Figure 2-7a. Weighted distribution of HbA1c (NHANES adjusted) by 2010 eligibility state. 
“BioElig-Respondent” refers to biomeasure eligible. 
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Figure 2-7b. Weighted distribution of HDL (NHANES adjusted) by 2010 eligibility state. 
“BioElig-Respondent” refers to biomeasure eligible. 
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Figure 2-7c. Weighted distribution of total cholesterol (NHANES adjusted) by 2010 eligibility 
state. “BioElig-Respondent” refers to biomeasure eligible. 
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Figure 2-7d. Weighted distribution of C-reactive protein (CRP) (NHANES adjusted) by 2010 
eligibility state. “BioElig-Respondent” refers to biomeasure eligible. 
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Figure 2-7e. Weighted distribution of Cystatin C (NHANES adjusted) by 2010 eligibility state. 





2.5.2 Bias in biomarker means 
 Tables 2-10a through 2-10e present the mean, bias (as specified in Equations (2.7) 
through (2.13)), and relative bias for each of the eligibility states. Corresponding figures (Figures 
2-8a through 2-8e) display these means and their 95% confidence intervals. 
For HbA1c (Table 2-10a; Figure 2-8a) there is a statistically significant shift in the mean 
percent HbA1c going from the full sample (5.81%) to the living sample (5.78%), though the 
relative bias is just over a half percent and has minimal substantive importance. Overall there is 
very little shift in the sample mean going from the living sample to the 2010 consenters though 
the general trend is negative. A positive shift is observed from the living respondents to the 2010 
respondents (5.784%), however this bias is not statistically significant with the Bonferroni 
correction. 
 Similar to HbA1c, there is no significant shift in the HDL mean from the living sample to 
the consenting sample (Table 2-10b; Figure 2-8b). The difference from the full sample to the 
living sample is not significant given the Bonferroni correction though the absolute relative bias 
is comparable to what was seen with HbA1c (0.6%). Total cholesterol (Table 2-10c; Figure 2-8c) 
also shows comparable patterns to HDL and HbA1c with a larger change from the full sample 
(203.0 mg/dL) to the living sample (204.2 mg/dL), but no significant bias for the other eligibility 
state transitions. 
 CRP experiences the largest absolute relative difference between the full sample and the 
living sample across all five biomarkers at 7.1%. However, there are no other large differences 
across various eligibility states though the general trend is a reduction in the mean CRP (Table 2-
10d; Figure 2-8d). 
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Cystatin C sees larger and more significant shifts in the means after removing the sources 
of non-observation then the previous biomarkers (Table 2-10e; Figure 2-8e). The large shift from 
the full sample to the living sample (1.08 mg/L to 1.03 mg/L) results in an absolute relative 
difference of over 4%. The difference between the all 2010 respondents and non-nursing home, 
self-respondents is also significant by reducing the mean Cystatin C by about 1.0%. The 
significant removal of proxy and nursing home respondents is reflected in both composite bias 
measures with the total non-observation bias (comparing the living respondents to the consenting 
respondents) showing an absolute relative bias of 1.2% and the total operational eligibility bias 
showing an absolute relative bias of 0.8%, though the latter is only marginally significant given 




Table 2-10a. Bias of mean HbA1c from HRS 2006 by 2010 eligibility state 
HbA1c (%) Mean (SE) Bias (SE) Relative bias 
Full sample 5.811 (0.017)   
Alive in 2010 5.777 (0.018) -0.034 (0.006)**** -0.6% 
Respondent in 2010 5.784 (0.019)  0.007 (0.002)** 0.1% 
Self-Respondent in 2010 5.778 (0.019) -0.006 (0.004) -0.1% 
BioElig-Respondent in 2010 5.782 (0.019)  0.005 (0.004) 0.1% 
Consent 2010 5.769 (0.020) -0.013 (0.007) -0.2% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.001 (0.005) 0.0% 
Total non-observation  
(Alive vs Consent)   -0.007 (0.009) -0.1% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-8a. Mean HbA1c from HRS 2006 by 2010 eligibility state with 95% confidence 




Table 2-10b. Bias of mean HDL from HRS 2006 by 2010 eligibility state 
HDL (mg/dL) Mean (SE) Bias (SE) Relative bias 
Full sample 54.468 (0.308)   
Alive in 2010 54.797 (0.351)  0.329 (0.099)** 0.6% 
Respondent in 2010 54.814 (0.362)  0.018 (0.058) 0.0% 
Self-Respondent in 2010 54.922 (0.387)  0.107 (0.056) 0.2% 
BioElig-Respondent in 2010 54.941 (0.417)  0.019 (0.077) 0.0% 
Consent 2010 54.977 (0.443)  0.036 (0.094) 0.1% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
  0.127 (0.110) 0.2% 
Total non-observation  
(Alive vs Consent)    0.181 (0.171) 0.3% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-8b. Mean HDL from HRS 2006 by 2010 eligibility state with 95% confidence interval. 
“Bio Eligible” refers to biomeasure eligible. 
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Table 2-10c. Bias of mean total cholesterol from HRS 2006 by 2010 eligibility state 
Total Cholesterol (mg/dL) Mean (SE) Bias (SE) Relative bias 
Full sample 202.984 (0.825)   
Alive in 2010 204.238 (0.886)  1.254 (0.198)**** 0.6% 
Respondent in 2010 204.057 (0.897) -0.181 (0.123) -0.1% 
Self-Respondent in 2010 204.042 (0.915) -0.015 (0.120) 0.0% 
BioElig-Respondent in 2010 204.063 (0.925)  0.021 (0.147) 0.0% 
Consent 2010 204.424 (0.919)  0.361 (0.181) 0.2% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
  0.006 (0.212) 0.0% 
Total non-observation  
(Alive vs Consent)    0.186 (0.336) 0.1% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-8c. Mean total cholesterol from HRS 2006 by 2010 eligibility state with 95% 
confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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Table 2-10d. Bias of mean C-reactive protein (CRP) from HRS 2006 by 2010 eligibility state 
CRP (ug/mL) Mean (SE) Bias (SE) Relative bias 
Full sample 4.472 (0.114)   
Alive in 2010 4.156 (0.113) -0.317 (0.069)**** -7.1% 
Respondent in 2010 4.177 (0.117)  0.021 (0.017) 0.5% 
Self-Respondent in 2010 4.158 (0.115) -0.019 (0.023) -0.5% 
BioElig-Respondent in 2010 4.170 (0.122)  0.013 (0.018) 0.3% 
Consent 2010 4.125 (0.129) -0.046 (0.035) -1.1% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.006 (0.032) -0.2% 
Total non-observation  
(Alive vs Consent)   -0.031 (0.053) -0.7% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-8d. Mean CRP from HRS 2006 by 2010 eligibility state with 95% confidence interval. 
“Bio Eligible” refers to biomeasure eligible. 
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Table 2-10e. Bias of mean Cystatin C from HRS 2006 by 2010 eligibility state 
Cystatin C (mg/L) Mean (SE) Bias (SE) Relative bias 
Full sample 1.081 (0.008)   
Alive in 2010 1.034 (0.007) -0.047 (0.005)**** -4.3% 
Respondent in 2010 1.036 (0.007)  0.002 (0.001) 0.2% 
Self-Respondent in 2010 1.026 (0.007) -0.010 (0.002)**** -0.9% 
BioElig-Respondent in 2010 1.027 (0.007)  0.001 (0.001) 0.1% 
Consent 2010 1.021 (0.007) -0.006 (0.002)** -0.6% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.009 (0.002)*** -0.8% 
Total non-observation  
(Alive vs Consent)   -0.013 (0.003)*** -1.2% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-8e. Mean Cystatin C from HRS 2006 by 2010 eligibility state with 95% confidence 
interval. “Bio Eligible” refers to biomeasure eligible. 
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2.5.3 Bias in proportions at risk 
 Following the same sequence as the estimate means, the full sample flagged 13.6% of 
consenting respondents as diabetic based on an HbA1c of 6.4% or greater (see Table 2-11a and 
Figure 2-9a). After removing the deceased respondents, the percentage of diabetics decreases to 
12.4% – a significant absolute relative difference of 9%. This drop corresponds with the drop in 
mean noted earlier as well as the declining upper percentiles. A second significant change is seen 
between the living participants and the 2010 respondents. However, instead of a decrease in the 
high risk proportion there is a relative increase of 2.3% raising the proportion at risk to 12.6%. 
None of the remaining transitions experience a significant change in the proportion at risk for 
diabetes. The summary bias measures (in particular, the total non-observation bias) do not detect 
the shift for respondents as the observed effect may be mitigated by the subsequent changes 
related to eligibility and consent, though not individually significant themselves.  
 Across the two cholesterol measures, there are no significant changes in the proportion of 
those at risk for low HDL with the percent at risk for the full sample being 20.0% and the 2010 
consenting sample at 19.7%, though the largest shift is to the living sample (2.3% absolute 
relative difference) (see Table 2-11b and Figure 2-9b). Considering total cholesterol, only one 
significant difference in the proportion of those with high cholesterol is found which is between 
the full sample and those alive in 2010 raising the proportion by a relative 3.5% from 18.6% to 
19.2% (see Table 2-11c). This proportion is generally maintained across the additional non-
observation transitions (see also Figure 2-9c).  
 The same pattern of observing a large shift from the full sample to the living sample is 
observed for CRP (38.1% to 36.8%) with no additional transitions exhibiting significant changes 
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(see Table 2-11d and Figure 2-9d). The non-observation bias shows a large negative cumulative 
effect across the subsequent sources of non-observation (relative bias of -1.9%), but not 
statistically different from the living sample.  
For the high risk proportion for Cystatin C, the full sample to living sample transition is 
significant cutting the identified proportion at risk by a quarter from 9.1% to 6.8% (see Table 2-
11e and Figure 2-9e). Like with the mean difference, the transition from all 2010 respondents to 
the non-nursing home, self-respondents is significant reducing the percent at risk from 6.9% to 
6.3%, or an 8% absolute relative bias. However, there are no significant drops for the composite 
bias measures given the Bonferroni correction though the total non-observation bias and sample 




Table 2-11a. Bias of HbA1c proportion at risk from HRS 2006 by 2010 eligibility state 
HbA1c >= 6.4% Proportion (SE) Bias (SE) Relative bias 
Full sample 0.136 (0.005)   
Alive in 2010 0.124 (0.005) -0.012 (0.002)**** -9.0% 
Respondent in 2010 0.126 (0.006)  0.003 (0.001)*** 2.3% 
Self-Respondent in 2010 0.125 (0.005) -0.002 (0.001) -1.2% 
BioElig-Respondent in 2010 0.125 (0.006)  0.000 (0.001) 0.1% 
Consent 2010 0.123 (0.006) -0.002 (0.001) -1.5% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.001 (0.002) -1.1% 
Total non-observation  
(Alive vs Consent)   -0.000 (0.002) -0.4% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-9a. HbA1c proportion at risk from HRS 2006 by 2010 eligibility state with 95% 
confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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Table 2-11b. Bias of HDL proportion at risk from HRS 2006 by 2010 eligibility state 
HDL < 40mg/dL Proportion (SE) Bias (SE) Relative bias 
Full sample 0.200 (0.006)   
Alive in 2010 0.195 (0.007) -0.005 (0.002)* -2.3% 
Respondent in 2010 0.196 (0.007)  0.001 (0.002) 0.6% 
Self-Respondent in 2010 0.196 (0.008) -0.001 (0.002) -0.3% 
BioElig-Respondent in 2010 0.197 (0.008)  0.001 (0.002) 0.7% 
Consent 2010 0.197 (0.009)  0.000 (0.002) -0.1% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
  0.001 (0.003) 0.3% 
Total non-observation  
(Alive vs Consent)    0.002 (0.004) 0.8% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-9b. HDL proportion at risk from HRS 2006 by 2010 eligibility state with 95% 
confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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Table 2-11c. Bias of total cholesterol proportion at risk from HRS 2006 by 2010 eligibility state 
Total Chol. >= 240mg/dL Proportion (SE) Bias (SE) Relative bias 
Full sample 0.186 (0.007)   
Alive in 2010 0.192 (0.008)  0.007 (0.002)*** 3.5% 
Respondent in 2010 0.192 (0.008)  0.000 (0.002) -0.1% 
Self-Respondent in 2010 0.192 (0.008) -0.001 (0.001) -0.3% 
BioElig-Respondent in 2010 0.192 (0.008)  0.000 (0.001) 0.2% 
Consent 2010 0.195 (0.009)  0.003 (0.002) 1.6% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
  0.000 (0.002) -0.1% 
Total non-observation  
(Alive vs Consent)    0.003 (0.003) 1.4% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-9c. Total cholesterol proportion at risk from HRS 2006 by 2010 eligibility state with 
95% confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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Table 2-11d. Bias of CRP proportion at risk from HRS 2006 by 2010 eligibility state 
CRP >= 3.0 ug/mL Proportion (SE) Bias (SE) Relative bias 
Full sample 0.381 (0.009)   
Alive in 2010 0.368 (0.010) -0.013 (0.003)**** -3.3% 
Respondent in 2010 0.366 (0.009) -0.002 (0.002) -0.4% 
Self-Respondent in 2010 0.365 (0.009) -0.001 (0.001) -0.4% 
BioElig-Respondent in 2010 0.364 (0.010) -0.001 (0.002) -0.2% 
Consent 2010 0.361 (0.010) -0.003 (0.003) -0.9% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.002 (0.002) -0.6% 
Total non-observation  
(Alive vs Consent)   -0.007 (0.004) -1.9% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-9d. CRP proportion at risk from HRS 2006 by 2010 eligibility state with 95% 
confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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Table 2-11e. Bias of Cystatin C proportion at risk from HRS 2006 by 2010 eligibility state 
Cystatin C > 1.55mg/L Proportion (SE) Bias (SE) Relative bias 
Full sample 0.091 (0.005)   
Alive in 2010 0.068 (0.004) -0.023 (0.002)**** -25.4% 
Respondent in 2010 0.069 (0.005)  0.001 (0.001) 1.2% 
Self-Respondent in 2010 0.063 (0.004) -0.006 (0.002)*** -8.2% 
BioElig-Respondent in 2010 0.064 (0.004)  0.001 (0.001) 1.7% 
Consent 2010 0.061 (0.004) -0.003 (0.001)* -5.2% 
    
Operational eligibility 
(Respondent vs BioElig-Respondent) 
 -0.005 (0.002)* -6.6% 
Total non-observation  
(Alive vs Consent)   -0.007 (0.002)** -10.4% 
Note. Bonferroni correction suggests a significance level of 0.000714 and are bolded.  
“BioElig-Respondent” refers to biomeasure eligible. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 
 
Figure 2-9e. Cystatin C proportion at risk from HRS 2006 by 2010 eligibility state with 95% 
confidence interval. “Bio Eligible” refers to biomeasure eligible. 
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2.5.4 Subgroup impact  
In order to ensure that the bias analyses were not impacted by subgroups (e.g., Simpson, 
1951; Blyth, 1972), regression models were run to test for any possible interaction between 
major demographic and health characteristics and the eligibility states on the five DBS 
biomarkers. A total of eight indicators were tested including age (50-74 vs. 75+), gender (male 
vs. female), race (non-Hispanic black vs. other), self-rated health (fair/poor vs. other), diabetes, 
chronic conditions (0-1 vs. 2+), mild vigorous activity (hardly/never vs. other), and functional 
limitations (0-4 vs. 5+). Crossing the five subgroup comparisons, the five biomeasures, and eight 
indicators, a total of 200 models were estimated.  
Of the 200 models analyzed, only 19 interactions were found to be significant. Of those 
19 significant interactions, 12 were associated with the transition from the full sample to the 
surviving sample and 9 were associated with Cystatin C. Using a Bonferroni adjustment for the 
multiple models (α = 0.00025), only the full to living sample transitions are significant and they 
are all related to Cystatin C. 
Overall, there is little statistical evidence to suggest that subsets of respondents have 
differential rates of change in the five biomeasures as the sample reduces from each successive 
source of non-observation. However, there are large, significant differences in the biomeasure 
values for the subsets, which are to be expected given the strong relationship between these 
health measures and the biomeasure outcomes. 
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2.5.5 Violation of assumptions 
 One strong assumption in these analyses is the consistency between the 2006 and 2010 
biomarker outcomes. Observing cases where a biomarker value was collected in both 2006 and 
2010, there is evidence to suggest that the biomarker values do change from wave to wave on 
average as the mean difference is statistically different from zero (see Table 2-12). However, the 
mean and median differences are practically zero and may not be substantively different based 
on the mean to range ratio. Some of these differences are suspect, since the minimum and 
maximum differences exceed the observed range of values for a particular year. For example, the 
absolute value of the minimum and maximum differences in HbA1c (8.73 and 8.68) exceed the 
range of the 2006 sample (10.18 – 4.65 = 5.53). Given the large variability and questionable 
extreme values, it is possible that many differences may be in fact due to differential quality in 
wave to wave blood sample as well as differences in collection, storage, and laboratories used.
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Table 2-12. Difference in 2010 and 2006 DBS biomarker values for respondents who provided biomeasures in both waves 
 Mean 𝐻𝐻0:𝑚𝑚� = 0 Min Q1 Median Q3 Max Range Mean/Range 
HbA1c (%) 0.07 **** -8.73 -0.28 0.06 0.40 8.68 17.41 0.38% 
HDL (mg/dL) -1.05 *** -73.79 -11.42 -0.21 9.87 71.56 145.35 0.72% 
Total cholesterol (mg/dL) -11.14 **** -169.55 -42.72 -10.34 21.24 199.18 368.73 3.02% 
CRP (ug/mL) -0.46 ** -217.24 -1.41 -0.16 0.73 182.25 399.49 0.11% 
Cystatin C (mg/L) 0.12 **** -2.15 -0.10 0.08 0.27 5.25 7.40 1.59% 






Figure 2-10. Difference in 2006 and 2010 DBS biomarker values (NHANES adjusted) for 
respondents who provided biomeasures in both waves. Red line is mean difference.
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2.6 Discussion 
 The five eligibility state outcomes had similar covariates. Cognitive ability was a 
significant predictor in four of the five continuation ratio models with higher cognitive scores 
predicting an increased likelihood of being in the successive eligibility state. Change in cognitive 
ability also was a significant predictor in the three-wave models. Other health measures like self-
rated health, physical activity (baseline and change), and number of chronic conditions appeared 
as significant predictors in at least two sub-models. Many of these factors are consistent with the 
literature reviewed previously. Regarding sociodemographic characteristics, age and 
race/ethnicity were significant predictors across many of the models while weekly church 
attendance appeared in the two-wave models and education appeared in the three-wave models. 
Baseline and changing household characteristics had little association with these models though 
they historically have a relationship with survey response. In general, these similar effects were 
in a consistent direction across non-observation states suggesting a cumulative biasing effect of 
these predictors on the final consenting sample in support of the first research question. The 
magnitude of those effects varied across the five models supported by the significant parallel 
slope tests rejecting the parallel slopes assumption for those associated variables. However, the 
majority of variables included in these models failed to reject the parallel slopes assumption. 
While a constrained partial continuation ratio logit model could be considered, many of these 
variables were non-significant predictors meaning that sub-models may contain too many 
uninformative variables. 
 When previous sources of non-observation were included in the predictive models, they 
were often predictors of their future eligibility state. Previous non-observation source indicators 
accounted for the significant respondent demographic and health predictors, often reducing 
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substantially coefficients in the three-wave models. Age and cognition often remained the only 
significant predictors in the expanded models. These findings emphasize the predictive power of 
one’s previous eligibility state positively answering the second research question. However, 
trying to utilize the sources of non-observation in predictive models does create complications in 
model interpretation given the endogeneity of these non-observation sources with 
sociodemographic and health factors. The previous eligibility state absorbs much of the 
explanatory power of single wave predictors or, rather, explains their contributions to later wave 
eligibility. Individual models for each eligibility state could be an option to reduce challenges 
with interpretability, but would prove less effective with small sample sizes. 
A weakness of the continuation ratio logit model is that the models cannot be viewed as 
causal, but rather only as descriptive due to reducing heterogeneity from eligibility outcome to 
eligibility outcome (Fullerton & Xu, 2016). In order to account for potential selection bias, one 
could alternately use sample selection models (Heckman, 1979). Heckman’s original model only 
focuses on a single selection mechanism, though others have examined the use of two or three 
selection mechanisms (see Catsiapis & Robinson, 1982; Ham, 1982; Fishe, Trost, & Lurie, 1981; 
Maddala, 1986). However, the exploration and benefit of using such an approach is unknown, 
especially when extended to five selection mechanisms, and could be considered for future work. 
When considering the specific biomarker outcomes, there was very little change in the 
means and proportions at risk for the five DBS measures after accounting for changes due to the 
loss of deceased sample. In reference to the third research question, these results suggest that 
there is minimal bias introduced for population estimates due to nonresponse, operational 
eligibility, and non-consent. Two notable exceptions were observed: 1) the living sample to 
survey respondent transition for the proportion at risk for diabetes and 2) the difference in means 
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for the respondent to non-nursing home, self-respondent transition for Cystatin C. While the 
former’s bias did not seem to have a lasting impact on the proportion at risk following the effects 
of the other sources of non-observation, the latter’s effect was still present and significant 
following the eligibility and non-consent exclusions. However, the relative bias is quite small 
and may not be substantively meaningful. In relation to the fourth and final research question 
exploring the impact of operational eligibility, only Cystatin C saw a larger bias due to 
ineligibility, primarily due to removing respondents who entered a nursing home or needed a 
proxy respondent. These differences are not large relative to the full sample before accounting 
for mortality, which for Cystatin C was less than a one percent relative change in the mean. 
However, operational eligibility accounted for more of the total bias than consent for Cystatin C  
These are reassuring findings considering the amount of loss of sample across waves in a 
longitudinal study due to attrition, operational eligibility, and non-consent. However, a limitation 
in this analysis is related to using historical biomarker values which do not account for 
potentially large individual changes due to changes in health which could impact any, if not all, 
of the five biomeasure outcomes considered here. It is difficult to disentangle natural human 
variation from actual improvements or declines in physical health and differences in biomeasure 
collection procedures across waves. 
The overwhelming difference in estimates from the full sample to the living sample in the 
biomarker means and proportions makes sense given the effects associated with a majority of the 
included health indicators. Each biomarker is related in some way to increased comorbidities, 
functional limitations, and poor quality of life, which are predictors of mortality. The statistically 
significant shift in the means and proportions estimated for HbA1c from the living to the 2010 
respondent sample seems to directly correspond to the significant odds ratios for the chronic 
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conditions index in both the two-wave and three-wave models for the response sub-model as 
diabetes is one of the included chronic conditions. In addition, the significant drop in Cystatin C 
when excluding nursing home and proxy respondents shows the linkage of healthy aging and 
declining cognition, significantly observed in both the two-wave and three-wave models, is 
associated with increased levels of Cystatin C (Sarnak et al., 2008; Yaffe et al., 2008). 
Something not examined in this paper is the impact of ineligible respondents becoming 
eligible in a future wave and the recruitment of new cohorts. To streamline the analysis, 
biomeasure ineligible cases in 2006 were excluded and not reintroduced into the analytic sample. 
While large shifts occurred due to mortality and (to a smaller extent) other eligibility transitions, 
the addition of new cohorts may serve to counterbalance some of these changes over time.  
One source of non-observation not discussed in this chapter is non-observation due to 
failed collection or an insufficient sample. Respondents may not have been able to provide 
sufficient blood for all six spaces on the blood spot card resulting in only a subset of biomarkers. 
Alternatively, specimens could have been improperly stored during transit and thus unable to be 
processed. This form of non-observation is ideally small (see Table 2-3), but may also result in 
sporadic patterns of item missingness of biomeasures as opposed to the more monotonic 
missingness evaluated in this chapter. Incorporating this form of non-observation and evaluating 
its (small) contribution to bias is a step for future consideration. 
The logic applied to divide operational eligibility into health and non-health reasons 
could also be applied to non-consent and could be useful in future explorations. Choosing not to 
participate in biomeasure collection because of general resistance to the survey or resistance to 
more sensitive requests could stem from very different reasoning than choosing not to participate 
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due to a health concern. HRS paradata does allow for these reasons to be distinguished and 
explored. This concept is briefly evaluated in Appendix B and expanded on in Chapter 3.  
The relative absence of large significant biases in the biomarkers is potentially reassuring 
when considering future steps to account or correct for this loss in biomeasure sample for 
longitudinal analyses. Imputation of biomarkers could prove beneficial to retain sample size of 
responding cases especially in the later sources of non-observation where there were fewer 
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Factors Influencing Recurrent Consent Requests for Biomeasures in a Longitudinal Survey 
3.1 Introduction 
 Due to the invasive nature of biomeasure collection, human subjects review requires 
respondents provide written consent for collection of biomeasures in addition to general consent 
to participate in the survey. Consent to biomeasure collection is the most direct form of potential 
non-observation because the respondent is actively choosing to participate (or not). There are a 
number of factors that appear to affect a respondent’s decision to consent to biomeasure 
collection. The research literature on consent to biomeasure collection by non-medically trained 
interviewers is still small and has only focused on consent in cross-sectional or single wave 
collection. For longitudinal panel surveys, the effect of recurrent consent requests on consent 
rates and patterns of missingness has not been explored.  
The purpose of this study is to investigate informative or selective factors that may be 
addressed by interventions to improve consent during recurrent biomeasure requests or used as 
additional adjustments in post-processing. Section 3.2 reviews the known predictors associated 
with single wave biomeasure consent while Section 3.3 considers potential predictors of 
longitudinal consent. Section 3.4 outlines the study goals and research questions, while Sections 
3.5 and 3.6 describe the methods and results of the analyses, respectively. Finally, Section 3.7 
will discuss the findings and implications of the analyses. 
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3.2 Predictors of single wave biomeasure consent 
 The primary factors associated with single wave biomeasure consent in population-based 
longitudinal surveys, most of which use interviewer administered collection, are 
sociodemographic characteristics, health status, survey resistance, and the effect of interviewers 
on biomeasure consent. 
3.2.1 Sociodemographic characteristics 
 The literature does not show a consistent effect of respondent age, gender, race, or 
education on biomeasure consent. One study of older adults in Germany found that the older the 
respondent the more likely they were to participate in a dried blood spot (DBS) assay 
(Korbmacher, 2014), while another study of older women asked to provide a vaginal swab 
experienced lower consent as the age of the female participants increased (Lindau et al., 2009). 
This latter example may be more indicative of the increasingly sensitive nature or the perceived 
needlessness of the request given advancing age.  
Gender has not generally been associated with differential rates of consent to 
biomeasures (Gavrilova and Lindau, 2009; Sakshaug et al., 2010; Korbmacher, 2014) though 
some studies have found females less likely to provide saliva samples (McClain, Lee, Faul, & 
Barba, 2015; Dykema et al., 2017).  
Blacks or African Americans have been found to be less likely to consent to biomeasure 
collection (Gavrilova and Lindau, 2009) though this is not always a statistically significant 
finding (Sakshaug et al., 2010). Research showing that deep-rooted distrust of medical research 
and scientific studies by blacks generally supports this finding (e.g., Gamble, 1997; Corbie-
Smith, Thomas, Williams, & Moody-Avers, 1999; Corbie-Smith, Thomas, & George, 2002).  
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Studies that examined those who attended some college versus high school or less found 
no measurable effect on consent (Gavrilova & Lindau, 2009; Sakshaug et al., 2010) while a 
study that examined college graduates versus lower education levels did find a higher consent 
rate among college graduates (Dykema et al., 2017). The earlier study of older females that asked 
for a vaginal swab found that female participants without a high school diploma were 
significantly less likely to consent (Lindau et al., 2009).  
One study where multiple household members could be eligible to participate in the study 
and provide biomeasures found that the presence of another eligible household member 
increased the chance of obtaining consent (Sakshaug et al., 2010). As these other household 
members could be a spouse, an adult child, or parent, the social expectation of another household 
member participating or earning the support of an intermediary may lead to another household 
member participating in the study. Making a gatekeeper or intermediary an ally instead of a 
hindrance can help facilitate a collaborative research environment as opposed to inhibiting 
research activities (McNeely & Clements, 1994; Porter & Lanes, 2000). 
Dykema and colleagues’ (2017) review of the relevant epidemiological literature 
suggested more religious persons – as measured by regular church attendance and belief in the 
Bible – would be less likely to consent to biomeasure collection. However, after controlling for 
sociodemographic, health, and other factors, results revealed weekly church attendance is 
associated with higher rates of consent than those who did not attend or attended infrequently. 
The authors posited that church attendance was capturing some facet of social participation 
(Dykema et al., 2017). Sakshaug et al. (2010) saw a similar effect size for those who attended 
religious services at least weekly.  
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3.2.2 Respondent health 
Given the collection of biomeasures is directly related to the respondent’s health at the 
time of collection, a number of physical health indicators are correlates of consent. Self-rated 
health is not a significant predictor of consent especially if indicators of specific health 
conditions are also considered (Gavrilova and Lindau, 2009; Lindau et al., 2009; Sakshaug et al., 
2010; Dykema et al., 2017). Diabetic respondents are significantly more likely to consent to 
collection, especially DBS, perhaps because these respondents observe and manage blood 
glucose levels regularly through the use of blood lancets (Sakshaug et al., 2010; Korbmacher, 
2014). Other chronic conditions (i.e., comorbidities) like cancer and heart disease have not been 
shown to be individually or collectively (e.g., comorbidity index) associated with biomeasure 
consent (Lindau et al., 2009; Sakshaug et al., 2010; Dykema et al., 2017). The number of 
functional limitations (areas of physical functioning where one needs assistance) that a 
respondent currently is experiencing as well as their difficulty with performing daily activities 
correspond to lower rates of biomeasure consent (Sakshaug et al., 2010; Korbmacher, 2014), 
though this effect is not always statistically significant (Dykema et al., 2017). Having had a 
recent physical exam or visit to the doctor corresponds with higher rates of biomeasure consent 
(Sakshaug et al., 2010; Dykema et al., 2017).  
Cognition, as a measure of one’s ability to acquire and recall knowledge, is of interest to 
survey researchers but has rarely been examined in the context of survey-related tasks. McClain 
et al. (2015) used word recall as a measure of cognition and found that higher word recall scores 
resulted in greater rates of consent to physical measurements (e.g., blood pressure, height, 
weight), but not to DBS or a saliva catch. Dykema et al. (2017) used adolescent IQ scores as a 
predictor of consent for a sample of older respondents and found that those with lower cognitive 
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ability were significantly less likely to provide consent for a saliva sample years later. These 
findings suggest that as cognition declines (regardless of the specific measure used) so does the 
likelihood of consenting to biomeasure collection. 
3.2.3 Survey resistance 
Because biomeasure collection is occurring within a survey, factors related to the overall 
survey experience may have an impact on a respondent’s consent decision. Paradata collected 
from interviewers during the survey process gives researchers an idea of the respondent’s 
resistance to participate both prior to and during the survey interview (Kreuter, 2013). Measures 
of survey resistance can include indicators such as contact difficulty (e.g., the number of contact 
attempts), respondent inquiries about the content or length of the survey, respondent enjoyment 
or cooperation, or refusal for sensitive items (e.g., household income). While interviewer-
observed paradata can be a good predictor of survey participation and used to design a successful 
intervention strategy (Sinibaldi & Eckman, 2015; Plewis, Calderwood, & Mostafa, 2017), such 
paradata are not available for all sample units and are not sufficiently predictive to be used for 
effective nonresponse adjustment for survey weights, including biomeasure-specific weights 
(Biemer, Chen, & Wang, 2013; Olson, 2013; Sinibaldi, Trappman, & Kreuter, 2014; West, 
Kreuter, & Trappmann, 2014). 
By using data from the most recent wave of data collection, both Sakshaug et al. (2010) 
and Dykema et al. (2017) found that those least likely to consent to biomeasures had a higher 
number of contact attempts for both the current and previous waves of data collection suggesting 
greater levels of general survey resistance. Respondents who voiced questions or concerns 
regarding confidentiality and the length of the interview in the previous wave were also much 
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less likely to consent to biomeasures. Interviewer assessments of a respondent’s level of 
cooperation and enjoyment in the previous wave were also associated with consent to 
biomeasures (Sakshaug et al., 2010). Dykema et al. (2017) found that those who refused to 
participate in the previous wave as well as those who did not complete the last wave were both 
less likely to consent to a saliva collection.  
Korbmacher (2014) found that respondents who failed to report their income had half the 
odds of consenting to a DBS assay compared to those who did report income.  
3.2.4 Interviewer effects 
 The interviewer can also play a role in a respondent’s consent decision. When 
considering biomeasure collection, the respondent’s assessment of the interviewer’s competence 
for collecting biomeasures might influence the decision to consent. Unfortunately, no direct 
measures of a respondent’s perception of the interviewer’s competence are routinely collected. 
Factors such as the interviewer’s age, education, race, and interviewing experience can serve as 
potential correlates of perceived experience and capability. One study found that respondents 
with older interviewers had significantly higher consent rates than respondents with younger 
interviewers, while respondents with interviewers who had medium or high levels of education 
had over six times the odds of obtaining blood spot consent than respondents whose interviewer 
had lower education (Korbmacher, 2014). On the other hand, Sakshaug et al. (2010) did not find 
evidence of a significant interviewer age effect on a respondent’s consent to biomeasures, and 
only a weak relationship between interviewer education and consent. Respondents whose 
interviewer was black were less likely to consent than those who had a white interviewer in the 
2006 wave of the HRS (Sakshaug et al., 2010), but improved training reduced the effect in the 
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subsequent wave of collection (Ofstedal et al., 2010). In one study, respondents who were 
interviewed by a new hire displayed no difference in consent from respondents who were 
interviewed by more experienced interviewers (Sakshaug et al., 2010). A second study found that 
was a negative effect of years of interviewing experience on biomeasure consent rates 
(Korbmacher, 2014). Sakshaug et al. (2010) and Korbmacher (2014) both found significant 
amounts of interviewer variance still unexplained in their final biomeasure consent models after 
controlling for interviewer attributes. 
3.3 Potential predictors of longitudinal biomeasure consent 
3.3.1 Changes in health 
Given the natural passage of time between waves in a panel study, there are likely to be 
changes in respondents’ health that cause them to make changes in their lifestyle.  For example, 
increased risk for type 2 diabetes due to impaired glucose tolerance (Tuomilehto et al., 2001) or a 
diagnosis of cancer (Demark-Wahnefried, Aziz, Rowland, & Pinto, 2005) could lead to changes 
in lifestyle. A recent diagnosis of a chronic disease or a sudden decrease in one’s ability to 
perform daily tasks may cause additional reluctance when presented with the request to collect 
various biomeasures. For example, a respondent who was recently diagnosed with diabetes may 
be more likely to consent to a DBS assay since they have started performing regular blood 
glucose tests, while another respondent who has become unable to perform many basic 
household tasks without aid may be less likely to consent to physical measurements. Depending 
on the nature of the health change, one might expect either a positive or negative impact on the 
likelihood of consent. 
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3.3.2 Factors influencing panel attrition and reengagement  
In the context of recurrent consent requests in longitudinal studies, a new perspective is 
needed. With the exception of Chapter 2 of this dissertation, no research to date has investigated 
the similarities between biomeasure consent and other sources of panel attrition. Biomeasure 
collection can be a time consuming and uncomfortable experience for respondents within an 
already long interview session. Factors associated with panel attrition may also be associated 
with failure to consent to biomeasure collection in a future wave. Thus, unit nonresponse may be 
a competing risk with consent (Loosveldt, Pickery, & Billiet, 2002; Mason, Lesser, & Traugott, 
2003; Yan & Curtin, 2010).  
Consent to a recurrent within-survey request may be closely tied to panel engagement 
itself. A respondent who is showing signs of resistance or panel fatigue may not choose to 
completely refuse the interview request, but instead turn down a module of the survey (e.g., 
biomeasure collection). Failure to consent to biomeasure collection at an earlier wave could 
correlate with future attrition, viewing consent as another measure of survey resistance 
(Loosveldt, Pickery, & Billiet, 2002). Factors associated with multiple mechanisms of survey 
attrition are might inform a model of recurrent biomeasure collection requests. 
Watson and Wooden (2009) provide a detailed overview of factors that are associated 
with panel attrition. With the goal of identifying correlates that can be applied to recurrent 
biomeasure consent, factors related to contact are not discussed here. In addition to the standard 
respondent characteristics, many of the factors Watson and Wooden (2009) discussed can be 
summarized into two main categories discussed previously: interview resistance and interviewer 
effects. 
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Respondents who enjoyed a survey interview are much less likely to dropout in 
subsequent waves (Laurie et al., 1999; Olsen, 2005; etc.). Respondents who refuse to answer 
survey items, especially more sensitive items like income, are much more likely to drop out in 
later waves of the survey (Laurie et al., 1999; Loosveldt et al., 2002; etc.). Both of these findings 
are consistent with what was discussed previously as factors for consent to biomeasure 
collection. Respondents who provide a straight refusal to a survey request as opposed to indirect 
reasons are significantly less likely to reengage in the study at a later wave (Watson & Wooden, 
2014). Applying this finding to recurrent biomeasure consent, a reasonable hypothesis is that 
those who did not provide a straight refusal at the previous consent request are more likely to 
provide biomeasure consent in future interviews.   
For face-to-face surveys, interviewer continuity has been found to have mixed results on 
attrition, with some studies supporting a positive retention effect (i.e., panelist responds, does not 
drop out of the study), while others observe no effect at all (Laurie et al., 1999; Campanelli & 
O’Muicheartaigh, 2002; Olsen, 2005; Lynn et al., 2014; etc.). Watson and Wooden (2014) 
looked at re-engagement in four different longitudinal studies and found that interviewer 
continuity lowered the chance of re-engaging a respondent if they had not responded in the 
previous wave. Such an effect could suggest that respondent-interviewer rapport is poor and 
changing the interviewer would result in increased chances of subsequent panel participation. 
This finding could be applied to biomeasure collection suggesting that interviewer continuity 




3.3.3 Previous consent 
 A strong predictor of future consent to a survey request (e.g. biomeasure) is previous 
consent to the same request. In addition to prediction of future behavior, previous consent is an 
excellent candidate when considering where to apply a design intervention to try to help improve 
future consent (for an example in the data linkage consent literature, see Sala, Knies, & Burton, 
2014). However, when trying to understand the mechanisms influencing the current consent 
decision, previous consent is a poor explanatory variable since factors like sociodemographics 
and health predict both previous as well as future consent (see Figure 3-1). In other words, 
previous consent absorbs most of the explanatory power of single wave predictors or explains 
their contributions to later wave consent. Second, previous consent is likely to be related to 
various survey resistance indicators for that wave. For example, when a respondent refuses to 
provide consent for biomeasures the interviewer may label the respondent as less cooperative in 
their post-interview debrief. Modeling future consent using both previous consent and paradata 
related to resistance as predictors is likely to generate findings that are difficult to interpret. 
Alternatively, one could condition the analysis on previous consent status, the approach followed 
in this chapter. 
As discussed in Chapter 2 regarding operational eligibility, the reason a classification of 
non-observation due to ineligibility was helpful in distinguishing different types of respondents. 
Consent to biomeasures is quite similar. The choice to not participate in biomeasure collection 
because of general resistance to surveys or resistance to sensitive requests could stem from very 
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different reasons than those choosing not to participate due to health concerns. For non-
consenters, including the reason for non-consent could help to disentangle different types of 
respondents helping in prediction.  
3.4 Research questions 
 This paper considers four fundamental questions to understand recurrent biomeasure 
consent in the context of operational considerations, causal relationships, and post-survey 
adjustment: 
Figure 3-1. Sample diagram of the endogeneity problem of previous consent in models of 
recurrent consent. Orange item and lines show how consent at time 1 is endogenous to 
consent at time 2. Green item and lines shows how consent influences interviewer 
observations which, in turn, impact consent at time 2. 
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(1) What are the similarities and differences in factors that predict future biomeasure 
consent for previous biomeasure consenters and non-consenters? 
(2) Do changes in a respondent’s physical and cognitive health effect a respondent’s 
likelihood to participate in biomeasure collection?  
(3) How does interviewer continuity affect the likelihood of biomeasure consent at the 
second request? Does the effect of interviewer continuity differ depending on whether 
the respondent originally consented or not? 
(4) Does a respondent’s reason for refusing to consent in a previous wave predict consent 
at a later wave? 
3.5 Methods 
3.5.1 Data 
 The HRS (Health and Retirement Study) is sponsored by the National Institute on Aging 
(grant number NIA U01AG009740) and is conducted by the Institute for Social Research (ISR) 
at the University of Michigan. HRS is a longitudinal survey of adults over the age of 50 living in 
the United States that collects various measures related to health, medical care, employment, 
income, and cognition. HRS began in 1992 with a cohort of preretirement-aged individuals born 
between 1931 and 1941. New birth cohorts are enrolled every 6 years (e.g., 1998, 2004, 2010) to 
refresh the sample at the younger ages. The HRS conducts about 20,000 interviews every 2 years 
with response rates between 65 and 85 percent in the baseline wave and between 85 and 95 
percent in follow-up waves. 
In 2006, HRS began alternating respondents between face-to-face and telephone 
interviews, with a random half sample of the full panel being assigned to each mode. Every two 
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years each half-sample switches to the other mode5. In face-to-face interviews, 
noninstitutionalized, non-proxy respondents are asked to provide measures of physical 
functioning (i.e., blood pressure, hand grip strength, a walking test, height, weight, etc.), a one-
time saliva sample (for DNA extraction and storage), and a dried blood spot assay (for measuring 
Hemoglobin A1c, cholesterol, and other biochemical measures). Saliva and blood samples have 
different collection, storage, and analysis procedures. Respondents are given three consent forms 
for each of the biomeasure components. HRS refers to this face-to-face interview with 
biomeasure collection and self-administered questionnaire on psychosocial topics as the 
enhanced face-to-face (E-FTF) interview. As the request for the saliva sample was not repeated 
over E-FTF interviews (i.e., saliva was only collected once per respondent), only the physical 
measurements (PM) and dried blood spot (DBS) samples are explored here.  
This study focuses on age-eligible respondents (50 years and older) who were eligible to 
provide biomeasures in two successive E-FTF waves: the HRS biomeasure eligible respondents 
in 2006 and 2010 (one half-sample) as well as 2008 and 2012 (a second half-sample; see Figure 
3-2). There were initially 7,954 eligible respondents in the 2006 E-FTF sample and 6,991 in 
2008. Approximately 12 percent of these respondents across both half samples died before the 
corresponding E-FTF interview four years later. Again, across half samples about 6 percent of 
the surviving sample members refused to respond to the second E-FTF wave, while an additional 
9 percent were ineligible for biomeasure collection. Further, E-FTF respondents were considered 
ineligible for biomeasure collection if they currently lived in a nursing home, had a proxy 
complete the interview on their behalf, preferred to be interviewed by telephone, or if they broke 
                                               
5 Respondents over the age of 80 alternate between FTF and E-FTF interviews unless they specifically request a 
telephone interview. 
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off the interview before the physical measures and biomarker collection. Deletions for mortality, 
attrition, and ineligibility of various types leaves about 75 percent of the original samples (5,927 
for the 2006 half-sample and 5,193 for 2008) as eligible for biomeasure collection in the second 
E-FTF wave.  
Biomeasure eligible participants are analyzed here, with two removals: 13 HRS 2010 and 
9 HRS 2012 cases were excluded due to missing interviewer ID needed for determining inter-
viewer continuity status. Three interviewers refused consent to using their sociodemographic 
data for research purposes, which led to a further loss of 131 HRS 2006 and 118 HRS 2008 
cases. The final analytic sample size consists of 5,783 HRS 2006 and 5,066 HRS 2008 cases.  
In order to draw broader conclusions on recurrent consent, the two half-samples are 
combined for this analysis for a total sample size of 10,849. In order to combine the two half-
samples, variables were matched corresponding to first E-FTF wave, or Wave 1 (W1). The most 
recent telephone6 wave (2008 for the 2006 E-FTF half-sample and 2010 for the 2008 E-FTF 
half-sample) is denoted as Wave 2 (W2). The follow-up E-FTF wave (2010 and 2012, 
respectively) is denoted as Wave 3 (W3). A visual depiction of this half-sample matching is 
shown in Figure 3-2. 
Two independent sets of models were explored for W1 consenters and W1 non-
consenters. This is to help disentangle the confounding with respondent predictors related to 
measures of survey resistance and biomeasure consent in W1. The combined 2006 and 2008 E-
FTF half-samples results in 10,268 PM consenters and 581 PM non-consenters, 9,424 DBS 
consenters and 1,425 DBS non-consenters (see Table 3-1). 
                                               
6 Not all respondents participate via telephone in W2. See footnote 5. 
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Figure 3-2. Wave matching of the Health and Retirement Study half-samples for combined analysis. Each row represents a random 
half-sample in the alternating survey mode design. Blue boxes represent data collected from the respondent. Orange boxes represent 
paradata from the interviewer about the interview or collected about the survey process. Gray boxes are not included. 
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Table 3-1. Wave 1 consent status of Wave 3 biomeasure-eligible respondents (combined 
2006/2008) 
Wave 1 Consent Physical measurements Dried blood spot 
Yes 10,268 (94.6%)   9,424 (86.9%) 
No      581 (5.4%)   1,425 (13.1%) 
Total 10,849 10,849 
 
  
All of the respondent-level data was obtained from the HRS Public Release data available 
at http://hrsonline.isr.umich.edu/index.php?p=avail. Interviewer characteristic data is controlled 
data obtained with permission from the Senior Staff Advisory Committee (SSAC) at the Survey 
Research Center (SRC) at the University of Michigan.  
3.5.2 Outcome measures 
 The outcomes of interest are the consent at W3 to PM and DBS. Because respondents 
could refuse to complete any particular measure after signing the consent form (e.g., consent to 
the collection of physical measurements but later refusal to be weighed), this analysis examines 
whether or not survey respondents signed consent forms, assessing initial willingness to 
complete the biomeasure collection. 
3.5.3 Predictors 
For this analysis a standard set of demographic variables are included to serve as control 
variables and well as predictors of consent. These variables include age at W3, gender, the 
interaction of race/ethnicity and language of interview (classified as non-Hispanic other, non-
Hispanic black, Hispanics interviewed in English, and Hispanics interviewed in Spanish), and 
education (classified as less than high school, high school graduate, some college, college 
graduate). Attending church service at least once a week will also be added to the model based 
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on findings from Dykema et al. (2016). This analysis also includes an indicator for whether there 
is another interviewed HRS respondent in the household. 
To test the hypothesis relating consent to a respondent’s physical health, self-rated 
physical health (excellent, very good, good, fair/poor), how often they performed mildly 
vigorous activities (at least once a week, 1-3 a month, hardly ever/never), and a medical 
diagnosis of diabetes are included in the models of consent. All of the single wave static health 
indicators are taken from the W1 survey interview. Body mass index (BMI), calculated from 
self-reported height and weight, is categorized into three groups: underweight/normal weight 
(BMI less than 25)7, overweight (BMI between 25 and 30), and obese (BMI of 30 or greater). 
Respondents who refused to provide either their height or weight were retained in the sample and 
were classified as a fourth group, not reporting BMI, serving as an indicator of item nonresponse. 
A functional limitation index is included as a summation of three separate scales: the six item 
basic activities of daily living (BADL) (Katz et al., 1963), the seven item instrumental activities 
of daily living (IADL) (Lawton & Brody, 1969), and the 10-point NAGI impairment scale (Nagi, 
1976). (Additional details about the inclusion of these measures in HRS is available in Fonda and 
Herzog (2004)). With each item in the three scales categorized as dichotomous responses, the 
functional limitation index has a maximum score of 23. Finally, an indicator of whether the 
respondent went to the doctor at all in the last two years is included.  
In order to measure if changes in health (e.g., development of disease, increase in 
physical limitations) influence future consent, responses from W1 were compared to those on the 
same measure in W3. For dichotomous indicators like diabetes, the change indicator denotes the 
                                               
7 Underweight and normal weight are combined due to small sample sizes for the underweight (BMI < 18.5) group. 
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development of the condition since W1 (e.g., did not have the condition in 2006, did have the 
condition in 2010)8. For ordinal health variables (i.e., self-rated health, BMI, performing mildly 
vigorous activity) a three-category indicator has categories of improvement, decline, or no 
change (i.e., the reference group) from W1 to W3. The indicator does not differentiate increase 
from normal weight to overweight or normal weight to obese. For number of functional 
limitations the change value is simply the W1 value subtracted from the W3 value, with positive 
values denoting more limitations and negative values fewer. There is an observed range of -16 to 
+19 for the change in functional limitations with a median of zero. While not directly a change 
indicator, a companion indicator of whether the respondent went to the doctor in the two years 
prior to W3 is included along with the W1 indicator of a prior doctor visit. 
Two cognitive status indices were created based on constructed variables developed by 
the HRS Health Working Group (Ofstedal, Fisher, & Herzog, 2005; Fisher, Hassan, Rodgers, & 
Weir, 2011). The first index measures memory through two word recall tasks including 10 
immediate word recall items and 10 delayed word recall items totaling to a maximum score of 
20. The second index measures the respondent’s overall mental status assessing knowledge, 
language, and orientation. It is comprised of three cognitive measures: a test to count backwards 
from 20 (score of 2), eight naming tasks (each with a score of 1), and a five-stage subtraction 
task known as the Serial 7’s test (each stage with a score of 1). This combination of three 
measures results in an index with a maximum score of 15. Participants under age 65 were not 
                                               
8 There are inconsistencies when a previous wave recorded a respondent giving an affirmative response to having a 
condition and in the new wave them refuting that assertion (e.g., in HRS 2010, there were a total of 107 across both 
the E-FTF and CATI interviews who reversed a previous diagnosis of diabetes). For purposes of this analysis, cases 
that go from having a condition (e.g., diabetes) to not having a condition are not flagged as having a change and the 
original affirmative response in wave 1 is maintained. 
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asked to complete the naming tasks in W3; the most recent available score (typically the initial 
wave when they entered the study) was used when calculating the under 65 mental status score9.  
As a dimension of changes in health and how that may impact changing a consent 
decision, change in cognition was also computed for each of these cognitive functioning indices. 
The simple difference of the W1 cognition score from the W3 cognition score yields a range of 
values from -16 to +15 for word recall (median of -1) and -13 to +9 for mental score (median of 
0). 
Contact before and behavior during the interview are also considered predictors of future 
consent. Multiple waves of interview paradata are used due to the nature of the alternating survey 
mode design of HRS. The number of contact attempts from the current wave is included as it 
precedes the consent decision (Sakshaug et al., 2010). In addition, survey resistance measures 
from the most recent wave are included. Respondents may behave differently during face-to-face 
interviews than during telephone interviews, or interviewers may differentially perceive 
respondent engagement in each interview mode (for more details, see Appendix C). In addition, 
there is interviewer variation across these measures, and respondents are not guaranteed to have 
the same interviewer across waves. Given the W2 interview was primarily conducted over the 
telephone, the inclusion of interviewer observations from the last E-FTF interview (W1) 
provides additional insights to the W2 observations given the similarities in the environment and 
circumstances between W1 and W3. 
                                               
9 This choice results in a slightly conservative measure of mental status change for those under 65 because they are 
guaranteed a change score of 0 for the 8 item naming task. The justification for retaining mental status score in this 
analysis comes from the retained backwards count from 20 and the Serial 7’s task which account for the remaining 7 
points of the score. 
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The number of call attempts is included for W1, W2, and W3 separately. In order to 
measure resistance to the survey itself, a number of questions regarding various aspects of the 
interview experience are asked of interviewers after the completion of the interview. Indicators 
were created for seven of the post-survey interviewer observations in order to form two indices: 
a confidentiality concern index and uncooperativeness index. These indices were adapted from 
earlier work by Sakshaug et al. (2012) on record linkage consent. Adaptations were necessary as 
to include items available in HRS 2006 and 2008. The confidentiality concern index includes: 
•  “During the interview, how often did the respondent express concern about whether 
his/her answers would be kept confidential?” (never, seldom, often)  
• “During the interview, how often did the respondent ask you why you needed to 
know the answer to some questions” (never, seldom, often) 
• “How truthful do you believe the respondent was regarding his/her answers on 
financial questions?” (completely truthful, mainly truthful, about half and half, 
mainly untruthful)  
The uncooperativeness index includes: 
• “How was the respondent’s cooperation during the interview?” (excellent, good, fair, 
poor)  
• “During the interview, how often did the respondent ask how much longer the 
interview would last?” (never, seldom, often) 
•  “How much did the respondent seem to enjoy the interview?” (a great deal, quite a 
bit, some, a little, not at all)  
• “How attentive was the respondent to the questions during the interview?” (not at all 
attentive, somewhat attentive, very attentive) 
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This final item in the uncooperativeness index replaces an earlier item in Sakshaug et al. (2012) 
that was only collected in HRS 2006: “How would you describe the level of resistance from the 
respondent?” Sakshaug et al. (2012) originally tested attentiveness as a separate covariate to 
measure acquiescence, but ultimately found it to be a non-significant predictor. As attentiveness 
encompasses the focus and relative interest a respondent may have during the survey interview, 
its inclusion in the uncooperativeness index is consistent with the other indicators like enjoyment 
and asking how much longer the interview would last. For both indices, a value of 1 was 
assigned if the interviewer recorded a negative response (i.e., expressing concern about 
confidentiality or displaying uncooperative behavior, which are denoted by the bold underlined 
responses above). This results in a confidentiality index range of 0 to 3 and an uncooperativeness 
index range of 0 to 4. These indices are included for both W1 and W2. Further exploration of 
these indices is included in Appendix C. 
In addition to wave specific resistance variables, variables corresponding to the 
longitudinal nature of the study are included to capture resistance due to panel fatigue and 
previous nonresponse: an indicator of whether a respondent was ever a nonrespondent before W1 
and an indicator if they were a nonrespondent in W2. 
As the interviewer is the one who administers consents and actually collects the 
biomeasures, a number of interviewer characteristics are included in this analysis including age 
(continuous), education (divided into high school graduate, some college, college graduate, and 
advanced degree), race/ethnicity (same breakdown as the respondent race/ethnicity), and if a new 
hire. In order to test whether interviewer continuity helps or harms the possibility for consent, an 
indicator was included that identified if the same interviewer made the biomeasure requests in 
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both W1 and W3. However, it does not account for interviewer continuity between W1 and W2 
or W2 and W3; it only denotes E-FTF interviewer continuity.  
For non-consenters, the respondent’s logic for refusing to consent to either PM or DBS 
could reflect concerns related to their health or current situation as opposed to general resistance 
to surveys or the nature of the biomeasure request itself. Someone willing to participate but 
concerned about compromising their health further may be differentially willing to participate at 
a future time if their health or situation improves. Thus, the reason for refusal could be 
informative for both explanatory and predictive purposes.  
When a respondent refuses to consent in HRS, interviewers immediately record the 
reason for the non-consent. Possible reasons include the respondent (or the interviewer) did not 
feel it safe to complete the collection, the respondent did not understand the instructions, the 
respondent had hemophilia or was taking a blood thinning medication (anticoagulant; unique to 
DBS), no suitable location for the collection, and respondent refusal or unwillingness to 
complete the measurement. The final reason is the only one that does not have an explicit 
situational or health related factor as a reason for the non-consent. These cases could be 
considered straight refusals, while the preceding reasons are health-related refusals. 
The reason for refusal to DBS collection was included in both 2006 and 2008, while the 
reason for refusal for PM was included in 2008. Because the reason for refusing PM is missing in 
2006, it was necessary to impute PM refusal. Using consent and reason for refusal data available 
in 2008 and 2010, proportions of straight refusals were estimated based on consent status to DBS 
in those years (see Table 3-2). Of DBS consenters, nearly two-thirds provided a straight refusal 
to PM. Straight refusals to DBS resulted in almost 90% also providing straight refusal to PM. 
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Health-related refusals to DBS had around 7% straight refusal to PM. Reason for PM refusals in 
2006 were imputed from random draws from a uniform distribution based on the observed rates 
of PM refusal.  
Item missingness for sociodemographic, health, cognition, and survey resistance 
variables was less than two percent over all items combined. A nearest-neighbor hot deck 
approach using the R package ‘HotDeckImputation’ (Joenssen, 2015) was used to impute these 
missing values. Imputation was not used for W2 survey variables for 122 respondents who did 
not respond in W2. The number of contact attempts is set to the maximum number of attempts 
for that wave and half-sample10. The missing interviewer attributes for the three interviewers in 
2010 and the two interviewers in 2012 were also not imputed. 
3.5.4 Statistical analyses  
  Two-level random effects logistic regression models were used to estimate the 
respondents’ likelihood of consenting to the biomeasure request, conditional on respondent- and 
interviewer-level covariates. The primary unit of analysis is the respondent with respondents 
                                               
10 Follow-up analyses found that use of the median or a higher percentile (e.g., 90th) of contact attempts made no 
difference in the W2 contact attempts estimate for any of the models. Number of contact attempts is available for 
non-respondents as restricted data. 
Table 3-2. Straight refusal to physical measurements based on consent status to dried blood 
spots 
 Straight refusal to PM given… 
HRS Consent to DBS Straight refusal to DBS Health-related refusal to DBS 
2008 66.7% 89.9% 7.1% 
2010 65.6% 87.6% 7.2% 
Average  66.2% 88.8% 7.2% 
 
Note. PM = physical measurement. DBS = dried blood spot. 
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nested within interviewers. The regression was performed using the MELOGIT procedure in 
Stata 15. Wald tests were used to evaluate the model fit of various analytic variable sets given 
the complex sample survey design (Heeringa, West, & Berglund, 2010).   
HRS uses a complex sample survey design that needed to be incorporated into this 
analysis to properly estimate standard errors for this model. The sample consists of 56 sampling 
strata with a pair of primary sampling units (PSUs) within each strata resulting in a total of 112 
PSUs. A jackknife variance estimation procedure with 112 replications (JKn)11 was performed to 
compute appropriate standard errors. Final sample weights accounting for selection and 
nonresponse were not incorporated into this analysis as the goal of this analysis was not to 
generalize to the overall HRS population.  
 The first two models are identical for both W1 consenters and non-consenters. The first 
model includes time independent sociodemographic characteristics, previous wave health and 
cognition (W1 in this analysis), survey resistance indicators from the most recent wave (W2 for 
this analysis), and current wave (W3) contact attempts and interviewer characteristics. This 
model is comparable to those used in Sakshaug et al. (2010) and Korbmacher (2014) for single 




� = 𝑿𝑿𝟏𝟏𝜷𝜷�𝟏𝟏 + 𝒖𝒖 (3.1) 
where 𝑌𝑌𝑠𝑠𝑗𝑗 denotes the consent outcome for PM or DBS of respondent i interviewed by 
interviewer j, 𝑿𝑿𝟏𝟏 represents the matrix of single wave first and second level covariates (including 
                                               
11 While the two PSU per strata design of the HRS would allow for a JK2 estimator to be used, JK2 is not 
theoretically supported for non-linear estimators like logistic regression coefficients (Valliant, Dever, & Kreuter, 
2013). Initial analyses using the JK2 estimator suggested there was an unstable covariance matrix. Instability may 
also be related to available degrees of freedom and the number of predictors in the model. 
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sociodemographics, W1 health and cognition measures, W2 survey resistance measures, W3 
contact attempts, and W3 interviewer attributes), 𝜷𝜷�𝟏𝟏 is the estimated regression parameter vector, 
and 𝒖𝒖 is the vector of random interviewer effects distributed as 𝑁𝑁(0,𝜎𝜎2).   
The second model addresses the longitudinal changes expected to influence recurrent 
consent decisions by expanding on the first model to include the longitudinal and change 
measures including changes in health and cognition (W1 to W3), previous E-FTF wave survey 





� = 𝑿𝑿𝟏𝟏𝜷𝜷�𝟏𝟏 + 𝑿𝑿𝟐𝟐𝜷𝜷�𝟐𝟐 + 𝒖𝒖 (3.2) 
where 𝑿𝑿𝟐𝟐 represents the additional first level covariates (including W1 to W3 health and 
cognition change indicators, W1 survey resistance measures, and W1 to W3 interviewer 
continuity) and 𝜷𝜷�𝟐𝟐 is the additional estimated regression parameter vector. These two models are 
the only models considered for previous consenters. 
For previous non-consenters, two additional models are considered. The third model for 
non-consenters expands the second model by including previous reason for refusal (the vector 





� = 𝑿𝑿𝟏𝟏𝜷𝜷�𝟏𝟏 + 𝑿𝑿𝟐𝟐𝜷𝜷�𝟐𝟐 + 𝑿𝑿𝟑𝟑𝜷𝜷�𝟑𝟑 + 𝒖𝒖 (3.3) 
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The fourth and final model for non-consenters includes an interaction between previous 
refusal and interviewer continuity (summarized as vector 𝑿𝑿𝟒𝟒) posing the question of whether 




� = 𝑿𝑿𝟏𝟏𝜷𝜷�𝟏𝟏 + 𝑿𝑿𝟐𝟐𝜷𝜷�𝟐𝟐 + 𝑿𝑿𝟑𝟑𝜷𝜷�𝟑𝟑 + 𝑿𝑿𝟒𝟒𝜷𝜷�𝟒𝟒 + 𝒖𝒖 (3.4) 
In order to better understand the impact of reasons for non-consent with interviewer 
continuity, a single post-hoc linear combination was performed to examine if the effect of 
interviewer continuity for those who provided a straight refusal to PM or DBS is different than 0. 
This post-hoc test is expressed as a test of log-odds with a null hypothesis of the form: 
 𝐻𝐻0: 𝛽𝛽𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑝𝑝 + 𝛽𝛽𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑝𝑝 × 𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎𝑖𝑖 = 0 (3.5) 
The sum of these two coefficients is the log-odds of interviewer continuity when straight refusal 
to PM or DBS is provided. Alternatively, this hypothesis can be expressed as an odds ratio: 
𝐻𝐻0: exp�𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶+𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 × 𝑅𝑅𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝑅𝑅� = exp�𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶�exp�𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 × 𝑅𝑅𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝑅𝑅� = exp0 
𝐻𝐻0: 𝑂𝑂𝑅𝑅𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑝𝑝 × 𝑂𝑂𝑅𝑅𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑝𝑝 × 𝑅𝑅𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎𝑖𝑖 = 1 
The primary reason for building these models this way is to illustrate the need for 
including more longitudinal information in consent models where the request is repeated across 
waves and specifically measure the impact of reason for refusal. 
3.6 Results 
Section 3.6.1 looks at PM and DBS consent from W1 to W3 and breaks down the 
bivariate relationships between both W3 consent indicators and the explanatory variables. 
Section 3.6.2 reviews the two models for previous consenters for physical measurements 
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followed by dried blood spots. Section 3.6.3 reviews the multiple models for previous non-
consenters. Any results cited in these sections as having a higher or lower rate are statistically 
significant at the α = 0.05 level. Given there are as many as 64 predictors in each model, a 
recommended Bonferroni correction for these models is α = 0.05/64 = 0.0008. Bonferroni 
adjusted critical values are denoted as statistically significant in this section. Additional results 
are also presented, but may be deemed insufficiently conservative as a test criterion to assess the 
null hypothesis. 
3.6.1 Outcome and sample characteristics  
Across the two half-samples, 94.1% of the eligible 2006 and 2008 W1 E-FTF 
respondents consented to the collection of physical measurements (PM) in W3 (see Table 3-3). 
Of those who consented to PM in W1, over 95% consented to collect PM at W3. Of those who 
did not consent to PM (for health or other reasons) at W1, over 72% consented in W3. This is a 
reassuring finding. With minimal wave-to-wave intervention, almost three-fourths of non-
consenting individuals eligible for biomeasure collection are likely to consent in the following E-
FTF wave. For DBS consent, nearly 88% of eligible respondents consented in W3. Over 92% of 
respondents who had consented previously consented in the subsequent E-FTF wave. Fifty-eight 
percent of W1 DBS non-consenters consented in W3. 
For PM consenters (see Table 3-4), college graduates have 2.22 odds of PM consent 
compared to those with less than high school with high school graduates and those with some 
college education having odds ratios higher than 1. Both non-Hispanic black and English 
interviewed Hispanic respondents have significantly lower odds of consent than non-Hispanic 
other respondents though Hispanic respondents interviewed in Spanish are quite similar. A 
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respondent living in a household with another eligible study member improved the odds of 
consenting to PM in W3. Regarding a respondent’s health status, the least healthy or physical 
active categories had low odds of PM consent. Respondents classified as having fair/poor self-
rated health have less than half odds of PM consent as do those who perform mildly vigorous 
activity hardly ever or never. Obese respondents have 0.66 odds of PM consent in W3, but 
respondents who refused height and weight only have 0.40 odds of consent. Respondents 
diagnosed with diabetes, hardly ever or never exercise, and have more functional limitations 
were less likely to consent to PM. Health status change indicators do not appear to be as 
important as W1 measures, though reductions in mildly vigorous activity (OR = 0.59) and 
increases in functional limitations (OR = 0.92) are significant predictors of W3 non-consent. 
Baseline cognition scores are significant predictors of W3 PM consent. Increases in the mental 
status cognition score resulted in higher odds of consent at W3. Both W1 and W2 survey 
Table 3-3. Wave 3 biomeasure consent rates for physical measurements and dried blood spots 
across two E-FTF waves 
 W3 PM Status  
W1 PM Status Consent Non-consent Total 
Consent    9,788 (95.3%)     480 (4.7%) 10,268  
Non-consent       420 (72.3%)     161 (27.7%)      581  
Health reason         81 (75.0%)       27 (25.0%)      108  
Non-health reason       339 (71.7%)     134 (28.3%)      473  
Total  10,208 (94.1%)     641 (5.9%) 10,849 
   
 W3 DBS Status  
W1 DBS Status Consent Non-consent Total 
Consent  8,697 (92.3%)     727 (7.7%)   9,424  
Non-consent     827 (58.0%)     598 (42.0%)   1,425 
Health reason     174 (71.0%)       71 (29.0%)      245  
Non-health reason     653 (55.3%)     527 (44.7%)   1,180  
Total  9,524 (87.8%)  1,325 (12.2%) 10,849 
    
Note. Italicized values are subsets of non-consent based on reason for non-consent. E-FTF = enhanced face-to-
face interview. PM = physical measurements. DBS = dried blood spot. 
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resistance indices are significant predictors. W2 and W3 contact attempts are also important. 
Those who kept the same interviewer between E-FTF waves had 0.77 odds of consenting to PM 
at W3 relative to those with a different interviewer at W1 and W3, though this effect is only 
significant at 0.05. Respondents interviewed by non-Hispanic black interviews had half odds of 
PM consent in W3 compared to respondents interviewed by non-Hispanic other interviewers. 
For PM non-consenters, few variables are significant given a multiple-comparisons 
adjustment and so that criterion is relaxed for purposes of discussion for this group. Those who 
originally performed mildly vigorous activity less than once a week were less likely to consent at 
W3 (OR = 0.51). In addition, the number of functional limitations at W1 has a negative 
relationship with W3 PM consent (OR = 0.95). The W1 survey resistance indices both predict 
W3 non-consent with those who were more uncooperative and concerned about confidentiality 
less likely to consent. Only the W2 confidentiality index has an effect on W3 consent. 
Interviewer continuity has a negative effect on future PM consent with those maintaining the 
same interviewer having half the odds of consenting in W3. Interviewer age and hire status also 
play a role for previous non-consenters. The reason for a W1 PM refusal (health-related or 
otherwise) does not show a relationship with future consent. 
DBS consenters have similar bivariate effects to PM consenters with the exceptions of 
respondent education, religious activity, diabetes, and change in BMI. In addition, interviewer 
continuity does not have an effect on W3 DBS consent. Unlike PM consent, changes in word 
recall scores from W1 to W3 do lead to increased odds of DBS consent and respondents who 
were a nonrespondent before W1 had 0.65 odds of DBS consent, both at the 0.05 level. 
Respondents with newly hired and more educated interviewers were less likely to consent. 
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DBS non-consenters (using a similar relaxation of the multiple-comparisons critical 
value) with higher education are less likely to consent to W3 DBS. No health or health change 
measures, except the W1 cognition scores, are significant predictors of W3 PM consent for 
previous DBS non-consenters. Among W2 survey resistance measures only the confidentiality 
index and both W1 resistance indices predict W3 consent. The reason for DBS refusal at W1 
does have an effect on W3 DBS consent with those refusing for non-health-related reasons 
having half the odds of consenting compared to those who did so for health-related reasons. 
Interviewer continuity is not significant at the 0.05 level, though there is a negative effect 
observed with continuity with those who had the same interviewer in both waves less likely to 
consent to DBS, similar to the result for PM consent. Respondents with older interviewers were 
less likely to consent to DBS in W3. Respondents interviewed by a non-Hispanic black 
interviewer were less likely to consent to DBS (OR = 0.79) while those interviewed by a 
Hispanic interviewer were more likely to consent (OR = 1.32) compared to those interviewed by 
non-Hispanic other interviewers. 
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Table 3-4. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 PM consent 
 W1 PM Consenters (n=10,268)  W1 PM Non-consenters (n=581) 













Respondent characteristics          
Age 71.89 (0.088) - 0.977 < 0.0001  71.29 (0.389) - 0.988 0.2278 
Gender          
     Male 0.409 0.955 ref.   0.439 0.690 ref.  
     Female 0.591 0.952 0.943 0.5373  0.561 0.749 1.336 0.1201 
Education          
     Less than HS (<12 years) 0.203 0.930 ref.   0.275 0.681 ref.  
     High school (12 years) 0.336 0.957 1.703   0.329 0.717 1.187  
     Some college (13-15 years) 0.225 0.954 1.572   0.213 0.782 1.681  
     College grad (16+ years) 0.236 0.967 2.217 < 0.0001  0.182 0.726 1.242 0.2988 
Race/ethnicity          
     Non-Hispanic other 0.778 0.960 ref.   0.658 0.723 ref.  
     Non-Hispanic black 0.137 0.928 0.549   0.248 0.694 0.875  
     Hispanic (English interview) 0.042 0.915 0.439   0.059 0.794 1.300  
Hispanic (Spanish interview) 0.042 0.956 0.919 < 0.0001  0.036 0.810 1.637 0.6059 
Religious activity          
     Less than 1/week 0.564 0.948 ref.   0.632 0.703 ref.  
     At least 1/week 0.436 0.960 1.293 0.0071  0.368 0.757 1.316 0.1581 
Other eligible household member          
     No 0.364 0.940 ref.   0.441 0.742 ref.  
     Yes 0.636 0.961 1.587 < 0.0001  0.559 0.708 0.841 0.3555 
Health status (W1)          
Self-rated health          
     Excellent 0.116 0.967 ref.   0.093 0.704 ref.  
     Very good 0.321 0.965 0.935   0.251 0.760 1.335  
     Good 0.321 0.953 0.684   0.301 0.743 1.216  
     Fair/Poor 0.243 0.931 0.459 < 0.0001  0.355 0.685 0.913 0.3948 
Body mass index (BMI)          
     Underweight/Normal (<25) 0.282 0.962 ref.   0.258 0.753 ref.  
     Overweight (25-29.9) 0.385 0.957 0.885   0.368 0.734 0.902  
     Obese (>30) 0.317 0.944 0.665   0.336 0.697 0.755  
     Refused 0.016 0.909 0.395 0.0003  0.038 0.636 0.573 0.5255 
(continued) 
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Table 3-4. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 PM consent (continued) 
 W1 PM Consenters (n=10,268)  W1 PM Non-consenters (n=581) 













Mildly vigorous activity          
     At least 1/week 0.872 0.956 ref.   0.811 0.745 ref.  
     1-3 times/month 0.060 0.961 1.131   0.069 0.600 0.513  
     Hardly ever/never 0.068 0.908 0.453 < 0.0001  0.121 0.643 0.615 0.0469 
Diabetes           
     No 0.798 0.956 ref.   0.790 0.736 ref.  
     Yes 0.202 0.942 0.749 0.0090  0.210 0.672 0.734 0.1639 
No. of functional limitations 3.39 (0.034) - 0.937 < 0.0001  4.30 (0.182) - 0.947 0.0079 
Visited the doctor in the last 2 years (W1)         
     No 0.045 0.950 ref.   0.072 0.667 ref.  
     Yes 0.955 0.953 1.069 0.7621  0.928 0.727 1.333 0.4061 
Change in health status          
Self-rated health change          
     No change 0.563 0.953 ref.   0.556 0.697 ref.  
     Declined 0.253 0.957 1.080   0.238 0.732 1.189  
     Improved 0.184 0.949 0.921 0.5316  0.207 0.783 1.575 0.1780 
BMI change          
     No change 0.788 0.955 ref.   0.794 0.703 ref.  
     Declined 0.097 0.961 1.160   0.093 0.796 1.653  
     Improved 0.115 0.937 0.710 0.0207  0.114 0.803 1.724 0.0940 
Mildly vigorous activity change          
     No change 0.788 0.958 ref.   0.725 0.746 ref.  
     Declined 0.145 0.929 0.585   0.191 0.676 0.710  
     Improved 0.067 0.955 0.943 < 0.0001  0.084 0.633 0.587 0.1222 
Diabetes change          
      No change 0.940 0.953 ref.   0.926 0.719 ref.  
      Developed 0.060 0.956 1.072 0.7279  0.074 0.767 1.288 0.4904 
Functional limitation change 0.84 (0.027) - 0.918 < 0.0001  0.84 (0.119) - 0.983 0.5966 
Visited the doctor in the last 2 years (W3)         
     No 0.0685 0.935 ref.   0.086 0.620 ref.  
     Yes 0.9315 0.955 1.473 0.0209  0.914 0.733 1.679 0.0985 
(continued) 
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Table 3-4. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 PM consent (continued) 
 W1 PM Consenters (n=10,268)  W1 PM Non-consenters (n=581) 













Cognition indices          
Word recall score (W1) 10.09 (0.031) - 1.101 < 0.0001  9.23 (0.131) - 0.999 0.9603 
Mental status score (W1) 13.04 (0.022) - 1.125 < 0.0001  12.17 (0.113) - 1.048 0.1574 
Change in word recall -0.84 (0.029) - 1.020 0.2222  -0.49 (0.127) - 1.038 0.2157 
Change in mental status score -0.55 (0.019) - 1.114 < 0.0001  -0.50 (0.087) - 1.075 0.1023 
Survey resistance (W1)          
No. of contact attempts 5.40 (0.042) - 0.989 0.2621  6.80 (0.280) - 1.018 0.2349 
Uncooperative index (range: 0 - 4) 0.66 (0.010) - 0.731 < 0.0001  1.71 (0.055) - 0.855 0.0260 
Confidentiality index (range: 0 - 3) 0.40 (0.007) - 0.685 < 0.0001  0.90 (0.040) - 0.712 0.0003 
Survey resistance (W2)          
W2 Respondent          
     No 0.009 0.880 ref.   0.017 0.600 ref.  
     Yes 0.991 0.954 2.811 0.0050  0.983 0.725 1.758 0.3982 
No. of contact attempts 6.66 (0.122) - 0.990 0.0010  9.17 (0.683) - 0.998 0.7322 
Uncooperative index (range: 0 - 4) 0.85 (0.011) - 0.851 < 0.0001  1.30 (0.052) - 0.982 0.8063 
Confidentiality index (range: 0 - 3) 0.35 (0.006) - 0.805 0.0016  0.56 (0.033) - 0.753 0.0119 
Survey resistance (W3)          
No. of contact attempts 5.76 (0.051) - 0.967 < 0.0001  6.85 (0.274) - 0.996 0.7497 
Panel status          
Ever a nonrespondent before W1          
     No 0.935 0.954 ref.   0.852 0.735 ref.  
     Yes 0.065 0.941 0.759 0.1177  0.148 0.651 0.672 0.1142 
Interviewer continuity          
E-FTF interviewer continuity          
     No 0.839 0.955 ref.   0.850 0.745 ref.  
     Yes 0.161 0.943 0.769 0.0295  0.150 0.598 0.509 0.0060 
Reason for non-consent (W1)          
Straight refusal for non-consent          
     No, health-related - - -   0.186 0.750 ref.  
     Yes - - - -  0.814 0.717 0.843 0.4818 
(continued) 
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Table 3-4. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 PM consent (continued) 
 W1 PM Consenters (n=10,268)  W1 PM Non-consenters (n=581) 













Interviewer attributes          
Age 50.93 (0.125) - 1.003 0.3601  50.81 (0.511) - 0.984 0.0361 
Gender          
      Male 0.166 0.938 ref.   0.155 0.778 ref.  
      Female 0.834 0.956 1.453 0.0014  0.845 0.713 0.709 0.1973 
Race/ethnicity          
     Non-Hispanic other 0.759 0.959 ref.   0.725 0.751 ref.  
     Non-Hispanic black 0.147 0.925 0.519   0.196 0.649 0.615  
     Hispanic 0.094 0.949 0.792 < 0.0001  0.079 0.652 0.623 0.0579 
Education          
     High school graduate 0.110 0.953 ref.   0.134 0.756 ref.  
     Some college 0.337 0.949 0.910   0.308 0.704 0.766  
     College graduate 0.294 0.950 0.940   0.267 0.742 0.926  
     Advanced degree 0.259 0.962 1.256 0.0611  0.291 0.710 0.789 0.7556 
New hire          
     No 0.563 0.953 ref.   0.571 0.687 ref.  
     Yes 0.437 0.954 1.008 0.9328  0.429 0.771 1.536 0.0237 




Table 3-5. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 DBS consent 
 W1 DBS Consenters (n=9,424)  W1 DBS Non-consenters (n=1,425) 













Respondent characteristics          
Age 71.99 (0.092) - 0.990 0.0147  70.98 (0.238) - 1.013 0.0347 
Gender          
     Male 0.409 0.929 ref.   0.421 0.585 ref.  
     Female 0.591 0.919 0.868 0.0746  0.579 0.577 0.968 0.7616 
Education          
     Less than HS (<12 years) 0.207 0.911 ref.   0.208 0.625 ref.  
     High school (12 years) 0.338 0.922 1.156   0.323 0.613 0.986  
     Some college (13-15 years) 0.224 0.929 1.279   0.225 0.545 0.719  
     College grad (16+ years) 0.231 0.928 1.244 0.1426  0.244 0.520 0.650 0.0059 
Race/ethnicity          
     Non-Hispanic other 0.783 0.930 ref.   0.698 0.566 ref.  
     Non-Hispanic black 0.131 0.897 0.666   0.224 0.586 1.102  
     Hispanic (English interview) 0.043 0.869 0.494   0.044 0.619 1.279  
     Hispanic (Spanish interview) 0.043 0.934 1.066 < 0.0001  0.034 0.792 2.916 0.0111 
Religious activity          
     Less than 1/week 0.561 0.918 ref.   0.612 0.572 ref.  
     At least 1/week 0.439 0.929 1.153 0.0683  0.388 0.593 1.090 0.4361 
Other eligible household member          
     No 0.362 0.911 ref.   0.411 0.573 ref.  
     Yes 0.638 0.930 1.284 0.0016  0.590 0.586 1.055 0.6231 
Health status (W1)          
Self-rated health          
     Excellent 0.116 0.940 ref.   0.106 0.517 ref.  
     Very good 0.321 0.930 0.847   0.290 0.559 1.188  
     Good 0.319 0.922 0.757   0.321 0.593 1.364  
     Fair/Poor 0.243 0.907 0.627 0.0026  0.284 0.611 1.472 0.1609 
Body mass index (BMI)          
     Underweight/Normal (<25) 0.283 0.925 ref.   0.267 0.558 ref.  
     Overweight (25-29.9) 0.382 0.930 1.076   0.392 0.572 1.058  
     Obese (>30) 0.319 0.915 0.869   0.314 0.603 1.202  
     Refused 0.016 0.850 0.458 0.0025  0.027 0.667 1.585 0.3765 
(continued) 
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Table 3-5. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 DBS consent (continued) 
 W1 DBS Consenters (n=9,424)  W1 DBS Non-consenters (n=1,425) 













Mildly vigorous activity          
     At least 1/week 0.874 0.927 ref.   0.837 0.581 ref.  
     1-3 times/month 0.059 0.919 0.886   0.074 0.524 0.794  
     Hardly ever/never 0.068 0.872 0.535 < 0.0001  0.089 0.622 1.187 0.3195 
Diabetes           
     No 0.796 0.922 ref.   0.808 0.571 ref.  
     Yes 0.204 0.925 1.031 0.7479  0.192 0.620 1.229 0.1331 
No. of functional limitations 3.40 (0.036) - 0.958 < 0.0001  3.65 (0.102) - 1.015 0.2909 
Visited the doctor in the last 2 years (W1)         
     No 0.044 0.928 ref.   0.063 0.596 ref.  
     Yes 0.956 0.923 0.927 0.6914  0.938 0.579 0.935 0.7644 
Change in health status          
Self-rated health change          
     No change 0.562 0.922 ref.   0.568 0.581 ref.  
     Declined 0.254 0.920 0.963   0.241 0.558 0.911  
     Improved 0.185 0.929 1.098 0.5378  0.191 0.607 1.112 0.4794 
BMI change          
     No change 0.787 0.925 ref.   0.802 0.578 ref.  
     Declined 0.098 0.926 1.026   0.087 0.637 1.280  
     Improved 0.116 0.909 0.817 0.2047  0.111 0.551 0.894 0.3241 
Mildly vigorous activity change          
     No change 0.790 0.927 ref.   0.749 0.576 ref.  
     Declined 0.143 0.898 0.689   0.174 0.617 1.184  
     Improved 0.067 0.924 0.947 0.0015  0.077 0.536 0.850 0.3149 
Diabetes change          
      No change 0.941 0.922 ref.   0.926 0.577 ref.  
      Developed 0.059 0.931 1.139 0.4439  0.074 0.623 1.210 0.3568 
Functional limitation change 0.85 (0.028) - 0.948 < 0.0001  0.76 (0.074) - 1.014 0.4673 
Visited the doctor in the last 2 years (W3)         
     No 0.069 0.923 ref.   0.072 0.602 ref.  
     Yes 0.931 0.923 0.997 0.9826  0.928 0.579 0.908 0.6440 
(continued) 
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Table 3-5. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 DBS consent (continued) 
 W1 DBS Consenters (n=9,424)  W1 DBS Non-consenters (n=1,425) 













Cognition indices          
Word recall score (W1) 10.05 (0.033) - 1.035 0.0048  9.95 (0.084) - 0.939 0.0002 
Mental status score (W1) 13.03 (0.023) - 1.059 0.0006  12.72 (0.064) - 0.949 0.0208 
Change in word recall -0.84 (0.030) - 1.040 0.0027  -0.66 (0.080) - 1.014 0.4286 
Change in mental status score -0.56 (0.019) - 1.075 0.0003  -0.49 (0.052) - 0.983 0.5279 
Survey resistance (W1)          
No. of contact attempts 5.37 (0.043) - 0.994 0.4692  6.17 (0.156) - 0.999 0.8798 
Uncooperative index (range: 0 - 4) 0.61 (0.010) - 0.779 < 0.0001  1.43 (0.034) - 0.920 0.0485 
Confidentiality index (range: 0 - 3) 0.37 (0.007) - 0.737 < 0.0001  0.80 (0.024) - 0.784 < 0.0001 
Survey resistance (W2)          
W2 Respondent          
     No 0.009 0.838 ref.   0.015 0.500 ref.  
     Yes 0.992 0.924 2.345 0.0112  0.985 0.582 1.390 0.4445 
No. of contact attempts 6.59 (0.125) - 0.992 0.0014  8.09 (0.399) - 0.996 0.2692 
Uncooperative index (range: 0 - 4) 0.83 (0.011) - 0.898 < 0.0001  1.17 (0.032) - 0.927 0.0797 
Confidentiality index (range: 0 - 3) 0.34 (0.006) - 0.822 0.0007  0.53 (0.020) - 0.800 0.0016 
Survey resistance (W3)          
No. of contact attempts 5.70 (0.052) - 0.965 < 0.0001  6.55 (0.160) - 0.989 0.2140 
Panel status          
Ever a nonrespondent before W1          
     No 0.937 0.925 ref.   0.888 0.583 ref.  
     Yes 0.064 0.890 0.653 0.0029  0.112 0.556 0.895 0.5130 
Interviewer continuity          
E-FTF interviewer continuity          
     No 0.840 0.921 ref.   0.839 0.592 ref.  
     Yes 0.161 0.931 1.144 0.2119  0.161 0.522 0.753 0.0501 
Reason for non-consent (W1)          
Straight refusal for non-consent          
     No, health-related - - -   0.172 0.710 ref.  
     Yes - - - -  0.828 0.553 0.506 < 0.0001 
(continued) 
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Table 3-5. Unweighted univariate descriptors of analysis variables with bivariate comparisons to wave 3 DBS consent (continued) 
 W1 DBS Consenters (n=9,424)  W1 DBS Non-consenters (n=1,425) 













Interviewer attributes          
Age 50.96 (0.131) - 1.002 0.5733  50.72 (0.335) - 0.989 0.0071 
Gender          
      Male 0.165 0.887 ref.   0.166 0.536 ref.  
      Female 0.835 0.930 1.692 < 0.0001  0.834 0.589 1.242 0.1298 
Race/ethnicity          
     Non-Hispanic other 0.764 0.930 ref.   0.716 0.586 ref.  
     Non-Hispanic black 0.143 0.889 0.598   0.196 0.527 0.786  
     Hispanic 0.094 0.915 0.809 < 0.0001  0.088 0.651 1.315 0.0496 
Education          
     High school graduate 0.111 0.949 ref.   0.116 0.667 ref.  
     Some college 0.335 0.916 0.581   0.333 0.561 0.639  
     College graduate 0.295 0.915 0.576   0.277 0.587 0.712  
     Advanced degree 0.259 0.929 0.703 0.0006  0.274 0.560 0.637 0.0850 
New hire          
     No 0.565 0.935 ref.   0.552 0.597 ref.  
     Yes 0.435 0.908 0.687 < 0.0001  0.448 0.560 0.861 0.1658 
Note. Mean estimates include standard errors in parentheses. DBS = dried blood spot. LR = likelihood ratio. W1 = Wave 1. W3 = Wave 3. HS = high school. 
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3.6.2 Two-level random effects models for previous consenters 
 Within the multiple logistic regression model, sociodemographic characteristics like 
education, race/ethnicity and having another eligible household member show no effects for 
previous consenters on W3 PM consent though significant in bivariate associations. Respondent 
age is significant with older respondents less likely to consent at W3. Hispanic respondents who 
were interviewed in English had half the odds of consenting to PM compared to non-Hispanic 
other respondents, though this effect is not significant using the Bonferroni correction. Attending 
religious services at least once a week results in around 1.4 odds of W3 PM consent, slightly 
greater than the corresponding bivariate odds ratio, but only at the 0.05 level. 
 Regarding wave 1 health indicators, obese (BMI > 30) respondents have about 0.70 odds 
of consenting to PM at W3 compared to those who are underweight or have a normal BMI. 
Those who refused to provide height and weight to calculate BMI had nearly half the odds of 
consent, but this effect is not significant with the multiple-comparison correction. Respondents 
who do little to no mildly vigorous activity are also less likely than those who are active at least 
once a week to consent again to PM at W3 (OR = 0.67 in Model 1). This activity-related effect is 
strengthened once accounting for longitudinal factors like changes in health status (OR = 0.52). 
While significant in bivariate analyses, self-rated health, diabetes, and the number of functional 
limitations all have no effect on consent to PM at W3.  
 Considering the longitudinal and change indicators introduced in Model 2, an increase in 
the number of functional limitations also results in a reduction in the odds of consent (OR = 
0.93) when holding the original number of limitations constant. A decline in mildly vigorous 
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activity from W1 to W3 results in 0.73 odds of consent to PM at W3 compared to no change in 
activity, but the effect is weak.  
 In Model 1, neither cognition index is a significant predictor of W3 PM consent. With the 
introduction of the cognition change variables in Model 2, both the mental status score and the 
change in mental status score are found to be significant with 1.06 and 1.07 odds for a unit shift 
(positive) in the change scores, respectively, but only at the 0.05 level. 
None of the W2 survey resistance measures explain W3 PM consent, but both the W1 
confidentiality and uncooperative indices do explain W3 consent, with about 0.80 odds of PM 
consent in W3 PM consent per unit on the index. Number of contact attempts in the current wave 
(W3) is also significant in both models with 0.97 odds of W3 PM consent for each additional 
contact attempt. Nonresponse, whether before W1 or during W2, did not predict PM consent in 
W3. 
Three W3 interviewer attributes for previous PM consenters were significant predictors 
in Model 2. Respondents with non-Hispanic black interviewers had nearly half the odds of PM 
consent compared to respondents with other non-Hispanic interviewers. Respondents with 
female interviewers had 1.45 odds of PM consent compared to those with male interviewers 
holding all respondent and interviewer attributes constant in Model 2 at the 0.05 alpha level. E-
FTF interviewer continuity from W1 to W3 results in about 0.60 odds of future PM consent, 
though not quite significant accounting for the Bonferroni correction. There is a significant 
amount of interviewer variance not explained by the interviewer attributes included in the model.  
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Table 3-6. Predictors of wave 3 physical measurement consent for wave 1 physical measurement 
consenters 
 Model 1  Model 2 
 Odds Ratio (95% CI)   Odds Ratio (95% CI) 
Respondent Characteristics    
Age (years) 0.97 (0.96, 0.98)****  0.98 (0.96, 0.99)** 
Female 1.08 (0.89, 1.29)   1.07 (0.88, 1.30)  
Education (ref: less than HS)    
High school  1.26 (0.96, 1.66)   1.19 (0.91, 1.55)  
Some college 1.04 (0.75, 1.44)   0.97 (0.71, 1.34)  
College graduate 1.28 (0.86, 1.92)   1.17 (0.79, 1.74)  
Race/ethnicity (ref: Non-Hispanic other)    
Non-Hispanic black 0.91 (0.64, 1.29)   1.01 (0.71, 1.45)  
Hispanic (English interview) 0.47 (0.30, 0.75)**  0.51 (0.32, 0.82)** 
Hispanic (Spanish interview) 1.87 (1.00, 3.49)  2.30 (1.21, 4.36)* 
Attends religious services at least 1/wk 1.42 (1.08, 1.85)*  1.35 (1.02, 1.78)* 
Another eligible HH member 1.27 (0.98, 1.66)   1.23 (0.94, 1.61)  
Health status indicators (W1)    
Self-rated health (ref: Excellent)    
     Very good 1.02 (0.68, 1.53)   1.07 (0.69, 1.64)  
     Good 0.83 (0.52, 1.32)   0.90 (0.53, 1.53)  
     Fair/Poor 0.73 (0.49, 1.10)   0.87 (0.52, 1.45)  
BMI (ref: Underweight/Normal)    
     Overweight 0.90 (0.72, 1.14)   0.87 (0.68, 1.11)  
     Obese 0.70 (0.56, 0.86)***  0.67 (0.53, 0.85)*** 
     Did not report 0.52 (0.30, 0.91)*  0.49 (0.29, 0.84)** 
Diabetes 1.03 (0.79, 1.34)   1.12 (0.85, 1.47)  
Mildly vigorous activity (ref: At least 1/wk)    
     1-3 times/month 1.43 (0.89, 2.32)   1.18 (0.64, 2.18)  
     Hardly ever/never 0.67 (0.50, 0.90)**  0.52 (0.37, 0.74)*** 
No. of functional limitations 0.99 (0.96, 1.02)   0.98 (0.95, 1.01)  
Ever visited doctor in last 2 years (W1) 1.10 (0.69, 1.76)   1.03 (0.63, 1.69)  
Change in health status    
Self-rated health (ref: No change)    
     Declined   1.05 (0.83, 1.31)  
     Improved   0.91 (0.68, 1.22)  
BMI (ref: No change)    
     Declined   1.02 (0.67, 1.55) 
     Improved   0.97 (0.76, 1.23)  
Developed diabetes   1.13 (0.68, 1.87)  
Mildly vigorous activity (ref: No change)    
     Declined   0.73 (0.54, 0.98)* 
     Improved   1.47 (0.85, 2.54)  
Change in no. functional limitations   0.93 (0.90, 0.96)**** 
Ever visited doctor in last 2 years (W3)   1.30 (0.88, 1.93)  
(continued)  
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Table 3-6. Predictors of wave 3 physical measurement consent for wave 1 physical measurement 
consenters (continued) 
 Model 1  Model 2 
 Odds Ratio (95% CI)  Odds Ratio (95% CI) 
Cognition indices    
Word recall score (W1) 1.03 (0.99, 1.08)   1.02 (0.96, 1.08)  
Mental status score (W1) 1.04 (1.00, 1.08)   1.06 (1.01, 1.11)* 
Change in word recall score   1.00 (0.96, 1.05)  
Change in mental status score   1.07 (1.01, 1.13)* 
Survey resistance (W1)    
No. of contact attempts   1.01 (0.99, 1.03)  
Uncooperative Index   0.80 (0.72, 0.88)**** 
Confidentiality Index   0.77 (0.69, 0.87)**** 
Survey resistance (W2)    
Nonrespondent in W2 0.57 (0.11, 2.94)   0.49 (0.09, 2.63)  
No. of contact attempts 1.00 (0.98, 1.01)   1.00 (0.98, 1.01)  
Uncooperative Index 0.90 (0.81, 1.01)   0.96 (0.86, 1.08)  
Confidentiality Index 0.86 (0.71, 1.03)   0.91 (0.75, 1.11)  
Survey resistance (W3)    
No. of contact attempts 0.97 (0.96, 0.99)****  0.97 (0.96, 0.99)**** 
Panel status    
Ever a nonrespondent before W1   0.98 (0.65, 1.48)  
Interviewer continuity    
E-FTF interviewer continuity   0.59 (0.40, 0.87)** 
Interviewer attributes (W3)    
Age (years) 1.00 (0.99, 1.00)   1.00 (0.99, 1.01) 
Female 1.33 (1.00, 1.78)   1.45 (1.09, 1.94)* 
Race (ref: Non-Hispanic other)    
     Non-Hispanic black 0.56 (0.42, 0.74)****  0.56 (0.42, 0.74)**** 
     Hispanic 1.04 (0.70, 1.55)   1.00 (0.64, 1.55)  
Education (ref: HS graduate)    
     Some college 0.93 (0.63, 1.38)   0.96 (0.64, 1.43)  
     College graduate 1.13 (0.72, 1.79)   1.19 (0.75, 1.90)  
     Advanced degree 1.46 (0.91, 2.34)   1.51 (0.92, 2.46)  
New hire 0.81 (0.63, 1.04)   0.76 (0.57, 1.01)  
Interviewer variance 3.17 (2.17, 4.63)****   3.31 (2.21, 4.95)**** 
Note. Confidence intervals are based on jackknife standard errors from a two-level random effects logistic 
regression model. CI = confidence interval. W1 = Wave 1. W2 = Wave 2. W3 = Wave 3. HS = high school. 





 For DBS consent in wave 3, few sociodemographics have an effect when controlling for 
the other variables (see Table 3-7). Hispanics who completed an English interview had 0.55 odds 
of consenting to DBS while Hispanics who completed a Spanish interview had 1.96 odds of 
consenting in Model 2 (OR = 1.70 in Model 1), though the latter effect is not significant given 
the Bonferroni correction. Older respondents are somewhat less likely to consent in Model 1, but 
accounting for health changes and W1 resistance eliminates that effect.  
 Regarding wave 1 health indicators, having a doctor’s diagnosis of diabetes resulted in 
1.41 odds of DBS consent in Model 2 (OR = 1.29 in Model 1). Respondents who do little to no 
mildly vigorous activity are also less likely to consent to DBS at W3 compared to those who are 
active at least once a week (OR = 0.64), similar to the PM model. This effect is amplified in 
Model 2 (OR = 0.48). Previous DBS consenters who failed to provide height and weight data for 
BMI at W1 had 0.52 odds of consenting to DBS collection in W3, but this effect is not 
significant given the Bonferroni correction. 
 When introducing the health change indicators in Model 2, a decline in mildly vigorous 
activity from W1 to W3 results in 0.76 odds of consent to W3 DBS compared to no change in 
activity. Increased mildly vigorous activity also was significant in Model 2 resulting in 1.67 odds 
of DBS consent in W3, an effect not observed in the PM model. However, both of these effects 
are not significant at the Bonferroni correction level of 0.0008. Similar to the PM model, a one 
unit increase in the number of functional limitations between W1 and W3 also results in a 
significant reduction in the odds of consent (OR = 0.96) though the original number of functional 
limitations has no measurable effect despite a large difference in the bivariate comparison.  
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 The cognition indices, significant in the bivariate relationships, are not significant for W3 
DBS consent (similar to the PM model). However, with the introduction of the change variables 
in Model 2, the change in word recall score is found to be 1.04 times the odds of DBS consent in 
W3 at the 0.05 level.  
Examining the survey resistance variables, a one-unit change in the W2 uncooperative 
index reduces the odds of W3 DBS consent by 0.89. Again, the number of previous wave contact 
attempts and the confidentiality index for W2 add nothing to the understanding of DBS consent. 
When adding the W1 survey resistance indicators, the W2 uncooperative index does not remain 
significant, but both the W1 confidentiality and uncooperative indices are significant each 
resulting in 0.81 and 0.88 the odds of W3 DBS consent, respectively. The number of contact 
attempts in the current wave (W3) is also significant in both versions of the model with 0.97 the 
odds of DBS consent for each additional contact just like PM consent. Any nonresponse before 
W1 and W2 nonresponse were not predictive of DBS consent in W3. 
Like PM consent, respondents with female and non-Hispanic black interviewers were 
more likely to DBS consent in W3 at the 0.05 level. In addition, respondents with older 
interviewers were less likely to consent (OR = 0.99) while respondents interviewed by new hires 
had 0.60 odds of DBS consent. Interviewer continuity remains unassociated for follow-up DBS 
consent, consistent with the bivariate results. Like the PM model, there is a significant amount of 
interviewer variance not explained by the interviewer attributes included in the model. 
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Table 3-7. Predictors of wave 3 dried blood spot consent for wave 1 dried blood spot consenters  
 Model 1  Model 2 
 Odds Ratio (95% CI)   Odds Ratio (95% CI) 
Respondent Characteristics    
Age (years) 0.98 (0.97, 0.99)**  0.99 (0.98, 1.01)  
Female 0.91 (0.79, 1.06)   0.87 (0.74, 1.02)  
Education (ref: less than HS)    
High school  1.01 (0.78, 1.29)   0.97 (0.75, 1.24)  
Some college 1.07 (0.79, 1.46)   1.02 (0.74, 1.39)  
College graduate 0.97 (0.69, 1.36)   0.88 (0.63, 1.23)  
Race/ethnicity (ref: Non-Hispanic other)    
Non-Hispanic black 0.86 (0.64, 1.16)   0.93 (0.68, 1.27)  
Hispanic (English interview) 0.54 (0.40, 0.72)****  0.55 (0.41, 0.75)**** 
Hispanic (Spanish interview) 1.70 (1.04, 2.77)*  1.96 (1.19, 3.23)** 
Attends church at least 1/wk 1.19 (0.99, 1.44)   1.15 (0.94, 1.39)  
Another eligible HH member 1.04 (0.87, 1.23)   1.01 (0.85, 1.20)  
Health status indicators (W1)    
Self-rated health (ref: Excellent)    
     Very good 0.89 (0.67, 1.19)   0.88 (0.66, 1.19)  
     Good 0.84 (0.62, 1.13)   0.81 (0.59, 1.11)  
     Fair/Poor 0.80 (0.57, 1.10)   0.77 (0.54, 1.11)  
BMI (ref: Underweight/Normal)    
     Overweight 1.07 (0.88, 1.30)   1.05 (0.85, 1.29)  
     Obese 0.91 (0.74, 1.12)   0.87 (0.69, 1.08)  
     Did not report 0.54 (0.34, 0.88)*  0.52 (0.32, 0.84)** 
Diabetes 1.29 (1.06, 1.57)**  1.41 (1.16, 1.72)*** 
Mildly vigorous activity (ref: At least 1/wk)    
     1-3 times/month 0.92 (0.70, 1.21)   0.72 (0.52, 0.98)* 
     Hardly ever/never 0.64 (0.47, 0.86)**  0.48 (0.34, 0.66)**** 
No. of functional limitations 0.99 (0.96, 1.01)   0.99 (0.96, 1.02)  
Ever visited doctor in last 2 years (W1) 0.93 (0.63, 1.38)   0.96 (0.66, 1.40)  
Change in health status    
Self-rated health (ref: No change)    
     Declined   0.92 (0.74, 1.14)  
     Improved   1.11 (0.88, 1.41)  
BMI (ref: No change)    
     Declined   0.94 (0.70, 1.25)  
     Improved   0.97 (0.77, 1.23)  
Developed diabetes   1.24 (0.90, 1.72)  
Mildly vigorous activity (ref: No change)    
     Declined   0.76 (0.61, 0.95)* 
     Improved   1.67 (1.14, 2.43)** 
Change in no. functional limitations   0.96 (0.94, 0.98)*** 
Ever visited doctor in last 2 years (W3)   0.97 (0.75, 1.27)  
(continued) 
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Table 3-7. Predictors of wave 3 dried blood spot consent for wave 1 dried blood spot consenters 
(continued) 
 Model 1  Model 2 
 Odds Ratio (95% CI)  Odds Ratio (95% CI) 
Cognition indices    
Word recall score (W1) 1.00 (0.97, 1.03)   1.01 (0.98, 1.06)  
Mental status score (W1) 1.01 (0.97, 1.05)   1.01 (0.97, 1.06)  
Change in word recall score   1.04 (1.01, 1.07)** 
Change in mental status score   1.04 (0.99, 1.08)  
Survey resistance (W1)    
No. of contact attempts   1.01 (0.99, 1.04)  
Uncooperative Index   0.88 (0.81, 0.96)** 
Confidentiality Index   0.81 (0.72, 0.90)*** 
Survey resistance (W2)    
Nonrespondent in W2 0.45 (0.15, 1.40)   0.42 (0.13, 1.32)  
No. of contact attempts 1.00 (0.99, 1.01)   1.00 (0.99, 1.01)  
Uncooperative Index 0.89 (0.81, 0.97)**  0.93 (0.85, 1.01)  
Confidentiality Index 0.90 (0.77, 1.06)   0.93 (0.79, 1.09)  
Survey resistance (W3)    
No. of contact attempts 0.97 (0.95, 0.98)****  0.97 (0.95, 0.98)**** 
Panel status    
Ever a nonrespondent before W1   0.82 (0.60, 1.14)  
Interviewer continuity    
E-FTF interviewer continuity   0.81 (0.61, 1.08)  
Interviewer attributes (W3)    
Age (years) 0.99 (0.98, 1.00)**  0.99 (0.98, 1.00)** 
Female 1.41 (1.12, 1.78)**  1.43 (1.13, 1.82)** 
Race (ref: Non-Hispanic other)    
     Non-Hispanic black 0.65 (0.50, 0.84)**  0.65 (0.50, 0.85)** 
     Hispanic 0.91 (0.64, 1.30)   0.89 (0.62, 1.29)  
Education (ref: HS graduate)    
     Some college 0.78 (0.54, 1.13)   0.80 (0.55, 1.16)  
     College graduate 0.87 (0.61, 1.26)   0.91 (0.62, 1.32)  
     Advanced degree 1.00 (0.69, 1.43)   1.04 (0.72, 1.51)  
New hire 0.61 (0.50, 0.76)****  0.59 (0.47, 0.74)**** 
Interviewer Variance 1.91 (1.49, 2.44)****   1.94 (1.50, 2.52)**** 
Note. Confidence intervals are based on jackknife standard errors from a two-level random effects logistic 
regression model. CI = confidence interval. W1 = Wave 1. W2 = Wave 2. W3 = Wave 3. HS = high school. 




3.6.3 Two-level random effects models for previous non-consenters 
 As noted with the bivariate associations, there are few significant predictors for the W3 
consent models for previous non-consenters. Results from the PM and DBS non-consenters are 
in Tables 3-8 and 3-9, respectively. Full results from the fourth model, which includes the 
interaction of continuity and consent refusal type, are not displayed in these tables, but are 
included in Appendix D. The relevant variables, along with the post-hoc test, are included for 
both PM and DBS in Table 3-10. Table 3-11 compares previous consenters (see Section 3.6.2) 
and non-consenters for PM. Table 3-12 does the same for DBS. 
Consistent with the bivariate breakdown, W1 PM non-consenters had very few 
informative predictors in the W3 model (see Table 3-8). No respondent characteristics were 
significant. While the odds ratio for Spanish interviewed Hispanics is quite large (10.56 in Model 
2), the variance is also quite large. Only two W1 health status or health change indicators are 
associated with W3 PM consent at the 0.05 level. Each functional limitation at W1 resulted in 
about 0.92 odds of consenting to PM in W3. Improving one’s BMI classification (e.g., obese to 
overweight, overweight to normal) had 2.50 odds of obtaining W3 PM consent compared to 
those with no change in their BMI classification. For cognition, W1 PM non-consenters with 
higher scores on their baseline word recall index had 0.90 odds to consent to PM in W3 for each 
point on the word recall scale.  
Survey resistance factors are also not as strong in the PM non-consenters model. The W2 
confidentiality index sees 0.67 the odds of W3 PM consent with each unit increase in the 
confidentiality index, but the effect disappears with the inclusion of W1 resistance measures for 
which the W1 confidentiality index is significant at the Bonferroni correction level (OR = 0.65 in 
Model 2). While there is a small odds ratio for W2 nonrespondents (OR = 0.22) in Model 2, the 
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standard error results in a very wide confidence interval: (0.01, 4.27). Unlike previous 
consenters, the number of contact attempts has no effect on PM consent in the current wave. 
Race of the interviewer is the only significant interviewer attribute predictor at 0.05. In 
Model 1, respondents with Hispanic interviewers had 0.25 odds of W3 PM consent compared to 
those with non-Hispanic other race interviewers. Respondents with non-Hispanic black 
interviewers have 0.46 odds of PM consent after introducing the longitudinal factors in Model 2. 
The variables included in this model do not leave a significant amount of interviewer variance 
unexplained by the interviewer attributes, though the magnitude is on par with the PM consenters 
model. Interviewer continuity is also not a significant predictor, though the 0.59 odds ratio is 
similar to what was seen with the PM consenters. 
When considering Model 3 which adds the type of refusal to the W1 PM collection, the 
effect is not significant, though the odds ratio is 0.62. The addition of refusal reason only results 
in some minor changes across the wider model. The inclusion of the interaction effect of 
interviewer continuity and previous refusal type is also not significant in Model 4 meaning there 
is no difference in the odds of consent for interviewer continuity between those who provided a 
straight refusal and those who provided a health-related refusal (see Table 3-10 or Appendix D). 
For PM non-consenters who gave a health-related refusal to PM in W1, interviewer continuity 
results in virtually no effect on the odds of PM consent in W3 (OR = 1.01). For those who gave a 
straight refusal to PM in W1, interviewer continuity results in 0.54 odds of PM consent in W3 
(OR = 1.01*0.53 = 0.54). The linear combination specified in Equation (3.5) to test this latter 
effect results in a Wald chi-square of 2.48 which is not significant at the 0.05 level (see Table 3-
10). Thus, the odds ratio of interviewer continuity for those who provided a straight refusal to 
PM consent in W1is not statistically different from one.  
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Table 3-8. Predictors of wave 3 physical measurement consent for wave 1 physical measurement 
non-consenters 
 Model 1  Model 2  Model 3 
  Odds Ratio   Odds Ratio   Odds Ratio 
Respondent Characteristics      
Age (years) 0.97 (0.95, 1.00)   0.98 (0.94, 1.01)   0.98 (0.94, 1.01)  
Female 1.39 (0.91, 2.13)   1.31 (0.86, 2.01)   1.28 (0.84, 1.95)  
Education (ref: less than HS)      
High school  1.20 (0.67, 2.15)   1.13 (0.60, 2.13)   1.17 (0.61, 2.26)  
Some college 1.74 (0.83, 3.64)   1.54 (0.67, 3.55)   1.59 (0.69, 3.68)  
College graduate 1.20 (0.54, 2.70)   1.10 (0.45, 2.69)   1.10 (0.45, 2.68)  
Race/ethnicity (ref: Non-Hispanic other)     
Non-Hispanic black 0.78 (0.40, 1.52)   0.77 (0.39, 1.51)   0.78 (0.41, 1.50)  
Hispanic (English interview) 1.28 (0.38, 4.33)   1.29 (0.36, 4.59)   1.27 (0.36, 4.48)  
Hispanic (Spanish interview) 7.06 (0.95, 52.26)  10.56 (0.99, 112.5)  10.28 (0.87, 121.3) 
Attends church at least 1/wk 1.28 (0.80, 2.04)   1.33 (0.81, 2.17)   1.35 (0.82, 2.22)  
Another eligible HH member 0.76 (0.48, 1.20)   0.73 (0.46, 1.16)   0.73 (0.46, 1.15)  
Health status indicators (W1)      
Self-rated health (ref: Excellent)      
     Very good 1.22 (0.52, 2.89)   1.01 (0.36, 2.84)   1.03 (0.36, 2.93)  
     Good 1.35 (0.55, 3.34)   1.19 (0.41, 3.51)   1.22 (0.42, 3.52)  
     Fair/Poor 1.32 (0.55, 3.17)   1.14 (0.36, 3.63)   1.16 (0.36, 3.69)  
BMI (ref: Underweight/Normal)      
     Overweight 0.87 (0.42, 1.82)   0.77 (0.37, 1.61)   0.79 (0.38, 1.64)  
     Obese 0.80 (0.41, 1.55)   0.71 (0.36, 1.41)   0.73 (0.37, 1.46)  
     Did not report 0.44 (0.12, 1.58)   0.55 (0.13, 2.42)   0.59 (0.13, 2.57)  
Diabetes 0.75 (0.38, 1.47)   0.87 (0.43, 1.77)   0.89 (0.43, 1.81)  
Mildly vigorous activity (ref: At least 1/wk)     
     1-3 times/month 0.52 (0.23, 1.16)   0.64 (0.25, 1.61)   0.59 (0.23, 1.51)  
     Hardly ever/never 0.81 (0.36, 1.83)   0.91 (0.29, 2.90)   0.86 (0.28, 2.63)  
No. of functional limitations 0.94 (0.88, 1.00)*  0.93 (0.86, 1.00)*  0.91 (0.85, 0.99)* 
Ever visited doctor in last 2 years (W1) 1.91 (0.80, 4.58)   1.46 (0.58, 3.72)   1.50 (0.58, 3.88)  
Change in health status      
Self-rated health (ref: No change)      
     Declined   1.15 (0.64, 2.05)   1.10 (0.62, 1.94)  
     Improved   1.56 (0.63, 3.88)   1.54 (0.62, 3.82)  
BMI (ref: No change)      
     Declined   1.49 (0.52, 4.27)  1.52 (0.51, 4.49) 
     Improved   2.49 (1.19, 5.18)*  2.50 (1.19, 5.25)* 
Developed diabetes   1.79 (0.63, 5.12)   1.86 (0.67, 5.17)  
Mildly vigorous activity (ref: No change)     
     Declined   0.84 (0.50, 1.42)   0.81 (0.47, 1.39)  
     Improved   0.72 (0.24, 2.14)   0.75 (0.25, 2.19)  
Change in no. functional limitations   0.96 (0.88, 1.04)   0.95 (0.88, 1.04)  
Ever visited doctor in last 2 years (W3)  1.69 (0.69, 4.17)   1.68 (0.68, 4.17)  
(continued) 
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Table 3-8. Predictors of wave 3 physical measurement consent for wave 1 physical measurement 
non-consenters (continued) 
 Model 1  Model 2  Model 3 
  Odds Ratio   Odds Ratio   Odds Ratio 
Cognition indices      
Word recall score (W1) 0.91 (0.84, 0.99)*  0.90 (0.81, 0.99)*  0.90 (0.82, 0.99)* 
Mental status score (W1) 1.06 (0.96, 1.17)   1.11 (0.98, 1.25)   1.10 (0.97, 1.25)  
Change in word recall score   1.00 (0.89, 1.12)   0.99 (0.88, 1.11)  
Change in mental status score   1.09 (0.94, 1.26)   1.08 (0.93, 1.25)  
Survey resistance (W1)      
No. of contact attempts   1.02 (0.98, 1.06)   1.02 (0.98, 1.06)  
Uncooperative Index   0.98 (0.82, 1.17)   0.96 (0.80, 1.16)  
Confidentiality Index   0.65 (0.51, 0.82)***  0.66 (0.52, 0.83)*** 
Survey resistance (W2)      
Nonrespondent in W2 0.32 (0.02, 5.20)   0.22 (0.01, 4.27)   0.20 (0.01, 4.43)  
No. of contact attempts 1.01 (0.99, 1.03)   1.01 (0.98, 1.04)   1.01 (0.98, 1.04)  
Uncooperative Index 1.11 (0.91, 1.35)   1.12 (0.92, 1.38)   1.13 (0.93, 1.39)  
Confidentiality Index 0.67 (0.51, 0.89)**  0.74 (0.55, 1.01)   0.73 (0.54, 1.00)  
Survey resistance (W3)      
No. of contact attempts 0.99 (0.96, 1.02)   0.99 (0.95, 1.02)  0.99 (0.95, 1.02)  
Panel status      
Ever a nonrespondent before W1  0.64 (0.32, 1.29)  0.66 (0.33, 1.33) 
Interviewer continuity      
E-FTF interviewer continuity   0.59 (0.29, 1.21)   0.60 (0.29, 1.24)  
Previous biomeasure consent      
Straight refusal to PM sample (W1)    0.62 (0.34, 1.13)  
Interviewer attributes      
Age (years) 0.99 (0.96, 1.02)   0.99 (0.97, 1.02)   0.99 (0.97, 1.02)  
Female 0.55 (0.30, 1.04)   0.55 (0.30, 1.02)   0.53 (0.28, 1.00)  
Race (ref: Non-Hispanic other)      
     Non-Hispanic black 0.52 (0.26, 1.01)   0.46 (0.22, 0.97)*  0.45 (0.22, 0.95)* 
     Hispanic 0.25 (0.09, 0.73)*  0.25 (0.08, 0.82)*  0.26 (0.08, 0.85)* 
Education (ref: HS graduate)      
     Some college 0.84 (0.38, 1.85)   0.88 (0.40, 1.93)   0.88 (0.39, 1.96)  
     College graduate 0.83 (0.36, 1.92)   0.85 (0.38, 1.87)   0.84 (0.38, 1.88)  
     Advanced degree 0.64 (0.28, 1.43)   0.62 (0.29, 1.32)   0.63 (0.29, 1.35)  
New hire 1.23 (0.66, 2.31)   1.18 (0.65, 2.14)   1.20 (0.67, 2.17)  
Interviewer variance 2.02 (0.46, 8.85)   1.81 (0.38, 8.75)   1.79 (0.38, 8.41) 
Note. Odd ratios 95% confidence intervals are based on jackknife standard errors from a two-level random effects 
logistic regression model. CI = confidence interval. PM = physical measurements. W1 = Wave 1. W2 = Wave 2. W3 
= Wave 3. HS = high school. 




The non-consenter DBS model produces very similar findings to those in the non-
consenter PM model. Only one health variable, obesity, is significant with previous DBS non-
consenters classified as obese having 1.33 odds of DBS consent in W3. No health change 
variables appear in the final models. While both W1 cognition indices were significant in the 
bivariate associations, neither is significant in the multivariate models. 
In Model 1, the confidentiality index is a significant predicator of W3 DBS consent with 
an odds ratio of 0.77. In Model 2 when the longitudinal factors are introduced, W1 
confidentiality index is resulting in 0.78 odds of DBS consent in W3 for each point in that index. 
None of the remaining W1, W2, or W3 survey resistance variables are significant in the latter 
models.  
Interviewer attributes do appear in the W3 DBS consent model for previous non-
consenters. Interviewer age and hire status have a negative effect on DBS consent with 
respondent interviewed by new hires having about 0.70 odds of obtaining W3 DBS consent. 
Respondents with non-Hispanic black interviewers have 0.72 odds of W3 DBS consent once the 
longitudinal factors are included in Model 2. Like the PM non-consenters, the variables included 
in this model do not leave a significant amount of interviewer variance unexplained by the 
interviewer attributes, though the magnitude is much less than the DBS consenters and the PM 
non-consenters. Interviewer continuity has no effect in these models.  
When introducing the reason for previous refusal in Model 3, those who provided a 
straight refusal to DBS in W1 had half the odds of future consent compared to those who 
declined for health reasons and is significant with the Bonferroni correction. The inclusion of 
this variable makes some minor changes in the broader model, but does not change coefficients 
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for previously identified factors. The interaction of interviewer continuity and reason for refusal 
is not significant similar to the PM model. For DBS non-consenters who gave a health-related 
refusal to DBS in W1, interviewer continuity does not result in a statistically significant effect on 
DBS consent in W3 (OR = 1.39). DBS non-consenters who gave a straight refusal in W1 had 
0.63 odds of DBS consent in W3 when they had the same interviewer in W1 as in W3 (OR = 
1.39*0.45 = 0.63). While the difference in interviewer continuity between the reasons for refusal 
may not be significant, the post-hoc linear combination does show that the odds ratio for 




Table 3-9. Predictors of wave 3 dried blood spot consent for wave 1 dried blood spot non-
consenters 
 Model 1  Model 2  Model 3 
  Odds Ratio    Odds Ratio    Odds Ratio  
Respondent Characteristics      
Age (years) 1.01 (1.00, 1.02)   1.01 (1.00, 1.03)   1.01 (0.99, 1.02)  
Female 0.91 (0.70, 1.17)   0.93 (0.72, 1.21)   0.92 (0.71, 1.18)  
Education (ref: less than HS)      
High school  1.23 (0.87, 1.74)   1.19 (0.83, 1.71)   1.19 (0.82, 1.73)  
Some college 0.90 (0.62, 1.31)   0.90 (0.60, 1.35)   0.91 (0.60, 1.36)  
College graduate 0.92 (0.60, 1.41)   0.93 (0.59, 1.47)   0.90 (0.57, 1.43)  
Race/ethnicity (ref: Non-Hispanic other)     
Non-Hispanic black 1.05 (0.71, 1.56)   1.03 (0.69, 1.53)   1.04 (0.71, 1.54)  
Hispanic (English interview) 1.29 (0.70, 2.40)   1.29 (0.70, 2.40)   1.32 (0.69, 2.51)  
Hispanic (Spanish interview) 2.69 (1.10, 6.58)*  2.72 (1.10, 6.73)*  2.71 (1.11, 6.62)* 
Attends religious services at least 1/wk 1.06 (0.82, 1.37)   1.05 (0.81, 1.38)   1.02 (0.78, 1.32)  
Another eligible HH member 1.13 (0.87, 1.46)   1.08 (0.84, 1.38)   1.06 (0.83, 1.36)  
Health status indicators (W1)      
Self-rated health (ref: Excellent)      
     Very good 1.12 (0.74, 1.71)   1.05 (0.66, 1.66)   1.04 (0.66, 1.65)  
     Good 1.24 (0.83, 1.85)   1.17 (0.73, 1.86)   1.12 (0.70, 1.81)  
     Fair/Poor 1.29 (0.84, 2.00)   1.15 (0.66, 1.99)   1.08 (0.62, 1.88)  
BMI (ref: Underweight/Normal)      
     Overweight 1.01 (0.76, 1.35)   1.08 (0.79, 1.47)   1.11 (0.81, 1.52)  
     Obese 1.18 (0.93, 1.49)   1.31 (1.02, 1.70)*  1.35 (1.04, 1.74)* 
     Did not report 1.36 (0.67, 2.75)   1.51 (0.74, 3.07)   1.57 (0.76, 3.26)  
Diabetes 1.14 (0.91, 1.43)   1.19 (0.95, 1.49)   1.20 (0.96, 1.50)  
Mildly vigorous activity (ref: At least 1/wk)     
     1-3 times/month 0.73 (0.49, 1.08)   0.80 (0.54, 1.19)   0.74 (0.49, 1.12)  
     Hardly ever/never 0.99 (0.64, 1.54)   1.17 (0.69, 1.98)   1.12 (0.66, 1.90)  
No. of functional limitations 0.98 (0.95, 1.02)   0.98 (0.94, 1.02)   0.97 (0.93, 1.01)  
Ever visited doctor in last 2 years (W1) 1.01 (0.61, 1.65)   0.95 (0.57, 1.58)   0.95 (0.56, 1.59)  
Change in health status      
Self-rated health (ref: No change)      
     Declined   0.89 (0.67, 1.20)   0.87 (0.65, 1.16)  
     Improved   1.09 (0.75, 1.56)   1.11 (0.77, 1.59)  
BMI (ref: No change)      
     Declined   1.42 (0.93, 2.17)   1.37 (0.91, 2.06)  
     Improved   0.81 (0.59, 1.11)   0.79 (0.57, 1.09)  
Developed diabetes   1.21 (0.74, 1.98)   1.19 (0.72, 1.97)  
Mildly vigorous activity (ref: No change)     
     Declined   1.18 (0.87, 1.61)   1.16 (0.86, 1.57)  
     Improved   0.83 (0.49, 1.39)   0.88 (0.52, 1.49)  
Change in no. functional limitations   1.00 (0.96, 1.04)   1.00 (0.96, 1.04)  
Ever visited doctor in last 2 years (W3)   1.05 (0.72, 1.55)   1.06 (0.73, 1.56)  
(continued) 
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Table 3-9. Predictors of wave 3 dried blood spot consent for wave 1 dried blood spot non-
consenters (continued) 
 Model 1  Model 2  Model 3 
  Odds Ratio    Odds Ratio   Odds Ratio  
Cognition indices      
Word recall score (W1) 0.96 (0.92, 1.00)   0.96 (0.92, 1.00)   0.96 (0.92, 1.00)  
Mental status score (W1) 0.99 (0.93, 1.04)   0.98 (0.92, 1.05)   0.99 (0.92, 1.05)  
Change in word recall score   1.00 (0.96, 1.04)   1.00 (0.96, 1.04)  
Change in mental status score   0.99 (0.90, 1.08)   0.99 (0.90, 1.08)  
Survey resistance (W1)      
No. of contact attempts   1.01 (0.99, 1.03)   1.01 (0.99, 1.03)  
Uncooperative Index   1.00 (0.90, 1.11)   1.02 (0.91, 1.14)  
Confidentiality Index   0.78 (0.68, 0.90)***  0.80 (0.69, 0.91)** 
Survey resistance (W2)      
Nonrespondent in W2 0.67 (0.14, 3.31)   0.65 (0.14, 3.00)   0.62 (0.13, 2.95)  
No. of contact attempts 1.00 (0.99, 1.01)   1.00 (0.99, 1.01)   1.00 (0.99, 1.01)  
Uncooperative Index 0.97 (0.88, 1.08)   0.97 (0.88, 1.07)   0.98 (0.89, 1.08)  
Confidentiality Index 0.77 (0.64, 0.92)**  0.81 (0.68, 0.98)*  0.82 (0.68, 0.99)* 
Survey resistance (W3)      
No. of contact attempts 0.99 (0.97, 1.01)   0.99 (0.97, 1.00)   0.99 (0.97, 1.01)  
Panel status      
Ever a nonrespondent before W1  0.83 (0.59, 1.18)   0.84 (0.59, 1.19)  
Interviewer continuity      
E-FTF interviewer continuity   0.71 (0.49, 1.01)   0.70 (0.49, 1.01)  
Previous biomeasure consent      
Straight refusal to DBS sample (W1)    0.50 (0.36, 0.69)**** 
Interviewer attributes      
Age (years) 0.98 (0.97, 0.99)**  0.99 (0.97, 1.00)*  0.98 (0.97, 1.00)** 
Female 1.23 (0.91, 1.66)   1.28 (0.92, 1.78)   1.29 (0.92, 1.79)  
Race (ref: Non-Hispanic other)      
     Non-Hispanic black 0.74 (0.56, 0.99)*  0.72 (0.53, 0.96)*  0.71 (0.53, 0.95)* 
     Hispanic 0.91 (0.59, 1.40)   0.91 (0.59, 1.41)   0.95 (0.62, 1.45)  
Education (ref: HS graduate)      
     Some college 0.84 (0.56, 1.27)   0.84 (0.55, 1.26)   0.80 (0.53, 1.22)  
     College graduate 0.94 (0.63, 1.40)   0.95 (0.64, 1.43)   0.92 (0.61, 1.38)  
     Advanced degree 0.86 (0.56, 1.32)   0.84 (0.54, 1.30)   0.84 (0.53, 1.30)  
New hire 0.74 (0.55, 1.00)*  0.70 (0.53, 0.91)**  0.68 (0.53, 0.88)** 
Interviewer variance 1.21 (0.91, 1.61)   1.18 (0.87, 1.59)   1.17 (0.87, 1.56) 
Note. Odd ratios 95% confidence intervals are based on jackknife standard errors from a two-level random effects 
logistic regression model. CI = confidence interval. DBS = dried blood spot. W1 = Wave 1. W2 = Wave 2. W3 = 
Wave 3. HS = high school. 




Table 3-10. Subset of predictors of wave 3 consent and post-hoc test on interviewer continuity 
and reason for wave 1 non-consent for physical measurements and dried blood spots 
 Model 2  Model 3  Model 4 
  Odds Ratio   Odds Ratio   Odds Ratio  
Physical measurements      
Interviewer continuity      
E-FTF interviewer continuity 0.59 (0.29, 1.21)   0.60 (0.29, 1.24)   1.01 (0.14, 7.08)  
Previous biomeasure consent      
Straight refusal to PM sample (W1)  0.62 (0.34, 1.13)   0.69 (0.36, 1.30)  
Continuity and consent interactions     
Interviewer continuity * PM refusal    0.53 (0.07, 4.09) 
     
Continuity | Health-related refusal to PM    1.01 
Continuity | Straight refusal to PM    0.54  
   Wald X
2 = 2.353 
      
Dried blood spots      
Interviewer continuity      
E-FTF interviewer continuity 0.71 (0.49, 1.01)   0.70 (0.49, 1.01)   1.39 (0.49, 3.93)  
Previous biomeasure consent      
Straight refusal to DBS sample (W1)  0.50 (0.36, 0.69)**** 0.56 (0.40, 0.80)** 
Continuity and consent interactions     
Interviewer continuity * DBS refusal    0.45 (0.16, 1.26)  
     
Continuity | Health-related refusal to DBS    1.39 
Continuity | Straight refusal to DBS    0.63* 
   Wald X
2 = 6.065 
Note. Wald X2 test corresponds to the post-hoc test of coefficient for interviewer continuity given straight refusal to 
PM or DBS being equal to zero (see Equation (3.5)). Full models 95% odds ratio confidence intervals (in 
parentheses) are based on jackknife standard errors from a two-level random effects logistic regression model. PM = 
physical measurements. DBS = dried blood spot. W1 = Wave 1. 




Table 3-11. Model summary by predictor set for wave 3 physical measurement consent 
  PM Consenters  PM Non-consenters 
  Model 1  Model 2  Model 1  Model 2  Model 3  Model 4 
Predictor set df χ2Wald  χ2Wald  χ2Wald  χ2Wald  χ2Wald  χ2Wald 
Respondent characteristics 10 50.39****  39.54****  12.99  11.69  11.15  10.83 
Health status 11 30.02**  33.32***  16.51  10.12  12.69  11.43 
Change in health status 9   40.12****    12.46  12.76  12.38 
Cognition W1 2   8.35*    9.17*    5.11    5.39    5.25    5.06 
Change in cognition 2     5.91      1.38    1.08    1.01 
Survey resistance W1 3   66.42****    18.54***  18.17***  17.99*** 
Survey resistance W2 3 18.82***    4.04    8.88*    4.37    4.45    4.47 
Survey resistance W3 1 15.20****  16.36****    0.42    0.53    0.48    0.45 
Panel status 2     0.70      2.65    2.53    2.40 
Interviewer attributes 8 38.90****  36.49****  21.04**  17.12*  17.07*  16.76* 
Interviewer continuity 1     7.26**      2.08    1.92    0.00 
Previous PM consent 1           2.42    1.33 
Continuity * Reason for refusal 1             0.37 
             
Log-likelihood  -1726.45  -1676.491  -309.2918  -292.4817  -291.3514  -291.0438 
Likelihood ratio test    99.91****      33.62       2.26 0.62 
ICC  0.260  0.267  0.176  0.153  0.150  0.152 
Note. Likelihood ratio test compares current model to the preceding model (e.g., Model 3 vs. Model 2). Panel status predictor set includes nonresponse before 
W1 and W2 nonresponse. PM = physical measurements. W1 = Wave 1. W2 = Wave 2. W3 = Wave 3. ICC = intraclass correlation.  




Table 3-12. Model summary by predictor set for wave 3 dried blood spot consent 
  DBS Consenters  DBS Non-consenters 
  Model 1  Model 2  Model 1  Model 2  Model 3  Model 4 
Predictor set df χ2Wald  χ2Wald  χ2Wald  χ2Wald  χ2Wald  χ2Wald 
Respondent characteristics 10 59.73****  57.88****  18.17  14.92  13.72  14.07 
Health status 11 34.26***  59.70****    8.77  13.30  15.68  14.96 
Change in health status 9   39.29****    10.63  10.71  11.52 
Cognition W1 2   0.22    0.90    3.77     3.49    3.51    3.48 
Change in cognition 2     9.02*      0.14    0.17    0.13 
Survey resistance W1 3   42.74****    15.33**  12.99**  13.33** 
Survey resistance W2 3 27.44****  11.01*  13.99**    8.19*    6.97    7.17 
Survey resistance W3 1 27.92****  28.31****    1.54    2.18    1.81    1.79 
Panel status 2     3.33      1.24    1.25    1.16 
Interviewer attributes 8 39.19****  40.77****  17.12*  20.86**  22.61**  22.57** 
Interviewer continuity 1     2.02      3.58    3.66    0.38 
Previous DBS consent 1         16.78****  10.32** 
Continuity * Reason for refusal 1             2.32 
             
Log-likelihood  -2383.61  -2342.82  -929.95  -916.54  -907.78  -906.25 
Likelihood ratio test    81.59****   26.81  17.52****  3.06 
ICC  0.164   0.168   0.054   0.048   0.045   0.044 
Note. Likelihood ratio test compares current model to the preceding model (e.g., Model 3 vs. Model 2). Panel status predictor set includes nonresponse before 
W1 and W2 nonresponse. DBS = dried blood spot. W1 = Wave 1. W2 = Wave 2. W3 = Wave 3. ICC = intraclass correlation. 





 This analysis has examined the impact of various factors on recurrent consent to 
biomeasures in a panel study. Change in health status, additional waves of survey resistance 
variables, and interviewer continuity were examined. Separate models were estimated for 
consent to PM and DBS. 
For previous consenters, there are a number of similar predictors between PM and DBS, 
including mildly vigorous activity, change in functional limitations, number of contact attempts 
in the current wave, and interviewer observed concerns regarding confidentiality and 
uncooperativeness. These common predictors, in support of the first research question, can be 
summarized into two general factors associated with recurrent biomeasure consent, regardless of 
the type of collection: physical wellbeing and survey resistance. One’s ability to be physically 
active and complete daily tasks is likely a constant barometer for older adults in gauging their 
ability to complete new, exertive undertakings. Limited capability for the usual and essential 
priorities of the day are likely to outweigh more demanding within-survey requests. While 
current survey resistance (measured by contact attempts) directly plays a role, a respondent’s 
reticence during a previous interview seems to carry forward into future waves of the survey. 
Even though a more recent survey interaction had taken place in the years between biomeasure 
requests, confidentiality concerns and uncooperative behavior in the previous E-FTF wave had a 
more salient impact in these analyses than anything from the intervening CATI interview. 
Additional negative effects observed for age and obesity with respect to PM consent agree with 
our expectations that increased difficulty with advancing age and unhealthy weight lead to 
reduced consent to more physically taxing tasks like the walking test. The connection between 
diabetes and frequent blood glucose testing makes the positive effect on DBS consent relatively 
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unsurprising (though a bivariate effect was not observed). Reduced consent to DBS for 
respondents interviewed by new hires may stem from the respondent questioning whether or not 
they trust the interviewer’s ability to safely collect a blood sample whether by some direct 
observation regarding the interviewer or some intuitive sense through the survey interaction.  
For previous non-consenters, the W1 confidentiality index (a measure of survey 
resistance) was the only significant predictor in both the PM and DBS models using the multiple-
comparison correction. This means in addition to the lack of previous consent, previous concerns 
and resistance to the survey have an enduring impact on future waves the survey, specifically in 
relation to biomeasure collection. The lack of significant predictors in the previous non-consent 
models is likely related to small sample sizes, due to the general success of biomeasure 
collection in HRS, as many significant factors in the previous consenter models had similar 
magnitudes of odds ratios as the non-consenters models, but increased variability. Given the 
differences observed across consent requests and the previous consent status, future 
examinations need to consider separating out previous consenters and non-consenters as they 
seem to have differential trajectories when it comes to recurrent consent. 
The majority of the evidence presented here suggests that participants who have 
decreasing activity levels or are experiencing more daily limitations are increasingly less likely 
to consent to future biomeasure collection for both PM and DBS for previous consenters in 
support of the second research question. These particular factors align with expectations, 
especially for PM, as the respondent’s ability to perform the various physical tasks are 
diminished due to increasing physical restrictions and thus respondents may be more cautious to 
avoid these potentially strenuous or harmful activities. Improvements in BMI classification (e.g., 
obese to overweight, overweight to normal weight) were also associated with a higher likelihood 
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of future PM consent for previous non-consenters. Healthy weight loss can result in increased 
energy and greater mobility reducing possible negative side effects such atypical physical 
exertion. The recent development of chronic diseases like diabetes have no measurable effect on 
the likelihood of obtaining future biomeasure consent suggesting that one’s general health as 
opposed to any one specific condition has the largest influence on future consent. These effects 
lead credence to the idea that there may be a causal relationship with changing health status and 
consent, especially in relation to the collection of physical measurements. The development of 
alternate protocols for older and more physically limited respondents could be investigated 
exploring the tradeoffs of obtaining less or simpler measures without any loss in measurement 
accuracy. Given the likely relationship between physical limitations and the outcomes of interest 
(specifically PM outcomes), the inclusion of physical limitations (the more recent the better) is 
important for adjustment models to help avoid nonresponse bias given the relationship to both 
consent and the outcome (Little & Vartivarian, 2005) which is currently accounted for in the 
HRS biomarker analysis weights (Crimmins et al., 2013). 
Interviewer continuity led to some interesting findings in relation to the third research 
question. Interviewer continuity between biomeasure requests was related to lower odds of DBS 
consent for previous non-consenters who had refused for non-health-related reasons (i.e., a 
straight refusal). This finding in particular is consistent with previous research from Watson and 
Wooden (2014) suggesting that respondents who have demonstrated previous resistance or 
refusal are less willing to cooperate at the survey or within survey level when the interviewer 
remains the same across waves. The difference in this effect was notable compared to those who 
refused DBS collection for health-related reasons, but the subsequent increase in odds compared 
to those who did not have the same interviewer in both E-FTF was not significant. While no 
168 
significant effect was seen for previous PM non-consenters, the effect was in the same direction 
as DBS. Given the constant turnover of interviewers, this is a potentially useful finding that a 
lack of interviewer continuity may help increase longitudinal biomeasure consent. However 
survey managers should be wary in directly reassigning interviewers as an intervention as the 
respondent/interviewer interaction is clearly accomplishing part of its purpose by obtaining a 
completed survey interview.  
Perhaps the larger concern is that interviewer continuity was related to lower odds of PM 
consent for previous consenters. Even previously established relationships that would be 
considered “good” given the previously affirmative consent request may not be sufficient to 
result in a repeated success for consent. It is also possible that interviewer continuity is 
associated with geographic factors. The fact that this effect persists after controlling for multiple 
survey resistance indicators across multiple waves is a concern. It is unclear if concerns 
regarding the respondent-interviewer interaction are not adequately accounted for in the survey 
resistance measures included in these models. Future research is needed to understand why this 
effect is present. One area that could be considered for previous consenters is what impact 
informing the interviewer of the respondent’s previous consent decision might have to encourage 
future consent or how it might be used as an intervention to remind the respondent of their 
previous affirmation (see Sala, Knies, & Burton, 2014). 
A straight refusal to DBS does result in nearly half the odds of future consent compared 
to those with a health-related refusal to DBS in support of the fourth research question. Future E-
FTF requests could enact interventions targeted at these more resistant respondents. While there 
was no evidence for this effect with PM, the odds ratio was in the same direction and may have 
been diminished due to the missing reason data that was imputed for 2006. 
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One finding not explicitly related to the stated research goals was the use and effect of 
mode equivalent, survey resistance indicators. In all of the models considered, the previous E-
FTF resistance indicators for confidentiality and cooperativeness indices (but only in the 
previous consenters model for the latter) were far more effective at predicting future consent than 
the most recent wave (W2), though the W2 confidentiality index was still significant for some 
models. The similarities in mode (e.g., type and length of social interaction, number and relative 
burden of within survey requests) likely play a large role in these stronger effects even though 
they are four years apart. Understanding the benefits and limitations of using one wave and 
mode’s interviewer observations over another, or using them in tandem, would enhance the 
general understanding of the utility such measures have in response models and potentially for 
adjustment. In general, researchers investigating paradata in similar kinds of panel surveys may 
also consider how consent to biomeasures (or similar consent measures like administrative data 
linkage) could be a good indicator of capturing multiple facets of survey resistance. 
Generalization of these results is limited given the unique data collection design of HRS. 
Four-year gaps between biomeasure collections may suggest large memory effects especially for 
an older adult population. Requests that are more frequent may result in a different set of 
relevant predictors. Again, reminders of previous consent behavior may also benefit recurrent 
consent requests (see Sala, Knies, & Burton, 2014). HRS also contains a rich source of 
interviewer-observation paradata that may not be available for all studies to be able to consider.   
Panel health surveys play a critical role in helping us understand the causal connections 
between human behavior and biological forces – especially when linked with biomeasure 
collection. This study is one of the first to help us better understand some of the human and 
survey design factors that influence our ability to obtain consent for recurrent biomeasure 
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requests key in drawing those causal links. Using data collected from previous panel waves – 
especially previous biomeasure consent and refusal, interviewer continuity, interviewer 
observation paradata, and overall respondent health and health changes – can help researchers 
ensure that subsequent waves of biomeasure collection are successful as the application of such 
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Evaluating Different Applications of Sequential Regression Multivariate Imputation for 
Imputing Longitudinal Biomarker Measures 
4.1 Introduction 
Even with some knowledge of the missing data mechanisms that could potentially reduce 
unit and item nonresponse rates for biomeasure collection, it is inevitable that biomarker 
measurements will be missing for some survey respondents. Analysts experience in analytic 
models a loss in precision (i.e., sample size reduction) and a potential for bias due to missing 
cases. To recover the statistical information present in cases with item missing data requires that 
some form of post-survey compensation like imputation be completed. Imputation ultimately 
results in a “rectangular” data set where all analytic variables are complete, allowing for 
consistent sample sizes across analyses, and possibly achieving increased precision and reduction 
in bias. The purpose of this chapter is to evaluate three imputation approaches for addressing 
missing data in longitudinal studies with biomarker measures. 
Imputation, as a well-studied area in statistics, is unnecessary in this setting to cover most 
of the methods available. The focus here is on imputation methods generally associated with 
addressing bias under a missing at random (MAR) assumption12. MAR missing data mechanisms 
                                               
12 The exclusion of methods to address the missing completely at random (MCAR) assumption is justified by results 
in Chapter 2 showing that there are demographic patterns to various forms of biomeasure missingness. 
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only depend on observed values within the survey, not on the missing values themselves. Item 
missing data for biomeasures may also result from a mechanism that implies the data are not 
missing at random (NMAR) where missingness depends on the values of the unobserved 
measures.  Under a generalized pattern of missing data, treatment of NMAR item missing data 
typically involves simulation of potential outcomes over a reasonable range of assumptions 
concerning the true mechanism (Little and Rubin, 2002).   
There are two important factors to consider when evaluating potential imputation 
methods for biomeasures: (1) many biomarker measures (e.g., concentrations) have skewed 
distributions, and (2) in longitudinal studies, past and/or future values may be known for some 
biomarkers.  
4.1.1 Imputing skewed variables 
Parametric imputation methods, such as the multivariate normal (MVN) imputation, 
require that distributional assumptions be met to avoid potentially unreliable or biased 
imputations. Von Hippel (2013) found that conditionally normal imputation of skewed variables 
can produce acceptable estimates for means, variances, and regression parameters, but not for 
distribution shape parameters like percentiles and coefficients of skewness. Von Hippel (2013) 
and Lee and Carlin (2017) suggested non-normal distributions for use in imputation including 
Tukey’s gh distribution (He & Raghunathan, 2006), the beta or Weibull density (Demirtas & 
Hedeker, 2008a), the generalized lambda distribution (Demirtas, 2009), and Fleishman power 
polynomials (Demirtas & Hedeker, 2008b; Demirtas, 2009). 
Some (e.g., White, Royston, & Wood, 2010) recommend transforming skewed variables 
to better approximate normality, but such transformations can result in bias if the transformed 
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variable does not achieve normality (von Hippel, 2013). In addition, both the imputation model 
and analysis model should be consistent, or congenial, to capture the relationship between 
important X and Y variables or risk bias in analyses (von Hippel, 2009, 2013; Bartlett et al., 
2015; Heeringa, West, & Berglund, 2017; Lee & Carlin, 2017). If the analysis uses 𝑋𝑋∗ = 𝑛𝑛(𝑋𝑋), 
then 𝑋𝑋∗ should be included in the imputation model. Von Hippel (2009) found that the best 
parametric approach for skewed variables is to “transform, then impute,” which produces 
unbiased regression estimates. However, imputed values were not always consistent with the 
observed distribution, because the imputation is attempting to maintain the relationship between 
𝑋𝑋∗ and Y. “The point of imputation is not that the imputed values should look like observed 
values. The point is that the imputed variable should act like the observed variable when used in 
analysis” (Von Hippel, 2013, p. 106). 
While direct parametric imputation techniques can be used to impute skewed data, 
alternative imputation approaches do not need to rely on a specific parametric model (e.g., 
multivariate normal). These methods rely on imputing from an observed distribution or a 
posterior predictive distribution. Two of the most frequently used of these imputation methods 
are predictive mean matching and sequential regression multivariate imputation. 
Predictive mean matching (PMM) is a hot deck imputation method that draws values or 
residuals from a set of observed values (i.e., donors) to retain the original distribution among 
observed values (Little, 1988) – a desirable property when dealing with skewed distributions. 
PMM implicitly avoids issues related to model misspecification (Little & Rubin, 2002; Andridge 
& Little, 2010; van Buuren, 2012). It also performs well when there are many possible donors 
for each recipient and large number of predictors are available (Andridge & Little, 2010). PMM 
focuses on a univariate distribution and has been found to perform well with skewed data 
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(Marshall, Altman, Royston, & Holder, 2010; Vink, Frank, Pannekoek, & van Buuren, 2014; Lee 
& Carlin, 2017). 
Sequential regression multivariate imputation (SRMI; Raghunathan, Lepkowski, Van 
Howeyk, & Solenberger, 2001), also known as multivariate imputation by chained equations 
(MICE; van Buuren & Groothuis-Oudshoorn, 2000) or fully conditional specification (FCS; van 
Buuren et al., 2006), employs a sequence of multiple regressions, handling a wide variety of 
variable types – continuous, binary, categorical, counts, and mixed (semi-continuous with a 
probability mass at zero). It uses all observed and imputed values for all available variables as 
potential covariates. Imputed values are ultimately treated as draws from the joint posterior 
predictive distribution, which is approximated by the sequence of draws from the conditional 
distributions for each variable as specified by the selected regression models.  
SRMI has been recommended for skewed data (White et al., 2011). Under SRMI, PMM 
may also replace regression as the mechanism to generate imputed values (He & Raghunathan, 
2009; White et al., 2011). The SRMI approach will be used in this paper to take advantage of the 
relationships among biomarkers and health measures, as well as its strength with skewed data. 
4.1.2 Longitudinal imputation 
 Given the focus on repeated biomeasure collection in longitudinal studies, there is a good 
chance of having at least one successful biomeasure collected for most panel members in either a 
previous or a future wave. This means that there may be readily available biomarker values – 
temporally distinct but still highly correlated with the missing biomarker of interest for a given 
individual.   
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There are common imputation methods used for longitudinal health or clinical data, such 
as the last observation carried forward (e.g., Kenward & Molenberghs, 2009; Lachin, 2016) or 
hot deck imputation (e.g., Andridge & Little, 2010). However, SRMI – mentioned in the 
previous section – also functions well in this framework. The approach of the SRMI model can 
use multiple waves of data (Raghunathan, Berglund, & Solenberger, 2018).  
A cross-sectional, or single wave, approach ignores the longitudinal nature of the data 
altogether and may not preserve individual correlations between biomarkers or their related 
covariates over time. Cross-sectional imputation is done in conjunction with timely data release 
since it is not dependent on past or future waves of data collection. Given timeliness goals, cross-
sectional imputation for item missing data or nonresponse is a common practice in longitudinal 
surveys (Ferro, 2014).  
Imputations can instead be performed consecutively as more waves of data are collected. 
While a preliminary wave of data collection (𝑤𝑤 = 1) would default to a cross-section imputation 
as previously described, imputations performed at 𝑤𝑤 > 1 would use all 𝑤𝑤 = 1, 2, …  𝑊𝑊 − 1 
waves within the imputation model. This preserves the “complete” data set from previous waves 
without the need to impute them again given the newly available data. From a practical 
standpoint, this can be done in tandem with individual wave data management, but does require 
greater resources as the number of available waves increases. Studies with a large number of 
planned waves need to consider the impact of over-fitting in later waves given the large number 
of data points and variables potentially available (Nevalainen, Kenward, & Virtanen, 2009). A 
fixed lag of waves (e.g., two) can be included in the imputation model at later time points.  
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A third approach – used by Raghunathan et al. (2018) – is to create a “wide” data file that 
allows an imputation model to include all available time points. This means that time 𝑤𝑤 can be 
imputed using past (e.g., 𝑤𝑤 − 1,𝑤𝑤 − 2) as well as future (e.g., 𝑤𝑤 + 1,𝑤𝑤 + 2) values. This 
approach thereby requires having all waves of data available at once. This is advantageous for 
earlier waves of data collection that do not benefit from future values in the previous approaches. 
Depending on the missingness pattern, the final wave of data collection may be equivalent to the 
consecutive, or sequential, imputation discussed previously assuming the missingness was more 
monotonic over time. Again, as the number of waves increase, so does the likelihood of over-
fitting the regression models (Nevalainen et al., 2009). 
4.1.3 Study goals 
Each of these approaches (cross-sectional, sequential, wide) uses differing amounts of 
information to inform imputation models for each variable. This choice among them may be 
based on the analytic needs of the researcher. This study examines all three using SRMI to 
compare the nature of the imputed values under each approach. 
4.2 Methods 
4.2.1 Data 
The HRS (Health and Retirement Study) is sponsored by the National Institute on Aging 
(grant number NIA U01AG009740) and is conducted by the Institute for Social Research (ISR) 
at the University of Michigan. HRS is a longitudinal survey of adults over the age of 50 living in 
the United States that collects various measures related to health, medical care, employment, 
income, and cognition. HRS began in 1992 with a cohort of preretirement-aged individuals born 
between 1931 and 1941. New birth cohorts are enrolled every 6 years (e.g., 1998, 2004, 2010) to 
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refresh the sample at the younger ages. The HRS conducts about 20,000 interviews every 2 years 
with response rates between 65 and 85 percent in the baseline wave and between 85 and 95 
percent in follow-up waves. 
In 2006, HRS began alternating respondents between face-to-face and telephone 
interviews, with a random half sample of the full panel being assigned to each mode. Every two 
years each half-sample switches to the other mode13. In face-to-face interviews, 
noninstitutionalized, non-proxy respondents are asked to provide measures of physical 
functioning (i.e., blood pressure, hand grip strength, a walking test, height, weight, etc.), a one-
time saliva sample (for DNA extraction and storage), and a dried blood spot assay (for measuring 
Hemoglobin A1c, cholesterol, and other biochemical measures). Saliva and blood samples have 
different collection, storage, and analysis procedures. Respondents are given three consent forms 
for each of the biomeasure components. HRS refers to this face-to-face interview with 
biomeasure collection and self-administered questionnaire on psychosocial topics as the 
enhanced face-to-face (E-FTF) interview. 
This study uses the 2006, 2010, and 2014 E-FTF HRS. Biomeasure eligible respondents 
to the 2006 HRS are included (n = 7,954). These analyses focus on biomarkers collected from 
the dried blood spot (DBS) assays. All respondent-level data was obtained from the HRS Public 
Release data available at http://hrsonline.isr.umich.edu/index.php?p=avail. Biomarker data, 
denoted as sensitive health data, were obtained through an application process (see 
http://hrsonline.isr.umich.edu/index.php?p=healthdat for details). 
                                               
13 Respondents over the age of 80 alternate between FTF and E-FTF interviews unless they specifically request a 
telephone interview. 
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The focus in this investigation is on two DBS biomarkers: C-reactive protein (CRP) and 
Cystatin C. These biomarkers were chosen because of their statistical and distributional 
properties. CRP measures have right-skewed distribution, which allows investigation of the 
“transform and impute” approach, while Cystatin C has a more symmetric distribution. These 
measures are also related to important health outcomes: CRP is associated with liver function 
and inflammation, and Cystatin C with kidney functioning as well as healthy aging (see Sarnak 
et al., 2008). Beyond their direct clinical utility, both CRP and Cystatin C have also been found 
to be related to cardiovascular disease (e.g., CRP: Ridker, Hennekens, Buring, & Rifai, 2000; 
Blake & Ridker, 2002; Ridker, Rifai, Rose, Buring, & Cook, 2002; Ridker, 2003; Ridker, Rafai, 
Cook, Bradwin, & Buring, 2005; Cystatin C: Shlipak et al., 2005; Taglieri, Koenig, & Kaski, 
2009; Battistoni, Rubattu, & Volpe, 2012). The cardiovascular connection allows a consolidation 
of analytic models to be explored. While results for other variables are not specifically discussed 
here, the remaining DBS biomarkers (HbA1c, HDL, and total cholesterol) are imputed along 
with CRP and Cystatin C. 
Given the skewed distribution of CRP, the natural logarithm transformation, a common 
transformation for CRP in psychological and sociological analyses (e.g., Demakakos, Nazroo, 
Breeze, & Marmot, 2008; Luchetti, Barkley, Stephan, Terracciano, & Sutin, 2014; Sutin, 
Stephan, Luchetti, & Terracciano, 2014; Stephan, Sutin, & Terracciano, 2015; Köhler-Forsberg 
et al., 2017; Chiang et al., 2019), is included in the imputation models. No transformation is used 
for Cystatin C. 
4.2.2 Analysis plan 
 Each of the descriptive and multivariate analyses use the stratum and cluster variables as 
part of the estimation. Details on the analysis weights used are described below. 
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To evaluate the univariate distributions of both biomarkers (Cystatin C and natural log 
transformed CRP), the descriptive analyses examine estimates of the means, the proportion at 
risk (specified in Table 4-1), and five percentiles – 5th, 25th (Q1), 50th (median), 75th (Q3), and 
95th. Descriptive analyses used PROC SURVEYMEANS in SAS 9.4 to compute weighted 
estimates. 
 The two selected biomarkers are also examined as predictor variables in multivariate 
(MV) regression models. The biomarker is specified as an independent variable: cross-sectional 
and longitudinal. A cross-sectional MV model will only utilize one wave of data for analysis, 
while a longitudinal MV model will use multiple waves.  
Both Cystatin C and CRP have been found to be associated with cardiovascular disease, 
though this is not their primary or intended purpose as a blood biomarker. Using a common 
health outcome not directly associated with either biomarker (e.g., kidney disease and Cystatin 
C) allows for a common analytic model with the same covariates. It also avoids confounding 
findings with the model being tested. In HRS, cardiovascular disease is measured with the 
question: “Has a doctor ever told you that you had a heart attack, coronary heart disease, angina, 
congestive heart failure, or other heart problems?”14 Hence logistic regression is used for each 
MV model.  
                                               
14 This is the question wording when the respondent is participating for the first interview. In reinterviews, 
respondents who previously reported “No” are asked: “Since we last talked to you [last] has a doctor told you that 
you have had a heart attack, have coronary heart disease, angina, congestive heart failure, or other heart problems?” 
Respondents who previously reported “Yes” are asked to confirm the previous response: “Our records from your 
interview in {INTERVIEW MONTH, YEAR} show that you had a heart problem.”  
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  In addition to Cystatin C and CRP as predictors of cardiovascular disease, demographic, 
health condition, and health behavior risk factors associated with cardiovascular disease15 were 
selected as model covariates including age, gender, race/ethnicity, diabetes, hypertension, 
obesity, physical exercise, and smoking status. Distributions of these predictors (e.g., continuous 
or categorical) are included in Table 4-2. 
For this model, age is centered at its mean (68.5 years). Gender is parameterized as 1 for 
females, 0 for males. Race/ethnicity is categorized as Hispanic, non-Hispanic black, and non-
Hispanic other (reference category). Obesity is a three-category Centers for Disease Control 
(CDC) specification of body mass index (BMI)16: BMI < 25 (underweight or normal; reference 
category), BMI ≥ 25 but < 30 (overweight), and BMI >= 30 (obese). Diabetes and hypertension 
are indicators based on self-reported doctor’s diagnosis. Mild vigorous activity is a self-reported 
measure with scale categories of: weekly (reference category), 1-3 times per month, and hardly 
ever/never. Current smoking status also uses three categories: current smoker, former smoker, 
and non-smoker (reference category).  
                                               
15 The Centers for Disease Control and Prevention (CDC) provide a list of common health conditions, health 
behaviors, family history and other characteristics that increase the risk of cardiovascular disease at 
https://www.cdc.gov/heartdisease/risk_factors.htm. 
16 https://www.cdc.gov/obesity/adult/defining.html 
Table 4-1. Dried blood spot biomarker thresholds for high or at risk levels 
Dried blood spot biomarker High/At risk level 
Total cholesterol >= 240 mg/dL 
HDL cholesterol < 40 mg/dL 
Glycosylated hemoglobin (HbA1c) >= 6.4% 
C-reactive protein (CRP) >= 3.0 ug/mL 
Cystatin C > 1.55 mg/L 
Note. Thresholds consistent with those defined by Crimmins et al. (2013). 
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Table 4-2. Imputation and analytic variables for multivariate analyses 
Imputation variable Detail Analytic variable 
Demographics 
Age (centered at age 68.5),  
Age (centered, squared) Continuous Yes 
Gender (female) Categorical (2) Yes 
Age by gender interaction Continuous Yes 
Race/ethnicity Categorical (3): Hispanic, non-Hispanic black, non-Hispanic other Yes 
Health conditions 
Body mass index 
Categorical (3): Underweight/normal 
weight (<25), overweight (25≤,<30), 
obese (>=30) 
Yes; change 
Diabetes Categorical (2) Yes; change 
Heart disease Categorical (2) Yes – outcome  
Hypertension Categorical (2) Yes; change 
Arthritis Categorical (2) No 
Cancer Categorical (2) No 
Chronic pain Categorical (2) No 
Lung disease Categorical (2) No 
Self-rated health Categorical (4): Excellent, very good, good, fair/poor No 
Stroke Categorical (2) No 
Health behaviors 
Mild vigorous activity Categorical (3): Weekly, 1-3 times/month, hardly ever/never Yes; change 
Smoking status Categorical (3): Current smoker, former smoker, non-smoker Yes; change 
Biomeasures 
C-reactive protein  
(natural log transform) Continuous Yes; change 
Cystatin C Continuous Yes; change 
HbA1c Continuous No 
HDL Continuous No 
Total cholesterol Continuous No 
Note. Analytic variables are those used in the models detailed in Section 4.2.2.3 and 4.2.2.4. “Change” refers to 
between-wave change variables used in Section 4.2.2.4. 
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For this model, age is centered at its mean (68.5 years). Gender is parameterized as 1 for 
females, 0 for males. Race/ethnicity is categorized as Hispanic, non-Hispanic black, and non-
Hispanic other (reference category). Obesity is a three-category Centers for Disease Control 
(CDC) specification of body mass index (BMI)17: BMI < 25 (underweight or normal; reference 
category), BMI ≥ 25 but < 30 (overweight), and BMI >= 30 (obese). Diabetes and hypertension 
are indicators based on self-reported doctor’s diagnosis. Mild vigorous activity is a self-reported 
measure with scale categories of: weekly (reference category), 1-3 times per month, and hardly 
ever/never. Current smoking status also uses three categories: current smoker, former smoker, 
and non-smoker (reference category). 
The cross-sectional MV model is also a logistic regression model where the dependent 
variable is cardiovascular disease at wave w, w = 2006, 2010, 2014. In addition to the variables 
described previously, the model also includes age-squared and an age-by-gender interaction. The 
final cross-sectional model is specified as: 
𝑚𝑚𝑂𝑂𝑛𝑛𝑚𝑚𝑂𝑂�𝑁𝑁(𝐶𝐶𝐶𝐶𝐷𝐷𝑤𝑤)� = 𝐴𝐴𝑛𝑛𝑂𝑂𝑤𝑤 + 𝐴𝐴𝑛𝑛𝑂𝑂𝑤𝑤2 + 𝐺𝐺𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂𝑓𝑓 + 𝐴𝐴𝑛𝑛𝑂𝑂𝑤𝑤 × 𝐺𝐺𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂𝑓𝑓 + 𝑅𝑅𝑎𝑎𝑂𝑂𝑂𝑂/𝐸𝐸𝑂𝑂ℎ𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚𝑂𝑂𝑚𝑚 +
𝐷𝐷𝑚𝑚𝑎𝑎𝑏𝑏𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎𝑤𝑤 + 𝐻𝐻𝐻𝐻𝑃𝑃𝑤𝑤 + 𝑂𝑂𝑏𝑏𝑂𝑂𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚𝑤𝑤 + 𝐴𝐴𝑂𝑂𝑂𝑂𝑚𝑚𝑜𝑜𝑚𝑚𝑂𝑂𝑚𝑚𝑤𝑤 + 𝑆𝑆𝑂𝑂𝑂𝑂𝑆𝑆𝑚𝑚𝑎𝑎𝑛𝑛𝑤𝑤 + 𝑚𝑚𝑎𝑎𝐶𝐶𝑅𝑅𝑃𝑃𝑤𝑤 +
𝐶𝐶𝑚𝑚𝑎𝑎𝑂𝑂𝑎𝑎𝑂𝑂𝑚𝑚𝑎𝑎𝐶𝐶𝑤𝑤  (4.1) 
The longitudinal MV model examines the development of cardiovascular disease 
between 2006 and 2014, with confirmed cardiovascular disease in 2014 as the dependent 
variable. The analysis is subset to include panel members without a cardiovascular disease 
diagnosis in 2006 (n = 4,357). This conditional inference, only including respondents who did 
not report having cardiovascular disease in 2006, limits sample size. 
                                               
17 https://www.cdc.gov/obesity/adult/defining.html 
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In addition to the variables listed in Equation 4.1, an indicator variable representing a 
change in status between waves is included for each of the health conditions, health behaviors, 
and biomarkers. For example, indicators for development of diabetes from 2006 to 2014, and an 
increase or decrease in mildly vigorous exercise between 2006 and 2014 are included as 
predictors. Obesity, mildly vigorous activity, and smoking each have two change indicators (e.g., 
increase and decrease, start and stop) while the other change indicators only denote the 
development of that condition18, or for the continuous biomarkers, the mathematical difference 
of 2014 from 2006. The final analytic model is: 
𝑚𝑚𝑂𝑂𝑛𝑛𝑚𝑚𝑂𝑂�𝑁𝑁(𝐶𝐶𝐶𝐶𝐷𝐷2014|𝐶𝐶𝐶𝐶𝐷𝐷2006 = 0)� = 𝐴𝐴𝑛𝑛𝑂𝑂 + 𝐴𝐴𝑛𝑛𝑂𝑂2 + 𝐺𝐺𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂𝑓𝑓 + 𝐴𝐴𝑛𝑛𝑂𝑂 × 𝐺𝐺𝑂𝑂𝑎𝑎𝑎𝑎𝑂𝑂𝑓𝑓 +
𝑅𝑅𝑎𝑎𝑂𝑂𝑂𝑂 𝐸𝐸𝑂𝑂ℎ𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚𝑂𝑂𝑚𝑚⁄ + 𝐷𝐷𝑚𝑚𝑎𝑎𝑏𝑏𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎2006 + ∆𝐷𝐷𝑚𝑚𝑎𝑎𝑏𝑏𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎 + 𝐻𝐻𝐻𝐻𝑃𝑃2006 + ∆𝐻𝐻𝐻𝐻𝑃𝑃 + 𝑂𝑂𝑏𝑏𝑂𝑂𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚2006 +
∆−𝑂𝑂𝑏𝑏𝑂𝑂𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚 + ∆+𝑂𝑂𝑏𝑏𝑂𝑂𝑎𝑎𝑚𝑚𝑂𝑂𝑚𝑚 + 𝐴𝐴𝑂𝑂𝑂𝑂𝑚𝑚𝑜𝑜𝑚𝑚𝑂𝑂𝑚𝑚2006 + ∆−𝐴𝐴𝑂𝑂𝑂𝑂𝑚𝑚𝑜𝑜𝑚𝑚𝑂𝑂𝑚𝑚 + ∆+𝐴𝐴𝑂𝑂𝑂𝑂𝑚𝑚𝑜𝑜𝑚𝑚𝑂𝑂𝑚𝑚+ 𝑆𝑆𝑂𝑂𝑂𝑂𝑆𝑆𝑚𝑚𝑎𝑎𝑛𝑛2006 +
∆−𝑆𝑆𝑂𝑂𝑂𝑂𝑆𝑆𝑚𝑚𝑎𝑎𝑛𝑛+ ∆+𝑆𝑆𝑂𝑂𝑂𝑂𝑆𝑆𝑚𝑚𝑎𝑎𝑛𝑛 + 𝑚𝑚𝑎𝑎𝐶𝐶𝑅𝑅𝑃𝑃2006 + ∆𝑚𝑚𝑎𝑎𝐶𝐶𝑅𝑅𝑃𝑃 + 𝐶𝐶𝑚𝑚𝑎𝑎𝑂𝑂𝑎𝑎𝑂𝑂𝑚𝑚𝑎𝑎𝐶𝐶2006 + ∆𝐶𝐶𝑚𝑚𝑎𝑎𝑂𝑂𝑎𝑎𝑂𝑂𝑚𝑚𝑎𝑎𝐶𝐶 (4.2) 
Here ∆ is the change between 2006 and 2014, with ∆− denoting a decreased change (e.g., lower 
BMI category, less physical activity, decreased smoking) and ∆+ denoting an increased change 
(e.g., higher BMI category, more physical activity, increased smoking).  
Both sets of logistic regression models (Equations 4.1 and 4.2) were estimated using 
PROC SURVEYLOGISTIC in SAS 9.4. The corresponding 2014 weights were used to analyze 
the model. 
The most relevant weights for this analysis are the core respondent weight (referring to 
the core HRS survey) and the respondent biomeasure weight. The respondent sample weight, 
                                               
18 It is assumed here that an individual cannot become “undiagnosed” with a health condition (e.g., hypertension, 
diabetes). 
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which will be referred to as the base weight in this paper, is the product of the inverse of the 
probabilities of selecting a household and the individual respondent within households. A 
poststratification adjustment is also incorporated, based on the American Community Survey 
(ACS), for differential nonresponse for the HRS survey based on age, gender, race/ethnicity, and 
geography (Ofstedal, Weir, Chen, & Wagner, 2011). The biomarker weight, also referred to here 
as the biomeasure weight, is the product of the base weight and a nonresponse adjustment based 
on a propensity model predicting the probability of completing the biomeasure portion of the 
interview, using as predictors age, sex, race/ethnicity, education, marital or partner status, and a 
number of health factors from the interview wave including self-rated health, number of physical 
limitations, hypertension, heart conditions, myocardial infarction, angina, congestive heart 
failure or stroke. Following the application of the nonresponse adjustment factor, the biomeasure 
weights were post-stratified to age, gender, and race distributions from the HRS sample 
(Crimmins et al., 2013).  
The biomeasure weight is the recommended weight to use when analyzing HRS 
biomarkers. However, the imputation models proposed in this study do include a large share of 
the predictor variables included in the nonresponse propensity model for the biomeasure weights, 
and impute beyond those who consented at each E-FTF cycle. Imputing biomarkers for core 
HRS respondents who did not provide consent to collect biomeasures, but do have a non-zero 
base weight, would greatly increase the sample size available for analyses. This is potentially 
advantageous to researchers because it would include non-consenters and proxy respondents 
(specific to HRS) especially when observed biomarker values in other waves are available for 
these respondents given the longitudinal data used in this study. The base weight is based on 
MAR. No adjustments were made to the base weights to ensure there is no confounding between 
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the imputation method and additional post-survey adjustments. In order to understand the impact 
of imputing and analyzing beyond the consenting E-FTF sample, the effect of both the 
biomeasure weight and the base weight are also explored. 
4.2.3 Imputation plan 
As discussed above there are three imputation approaches to be considered in relation to 
SRMI. The SRMI algorithm is based on an approximation of a Gibbs sampling algorithm 
(Geman & Geman, 1984; Gelfand & Smith, 1990) and draws missing values from a predictive 






(𝑐𝑐−1),𝑋𝑋, 𝜃𝜃𝑗𝑗� = 𝑛𝑛𝑗𝑗�𝑌𝑌𝑗𝑗�𝑋𝑋,𝜃𝜃𝑗𝑗� (4.3) 
where 𝑋𝑋 is an 𝑎𝑎 × 𝑁𝑁 matrix containing all variables with no missing values; 𝑌𝑌1,𝑌𝑌2, …𝑌𝑌𝑘𝑘 denote k 
variables with missing values, ordered by the amount of missing cases, from least to most; 𝑛𝑛𝑗𝑗 is 
the conditional density specified by the regression defined by the variable type of 𝑌𝑌𝑗𝑗; 𝜃𝜃𝑗𝑗 is a 
vector of unknown regression parameters (i.e., regression coefficients) with a non-informative 
prior; and t is the imputation iteration round. During the first imputation iteration, 𝑌𝑌1 (the 
variable with the smallest amount of missing data) is regressed on variables with complete data 
and values are drawn from the predictive distribution defined by the imputation model for that 
variable for all applicable cases. This process is followed by 𝑌𝑌2 (the variable with the second 
smallest amount of missing data) which is regressed on all the complete data variables as well as 
𝑌𝑌1 and a similar draw from its predictive distribution, or mathematically, 𝑛𝑛2�𝑌𝑌2�𝑌𝑌1
(1),𝑋𝑋,𝜃𝜃2�. The 
algorithm repeats this process through all k variables with missing data. During the remaining 
imputation rounds (t > 1), all missing values are re-imputed using the new imputed values from 
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the previous round using re-estimated regression models for each variable. After an initial “burn 
in” series of iterations, multiple final draws are made from the predictive posterior for each 
variable with item missing data.  Typically, M >= 10 imputed values are generated (Rubin, 1987; 
Schafer, 1997) with more recent research supporting larger numbers of MI replicates for some 
missing data problems (see Bodner, 2008). 
The SRMI approach was used in each of three imputation plans to consider alternative 
ways of handling the longitudinal features of the biomarker data considered in this investigation.  
1) Cross-sectional approach – In general, the imputation model for each wave of data (w = 
1, 2,…W) only includes variables collected in that wave of data collection. Thus the p 
variables in X and k variables with missing values in Equation 4.3 are limited to wave w. 
Imputation models are independent of other waves. This approach ignores the 
longitudinal nature of the data collection. 
2) Sequential approach – Here each wave of data is imputed using all of the waves 
preceding it. For wave w = 1, there are no previous waves used as part of the imputation 
model and thus looks like the cross-sectional approach for w = 1. This means that the 
sequential imputation model for wave 1 should resemble the cross-sectional imputation 
model for wave 1 given neither utilizes additional waves of data in the imputation 
models. For waves w > 1, fully observed and imputed variables from waves 1,…,w-1 are 
included in the imputation model as part of matrix X. 
3) Wide approach – Wide refers to the imputation model in which missing data for all 
waves are imputed simultaneously. In this study, data from all W waves are included in a 
single imputation model. This means that in relation to Equation 4.3, the X matrix 
includes all complete variables across all W waves, and the k variables with missing data 
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includes all variables across all W waves. This approach would result in similar 
imputation models for wave W variables compared to the sequential approach for wave W 
if the missingness pattern was monotonic (which it is not). 
For this study, W = 3 with w corresponding to HRS 2006, 2010, and 2014. Each of the 
three approaches corresponding to the HRS waves used in this study are detailed visually in 
Figure 4-1. Like in Equation 4.3, Y denotes variables with missing values, X denotes fully 
observed variables, and X* denotes fully observed variables as well as variables “complete” 
through imputation. Items in the diagonal represent variables in the imputation model from the 
current wave. Items in the lower off-diagonal represent variables included in the imputation 
model from before wave w while items in the upper off-diagonal represents variables in the 
model coming after wave w. 
Cross-sectional Years used in imputation model… 
  2006 2010 2014 
…for w = 
2006 X,Y   
2010  X,Y  
2014     X,Y 
  
Sequential Years used in imputation model… 
 
 2006 2010 2014 
…for w = 
2006 X,Y   
2010 X* X,Y  
2014 X* X* X,Y 
  
Wide Years used in imputation model… 
 
 2006 2010 2014 
…for w = 
2006 X,Y X,Y X,Y 
2010 X,Y X,Y X,Y 
2014 X,Y X,Y X,Y 
     
Figure 4-1. Cross-sectional, sequential, and wide imputation approaches by wave. Y denotes 
variables with missing data, X denotes variables fully observed, and X* denotes variables 
fully observed and variables “complete” due to imputation. 
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All of the potential variables included in the imputation models are detailed in Table 4-2. 
Distributions of the continuous variables are included in Table 4-3a while distributions of 
categorical variables are included in Table 4-3b. Because imputation models should be congenial 
with the analysis model (e.g., von Hippel, 2009, 2013; Heeringa et al., 2017), all of the 
demographic, health condition, and health behavior variables used in the cross-sectional 
multivariate analysis mentioned previously are included in the imputation model. In addition to 
these variables, a broader set of health related measures and conditions associated with the HRS 
biomeasure weighting and the remaining biomarkers are included in the model (e.g., Heeringa et 
al., 2017) including self-rated health, stroke, arthritis, lung disease, cancer, and chronic pain. 
Self-rated health is included in the model with four categories with “Fair” and “Poor” combined 
(“Fair/Poor”) due to small sample sizes in the latter. The remaining health conditions are all 
dichotomous indicators, based on self-report of a doctor’s diagnosis. Although the HRS cohort 
sample recruitment was based on a complex multistage probability sample design, the imputation 
models applied here do not explicitly include strata and cluster variables or the HRS weights as 
predictors in the imputation model (Heeringa et al., 2017). This omission could lead to bias if the 
design variables are informative to the multiple imputation estimates (Reiter, Raghunathan, & 
Kinney, 2006).  
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Table 4-3a. Unweighted distributions of observed unimputed continuous variables for imputation by year 
Variable Year Sample size Min P5 Q1 Median Mean Q3 P95 Max StdDev 
Age in 2006 
(centered at age 68.5) 
2006 7,954 -18.50 -14.50 -8.50 -0.50 0.00 6.50 17.50 35.50 9.99 
2010 6,631 -18.50 -15.50 -9.50 -2.50 -1.75 4.50 14.50 35.50 9.49 
 2014 5,406 -18.50 -15.50 -10.50 -3.50 -3.12 2.50 12.50 27.50 8.80 
Functional limitations 2006 7,954 0.00 0.00 1.00 2.00 3.85 6.00 12.00 22.00 3.91 
 2010 6,631 0.00 0.00 1.00 3.00 4.30 6.00 13.00 22.00 4.11 
 2014 5,406 0.00 0.00 1.00 3.00 4.62 7.00 14.00 22.00 4.35 
HbA1c 2006 6,159 4.07 4.88 5.34 5.69 5.87 6.15 7.53 15.14 1.00 
 2010 5,130 3.78 5.02 5.40 5.68 5.89 6.06 7.67 15.17 0.95 
 2014 4,361 3.60 4.96 5.42 5.72 6.02 6.32 7.99 15.85 1.02 
HDL 2006 4,755 14.08 32.00 43.20 52.16 54.46 64.48 84.64 139.52 16.02 
 2010 5,054 13.64 31.96 42.74 51.36 53.54 62.13 83.68 121.40 15.69 
 2014 4,036 4.89 33.68 43.05 52.95 55.32 64.53 85.71 217.39 16.89 
Total cholesterol 2006 5,853 89.10 140.08 169.22 196.27 201.16 227.48 281.59 405.41 42.18 
 2010 5,052 91.32 123.77 158.82 188.67 190.96 218.52 267.84 376.87 43.39 
 2014 4,310 104.87 128.26 161.56 189.20 192.13 218.96 265.74 365.66 42.30 
Cystatin C 2006 5,778 0.28 0.65 0.84 1.04 1.12 1.24 1.82 10.17 0.53 
 2010 5,062 0.07 0.66 0.87 1.06 1.17 1.33 2.01 9.09 0.51 
 2014 4,342 0.31 0.69 0.91 1.10 1.23 1.39 2.07 9.33 0.55 
CRP 2006 5,874 0.03 0.27 0.94 2.06 4.69 5.00 16.56 280.00 9.57 
 2010 5,053 0.05 0.26 0.83 1.84 3.86 3.98 12.83 185.36 8.14 
 2014 4,335 0.02 0.13 0.51 1.37 3.75 3.69 14.37 164.66 8.05 
ln(CRP) 2006 5,874 -3.51 -1.31 -0.06 0.72 0.75 1.61 2.81 5.63 1.25 
 2010 5,053 -3.00 -1.35 -0.19 0.61 0.60 1.38 2.55 5.22 1.19 
 2014 4,335 -4.17 -2.06 -0.68 0.32 0.31 1.30 2.66 5.10 1.45 
Note. Only includes HRS 2006 biomeasure eligible respondents.  
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Table 4-3b. Unweighted proportions of observed unimputed categorical variables for imputation by year 
Variable  2006 2010 2014   Variable  2006 2010 2014 
Gender Male 42.3% 41.3% 39.9%  Hypertension No 41.9% 35.9% 32.6% 
 Female 57.7% 58.7% 60.1%   Yes 58.0% 63.9% 67.3% 
Race/ethnicity Non-Hispanic other 77.7% 77.7% 77.4%   Missing 0.1% 0.2% 0.1%  Non-Hispanic black 14.2% 14.1% 14.1%  Diabetes  No 79.4% 75.4% 73.7% 
 Hispanic 8.1% 8.2% 8.5%   Yes 20.5% 24.6% 26.3% 
Education Less than high school 25.4% 23.1% 21.5%   Missing 0.1% <0.01% <0.1% 
 High school graduate 49.1% 49.6% 49.9%  Cancer No 84. 9% 82.2% 80.3%  Some college 4.4% 4.7% 4.7%   Yes 15.1% 17.7% 19.6% 
 College graduate 21.1% 22.7% 23.9%   Missing 0.1% 0.1% 0.1% 
Self-rated health Excellent 11.1% 9.0% 7.2%  Lung disease No 89. 7% 88.4% 88.0% 
 Very good 29.8% 31.2% 29.5%   Yes 10.2% 11.5% 11.9% 
 Good 30.7% 32.5% 34.6%   Missing 0.1% 0.1% 0.1%  Fair/Poor 28.4% 27.2% 28.7%  Heart disease No 74.7% 72.2% 69.3% 
 Missing 0.1% 0.1% 0.1%   Yes 25.3% 27.7% 30.7% 
Mildly vigorous 
activity 
At least 1/week 83.5% 78.8% 77.3%   Missing <0.1% 0.1% 0.1% 
1-3 times/month 6.4% 8.3% 8.6%  Stroke No 93.2% 91.7% 90.6% 
 Hardly ever/never 10.1% 12.8% 14.0%   Yes 6.3% 7.7% 8.6% 
 Missing 0.0% 0.1% 0.2%   Missing 0.5% 0.6% 0.1% 
Body mass index 
(BMI) 
Underweight/Normal (<25) 30.3% 29.9% 30.0%  Arthritis No 38. 7% 34.1% 31.3% 
Overweight (25-29.9) 37.6% 36.4% 36.1%   Yes 61.3% 65.7% 68.6% 
 Obese (>30) 30.1% 31.9% 32.2%   Missing <0.1% 0.2% 0.1% 
 Missing 2.1% 1.8% 1.8%  Chronic pain No 77.9% 76.2% 74.2% 
Smoking status Non-smoker 43.6% 44.6% 46.4%   Yes 22.0% 23.5% 25.2%  Former smoker 43.1% 44.4% 44.3%   Missing 0.1% 0.2% 0.6% 
 Current smoker 13.3% 10.9% 9.3%       
 Missing 0.0% 0.0% <0.1%       
Note. Only includes HRS 2006 biomeasure eligible respondents. 2006 sample size = 7,954. 2010 sample size = 6,631. 2014 sample size = 5,406.
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All SRMI imputations were conducted using IVEware (Raghunathan, Solenberger, 
Berglund, & van Hoewyk, 2016), an imputation package developed by the Survey Research 
Center at the Institute for Social Research at the University of Michigan to conduct SRMI 
imputations and analysis. In terms of building the SRMI imputation models (i.e., predictive 
distributions) for individual variables, a minimum R2 (MINRSQD) for variable inclusion in the 
imputation model was set at 0.005 to eliminate non-informative variables in the imputation 
model19. An imputation bound was set for Cystatin C to prevent imputing negative values.  
Multiple imputation was employed for each imputation approach (cross-sectional, 
sequential, and wide). Multiple imputation inference (Rubin, 1987) repeats the imputation 
process over a set of independent repetitions l = 1,2,…M. Multiple imputation is a method that 
allows the uncertainty due to imputation to be reflected in the construction of standard errors and 
confidence intervals for estimated statistics. Ten independent imputations (M = 10)20, or 
repetitions, were completed for each approach.  
Because of the multi-step procedure of the sequential approach imputation, multiple 
imputation is not conducted at each wave.  Rather, M imputations are performed at wave 1 and 
then a single imputation is done for subsequent waves using the imputation m from w = 1 as the 
base. The final result is M independent imputations at wave 1, and M “dependent” imputations 
(dependent on imputed values from wave 1 at a subsequent wave) for the second and third 
waves.  
                                               
19 Alternative fixed covariate imputation model including demographics, current wave binary health effects, and 
current wave biomeasures were also tested to confirm that the R2 selection criterion was not adding unnecessary 
variability into the between imputation variance. There was no systematic evidence to support this assertion. 
20 Additional tests using m=100 repetitions were also run to verify the results of m=10 and resulted in very similar 
final estimates.  
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The multiple imputation estimates are generated using Rubin’s combining rules (Rubin, 
1987) programmed in PROC MIANALYZE in SAS 9.4 using the estimates for each repetition 
from SURVEYMEANS OR SURVEYLOGISTIC to incorporate the complex survey sample 
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A statistic used to evaluate the quality of the multiple imputation is the fraction of 
missing information (FMI) – a measure of uncertainty about the imputed values – calculated 
from the ratio of between-imputation variance to the total variance: 
𝛾𝛾�𝑏𝑏𝑠𝑠 = �
�𝑀𝑀 + 1𝑀𝑀 � ∙ 𝐻𝐻
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�
� =  �
�𝑀𝑀 + 1𝑀𝑀 � ∙ 𝐻𝐻
𝑇𝑇 � 
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FMI is commonly compared to the missing rate for a variable as a measure of the relative 
efficiency of recovering statistical information. FMI is multiplied by 100% in this paper to 
emphasize this comparison. Good predictors in an imputation model will decrease the between-
imputation variance (B) and thus decrease the FMI below the missing rate. An FMI at or close to 
the missing rate suggests poor prediction from the imputation model. However, instability in the 
imputation can lead to instability in the FMI leading to values that can exceed the missing data 
rate (Bodner, 2008). In addition, FMI for estimates based on multiple variables (e.g., linear or 
logistic regression coefficients) are not as straightforward to interpret as for means or proportions 
for a single variable. 
 One final metric used is the coefficient of variation used with the means and proportions 
as a standardized measure of dispersion or a measure of estimate stability. The coefficient of 





4.2.4 Research questions 
For each of the descriptive and multivariate models, the research questions are: 
(1) How do point estimates (e.g., means, proportions, regression coefficients) differ 
under each longitudinal imputation approach? 
(2) Is there a consistent reduction in the variances of the point estimates across the 
differing imputation approaches? 
(3) For univariate measures, how much do the different imputation approaches reduce the 
fraction of missing information (FMI) compared to the item missing rate? Is the 
reduction pattern consistent across estimates within imputation approaches? 
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(4) What additional impact does switching to the base respondent weights from the 
biomeasure weights and increasing the analyzable sample have on the above issues? 
4.3 Results 
 This section focuses on the results of the multiple univariate and multivariate analyses 
proposed in Section 4.2.2 using the various imputation approaches described in Section 4.2.3. 
Sections 4.3.1 and 4.3.2 examine the descriptive statistics (means, the proportion at risk, and 
percentiles) by E-FTF wave for both Cystatin C and CRP, respectively. Section 4.3.3 compares 
and summarizes the univariate results from the two previous sections. Section 4.3.4 examines the 
cross-sectional multivariate model looking at the logistic regression coefficients and associated 
standard errors across the imputation strategies. Similarly, Section 4.3.5 examines the 
longitudinal multivariate model and its logistic regression coefficients and standard errors by 
imputation approach. Each section looks first at the biomeasure weighted analyses and then the 
HRS base weighted analyses.  
 Interpretation of the observed cases and imputed estimates should be made with caution. 
Estimates based on observed cases are complete case analysis, and assume missing data to be 
MCAR. Biomarker weighted analysis of the observed data implies that item missing data among 
consenting respondents is MCAR and that item missing data among non-consenters is MAR 
based on the weighting model. Base weighted analysis of the observed data assumes that both the 
non-consent and item missing data are MCAR.  
4.3.1 Cystatin C – univariate characteristics 
The sample size, mean, standard error, CV, and FMI (missing rate for observed cases) for 
Cystatin C are provided in Table 4-4 by imputation approach nested within years (rows) and 
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weighting variable (columns). Biomeasure weighted estimates are displayed before base 
weighted estimates. Overall, there are 5,724 observed cases with Cystatin C measurement out of 
6,203 possible cases with biomeasure weights for the 2006 data resulting in an item missing rate 
of 7.7%. The observed mean for Cystatin C is 1.081 mg/L with a standard error of 0.0075 mg/L. 
The imputed means shift the estimate of the mean less than a hundredth of a mg/L for each of 
three imputation approaches, and the standard errors of the imputation-based estimates of means 
are close to the observed standard error of the mean. The CVs are equivalent across imputation 
approaches. The FMI of the mean is smaller than the missing rate by anywhere from a quarter 
(sequential approach) to a half (wide approach). Overall, the wide approach sees a smaller 
change in the mean, but the largest decrease in FMI from the missing rate. 
When applying the base weights, there is a slightly larger sample size for 2006 (n = 
5,778), but a much larger missing rate (27.4%). The base weights result in a slightly lower 
complete case mean (1.074 mg/L) and standard error (0.0070) for Cystatin C compared to the 
biomeasure weighted mean. When using the multiply imputed values with a total sample size of 
7,954, means increased sample size for each of the three approaches rising to 1.090 mg/L for the 
cross-sectional approach, 1.092 mg/L for the sequential approach, and 1.085 mg/L for the wide 
approach. Similar to the biomeasure weighted estimates, no meaningful difference is seen in the 
standard errors of the mean or CVs even though there was an increase of over 2,150 
observations. While the sequential approach resulted in the least change in FMI under the 
biomeasure weights, it exhibits the largest change under the base weights with more than a three-
fifths relative reduction to 10.2%. Both the cross-sectional and wide methods show a decrease in 
the FMI to 21.1% and 19.1% from the missing rate, respectively. 
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Similar but less prominent patterns appear for Cystatin C in 2010. With 5,062 observed 
cases and a 3.2% missing rate, the mean Cystatin C in 2010 is slightly larger than what was 
observed in 2006 with a mean of 1.133 mg/L, a relative increase of about 5%. This increase is 
expected given Cystatin C is associated with healthy aging (Sarnak et al., 2008). When 
examining the estimates for the imputed data, the means, standard errors, and CVs are virtually 
the same as the observed. However, the FMIs for the three approaches do see a significant drop, 
as with the 2006 estimates. 
Estimates change more when applying the base weights to Cystatin C in 2010. Just as 
with the 2006 data, the base weighted complete case mean is slightly lower than the biomeasure 
weighted mean, down to 1.130 mg/L. The mean estimates rise to 1.137 mg/L for the cross-
sectional, to 1.143 mg/L for the sequential, and 1.146 mg/L for the wide approach. The standard 
error remains relatively consistent, even with sample size increases. The pattern of the FMIs is 
not consistent with previous findings. There is an FMI (for the sequential approach) above the 
missing rate of 23.7%, with an FMI of 24.6%. The wide imputation only sees a small drop in 
FMI down to 22.8% while the cross-sectional sees a larger drop down to 15.2%. 
The 2014 Cystatin C estimates are more reminiscent of the 2010 data than the 2006 data. 
With a missing rate of 1.6% and 4,342 observed cases, the means and standard errors do not shift 
at all across the different approaches from a mean of 1.189 mg/L (another small increase) and 
standard error of around 0.0103 when using the biomeasure weights. When using the imputed 
values, the sample size increases by less than 100 cases to 4,413. While the sequential and wide 
approaches see FMIs half of the missing rate, the cross-sectional FMI are unstable, exceeding the 
missing rate.  
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When applying the base weights, the observed mean only shifts about a thousandth of a 
mg/L. The inclusion of the nearly 1,100 additional sample cases (n = 5,406) does change the 
mean Cystatin C across the three imputation approaches (1.197, 1.203, and 1.206, respectively), 
but the FMIs for the cross-sectional and sequential mean estimates both exceed the base weight 
missing rate for Cystatin C of 19.7%, with the wide approach matching the missing rate of 
19.5%. 
The proportion at risk of chronic kidney disease refers to those with a value of Cystatin C 
greater than 1.55 mg/L. The 2006 observed data produces a biomeasure weighted estimate of 
9.2% at risk of chronic kidney disease (see Table 4-5). Increases in the proportion at risk are seen 
across all three approaches corresponding with the rising means in the previous section. 
Consistent with the increase in means, the estimated proportion at risk for the cross-sectional and 
sequential approaches is 10.0%, while under the wide approach, the proportion did not rise as 
much. No substantive change is seen in the standard error of the proportions, but the CVs all see 
some decrease due to change in the estimate of the denominator. While the FMI of the means all 
shows a decrease for the 2006 biomeasure weighted Cystatin C, the decreases are not as 
substantial for proportion at risk. The cross-sectional and wide approaches FMIs drop by about a 
tenth of a percent from the missing rate of 7.7%, but the sequential FMI increases to exceed the 
missing rate. 
The Cystatin C proportion at risk drops slightly to 8.6% for the observed cases when 
applying the base weight. The various imputation approaches have a large effect on the 
proportion at risk rising to 12.0% for the cross-sectional, 12.1% for the sequential, and 10.9% for 
the wide. While there is a substantial gain in the sample size, the standard errors actually increase 
across the different approaches from 0.0043 to 0.0054 for cross-sectional, 0.0050 for sequential, 
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and 0.0051 for wide. The CVs are lower and the confidence intervals for these proportions do not 
overlap with the complete case analysis unlike the biomeasure weighted confidence intervals 
(see Figure 4-2). Abnormal patterns in the FMIs are also observed with the cross-sectional FMI 
increasing to 34.2% (27.4% missing rate) and the wide increasing to 42.2%. The sequential 
approach FMI is lower at 17.0%. 
The 2010 biomeasure weighted proportion at risk increases from the 2006 proportion to 
12.6%, corresponding with the increase in mean Cystatin C. Small increases in the proportion at 
risk are observed across the different imputation approaches. CVs and FMIs all show reductions. 
When using the base weights, the estimated proportions increase by over two full percentage 
points which place the confidence intervals for each of the approaches nearly, if not completely, 
outside of the observed data confidence intervals (see Figure 4-2). Relatively unchanging 
standard errors result in lower CVs across the imputation approaches. The sequential FMI again 
sits above the missing rate while the others do exhibit some recovery of statistical information. 
For the 2014 Cystatin C, the proportion at risk increases slightly to 14.5% consistent with 
the increase in the mean. Comparing the complete case proportions to the imputed proportions, 
the proportions at risk again change less than half a percentage point for the biomeasure 
weighted cases. While the FMIs for the sequential and wide approaches are nearly half the 
missing data rate, a doubling in FMI for the cross-sectional imputation is present, as with the 
means. The base weights do not change the complete case proportion at risk, but do result in 
shifts for the three imputation approaches, increasing each by at least 2.5 percentage points, up to 
as much as 17.4% for the wide imputation. This also results in lower CVs. Again, the confidence 
intervals for 2014 Cystatin C imputed proportions compared to the complete case proportions do 
not overlap (see Figure 4-2). The sequential approach FMI for the proportion at risk is seen to 
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increase above the missing rate here (21.9% compared to 19.7%), but decreases are observed for 
the other two imputation approaches. 
Table 4-6 displays the estimated values for the 5th, 25th (Q1), 50th (median), 75th (Q3), 
and 95th percentiles across the columns with their associated standard errors underneath in 
parentheses. When considering the overall distribution for Cystatin C, there is little change in the 
lower half of the distribution in relation to the 5th, 25th, and 50th percentiles for the biomeasure 
weighted cases across the three imputation approaches with most cases changing less than three 
hundredths of a mg/L (see Table 4-6). The more notable changes are on the higher, more skewed 
end of the distribution (75th and 95th) where the change is closer to a tenth of a mg/L, though this 
effect is more pronounced in the 2006 data than 2014 data (see Figure 4-3). There are some large 
increases in the standard error estimates of these upper percentiles for some imputation 
approaches (e.g., 75th percentile of the 2006 biomeasure weighted Cystatin C using the cross-
sectional approach). This inflation is primarily due to the increased variability across the 10 
repetitions. When expanding to all HRS base weighted observations, even larger increases in the 
75th and 95th percentiles can be observed while a decrease in the 5th percentile emerges 
suggesting the increase of sample using the base weights generally broadens the entire 
distribution and not just the top quartile. 
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Table 4-4. Observed and imputed means and standard errors of Cystatin C by year and imputation approach 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) n Mean SE CV FMI  n Mean SE CV FMI 
2006            
Observed 5,724 1.081 0.0075 0.0070 7.7%  5,778 1.074 0.0070 0.0065 27.4% 
Cross-sectional 6,203 1.085 0.0076 0.0070 4.7%  7,954 1.090 0.0073 0.0067 21.1% 
Sequential 6,203 1.085 0.0076 0.0070 5.8%  7,954 1.092 0.0071 0.0065 10.2% 
Wide 6,203 1.083 0.0075 0.0069 3.7%  7,954 1.085 0.0071 0.0066 19.1% 
2010            
Observed 5,062 1.133 0.0090 0.0079 3.2%  5,062 1.130 0.0086 0.0076 23.7% 
Cross-sectional 5,228 1.134 0.0090 0.0079 1.7%  6,631 1.137 0.0085 0.0075 15.2% 
Sequential 5,228 1.134 0.0089 0.0078 0.9%  6,631 1.143 0.0090 0.0079 24.6% 
Wide 5,228 1.133 0.0090 0.0079 1.8%  6,631 1.146 0.0086 0.0075 22.8% 
2014            
Observed 4,342 1.189 0.0103 0.0087 1.6%  4,342 1.188 0.0101 0.0085 19.7% 
Cross-sectional 4,413 1.189 0.0104 0.0087 3.2%  5,406 1.197 0.0104 0.0087 22.2% 
Sequential 4,413 1.189 0.0103 0.0087 0.7%  5,406 1.203 0.0102 0.0085 20.8% 
Wide 4,413 1.189 0.0103 0.0087 0.9%  5,406 1.206 0.0103 0.0086 19.5% 
Note. FMI for observed is the missing rate. 
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Table 4-5. Observed and imputed proportion at risk for Cystatin C by year and imputation approach 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Mean SE CV FMI  n Mean SE CV FMI 
2006            
Observed 5,724 0.092 0.0046 0.0504 7.7%  5,778 0.086 0.0043 0.0501 27.4% 
Cross-sectional 6,203 0.100 0.0048 0.0481 6.9%  7,954 0.120 0.0054 0.0449 34.2% 
Sequential 6,203 0.100 0.0048 0.0479 9.2%  7,954 0.121 0.0050 0.0417 17.0% 
Wide 6,203 0.097 0.0046 0.0475 7.0%  7,954 0.109 0.0051 0.0469 42.2% 
2010            
Observed 5,062 0.126 0.0063 0.0500 3.2%  5,062 0.124 0.0061 0.0492 23.7% 
Cross-sectional 5,228 0.129 0.0063 0.0491 1.7%  6,631 0.147 0.0061 0.0414 20.4% 
Sequential 5,228 0.129 0.0063 0.0489 1.8%  6,631 0.150 0.0066 0.0437 25.8% 
Wide 5,228 0.127 0.0063 0.0493 2.8%  6,631 0.148 0.0062 0.0421 21.3% 
2014            
Observed 4,342 0.145 0.0067 0.0461 1.6%  4,342 0.145 0.0068 0.0468 19.7% 
Cross-sectional 4,413 0.148 0.0067 0.0457 3.1%  5,406 0.171 0.0068 0.0398 15.3% 
Sequential 4,413 0.147 0.0067 0.0454 0.8%  5,406 0.173 0.0072 0.0417 21.9% 
Wide 4,413 0.147 0.0067 0.0457 0.9%  5,406 0.174 0.0071 0.0407 18.0% 
Note. FMI for observed is the missing rate. 
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Figure 4-2. Proportion at risk for Cystatin C by year, analysis weight, and imputation approach. 95% confidence interval of the 
proportions included. 
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Table 4-6. Observed and imputed percentiles of Cystatin C by year and imputation approach 
 Biomeasure weighted 
 Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th  5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.643 0.805 0.945 1.153 1.757  0.646 0.805 0.946 1.149 1.727 
(SE) (0.010) (0.005) (0.006) (0.009) (0.031)  (0.010) (0.005) (0.005) (0.009) (0.031) 
Cross-sectional 0.647 0.838 0.969 1.212 1.817  0.577 0.840 0.978 1.240 1.877 
(SE) (0.016) (0.015) (0.014) (0.034) (0.016)  (0.013) (0.014) (0.023) (0.017) (0.025) 
Sequential 0.649 0.837 0.969 1.205 1.815  0.579 0.840 0.988 1.240 1.879 
(SE) (0.018) (0.015) (0.015) (0.030) (0.017)  (0.013) (0.015) (0.022) (0.016) (0.029) 
Wide 0.649 0.838 0.969 1.170 1.814  0.584 0.840 0.970 1.240 1.826 
(SE) (0.017) (0.015) (0.015) (0.015) (0.018)  (0.012) (0.014) (0.015) (0.015) (0.019) 
2010            
Observed 0.650 0.849 1.025 1.269 1.943  0.647 0.848 1.025 1.266 1.924 
(SE) (0.009) (0.006) (0.007) (0.012) (0.035)  (0.010) (0.006) (0.007) (0.012) (0.034) 
Cross-sectional 0.646 0.849 1.029 1.280 1.948  0.586 0.846 1.049 1.332 1.959 
(SE) (0.010) (0.007) (0.007) (0.013) (0.035)  (0.014) (0.009) (0.007) (0.013) (0.026) 
Sequential 0.645 0.849 1.029 1.277 1.946  0.590 0.849 1.049 1.336 1.977 
(SE) (0.010) (0.006) (0.007) (0.012) (0.034)  (0.014) (0.007) (0.009) (0.014) (0.027) 
Wide 0.646 0.849 1.029 1.277 1.944  0.605 0.851 1.050 1.334 1.982 
(SE) (0.010) (0.006) (0.007) (0.012) (0.035)  (0.014) (0.008) (0.007) (0.012) (0.028) 
2014            
Observed 0.669 0.890 1.072 1.338 1.984  0.667 0.889 1.072 1.339 1.981 
(SE) (0.007) (0.006) (0.007) (0.013) (0.040)  (0.008) (0.006) (0.007) (0.013) (0.039) 
Cross-sectional 0.668 0.892 1.074 1.347 1.988  0.619 0.892 1.092 1.397 2.043 
(SE) (0.008) (0.006) (0.007) (0.014) (0.038)  (0.016) (0.006) (0.010) (0.013) (0.035) 
Sequential 0.666 0.891 1.075 1.344 1.987  0.625 0.894 1.095 1.400 2.062 
(SE) (0.008) (0.006) (0.006) (0.013) (0.039)  (0.016) (0.005) (0.010) (0.013) (0.035) 
Wide 0.667 0.890 1.074 1.345 1.988  0.630 0.894 1.094 1.400 2.083 
(SE) (0.008) (0.005) (0.007) (0.014) (0.038)  (0.015) (0.004) (0.011) (0.014) (0.041) 
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Figure 4-3. Distribution of Cystatin C by year, analysis weight, and imputation approach. Ends of whisker plot represent 5th and 95th 
percentiles corresponding with values in Table 4-6. Black squares represent means. 
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4.3.2 C-reactive protein – univariate characteristics 
Table 4-7 displays the means and associated standard errors of the natural log 
transformed CRP, ln(CRP). The original scale CRP values are not displayed here but are 
included in Appendix E. 
The observed mean of 2006 biomeasure weighted ln(CRP) is 0.718 (corresponding to 
2.050 ug/mL on the original CRP scale) with a standard error of 0.0193 and an item missing rate 
of 6.2% (n = 5,817). Looking across the three imputation approaches, the mean ln(CRP) is 
virtually unchanged, but with minor drops in the standard errors resulting in slightly reduced 
CVs. The FMI of the means all decrease with the cross-sectional and sequential approach FMIs 
dropping to almost half of the missing rate (3.5% and 3.3%, respectively). 
The 2006 base weighted ln(CRP) estimates show a similar pattern to Cystatin C of 
increasing means. The estimates of ln(CRP) means under the cross-sectional and sequential 
approaches both increase to 0.731 and 0.732, respectively, from the observed 0.721. Overall the 
observed standard error is larger than the standard errors of the imputed means corresponding 
with the sample size increase. The FMI for the cross-sectional and sequential imputations is 
reduced from the item missing rate of 26.2% to 16.5% and 14.3%, respectively. One deviation 
from this overall pattern is the wide approach where the mean and standard error do not change 
and the estimated FMI is slightly larger than the item missing rate.  
The 2010 biomeasure weighted ln(CRP) mean is lower than the 2006 mean at 0.563, the 
reverse effect observed with Cystatin C. This suggests that the retained sample has lower 
inflammation levels, perhaps due to panel loss due to mortality. The imputed means are slightly 
lower than the observed mean at around 0.560 on average. The FMIs of the mean are all smaller 
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than the missing rate (3.3%) at 2.4% for cross-sectional, 1.5% for sequential, and 0.7% for wide 
approaches. When applying the base weights, the ln(CRP) mean drops slightly to 0.556 with an 
item missing rate of 23.8%. The mean ln(CRP) for the sequential approach is in the same general 
range as the biomeasure weighted estimates, but the cross-sectional and wide approaches result 
in slightly higher means (0.567 and 0.571, respectively). The 2010 base weighted estimates is 
also the first real variability in the standard errors seen here with the cross-sectional standard 
error dropping from the observed 0.0198 to 0.0185 and the wide standard error increasing to 
0.0212. The FMI associated with the cross-sectional mean (17.3%) sees a significant drop from 
the missing rate (23.8%), while the sequential FMI (23.1%) is sits close to the missing rate and 
the wide is significantly larger than the missing rate. 
Finally the 2014 biomeasure weighted ln(CRP) means decrease to 0.254, with a standard 
error increasing to 0.0236. Nearly two percent of cases had missing values. While the sample 
size increase using imputation is small given the biomeasure weights, there are no differences in 
the means, standard errors, or CVs for ln(CRP). The sequential approach FMI is much smaller 
than the missing rate at 0.3% while the wide approach FMI is slightly larger at 2.2%. The use of 
the base HRS weights slightly increases the observed mean (0.257) with the wide approach 
displaying largest shift in the estimated means (0.269). Some minor reductions in the standard 
errors and CVs are present, but the cross-sectional and wide approaches FMIs are higher than the 
missing rate (19.8%), where the sequential approach FMI drops to only 4.1%.  
Examining the proportion at risk of high CRP (i.e., high levels of systemic 
inflammation), the estimated proportions (and their associated standard errors) remain virtually 
the same across imputation approaches when using the biomeasure weights for each of the three 
years (see Table 4-8 and Figure 4-4). Some 38.1% had high levels of systemic inflammation in 
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2006, 31.8% in 2010, and 28.4% in 2014. This drop is consistent with the decreasing means in 
ln(CRP) noted in the previous section. A consistent decrease in the associated FMI is observed 
across all imputation approaches and years, the one exception being the cross-sectional 
imputation for 2014). In general, the different imputation approaches do very little to change the 
estimated proportion at risk. 
When applying the base weights, some movement in the estimates occurs compared to 
the biomeasure weights. The base weighted proportion at risk estimated from the observed data 
for 2006 remains the same as the biomeasure weighted proportion, but there is a very weak effect 
increasing the proportion at risk for the cross-sectional and sequential approaches. The 
proportion at risk using the wide approach is not different from the observed. The cross-sectional 
and wide approach standard errors and CVs are smaller. The FMIs of the proportion are all 
smaller than the missing rate (26.2%), with the base weights for 2006 having the smallest 
reduction for the wide approach at 19.1%, and the largest reduction for the cross-sectional 
approach at 12.7%. 
The 2010 base weighted observed proportions at risk are slightly below the biomeasure 
weighted estimate of 31.8%. Minor increases occur in the estimated proportion at risk with the 
wide imputation approach having the largest increase to 32.2%. Minor increases in standard 
errors and CV are seen across all imputation approaches. However, the FMIs for the proportion 
at risk using the base weights in 2010 range from slightly reduced in the sequential approach at 
22.2% to largely increased at 26.9% for the cross-sectional approach compared to the missing 
rate of 23.8%.  
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Finally, the 2014 estimates using the base weights are relatively unchanged compared to 
the biomeasure weights. The various imputations do little to change the proportion at risk. Again, 
variability is seen in the FMIs for the CRP proportion at risk. While the missing rate is 19.8%, 
the sequential approach results in a lower FMI of 8.7% while the cross-sectional approach FMI 
remains below the missing rate and the wide approach FMI is increases nearly 50 percent larger.  
Consistent with the previous evaluation of the means and proportion at risk, there is no 
strong change in the selected percentiles nor in their associated standard errors for ln(CRP) 
regardless of the analysis weight used (see Table 4-9 and Figure 4-5). Table 4-9 shows some 
small differences across the percentiles in the hundredths place, but these changes are virtually 
indistinguishable in Figure 4-5. No reduction or major change in the standard errors is observed 
in Table 4-9. This effect seems consistent across years. Overall, the imputation of CRP appears 
to change any univariate descriptive measure compared to the observed cases. 
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Table 4-7. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI  n Mean SE CV FMI 
2006            
Observed 5,817 0.718 0.0193 0.0269 6.2%  5,874 0.721 0.0203 0.0281 26.2% 
Cross-sectional 6,203 0.719 0.0185 0.0257 3.5%  7,954 0.731 0.0195 0.0267 16.5% 
Sequential 6,203 0.720 0.0189 0.0262 3.3%  7,954 0.732 0.0198 0.0270 14.3% 
Wide 6,203 0.717 0.0186 0.0260 5.8%  7,954 0.721 0.0195 0.0271 26.9% 
2010            
Observed 5,053 0.563 0.0194 0.0345 3.3%  5,053 0.556 0.0198 0.0357 23.8% 
Cross-sectional 5,228 0.560 0.0195 0.0347 2.4%  6,631 0.567 0.0185 0.0325 17.3% 
Sequential 5,228 0.561 0.0195 0.0347 1.5%  6,631 0.562 0.0201 0.0357 23.1% 
Wide 5,228 0.560 0.0194 0.0347 0.7%  6,631 0.571 0.0212 0.0371 28.7% 
2014            
Observed 4,335 0.254 0.0236 0.0929 1.8%  4,335 0.257 0.0246 0.0955 19.8% 
Cross-sectional 4,413 0.254 0.0241 0.0949 1.8%  5,406 0.258 0.0246 0.0952 21.4% 
Sequential 4,413 0.254 0.0236 0.0929 0.3%  5,406 0.263 0.0225 0.0858 4.1% 
Wide 4,413 0.254 0.0240 0.0943 2.2%  5,406 0.269 0.0241 0.0897 21.5% 




Table 4-8. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI  n Mean SE CV FMI 
2006            
Observed 5,817 0.381 0.0086 0.0225 6.2%  5,874 0.381 0.0088 0.0230 26.2% 
Cross-sectional 6,203 0.381 0.0082 0.0215 3.7%  7,954 0.385 0.0079 0.0206 12.7% 
Sequential 6,203 0.381 0.0083 0.0218 4.7%  7,954 0.384 0.0084 0.0218 16.6% 
Wide 6,203 0.381 0.0082 0.0215 4.4%  7,954 0.381 0.0079 0.0207 19.1% 
2010            
Observed 5,053 0.318 0.0067 0.0210 3.3%  5,053 0.315 0.0069 0.0218 23.8% 
Cross-sectional 5,228 0.318 0.0067 0.0211 2.4%  6,631 0.320 0.0073 0.0230 26.9% 
Sequential 5,228 0.318 0.0068 0.0212 1.9%  6,631 0.318 0.0071 0.0222 22.2% 
Wide 5,228 0.318 0.0068 0.0212 2.2%  6,631 0.322 0.0071 0.0220 26.3% 
2014            
Observed 4,335 0.284 0.0073 0.0258 1.8%  4,335 0.285 0.0075 0.0263 19.8% 
Cross-sectional 4,413 0.284 0.0075 0.0262 2.6%  5,406 0.283 0.0074 0.0263 18.7% 
Sequential 4,413 0.284 0.0074 0.0260 0.8%  5,406 0.284 0.0075 0.0263 8.7% 
Wide 4,413 0.284 0.0074 0.0261 1.7%  5,406 0.287 0.0079 0.0276 27.9% 




Figure 4-4. Proportion at risk for C-reactive protein by year, analysis weight, and imputation approach. 95% confidence interval of 
the proportions included. 
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Table 4-9. Observed and imputed percentiles of C-reactive protein (natural log transform) by year and imputation approach 
 Biomeasure weighted 
 Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th  5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.381 -0.099 0.675 1.571 2.768  -1.367 -0.090 0.677 1.560 2.767 
(SE) (0.052) (0.033) (0.032) (0.029) (0.044)  (0.050) (0.035) (0.032) (0.030) (0.045) 
Cross-sectional -1.372 -0.100 0.677 1.578 2.773  -1.336 -0.086 0.717 1.579 2.789 
(SE) (0.051) (0.034) (0.033) (0.029) (0.043)  (0.043) (0.030) (0.033) (0.029) (0.041) 
Sequential -1.367 -0.101 0.676 1.576 2.775  -1.337 -0.089 0.717 1.579 2.792 
(SE) (0.051) (0.034) (0.033) (0.029) (0.043)  (0.045) (0.036) (0.033) (0.029) (0.042) 
Wide -1.374 -0.105 0.676 1.572 2.769  -1.343 -0.099 0.701 1.560 2.776 
(SE) (0.051) (0.033) (0.033) (0.029) (0.045)  (0.047) (0.032) (0.035) (0.034) (0.041) 
2010            
Observed -1.397 -0.233 0.557 1.331 2.521  -1.388 -0.236 0.545 1.326 2.516 
(SE) (0.038) (0.028) (0.027) (0.025) (0.028)  (0.039) (0.028) (0.028) (0.025) (0.033) 
Cross-sectional -1.395 -0.235 0.555 1.331 2.520  -1.362 -0.221 0.557 1.342 2.532 
(SE) (0.040) (0.029) (0.027) (0.024) (0.030)  (0.027) (0.027) (0.023) (0.026) (0.032) 
Sequential -1.397 -0.232 0.555 1.332 2.522  -1.378 -0.231 0.559 1.339 2.525 
(SE) (0.039) (0.030) (0.026) (0.025) (0.030)  (0.036) (0.032) (0.025) (0.025) (0.035) 
Wide -1.400 -0.236 0.555 1.333 2.522  -1.373 -0.218 0.564 1.349 2.528 
(SE) (0.039) (0.028) (0.025) (0.025) (0.029)  (0.032) (0.031) (0.025) (0.026) (0.030) 
2014            
Observed -2.198 -0.728 0.250 1.252 2.625  -2.186 -0.726 0.248 1.255 2.628 
(SE) (0.059) (0.031) (0.036) (0.029) (0.054)  (0.066) (0.032) (0.037) (0.028) (0.056) 
Cross-sectional -2.195 -0.727 0.250 1.253 2.623  -2.137 -0.719 0.248 1.252 2.625 
(SE) (0.060) (0.032) (0.036) (0.029) (0.053)  (0.070) (0.030) (0.036) (0.031) (0.056) 
Sequential -2.190 -0.726 0.250 1.251 2.623  -2.138 -0.715 0.253 1.254 2.643 
(SE) (0.060) (0.031) (0.037) (0.029) (0.052)  (0.066) (0.032) (0.035) (0.030) (0.052) 
Wide -2.202 -0.727 0.252 1.252 2.626  -2.150 -0.712 0.267 1.268 2.642 
(SE) (0.057) (0.032) (0.037) (0.029) (0.056)  (0.064) (0.032) (0.036) (0.033) (0.054) 
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Figure 4-5. Distribution of C-reactive protein (natural log transform) by year, analysis weight, and imputation approach. Ends of 
whisker plot represent 5th and 95th percentiles corresponding with values in Table 4-9. Black squares represent means. 
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4.3.3 Summary of univariate findings 
 In order to better generalize over the multiple univariate estimates, the mean and median 
CV and FMI were calculated for each imputation approach and weight combination. Each mean 
and median is computed across both biomeasures, both parameters (mean and proportion), and 
all three waves21. Given variability in CVs across biomeasure, parameter, and wave, a mean and 
median relative difference was also calculated to better account for differences in scale22. The 
same calculation was done for FMI.  
 For the biomeasure weighted estimates, there are very little gains in the CV for the three 
imputation approaches which makes sense given the relatively small sample size increase (see 
Table 4-10). The sequential approach has the largest reduction in mean CV and mean relative 
difference in CV, though the latter is only about a 1% improvement. For the median CV, the 
cross-sectional approach narrowly comes out on top while the median relative difference again 
favors the sequential approach. Similarly, the average and median FMI are much lower than the 
missing data rate with the sequential approach showing the largest drop. The mean relative 
difference for the sequential approach is 55% (50% for the median) of the observed missing rate 
followed by the wide approach at 72% (68% for the median). 
                                               
21 For example, the mean CV would be calculated as follows: 
𝐶𝐶𝐶𝐶����𝑤𝑤𝑐𝑐,𝑠𝑠𝑏𝑏𝑝𝑝 = ����𝐶𝐶𝐶𝐶𝑠𝑠 ,𝑗𝑗,𝑤𝑤,𝑤𝑤𝑐𝑐,𝑠𝑠𝑏𝑏𝑝𝑝
𝑤𝑤𝑗𝑗𝑠𝑠
� /𝐼𝐼𝐽𝐽𝑊𝑊 
where i is the parameter, j is the biomeasure, w is the wave, wt is the weighting variable, and imp is the imputation 
approach. I, J, and W would result in a value of 12 based on the two parameters for two biomeasures across three 
waves of data. 
22 For example, the CV relative difference would be calculated as follows: �𝐶𝐶𝐶𝐶𝑠𝑠 ,𝑗𝑗,𝑤𝑤,𝑤𝑤𝑐𝑐,𝑠𝑠𝑏𝑏𝑝𝑝 − 𝐶𝐶𝐶𝐶𝑠𝑠 ,𝑗𝑗,𝑤𝑤,𝑤𝑤𝑐𝑐,Observed�/
𝐶𝐶𝐶𝐶𝑠𝑠,𝑗𝑗,𝑤𝑤,𝑤𝑤𝑐𝑐,Observed. If calculating the mean, this value is then substituted in the formula in footnote 21. 
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 When considering the base weighted estimates, some larger gains are seen for the CV of 
the estimates. The sequential again has the lowest mean CV while the cross-sectional has the 
lowest median CV. Alternatively when considering the mean relative difference, the cross-
sectional has the advantage with an improvement of nearly 4.8% compared to sequential at 
around 4.5%. This is echoed in the median values. The results for the FMI are consistent 
showing the sequential approach to have the largest gains in recovering statistical information. 
The wide imputation using the base weights shows a mean FMI, as well as a median and mean 
relative difference in FMI, exceeding the complete case analysis. 
Table 4-10. Mean and median univariate CV and FMI across biomeasures, parameters, and years 
  Mean CV Mean FMI 
Mean Relative 
Difference in CV 
Mean Relative 
Difference in FMI 
Biomeasure weighted     
Observed 0.0328 3.97% - - 
Cross-sectional 0.0326 3.14% 99.21% 96.36% 
Sequential 0.0324 2.64% 98.91% 55.12% 
Wide 0.0325 2.83% 99.03% 71.93% 
Base weighted     
Observed 0.0333 23.41% - - 
Cross-sectional 0.0311 20.14% 95.17% 86.85% 
Sequential 0.0307 17.44% 95.52% 75.20% 
Wide 0.0314 24.44% 96.34% 104.76% 
  Median CV Median FMI 
Median Relative 
Difference in CV 
Median Relative 
Difference in FMI 
Biomeasure weighted     
Observed 0.0263 3.26% - - 
Cross-sectional 0.0260 2.86% 99.96% 71.59% 
Sequential 0.0261 1.60% 99.28% 50.92% 
Wide 0.0261 2.20% 99.59% 67.75% 
Base weighted     
Observed 0.0272 23.73% - - 
Cross-sectional 0.0265 19.50% 96.66% 81.94% 
Sequential 0.0267 18.90% 98.00% 78.21% 
Wide 0.0273 22.16% 97.52% 100.90% 
Note. CV = coefficient of variation. FMI = fraction of missing information. 
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Figure 4-6. Relative difference in univariate CV from observed across biomeasures, parameters, and years.  
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Figure 4-7. Relative difference in univariate FMI from observed across biomeasures, parameters, and years.
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4.3.4 Cross-sectional multivariate model 
 Given similarities among the models results for the three years, only the 2006 model and 
its coefficient estimates are discussed in this section. The 2006 data have the largest change in 
sample size and should therefore reflect the largest changes in coefficients and standard errors. 
Model results for 2010 and 2014 are included Appendix F. Notable differences between years 
will be highlighted at the end of the section. Statistical significance in this section is defined at a 
critical value of 0.05. 
The complete case analysis modeling cardiovascular disease in 2006 using the 
biomeasure weights has 5,614 cases. Beginning with the demographic controls (see Table 4-11), 
females and those of Hispanic ethnicity are both less likely to be diagnosed with cardiovascular 
disease over males and other non-Hispanic, respectively. Age increases the likelihood of 
receiving this diagnosis though the effect is somewhat reduced for females. Health conditions 
including hypertension and diabetes expectedly show up as significant predictors as they are 
common comorbidities with cardiovascular disease. Obesity (BMI > 30) counterintuitively 
estimates a negative effect on the likelihood of cardiovascular disease in this estimated model 
relative to those with a BMI under 25, though this may be a multivariable finding given other 
variables in the model. For health behaviors, respondents with hardly any or no mildly vigorous 
activity have a much larger chance of being diagnosed with cardiovascular disease over those 
who perform weekly activity as are current smokers compared to those who have never smoked. 
Of the two biomarkers included in the model, only Cystatin C had a significant observed effect 
on the likelihood of cardiovascular disease.  
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For each of the imputed models, regardless of approach, the overall analytic sample size 
increased by over 10 percent to a final sample size of 6,203. Starting with the cross-sectional 
imputation approach, reductions in multiple standard errors of the logistic regression coefficients 
are seen which are anticipated given the substantial sample size increase. Larger, more notable 
standard error reductions include overweight (𝑆𝑆𝐸𝐸�?̂?𝛽𝐵𝐵𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� = 0.115 down to 
𝑆𝑆𝐸𝐸�?̂?𝛽𝐶𝐶𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖� = 0.097), non-Hispanic blacks (0.111 down to 0.099), hardly ever/never 
mildly vigorous activity (0.130 down to 0.120), and Cystatin C (0.081 down to 0.074). Few 
standard errors (namely obesity) increased from the observed model to the cross-sectional 
approach imputation. Many of the significant coefficients remain similar to the observed 
parameter estimates. Some of the larger coefficient changes include obesity (?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖  =    
-0.191 down from ?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = -0.245), non-Hispanic black (-0.204 up to -0.178), and Cystatin C 
(0.401 down from 0.436).  
The sequential approach results look very similar to the cross-sectional results in terms of 
coefficients and standard errors. The wide approach also exhibits a number of similarities across 
the other approaches. One notable deviation is the coefficient for Cystatin C which to is closer to 
zero for the wide approach while maintaining the standard error reduction seen with the cross-
sectional and sequential approaches. However this attenuation is not significantly large enough 
to change the general interpretation of the effect (see Figure 4-8). While still a non-significant 
variable in the model, ln(CRP) also sees attenuation of the estimated coefficient, but no real 
change in the standard error. 
When applying the base HRS weights to the analysis, the observed sample size increases 
by less than 100 cases from the biomeasure weighted analysis up to 5,667. Most of the same 
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patterns above hold with most logistic regression coefficients maintaining the relatively same 
estimate scale moving less than a few hundredths in either direction for the observed data (see 
Table 4-12). One exception is the coefficient for Hispanics increasing from ?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠  = -0.396 
to ?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠  = -0.513 for the observed model.  
When using all of the imputed values, the analytic sample size rises to 7,954 – nearly a 
forty percent increase in available sample. Most of the imputed estimates (regardless of 
imputation approach) also see minimal changes. Some larger changes are Hispanics 
(?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = -0.513 to ?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖 = -0.609), non-Hispanic blacks (-0.213 to -
0.261), former smokers (0.153 to 0.194), and Cystatin C (0.440 to 0.348), with the former three 
getting larger. Regarding the latter, the imputed base weighted Cystatin C coefficients see much 
more attenuation toward zero (?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 0.440 to ?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠  = 0.350) than with the 
biomeasure weighted coefficients (?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠,𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 0.436 to ?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠,𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠  = 0.389), but 
also see a large reduction in standard errors especially for the wide approach (𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� 
= 0.080 to 𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠,𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠� = 0.061 vs. 𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠,𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� = 0.081 to 𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠,𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠� 
= 0.073) (see also Figure 4-8). 
Given the increase in sample size, there are consistent reductions in standard errors 
within the imputation models, more so than with the biomeasure weighted model. This is seen 
particularly in the standard error of the coefficients for females (0.081 to 0.067 using the wide 
approach), Hispanics (0.136 to 0.122), overweight (0.099 to 0.073), obese (0.109 to 0.085), and 
current smoker (0.128 to 0.096). In particular Cystatin C sees one of the largest gains with the 
wide approach having an estimated coefficient standard error of 0.061 compared to the fully 
observed 0.080. Most standard errors remain fairly close to the biomeasure weighted model, but 
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some indicators do experience larger changes (e.g., Hispanic, from ?̂?𝛽 = -0.434 to ?̂?𝛽 = -0.609). 
Cystatin C sees greater attenuation in the regression coefficients with the base weights in contrast 
to reduced standard errors. In general however, the interpretation and conclusions of the model 
do not fundamentally change. 
Figure 4-8 displays odds ratios and confidence intervals for both ln(CRP) and Cystatin C 
for the 2006 models using both the biomeasure and base weights. Given relative ranges and 
scales of both biomarkers (Cystatin C has a range of less than 7; ln(CRP) has a range of less than 
5), it is less informative to use a one unit increase to examine these coefficient estimates. A one 
standard deviation change was used for each biomarker coefficient. Using the observed data, one 
standard deviation was calculated to be about 1.25 for ln(CRP) and about 0.50 for Cystatin C. 
Using these values, Figure 4-8 shows how the imputed values seem to attenuate the effect of 
each biomarker, though the confidence intervals – even for the significant predictor Cystatin C – 
do not fundamentally change.  
When looking at the 2010 and 2014 data, there are some minor differences from the 
estimated models compared to 2006 (see Appendix F). The estimated effects for females (?̂?𝛽2006 
= -0.254 to ?̂?𝛽2014 = -0.373) and Hispanics (?̂?𝛽2006 = -0.396 to ?̂?𝛽2014 = 0.482) do increase across 
the three waves likely due to the changing demographic profile from wave to wave given the 
restriction to include only those who were biomeasure eligible in 2006. The puzzling negative 
coefficient for those classified as obese goes away in both 2010 and 2014. While the 2006 model 
saw a significant increase in the odds of having cardiovascular disease in current smokers 
(holding all other factors constant), the 2010 and 2014 models saw former smoker status as the 
larger, significant predictor of cardiovascular disease (?̂?𝛽2006 = 0.184 to ?̂?𝛽2014 = 0.260) with 
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current smoker showing no significant effect (?̂?𝛽2006 = 0.286 to ?̂?𝛽2014 = 0.200). In 2010, the 
effects for non-Hispanic blacks increased (?̂?𝛽2006 = -0.178 to ?̂?𝛽2010 = -0.306) while the effect for 
little to no activity (?̂?𝛽2006 = 0.397 to ?̂?𝛽2010 = 0.230) goes away. These changes are not observed 
in the 2014 models. Regarding the included biomarkers, the effect for Cystatin C (and the non-
significant ln(CRP)) remains fairly constant across the waves. In terms of the different 
approaches and weights, there are no patterns observed that differed from what was shared 
previously. 
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Table 4-11. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights 
  Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.047 (0.007)****  0.049 (0.006)****  0.049 (0.006)****  0.049 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.254 (0.086)** -0.264 (0.081)** -0.266 (0.081)** -0.262 (0.081)** 
Age x Female -0.017 (0.007)* -0.014 (0.007)* -0.014 (0.007)* -0.014 (0.007)* 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.396 (0.142)** -0.434 (0.136)** -0.433 (0.136)** -0.431 (0.136)** 
Non-Hispanic black -0.178 (0.111)  -0.204 (0.099)* -0.204 (0.099)* -0.200 (0.098)* 
Health conditions     
Hypertension  0.734 (0.082)****  0.734 (0.080)****  0.733 (0.080)****  0.734 (0.080)**** 
Diabetes  0.580 (0.063)****  0.596 (0.060)****  0.593 (0.061)****  0.590 (0.061)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.166 (0.115)  -0.178 (0.097)  -0.179 (0.096)  -0.178 (0.099)  
Obese (BMI > 30)                  -0.245 (0.104)* -0.191 (0.110)  -0.189 (0.109)  -0.187 (0.109)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.115 (0.154)   0.087 (0.142)   0.089 (0.142)   0.091 (0.142)  
Hardly ever/never   0.397 (0.130)**  0.399 (0.122)**  0.394 (0.121)**  0.400 (0.121)** 
Smoking status (ref: never smoked)    
Current smoker           0.286 (0.134)*  0.294 (0.129)*  0.292 (0.129)*  0.295 (0.128)* 
Former smoker            0.184 (0.104)   0.203 (0.105)   0.203 (0.104)   0.202 (0.104)  
Biomeasures     
ln(CRP)  0.035 (0.032)   0.023 (0.031)   0.026 (0.031)   0.022 (0.031)  
Cystatin C  0.436 (0.081)****  0.401 (0.074)****  0.399 (0.073)****  0.389 (0.073)**** 
Intercept                           -2.092 (0.166)**** -2.078 (0.164)**** -2.075 (0.163)**** -2.065 (0.162)**** 
Note. Sample sizes: observed n = 5,614; imputed n = 6,203.  
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001. 
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Table 4-12. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.047 (0.007)****  0.053 (0.006)****  0.052 (0.006)****  0.053 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.249 (0.081)** -0.283 (0.068)**** -0.286 (0.068)**** -0.275 (0.067)**** 
Age x Female -0.018 (0.007)* -0.013 (0.005)* -0.013 (0.005)* -0.013 (0.005)* 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.513 (0.149)** -0.609 (0.122)**** -0.610 (0.122)**** -0.602 (0.122)**** 
Non-Hispanic black -0.213 (0.112)  -0.261 (0.109)* -0.260 (0.108)* -0.251 (0.108)* 
Health conditions     
Hypertension  0.730 (0.083)****  0.724 (0.069)****  0.723 (0.069)****  0.723 (0.069)**** 
Diabetes  0.552 (0.062)****  0.533 (0.064)****  0.531 (0.064)****  0.522 (0.064)**** 
BMI (ref: under/normal weight)    
Overweight (25 ≤ BMI < 30) -0.159 (0.115)  -0.131 (0.073)  -0.136 (0.072)  -0.126 (0.073)  
Obese (BMI > 30)                  -0.225 (0.101)  -0.134 (0.088)  -0.139 (0.086)  -0.121 (0.085)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.075 (0.154)   0.068 (0.143)   0.069 (0.142)   0.074 (0.143)  
Hardly ever/never   0.364 (0.135)**  0.340 (0.098)***  0.337 (0.099)***  0.353 (0.098)*** 
Smoking status (ref: never smoked)    
Current smoker           0.256 (0.133)   0.234 (0.097)*  0.232 (0.097)*  0.242 (0.096)* 
Former smoker            0.153 (0.100)   0.194 (0.081)*  0.195 (0.081)*  0.196 (0.081)* 
Biomeasures     
ln(CRP)  0.036 (0.032)   0.029 (0.031)   0.033 (0.028)   0.024 (0.028)  
Cystatin C  0.440 (0.080)****  0.348 (0.077)****  0.358 (0.067)****  0.350 (0.061)**** 
Intercept                           -2.084 (0.158)**** -1.965 (0.139)**** -1.974 (0.129)**** -1.974 (0.128)**** 
Note. Sample sizes: observed n = 5,667; imputed n = 7,954.  





Figure 4-8. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2006 by imputation approach and analysis weight. 
Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) and 0.50 
for Cystatin C. 95% confidence interval of the odds ratio included. 
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4.3.5 Longitudinal multivariate model 
 Using the biomeasure weight, the observed sample size for the longitudinal multivariate 
model is 2,728 while the imputed sample size is 3,545, a 30% increase in analytic sample size, 
which primarily is due to the addition of over 600 cases that did not consent to biomeasure 
collection in 2006. Statistical significance in this section is defined at a critical value of 0.05. 
In the observed model, age, gender, diabetes, and former smoker are all significant 
predictors of developing cardiovascular disease, similar to the cross-sectional model (see Table 
4-13). These findings are also consistent with the literature as potential risk factors. However, 
race/ethnicity, hypertension, obesity, and mildly vigorous activity as well as the age by gender 
interaction are not found to be significant in these models like in the cross-sectional model 
though the coefficients for Hispanic and hypertension are relatively similar to the coefficients 
from the cross-sectional model. Cystatin C is also a significant predictor in this model (?̂?𝛽 = 
0.694) along with the change variable for Cystatin C (?̂?𝛽 = 0.367). The initial wave of Cystatin C 
measurement appears to have a larger effect than more recent changes on the likelihood of 
developing cardiovascular disease than recent changes in one’s kidney health. The transformed 
CRP has virtually no predictive power for predicting the development of cardiovascular disease 
(?̂?𝛽 = 0.000) with the inclusion of Cystatin C and other known risk factors. 
Focusing first on the cross-sectional approach, large drops in the standard errors are fairly 
consistent across all of the predictors including for Hispanic (𝑆𝑆𝐸𝐸�?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� = 0.286 down to 
𝑆𝑆𝐸𝐸�?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖� = 0.231), hypertension (0.229 down to 0.183), current smoker (0.231 down 
to 0.184), recently quit smoking (0.336 down to 0.258), and Cystatin C (0.217 down to 0.179). In 
conjunction with larger estimated coefficients, this led to large changes in statistical significance 
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for hypertension and recently quit smoking. However many coefficients attenuated toward zero 
including females and Cystatin C effecting the statistical significance of the former, but not the 
latter. 
Similar to the cross-sectional analysis, a comparison of the three approaches does little to 
differentiate them from each other when looking at the coefficients and their associated standard 
errors. Much of the variability in the imputation approaches has to do with Cystatin C. All three 
approaches do see a large drop in the Cystatin C regression coefficients and the associated 
standard errors. The sequential approach is the closest to the observed estimates with the wide 
approach showing the largest drop for both the coefficient and standard error (see Figure 4-9). 
The variation in the Cystatin C change variable is not as drastic as the main Cystatin C though 
the wide approach does result in a larger drop in the coefficient, but not in the standard error. 
These result in very similar confidence intervals (see Figure 4-10). 
When applying the base weights, the observed sample size remains the same, but the 
imputed sample size rises to 4,357 – a 60% increase in sample size. This increase includes the 
600 that did not consent to biomeasure collection in 2006, nearly 500 that did not consent in 
2014, about 325 who did consent in either 2006 or 2014, and the remainder some other form of 
missingness across the many analysis variables and biomarkers. 
Reviewing the observed data model, the general findings discussed above do not really 
change with many of the coefficients and standard errors being relatively comparable (see Table 
4-14). In terms of the model interpretation, the only difference is that the indicator for recently 
quit smoking is significant in the observed model with the coefficient rising from ?̂?𝛽𝑖𝑖𝑠𝑠𝑐𝑐𝑏𝑏𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠  = 
0.658 up to ?̂?𝛽𝑖𝑖𝑎𝑎𝑠𝑠𝑠𝑠  = 0.735 with only a moderate increase in the standard error.  
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The three imputation approaches do see more differences given the large sample increase. 
Under the cross-sectional approach with the base weights, the female coefficient remains a 
significant predictor seeing a large drop in the coefficient standard error. A previous diagnosis of 
hypertension (as of 2006) becomes significant in the cross-sectional imputation similar to when 
using the biomeasure weight, but a recent diagnosis of hypertension (between 2006 and 2014) is 
also found to be significant seeing a large jump with the coefficient (?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 0.137 up to 
?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖 = 0.456) as well as a large drop in the standard error (𝑆𝑆𝐸𝐸�?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� = 0.216 
down to 𝑆𝑆𝐸𝐸�?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖� = 0.154). The coefficient for recently quit smoking remains 
significant in the cross-sectional imputation, but also sees the current smoker as of 2006 
indicator as significant thanks to an enlarged coefficient and reduced standard error. Cystatin C 
under the cross-sectional approach sees a similar attenuation of the coefficient and reduction in 
standard error as with the biomeasure weights. 
The sequential and wide approaches offer few differences from the cross-sectional 
approach estimates. The wide approach does see recent weight gain (as measured by 
transitioning up a BMI category) as a significant predictor of developing cardiovascular disease. 
Most of the difference again focuses around Cystatin C. The 2006 Cystatin C concentration sees 
some variability with the sequential approach not enjoying as large of a standard error drop 
(𝑆𝑆𝐸𝐸�?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� = 0.225 down to 𝑆𝑆𝐸𝐸�?̂?𝛽𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑎𝑎𝑖𝑖� = 0.198) as compared to the cross-sectional or 
wide approaches (𝑆𝑆𝐸𝐸�?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖� = 0.168; 𝑆𝑆𝐸𝐸�?̂?𝛽𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠� = 0.158), which is similar to the 
biomeasure weighted results. The wide approach also sees the largest attenuation of the logistic 
regression coefficient (?̂?𝛽𝑤𝑤𝑠𝑠𝑠𝑠𝑠𝑠  = 0.432 down from ?̂?𝛽𝑐𝑐𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 0.685) compared to the other 
approaches (?̂?𝛽𝑑𝑑𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠−𝑠𝑠𝑠𝑠𝑑𝑑𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑎𝑎𝑖𝑖 = 0.540; ?̂?𝛽𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑠𝑠𝑎𝑎𝑖𝑖 = 0.500). However, these differences do not 
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substantially alter the overall interpretation and are generally consistent with the results when 
using the biomeasure weights for analysis (see Figure 4-9). A similar conclusion is reached for 
the Cystatin C change variable (see Figure 4-10). 
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Table 4-13. Logistic regression logit coefficients and standard errors of predicting development 
of cardiovascular disease by 2014 (biomeasure weight) 
  Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.052 (0.014)***  0.052 (0.010)****  0.051 (0.010)****  0.052 (0.010)**** 
Age (squared)  0.000 (0.001)  0.000 (0.001)  0.000 (0.001)  0.000 (0.001) 
Female -0.313 (0.140)* -0.228 (0.122) -0.233 (0.123) -0.227 (0.122) 
Age x Female -0.012 (0.016) -0.010 (0.013) -0.009 (0.013) -0.009 (0.013) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.527 (0.286) -0.351 (0.231) -0.346 (0.232) -0.344 (0.231) 
Non-Hispanic black -0.071 (0.188) -0.110 (0.160) -0.114 (0.161) -0.103 (0.161) 
Health conditions     
Hypertension (2006)  0.417 (0.229)  0.480 (0.183)**  0.472 (0.183)**  0.471 (0.183)** 
Recent HBP diagnosis  0.172 (0.214)  0.347 (0.188)  0.331 (0.190)  0.327 (0.188) 
Diabetes (2006)  0.619 (0.159)***  0.567 (0.142)****  0.566 (0.143)****  0.559 (0.143)**** 
Recent diagnosis diabetes  0.153 (0.203)  0.250 (0.162)  0.251 (0.163)  0.251 (0.162) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.043 (0.190)  0.106 (0.142)  0.090 (0.142)  0.111 (0.144) 
Obese (2006)  0.074 (0.157)  0.024 (0.166)  0.023 (0.168)  0.028 (0.169) 
Decreased BMI category -0.142 (0.214)  0.052 (0.187)  0.024 (0.188)  0.003 (0.190) 
Increased BMI category  0.180 (0.162)  0.143 (0.143)  0.143 (0.139)  0.159 (0.140) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.142 (0.304) -0.314 (0.249) -0.317 (0.249) -0.329 (0.247) 
Hardly ever/never (2006) -0.078 (0.347) -0.190 (0.331) -0.185 (0.333) -0.196 (0.330) 
Decreased daily activity -0.154 (0.357) -0.007 (0.247) -0.017 (0.245)  0.007 (0.245) 
Increased daily activity -0.008 (0.188)  0.010 (0.185)  0.005 (0.185)  0.007 (0.185) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.193 (0.231)  0.268 (0.184)  0.283 (0.185)  0.273 (0.185) 
Former smoker (2006)  0.304 (0.118)*  0.278 (0.113)*  0.279 (0.114)*  0.277 (0.112)* 
Recently quit smoking  0.658 (0.336)  0.754 (0.258)**  0.722 (0.259)**  0.752 (0.261)** 
Recently started smoking -0.160 (0.751) -0.491 (0.701) -0.481 (0.700) -0.477 (0.700) 
Biomeasures     
ln(CRP) (2006)  0.000 (0.057)  0.022 (0.050)  0.025 (0.052)  0.033 (0.048) 
ln(CRP) change -0.072 (0.054) -0.034 (0.042) -0.034 (0.042) -0.037 (0.046) 
Cystatin C (2006)  0.694 (0.217)**  0.511 (0.179)**  0.553 (0.189)**  0.487 (0.172)** 
Cystatin C change  0.367 (0.128)**  0.354 (0.093)***  0.355 (0.096)***  0.338 (0.110)** 
Intercept -2.778 (0.251)**** -2.734 (0.234)**** -2.761 (0.245)**** -2.703 (0.224)**** 
Note. Sample sizes: 2,728 for observed, 3,545 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001. 
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Table 4-14. Logistic regression logit coefficient and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) 
  Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.051 (0.015)**  0.052 (0.011)****  0.052 (0.010)****  0.053 (0.010)**** 
Age (squared)  0.000 (0.001)  0.000 (0.000)  0.000 (0.000)  0.000 (0.000) 
Female -0.294 (0.143)* -0.273 (0.103)** -0.275 (0.103)** -0.266 (0.101)** 
Age x Female -0.011 (0.016) -0.013 (0.012) -0.013 (0.012) -0.012 (0.012) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.510 (0.277) -0.328 (0.168) -0.318 (0.168) -0.316 (0.169) 
Non-Hispanic black -0.079 (0.194) -0.244 (0.154) -0.239 (0.155) -0.233 (0.155) 
Health conditions     
Hypertension (2006)  0.409 (0.235)  0.514 (0.149)***  0.502 (0.149)***  0.504 (0.150)*** 
Recent HBP diagnosis  0.137 (0.216)  0.456 (0.154)**  0.427 (0.153)**  0.422 (0.152)** 
Diabetes (2006)  0.612 (0.160)***  0.527 (0.127)****  0.524 (0.129)****  0.522 (0.127)**** 
Recent diagnosis diabetes  0.207 (0.206)  0.288 (0.157)  0.293 (0.158)  0.296 (0.158) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.064 (0.155) -0.073 (0.144) -0.065 (0.146) -0.073 (0.143) 
Obese (2006)  0.050 (0.192) -0.016 (0.141) -0.019 (0.139) -0.008 (0.136) 
Decreased BMI category -0.163 (0.211)  0.039 (0.168)  0.023 (0.166)  0.012 (0.168) 
Increased BMI category  0.174 (0.158)  0.285 (0.156)  0.294 (0.150)  0.303 (0.153)* 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.092 (0.307) -0.403 (0.233) -0.413 (0.237) -0.425 (0.235) 
Hardly ever/never (2006) -0.069 (0.348) -0.229 (0.279) -0.224 (0.280) -0.228 (0.277) 
Decreased daily activity -0.176 (0.356)  0.021 (0.223)  0.013 (0.222)  0.030 (0.225) 
Increased daily activity -0.013 (0.186)  0.145 (0.142)  0.151 (0.142)  0.150 (0.143) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.172 (0.233)  0.360 (0.165)*  0.369 (0.164)*  0.374 (0.163)* 
Former smoker (2006)  0.307 (0.121)*  0.247 (0.108)*  0.249 (0.108)*  0.250 (0.107)* 
Recently quit smoking  0.735 (0.350)*  0.600 (0.227)**  0.589 (0.227)**  0.605 (0.229)** 
Recently started smoking -0.114 (0.743) -0.658 (0.688) -0.654 (0.688) -0.643 (0.687) 
Biomeasures     
ln(CRP) (2006)  0.016 (0.057)  0.036 (0.058)  0.044 (0.053)  0.050 (0.045) 
ln(CRP) change -0.080 (0.056) -0.025 (0.045) -0.032 (0.046) -0.040 (0.045) 
Cystatin C (2006)  0.685 (0.225)**  0.540 (0.168)**  0.500 (0.198)*  0.432 (0.158)** 
Cystatin C change  0.388 (0.131)**  0.306 (0.093)**  0.327 (0.101)**  0.305 (0.107)** 
Intercept -2.792 (0.253)**** -2.641 (0.214)**** -2.604 (0.244)**** -2.539 (0.207)**** 
Note. Sample sizes: 2,728 for observed, 4,357 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.   
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.
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Figure 4-9. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting the 
development of cardiovascular disease by 2014 by imputation approach and analysis weight. 
Odds ratio is based on 1 standard deviation change in each biomarker: 0.50 for Cystatin C and 
1.25 for ln(CRP). 95% confidence interval of the odds ratio included. 
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Figure 4-10. Odds ratios of change in Cystatin C and change in ln(CRP) in logistic regression 
model predicting the development of cardiovascular disease by 2014 by imputation approach and 
analysis weight. Odds ratio is based on 1 standard deviation change in each biomarker: 0.50 for 
Cystatin C and 1.25 for ln(CRP). 95% confidence interval of the odds ratio included.  
240 
4.3.6 Subgroup impact 
 In addition to primary analyses investigating the whole sample, it was important to verify 
that the findings from the previous sections would hold in subgroup analyses. In order to confirm 
this issue, all of the previous univariate and multivariate analyses were reexamined by two 
common subgroup variables: gender and race/ethnicity. Analyzing by these subgroups resulted in 
few differences in the missingness rate for Cystatin C and CRP. 
The results show that the general patterns observed in the previous sections for both the 
univariate and multivariate analyses hold for both males and females (see Appendix G). In terms 
of distributional measures, the overall pattern between males and females is different with 
females having consistently higher levels of Cystatin C (see Tables G1-1 through G1-4 and 
Figure G1-1) and CRP (see Tables G1-7 through G1-10 and Figure G1-2) than males (and thus 
higher proportions of those at risk). The different imputation approaches positively also shift the 
female means or proportions more than the male’s. Cases of FMIs for means and proportions 
exceeding the missing rate is increased when looking at these subgroups, with females more 
likely to have an FMI larger than the missing rate. 
When looking at gender subgroups for the multivariate models, there are differences in 
the key substantive findings for the cross-sectional model. For example, significant negative 
coefficients for Hispanic and non-Hispanic black are only present for males but not females, and 
little to no mildly vigorous activity is only significant for females. However, the general patterns 
related to the weights and imputation approaches are consistent. First, the sample size increase 
greatly benefits the standard errors of all analysis variables, with the biomarkers (specifically 
Cystatin C) seeing particularly acute gains. Second, while there are small coefficient shifts across 
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all analysis variables, the heavily imputed biomarkers (Cystatin C in particular) see consistent 
attenuation in the coefficient. The longitudinal analysis models conclude similarly. 
For the race/ethnicity subgroups (see Appendix H), non-Hispanic black respondents have 
consistently higher Cystatin C levels than non-Hispanic other respondents and Hispanic 
respondents, which are relatively similar (see Tables H1-1 through H1-6 and Figure H1-1). A 
similar pattern emerges for ln(CRP) with non-Hispanic black respondents having higher levels 
than Hispanic respondents which is higher than the levels for non-Hispanic other respondents, 
though this effect diminishes from 2006 to 2014 (see Tables H1-10 through H1-15 and Figure 
H1-3). The different imputation approaches positively shift the subgroup means and proportions 
for all race/ethnic subgroups. Like the gender subgroups, the number of FMIs for means and 
proportions exceeding the missing rate increased when looking at these subgroups with the 
Hispanic subgroup having a majority of FMIs larger than the missing rate. 
When looking at race/ethnic subgroups for the multivariate models, there are differences 
in the key substantive findings for the cross-sectional model. Like the subgroup analysis by 
gender, the general patterns related to the weights and imputation approaches are consistent with 
the full sample with the sample size increase benefiting the standard errors of all analysis 
variables, with the biomarkers (specifically Cystatin C) seeing particularly acute gains. Second, 
while there are small coefficient shifts across all analysis variables, the heavily imputed 
biomarkers (Cystatin C in particular) see consistent reduction in the coefficient toward zero. The 
longitudinal analysis models conclude similarly. The observed longitudinal models for Hispanics 
suffer greatly from small samples size with repeated warnings of questionable model fit which 
can be observed with overly large coefficients (e.g., mildly vigorous activity 1-3 times/month, 
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smoking status). The imputed models mostly remove these large coefficients (the one exception 
being recently started smoking using when estimated with the biomeasure weights). 
4.4 Discussion 
In this study, three alternative imputation approaches – cross-sectional, sequential, and 
wide – for sequential regression multivariate imputation (SRMI) were examined for two 
recurrently collected biomarkers (one transformed and one not) from a three wave longitudinal 
study. In addition, two sets of analysis weights – one restricted to biomeasure eligible 
respondents and one encompassing all core respondents – were compared to evaluate how these 
imputation approaches impacted an expanded inference space while also increasing the analytic 
sample size. The impact of these imputation approaches and weighting decisions was measured 
on distributional characteristics including means, proportions, and percentiles as well as within 
two multivariate logistic regression models using cross-sectional and longitudinal variables.  
For univariate measures, the various imputation approaches had the same means, 
proportions, and an overall response distribution when using biomeasure weights for either 
Cystatin C or ln(CRP). This is most likely because the sample size gain is relatively small (less 
than a 10% increase) given very few biomarkers were missing when the biomeasure was 
successfully collected. These results seem consistent with the assertion from Schafer (1999) that 
missingness below 5% is inconsequential and may suggest that imputing for only biomeasure 
consenters with a valid biomarker weight is not worth the estimation effort for negligible 
changes. However the FMI was consistently less than the missing data rate for all three 
approaches suggesting that the multiple imputation models benefited, at least somewhat, from 
utilizing the multivariate relationship between the biomarkers and other covariates.  
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When expanding the analysis to all cases with a valid base weight, significant shifts in the 
means, proportions, and distributional extremes (5th and 95th percentiles) were seen for Cystatin 
C, but not for ln(CRP). This suggests that the decision to exclude imputed cases with non-zero 
base respondent weights could lead to substantively underestimating the population prevalence 
of poor kidney function for those aged 50 or older by as much as 40%. Expanding the imputed 
sample led to large sample size gains and standard error reductions, but a corresponding 
proportional reduction in the standard errors was not consistently observed. In addition, a 
consistent reduction in the FMI from the missing rate like with the biomeasure weights was not 
seen with a higher rate of FMIs often exceeding the missing data rate. This may suggest that the 
imputations for this expanded respondent set may be less reliable given these cases are less likely 
to have concurrent, prior, or future biomarker values from which to base the imputation, being 
the most important predictors in the imputation models.  
For multivariate analyses, the various imputation approaches resulted in some coefficient 
change across the predictor and control variables, but overall reduced the coefficient standard 
errors across the majority of included variables due to the sizable increases in analytic sample 
size. This helped solidify the statistical significance of many risk factors within the model 
associated with cardiovascular disease. Cystatin C saw consistent downward trend of the 
coefficient towards zero in these multivariate models, but also significant reductions in the 
standard errors. Simulation studies have shown this downward trend grows as the missing rate 
increases and as the number of auxiliary variables increases (Hardt, Herke, & Leonhart, 2012). 
The natural log transformed CRP saw minimal change due to its small coefficient size in all 
models after controlling for Cystatin C. The use of base weights amplified the above effects 
slightly.  
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In comparing imputation approaches, the imputed estimates (e.g., means, regression 
coefficients) when using the biomeasure weights were not statistically or substantively different 
from one another responding to the first research question on whether there are differences in 
point estimates between the three approaches. However these estimates were occasionally 
statistically different from the observed estimates especially when using the base weights. In 
addition, research question two was answered affirmatively as reductions in point estimate 
standard errors were generally observed, mostly attributable to the increase in sample size. While 
there was some variability across individual estimated parameters and years, the sequential 
approach resulted in the largest average reductions in CV and FMI for both the biomeasure and 
base weighted univariate estimates.  
One finding that seemed relatively unexpected was that the wide imputation approach, 
using all waves available including future biomarker values, did not result in the largest 
reductions in FMI. For the univariate estimates, the wide imputation was typically second-best 
when using biomeasure weights, but equivalent to, if not worse than, the complete case analysis 
results when using the base weights. In the multivariate regression models, the wide approach 
often resulted in the largest attenuation of logistic regression coefficients as well as the largest 
reduction in standard errors, though this finding did not result in substantive changes. It is 
possible this is a result of model over-fitting and that the cross-wave correlations of the health 
measures and biomarker values may be adding unanticipated noise to the estimates, though this 
is generally associated with smaller sample sizes (e.g., clinical trials). 
Related to this issue is the instability in the FMIs, which is a cause for concern for some 
of these conclusions as a number of the univariate estimates had FMIs exceeding the missing 
data rate. This seemed of particular concern for the 2014 values and when the base weights were 
245 
applied. Historically 10 repetitions has been recommended as sufficient for multiple imputation 
(Rubin, 1987; Schafer, 1997). Historical measures of imputation efficiency like Rubin’s (1987) 




, suggest that even with the largest missingness observed in these analyses 
(i.e., 2006 base weighted Cystatin C at 27.4% missing) that those estimates would be 97.3% as 
efficient as having ∞ replicates. Follow-up analyses using 100 repetitions (see footnote 20) did 
not seemingly improve the FMI stability. However, more recent studies have found that these 
historical recommendations and measures may be insufficient given imputation variability 
(Bodner, 2008). For example, Madley-Dowd, Hughes, Tilling, and Heron (2019) showed that the 
FMI for a simulated bivariate regression could take nearly 1,000 repetitions before achieving 
FMI stability. Reproducing these analyses with 1,000 repetitions (or more) may resolve some 
concerns regarding the instability in the FMI and whether a particular imputation approach is 
truly better at recovering statistical information than another and allow the third research 
question to be more clearly answered. 
The secondary component of this study is the imputation of all biomeasure eligible cases 
and including them in analyses by applying the base respondent weights. In general, the 
imputation and use of these additional cases has clear sample size advantages for the univariate 
and multivariate analyses which is primarily beneficial for decreasing standard errors. However, 
the significant shifts in high-levels of Cystatin C (i.e., proportion at risk) show that with higher 
levels of missingness (>20%), multiple imputation may be able to correct for potential biases in 
biomarkers due to non-consent. This affirmatively answers the fourth research question, but this 
should not be taken as a general rule. The results for ln(CRP) suggest that the weights made little 
difference in the point estimates and that benefits of expanding the analytic sample may be 
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biomarker dependent. One area of concern regarding use of the base weights is that no 
adjustment was made to account for the change in the estimable population. 
Ultimately, the multiple imputation approach one chooses may be dependent on data 
availability and the specific needs of the study as opposed to the nature of the data collection 
itself. For studies considering multiple imputation for this type of biomeasure data, the sequential 
imputation approach might be recommended as it maximizes the amount of informative 
covariates to date, especially other biomarkers, which can be used in the imputation model. This 
imputation approach is straightforward to implement for existing studies and can be integrated 
into data processing without needing to wait for future waves of data collection like the wide 
approach. 
 As mentioned at the beginning of this chapter, there are a number of other imputation 
methods that could be considered for longitudinal biomeasure data. A direct comparison to 
predictive mean matching (PMM) could serve as a good contrast to SRMI in that it does not 
make use of the multivariate relationships of biomarkers with other demographic, health, and 
biomeasure variables. However there are other factors not covered previously that could extend 
and further inform this work.   
The data used in this chapter only had three waves of data collection. But studies with a 
much large number of waves may need to restrict how many waves are included in a wide (or 
wide-like) approach. One example is two-fold fully conditional specification (FCS; Nevalainen 
et al., 2009) alternately known as the moving time window (MTW) approach (Kalaycioglu, 
Copas, King, & Omar, 2016). Two-fold FCS is a variant of standard FCS (another name for 
SRMI or MICE) which explicitly uses the temporal relationship between variables in 
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longitudinal data to impute like the wide approach, but only uses a particular time window. The 
core idea behind two-fold FCS is to take observations that are time adjacent (e.g., w-2, w-1, w+1, 
w+2) to impute wave w. Therefore this method is only optimal for studies with a large number of 
waves. Two-fold FCS is also doubly iterative as it imputes 𝑏𝑏𝑤𝑤 within-time iterations (using 
previous and future values only as predictors) followed by 𝑏𝑏𝑎𝑎 between-time iterations. When 
𝑏𝑏𝑎𝑎 = 1, then two-fold FCS is essentially traditional FCS.  
Welch, Bartlett, & Petersen (2014) describe the Stata command twofold which completes 
two-fold FCS using the mi impute chained command, and is the only packaged implementation 
of this approach to date. This command limits the types of imputation that mi impute chained can 
perform to parametric imputation models including linear, logistic, and multinomial.  
A fact observed in previous chapters was that multiple mechanisms might be at play for 
why biomeasures may be missing from a data set. For example, missingness due to non-consent 
may have a differential impact on biomeasures then missingness due to ineligibility. Unlike the 
concepts described previously in this chapter, this issue can often be at the biomeasure level 
(e.g., dried blood spot assay) rather than the biomarker level (e.g., Cystatin C). This may mean 
that the appropriate predictors for imputing one missing value may not be sufficient to impute 
another. 
One proposed method to address multiple sources of missingness is called two-stage 
imputation. Two-stage multiple imputation (Harel, 2003, 2007) accounts for multiple 
missingness mechanisms in the model by specifying 𝑌𝑌 = (𝑌𝑌𝑐𝑐𝑖𝑖𝑠𝑠,𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠) where 𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠 = �𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠𝐴𝐴 ,𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠𝐵𝐵 �. 
𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠𝐴𝐴  and 𝑌𝑌𝑏𝑏𝑠𝑠𝑠𝑠𝐵𝐵  are imputed independently each with its unique set of m and n imputations, 
respectively, resulting in a total of 𝑁𝑁 = 𝑂𝑂 × 𝑎𝑎 data sets. Two-stage multiple imputation utilizes 
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adapted combining rules from Rubin (1987) with extensions from Shen (2000). The approach 
described by Harel (2003, 2007) only focuses on two missing data mechanisms, but could be 
expanded if multiple missing data mechanisms could be reasonably measured and identified.  
One critique to the two-stage imputation approach for this type of missing data is that one 
(or more) mechanisms may be directly related to the missingness itself (e.g., non-consent, 
biomeasure ineligibility) suggesting a not missing at random (NMAR) mechanism is at play. The 
exclusion of NMAR methods is a limitation of what is covered here in this paper. While there 
may be a fair amount of understanding regarding the general patterns of missingness for 
biomeasures, there are still factors and situations that may not be able to be properly accounted 
for using the observable variables. One of the most common NMAR imputation methods are 
pattern-mixture models (Little, 1993, 2009). Pattern-mixture models assume that the 
distributions of Y are a combination of responders and nonresponders using the missing data rate 
of Y as the mixing probabilities. A variety of assumptions can be set for the unobserved 
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5.1 Future research 
 While this research is some of the first to consider the implications of recurrent 
biomeasure collection, much has yet to be explored in relation to longitudinal collection of 
biomeasures. HRS, SHARE, and NSHAP (to name a few) all have opportunities to explore 
recurrent biomeasure consent and collection, and explore methodological and statistical issues 
beyond those discussed in this dissertation. Some opportunities for future research are described 
below: 
Expand continuation ratio logit model covariates to include survey resistance measures. 
The expansion of indicators for the consent model in Chapter 3 provided valuable insights into 
biomeasure consent as a within survey request. Survey response and ineligibility due to mode are 
fundamentally tied to survey resistance as well. Including survey resistance measures in the 
continuation ratio models examined in Chapter 2 may add additional insights into these sources 
of non-observation. 
Incorporate recent eligibility and new cohort recruitment into bias analyses. The bias 
analysis conducted in Chapter 2 strategically excluded respondents not biomeasure eligible in 
2006 and new cohort respondents added in 2010. These exclusions, in order to focus on 2006 
biomeasure eligible respondents, have their own implications on bias of estimates in 2010 and 
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the outcome distribution as a whole, potentially counteracting the large shifts in estimates due to 
mortality. Such assertions cannot be substantiated without such an investigation. 
Interviewer continuity experiments. As interviewer continuity generally resulted in 
increased non-consent for both consenters and non-consenters, only an experiment randomly 
assigning returning interviewers to recontact and reinterview a subset of previous respondents 
can confirm how much of this effect is due directly to interviewer continuity as opposed to some 
other factor (e.g., time between biomeasure collections). 
Additional analyses on the interplay of interviewer continuity with survey response and 
biomeasure consent. While interviewer continuity generally had a negative effect on biomeasure 
consent in these analyses, some theory suggests that interviewer continuity should benefit survey 
response generally. Additional analyses investigating the impact of interviewer continuity on 
HRS response relative to biomeasure consent may help to better understand potential tradeoffs. 
Replication of longitudinal consent findings. Further investigations into changes in 
health, interviewer continuity, and reasons for non-consent should be replicated for other 
longitudinal surveys collecting biomeasures to confirm whether these findings hold. In 
particular, surveys with a shorter between-wave biomeasure collection window would be ideal to 
help disentangle factors that are associated with time given the four-year window between 
biomeasures requests in HRS. In addition, different biomeasure collection approaches outside of 
non-medically trained field interviewers, like the mail-back approach, would also benefit from 
this type of investigation. 
Consent wording experiment to remind respondents of previous response. Respondent 
memory and cognition had a significant effect for previous consenters in consenting to a second 
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wave of biomeasures. Almost 8% of previous DBS consenters chose not to consent in the 
following E-FTF wave. Given the four-year gap between biomeasure requests in HRS, 
respondents with poor memory or memory loss may be more likely to forget the previous request 
and their associated response. Previous work in administrative data linkage consent has found 
that reminding a respondent of their previous consent behavior can increase the rate of consent 
(Sala, Knies, & Burton, 2014). A consent wording experiment that reminded a random subset of 
biomeasure eligible respondents of their previous consent could be conducted to see if the 
reminder elicits increased consent. This would be a beneficial experiment for HRS to conduct in 
the future. 
Responsive design for biomeasure collection. Chapters 2 and 3 provided plenty of 
evidence regarding how previous patterns of behavior influenced future biomeasure eligibility 
and consent. Knowledge regarding previous eligibility or the type of refusal to biomeasure 
collection could be harnessed through responsive design to directly target particular respondent 
groups with appropriate interventions (e.g., reminder of previous consent) to improve consent in 
future waves. 
Further exploration of mixed mode survey resistance measures. While not specific to 
biomeasure collection, the initial investigations into mode-specific survey resistance measures 
could potentially have implications for mixed mode panel studies more broadly. Further effort 
should be considered relating to alternative survey resistance measures and indices, differences 
in survey resistance measures and indices by mode, and sources of interviewer variance.  
Confirm imputation approach conclusions with increased replications. The findings in 
Chapter 4 are somewhat uncertain due to the potentially unstable fractions of missing 
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information (FMI) which were a primary indicator of imputation quality in these analyses. 
Increasing the number of imputation replications to at least 1,000 will help to solidify whether 
the sequential approach is truly the superior of the three approaches considered. In addition, the 
examination of the remaining biomarker outcomes, especially HbA1c, could serve to confirm 
and expand the understanding of these imputation approaches and their relative benefits. 
Consider additional imputation approaches for longitudinal biomarkers. Chapter 4 
barely scratched the surface of the imputation approaches to consider for longitudinal 
biomarkers. Section 4.4.1 identified multiple approaches to consider in future investigations. 
Predictive mean matching is a common imputation technique known to do well with skewed data 
and would serve as a foil to SRMI that relies on a univariate distribution and not conditional 
distributions. Two-fold fully conditional specification would be a natural extension of the 
sequential and wide approaches considered here by using the data immediately preceding and 
following the given time point. Two-stage imputation would potentially allow separate models to 
be estimated, for example, for biomeasure consenting respondents and non-consenting 
respondents assuming the mechanisms are fundamentally different. Finally, pattern-mixture 
models could help to test the sensitivity of the missing at random and not missing at random 
assumptions for these biomeasures. 
   
259 
5.2 References 
Sala, E., Knies, G., & Burton, J. (2014). Propensity to consent to data linkage: experimental 
evidence on the role of three survey design features in a UK longitudinal panel. 








Predictors of Nursing Home and Proxy States 
In order to evaluate the appropriateness of combining nursing home and proxy 
respondent ineligibles as a single eligibility group, two logistic regression models were estimated 
predicting being a nursing home respondent and a proxy respondent, respectively. The covariates 
were the same used in the nested analytic model referenced in Equation 2.2 and estimated in 
Section 2.4.2 including respondent characteristics, household characteristics, cognition, and 
health measures. One final logistic regression model was estimated combining the two possible 
outcomes. 
There are a number of similar significant covariates between the two separate models 
(see Table A-1). Age and both cognition measures were significant predictors of each ineligible 
state and had similar magnitudes of effect across the two models with older respondents having 
an increased odds of being in either eligibility group and higher cognition scores – denoting 
better cognitive functioning – decreasing the odds of group membership. Education also saw 
similar symmetry across the two models though the odds ratios for each education level were 
much higher in the nursing home model compared to the proxy model. Non-Hispanic blacks 
were significantly less likely to be a nursing home and proxy respondent compared to non-
Hispanic other in both models. Those with less frequent physical activity (1-3 times a week for 
the proxy respondent model and hardly ever/never for the nursing home respondent model) are 
more likely to be categorized into these groups.  
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There are two significant covariates that are very different across the two prediction 
models. First, the effects for Hispanics were very different across the two eligibility models with 
Hispanics being significantly less likely to be in a nursing home than non-Hispanic other but no 
significant effect for the proxy model. Employment status also saw a large negative effect with 
those currently working having 0.17 times the odds of being a nursing home respondent. The 
proxy model does not see any uniquely significant variables. 
When combining the nursing home and proxy states into a single outcome, many of the 
effects observed previously remain including age, education, cognition, and mildly vigorous 
activity. Combining the two eligibility outcomes does negate the effect for Hispanics and current 
employment and does result in a significant effect for fair/poor self-rated health. These 
commonalities serve as good evidence to combine these two eligibility outcomes.
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Table A-1. Logistic regression models predicting proxy and nursing home state of 2010 HRS 
respondents ineligible for biomeasure collection 
    
  Proxy respondent 
Nursing home 
respondent 
Proxy or nursing 
home respondent 
Respondent characteristics    
Age (years) 1.08 (0.009)**** 1.08 (0.012)**** 1.08 (0.008)**** 
Female 0.86 (0.129)  1.32 (0.276)  0.90 (0.125)  
Education (ref: less than HS)    
High school 1.47 (0.241)* 1.83 (0.414)** 1.51 (0.232)** 
Some college 1.60 (0.647)  2.61 (1.362)  1.75 (0.640)  
College graduate 1.57 (0.364)  2.15 (0.667)* 1.59 (0.345)* 
Race/ethnicity (ref: Non-Hispanic other)   
Non-Hispanic black 0.50 (0.105)*** 0.38 (0.108)*** 0.51 (0.097)**** 
Hispanic 1.27 (0.282)  0.23 (0.104)*** 1.05 (0.225)  
Currently employed 1.17 (0.234)  0.16 (0.098)** 0.97 (0.186)  
Attends religious services at least 1/wk 0.90 (0.123)  1.24 (0.227)  0.92 (0.116)  
Household characteristics    
Impediments to entry 0.69 (0.157)  0.86 (0.231)  0.75 (0.150)  
Own home 1.37 (0.254)  0.65 (0.144)  0.93 (0.149)  
Rural 0.84 (0.125)  0.89 (0.175)  0.90 (0.124)  
Another eligible HH member 1.18 (0.186)  0.91 (0.187)  1.06 (0.152)  
Cognition and health    
Word recall score 0.83 (0.020)**** 0.80 (0.027)**** 0.83 (0.019)**** 
Mental status score 0.79 (0.019)**** 0.88 (0.030)**** 0.82 (0.019)**** 
Self-rated health (ref: Excellent)    
     Very good 1.24 (0.352)  2.10 (1.050)  1.22 (0.335)  
     Good 1.24 (0.356)  1.45 (0.736)  1.20 (0.328)  
     Fair/Poor 1.75 (0.522)  2.29 (1.184)  1.75 (0.497)* 
Mildly vigorous activity (ref: At least 1/wk)   
     1-3 times/month 1.73 (0.380)* 1.50 (0.473)  1.93 (0.387)*** 
     Hardly ever/never 1.43 (0.279)  2.00 (0.480)** 1.51 (0.271)* 
No. of functional limitations 0.99 (0.020)  1.03 (0.025)  1.01 (0.018)  
No. of chronic conditions 1.02 (0.057)  1.11 (0.080)  1.03 (0.053)  
Note. Models conditional on HRS 2006 biomeasure eligible respondents. Sample size = 699. Odds ratios and 
standard errors presented.  





Reason for Previous Non-consent as a Predictor of Eligibility State 
The respondent’s logic for refusing to consent to biomeasure collection could be 
reflective of concerns related to their health or current situation as opposed to a general 
resistance toward the survey or the nature of the biomeasure request itself. Someone willing to 
participate but concerned about compromising their health further may be differentially willing 
to participate at a future time. HRS paradata allows for disentangling those reasons. 
When a respondent refused to consent, interviewers immediately recorded the reason(s) 
for the refusal (survey item KI953 for HRS 2006) including the respondent (or the interviewer) 
did not feel it safe to complete the collection, the respondent did not understand the instructions, 
the respondent had hemophilia or was taking a blood thinning medication (anticoagulant), there 
was no suitable location for the collection, and the respondent refused or was not willing to 
complete the measurement. The final reason is the only one that does not have an explicit 
situational or health related factor as a reason for non-consent. These cases can be classified as 
straight refusals while the other reasons could be categorized as health-related refusals. 
Looking at the two-wave model, the single indicator of DBS non-consent in Table 2-7b 
can be replaced with the dual indicators divided by health and non-health related reasons. 
Changing to two indicators adds nothing significant to the mortality model and do not result in 
substantive changes in the previous interpretation (Table B-2). In the nonresponse model, those 
264 
who provided a straight refusal to DBS collection in the previous wave had only 0.36 times the 
odds of responding in the current wave compared to those who consented previously suggesting 
a useful indicator of future nonresponse in the reason for DBS refusal. The health-related refusal 
to consent had no significant effect in predicting future response (OR = 1.14). The addition of 
these indicators made little substantive change in the odds ratios for this model. 
 Health-related refusals had nearly 0.6 times the odds of non-nursing home, self-response 
over those who consented previously. The straight refusal did not show a significant difference 
from previous consenters. The addition of previous DBS non-consent does remove the 
significant effect of “fair/poor” self-rated health. 
 For the biomeasure eligibility model, straight refusal results in 0.35 times the odds of 
being a biomeasure eligible respondent in the subsequent E-FTF wave compared to consenters 
with no significant effect observed for health-related refusals. As this transition is related to 
completing a telephone interview, this suggests that straight refusal to previous DBS collection 
serves as a general indicator of survey resistance. The only notable change of the remaining odds 
ratios is non-Hispanic black whose effect is strengthened from 1.65 times the odds compared to 
non-Hispanic other to 1.82 times the odds when holding previous DBS consent constant. 
 Both health-related and straight refusal to previous DBS consent are significant in 
predicting future consent but at differential rates. A straight refusal results in a tenth of the odds 
of future consent while health-related refusal is a quarter of the odds of consent compared to 
previous consenters. There are many more demographic and health variable coefficients that 
change with the inclusion of reason for previous non-consent given the correlated nature of the 
new variables and the outcome. The significant effect of non-Hispanic blacks is no longer 
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present. The number of chronic conditions also becomes insignificant. The significance levels for 
church attendance, mental status score, and little/no mildly vigorous activity diminish due to 
increased standard errors and odds ratios getting closer to one. 
 The reason for previous consent refusal is informative about future nonresponse and 
eligibility related to mode. These results strengthen the idea that biomeasure consent can serve as 
a good indicator of survey resistance when considering future waves of data collection. The 
significant effect of health-related consent refusal with proxy and nursing home respondents 
suggests that their compromised health status when asked to provide biomeasures may be 
indicative of an increased need for help and support in the future.
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Table B-1. Continuation ratio logit model odds ratios predicting sequential 2010 eligibility states based on 2006 respondent and 
household characteristics and reason for dried blood spot consent refusal 
  Alive vs. Deceased 
Respondent vs. 
Non-respondent 











Respondent characteristics       
Age (years) 0.95 (0.004)**** 1.00 (0.007)  0.93 (0.007)**** 1.00 (0.008)  0.99 (0.006)  **** 
Female 1.58 (0.137)**** 0.94 (0.113)  1.10 (0.153)  0.84 (0.103)  0.92 (0.086)  **** 
Education (ref: less than HS)       
High school 0.96 (0.091)  1.03 (0.154)  0.66 (0.101)** 1.16 (0.177)  0.98 (0.114)    
Some college 1.14 (0.284)  0.72 (0.192)  0.57 (0.207)  1.22 (0.370)  1.42 (0.346)    
College graduate 1.03 (0.137)  0.85 (0.157)  0.63 (0.136)* 0.94 (0.177)  0.89 (0.130)    
Race/ethnicity (ref: Non-Hispanic other)      
Non-Hispanic black 1.44 (0.172)** 1.40 (0.249)  2.00 (0.385)**** 1.82 (0.368)** 0.89 (0.112)  ** 
Hispanic 1.47 (0.223)* 0.99 (0.200)  0.97 (0.209)  0.74 (0.146)  0.92 (0.156)    
Currently employed 1.55 (0.205)*** 1.11 (0.155)  1.03 (0.198)  0.79 (0.107)  1.09 (0.116)  * 
Attends church at least 1/wk 1.39 (0.114)**** 0.98 (0.112)  1.08 (0.137)  1.42 (0.170)** 1.23 (0.109)*   
Household characteristics       
Impediments to entry 1.14 (0.139)  1.40 (0.285)  1.38 (0.279)  0.95 (0.171)  1.00 (0.140)    
Own home 1.20 (0.118)  0.90 (0.145)  1.07 (0.174)  1.33 (0.202)  1.00 (0.122)    
Rural 1.16 (0.102)  1.33 (0.171)* 1.11 (0.153)  0.96 (0.120)  0.91 (0.087)    
Another eligible HH member 1.25 (0.113)* 1.04 (0.134)  0.95 (0.137)  0.96 (0.127)  1.07 (0.107)    
Cognition and health       
Word recall score 1.08 (0.015)**** 1.05 (0.021)* 1.20 (0.027)**** 1.01 (0.021)  0.98 (0.015)  **** 
Mental status score 1.05 (0.016)** 1.08 (0.024)*** 1.22 (0.029)**** 1.04 (0.026)  1.05 (0.020)* **** 
Self-rated health (ref: Excellent)       
     Very good 0.79 (0.172)  0.92 (0.168)  0.82 (0.224)  0.73 (0.147)  1.00 (0.147)    
     Good 0.50 (0.106)*** 1.00 (0.193)  0.84 (0.230)  0.62 (0.127)* 0.96 (0.147)    
     Fair/Poor 0.36 (0.078)**** 0.82 (0.181)  0.58 (0.166)  0.82 (0.200)  1.05 (0.187)  ** 
Mildly vigorous activity (ref: At least 1/wk)      
     1-3 times/month 1.15 (0.175)  0.96 (0.211)  0.52 (0.105)*** 1.24 (0.315)  0.83 (0.137)  * 
     Hardly ever/never 0.56 (0.058)**** 1.01 (0.223)  0.67 (0.122)* 0.97 (0.222)  0.72 (0.116)* * 
No. of functional limitations 0.96 (0.010)**** 1.03 (0.021)  1.00 (0.018)  0.99 (0.020)  0.98 (0.014)  * 
No. of chronic conditions 0.87 (0.028)**** 1.17 (0.060)** 0.96 (0.050)  1.08 (0.056)  1.07 (0.042)  **** 
Previous non-observation source       
Health-related DBS consent refusal 0.80 (0.127)  1.14 (0.399)  0.59 (0.146)* 1.20 (0.475)  0.27 (0.049)**** **** 
Straight refusal to DBS consent 0.88 (0.097)  0.36 (0.045)**** 0.73 (0.125)  0.35 (0.045)**** 0.10 (0.009)**** **** 
Note. The parallel slopes test is a Wald chi-square test with 4 degrees of freedom. HS = high school. DBS = dried blood spot.  






Survey Resistance Measure Multicollinearity 
C.1 Accounting for multicollinearity between survey resistance variables 
 There are many dimensions of survey resistance (Sakshaug, Couper, & Ofstedal, 2010; 
Sakshaug, Couper, Ofstedal, & Weir, 2012). Some measures of resistance in an interviewer 
administered survey come in the form of post-survey interviewer observations. These interviewer 
observations include behavioral observations of the respondent (e.g., “Did the respondent ask 
about the length of interview?”) and subjective assessments of the respondent during the survey 
interview (e.g., “How attentive was the respondent?”). Attempting to use a large number of these 
observations in a single analysis quickly uses up degrees of freedom and raises the potential 
issue of collinearity between items, both of which may have unknown or undesirable 
consequences on an analysis. This problem intensifies if one wishes to use variables from 
multiple waves of collection. 
Sakshaug et al. (2012) created two indices from seven post-survey observations collected 
in the Health and Retirement Study (HRS) from the previous wave of data collection to 
summarize two aspects of survey resistance: uncooperativeness and confidentiality concerns. 
The confidentiality concern index includes: 
• “During the interview, how often did the respondent express concern about whether 
his/her answers would be kept confidential?” (never, seldom, often)  
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• “During the interview, how often did the respondent ask you why you needed to 
know the answer to some questions” (never, seldom, often) 
• “How truthful do you believe the respondent was regarding his/her answers on 
financial questions?” (completely truthful, mainly truthful, about half and half, 
mainly untruthful)  
The uncooperativeness index includes: 
• “How was the respondent’s cooperation during the interview?” (excellent, good, fair, 
poor)  
• “During the interview, how often did the respondent ask how much longer the 
interview would last?” (never, seldom, often) 
• “How much did the respondent seem to enjoy the interview?” (a great deal, quite a 
bit, some, a little, not at all)  
• “How would you describe the level of resistance from the respondent?” (low/passive, 
moderate, high) 
For both indices, a value of 1 was assigned if the interviewer recorded a negative 
response (e.g., expressing concern about confidentiality or displaying uncooperative behavior) 
which are denoted by the bold underlined responses above. This results in a confidentiality index 
range of 0 to 3 and an uncooperativeness index range of 0 to 4. 
These indices are reasonable, but little detail is provided in Sakshaug et al. (2012) as to 
how these indices were formulated beyond the theoretical explanation provided. The use of these 
indices is a potential solution to correct for problems with multicollinearity in analytic models.  
269 
 
However, the final indicator of the uncooperative index – level of resistance – was only 
collected in HRS 2006 and is therefore not applicable for any other years which impacts the 
analyses conducted in Chapter 3. Another post-survey interviewer observation is a potential 
replacement in the uncooperative index: respondent attentiveness. Sakshaug et al. (2012) did test 
attentiveness independently in their analysis as a measure of acquiescence, though this proved to 
be an insignificant factor in their final model. As attentiveness encompasses the focus and 
relative interest a respondent may have during the survey interview, its inclusion in the 
uncooperativeness index seems consistent with the other indicators like enjoyment and asking 
how much longer the interview would last. Attentiveness is included in the uncooperativeness 
index as follows:  
• “How attentive was the respondent to the questions during the interview?” (not at all 
attentive, somewhat attentive, very attentive) 
In order to explore the creation and use of these indices, a number of different approaches 
on how to account for or summarize these measures are considered: (1) tetrachoric correlations, 
(2) exploratory factor analysis, and (3) latent class analysis. Response options for all seven 
potential resistance variables were collapsed to match the indices in Sakshaug et al. (2012). 
C.1.1 Tetrachoric correlations 
Tetrachoric correlations were used as opposed to the more common Pearson correlations 
because the indicators are dichotomous and not continuous. The tetrachoric correlations between 
the seven variables are examined independently for both wave 1 (W1; E-FTF) and wave 2 (W2; 
CATI) consistent with the definitions provided in Chapter 3. 
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The tetrachoric correlations within each wave suggest anywhere from a weak (minimum: 
0.18) to moderately strong (maximum: 0.68) correlation between within wave indicators (Table 
C-1). The pattern in the correlations is very consistent for both W1 and W2. The cooperation 
indicator has the most moderately strong correlations (between 0.50 and 0.70) with respondent 
attentiveness, enjoyment, being rated as truthful on financial questions, and never asking why 
this information was needed. Ever asking why this information was needed is also moderately 
correlated with asking how long the interview would take and if they expressed concern with 
confidentiality. Attentiveness is moderately correlated with respondent enjoyment and 
truthfulness on financial questions. 
 These findings indicate that there is a potential concern regarding multicollinearity of 
these resistance variables. Practically this could mean that if any one of these variables was 
found to be significant in the consent model that it could be containing information related to any 














































































































How long W1 1              
Confidentiality W1 0.38 1             
Cooperative W1 0.38 0.42 1            
Enjoy W1 0.40 0.27 0.61 1           
Why need W1 0.58 0.65 0.52 0.40 1          
Truth financial W1 0.32 0.34 0.60 0.43 0.40 1         
Inattentive W1 0.35 0.21 0.68 0.54 0.33 0.53 1        
How long W2 0.36 0.16 0.20 0.18 0.24 0.17 0.20 1       
Confidentiality W2 0.16 0.31 0.19 0.10 0.26 0.14 0.12 0.38 1      
Cooperative W2 0.18 0.13 0.31 0.25 0.21 0.26 0.27 0.44 0.39 1     
Enjoy W2 0.18 0.10 0.24 0.33 0.15 0.19 0.24 0.39 0.19 0.62 1    
Why need W2 0.20 0.27 0.22 0.13 0.35 0.13 0.17 0.60 0.63 0.54 0.33 1   
Truth financial W2 0.12 0.13 0.23 0.21 0.19 0.31 0.24 0.34 0.35 0.66 0.43 0.42 1  
Inattentive W2 0.15 0.06 0.23 0.20 0.12 0.21 0.29 0.43 0.25 0.68 0.51 0.40 0.59 1 
               
Note. Orange background encompasses all W1 variables; blue background encompasses all W2 variables. Red diagonal are between-wave correlations 
between the W1 and W2 variables. W1 = Wave 1 (2006/2008). W2 = Wave 2 (2008/2010). 
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C.1.2 Exploratory factor analysis 
 The tetrachoric correlation matrix was used as the base for an exploratory factor analysis 
followed by a Varimax rotation on the factor loadings. Random interviewer effects are not 
accounted for in these exploratory models. Again, the results for W1 and W2 are quite similar 
(see Table C-2). The exploratory factor analysis produced a three-factor model. However, the 
variance accounted for by the third factor was far below the first two factors even though the 
factor eigenvalues are positive, and all of the factor loadings were below 0.50. Therefore only the 
first two factors are presented and discussed here.  
The first factor contains large factor loadings (based on a cutoff of 0.50) for 
cooperativeness, enjoyment, attentiveness, and truth on financial questions. This set of variables 
is very similar to the components of the uncooperativeness index established by Sakshaug et al. 
(2012) replacing how the long the interviewer would take with the truthfulness on financial 
questions. The second factor has a similar structure to the earlier confidentiality index with 
indicators for expressing concerns about confidentiality, asking why this information was 
necessary, and how long the interview would take. The latter indicator replaces the truthfulness 
on financial questions from the original index. 
 Upon further consideration, the first factor produced by the factor analysis contains all 
relative interviewer ratings of a respondent (e.g., “How cooperative was the respondent?” “How 
much did the respondent enjoy the interview?”) while the second factor contains more factual 
indicators (e.g., “How often did…?”). This may suggest that the factor analysis is detecting 
similarities due to the nature of the measure beyond being similar conceptual factors. Further 
investigation is needed to verify this assumption. 
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Table C-2. Varimax rotated factor loadings for exploratory factor analysis of survey resistance 
indicators 
 Wave 1 
 Wave 2 
  Factor 1 Factor 2 Uniqueness  Factor 1 Factor 2 Uniqueness 
How long 0.320 0.540 0.605  0.376 0.542 0.565 
Confidentiality 0.184 0.682 0.500  0.176 0.661 0.532 
Cooperative 0.772 0.355 0.279  0.794 0.346 0.250 
Enjoy 0.634 0.268 0.527  0.644 0.172 0.555 
Why need 0.302 0.774 0.310  0.320 0.770 0.305 
Truth financial 0.606 0.287 0.550  0.658 0.281 0.488 
Inattentive 0.767 0.152 0.389  0.741 0.218 0.403 
Note. Factor loadings in bold black text are above a threshold of 0.50. 
 
C.1.3 Latent class analysis 
 Given these resistance indicators are dichotomous, a latent class model is also considered 
to potentially reduce the number of dimensions for this problem. Only a simple latent class 
model with two and three latent classes is investigated here (see Table C-3). Random interviewer 
effects are not accounted for in these exploratory models.  
 Looking first at the W1 resistance indicators, the two class model reveals a “great” 
respondent class and a “poor” respondent class. The first latent class encompasses over three-
fourths of the sample and is most likely to receive a positive response on all seven indicators. 
The lowest conditional probability is on high enjoyment (0.864). The second latent class sees 
more instances of negative ratings on cooperation, enjoyment, and truth on financial questions 
each with conditional probabilities less than 0.50 (0.294, 0.350, and 0.442, respectively). The 
remaining indicators have a conditional probability between 0.50 and 0.67 favoring a positive 
response. This “poor” respondent class has some similarities to the uncooperativeness index. 
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 The first latent class in the 3-class model matches the 2-class model – the “great” 
respondent class – both in terms of conditional probabilities and the class probability. The 
second largest latent class (13.8% of the sample) is a slightly more extreme version of the “poor” 
respondent class with lower conditional probabilities of excellent cooperation (0.123), high 
enjoyment (0.221), and truthful on financial questions (0.340). Attentiveness is a nearly even 
split while the remaining three variables (asking how long, asking why needed, and expressing 
concerns about confidentiality) are all near or above a conditional probability of 0.70. The final 
class boasts very high attentiveness (0.934), but very middle of road probabilities for everything 
else.  
 Examining the W2 models, a similar patterns for the 2-class model is observed. A “great” 
respondent class includes the majority of cases (76.4%) though the conditional probability for 
enjoyment is not as high (0.755) as the W1 model. The second class has low conditional 
probabilities for enjoyment (0.245) and truthful on financial questions (0.378), but a much higher 
conditional probability for excellent cooperation (0.636). 
 The W2 3-class model again repeats the “great” respondent class and the “poor” 
respondent classes from the 2-class model. The third class is quite different with low conditional 
probabilities for never asking how long (0.352), never asking why this was needed (0.189), high 
enjoyment (0.303), and truthfulness on financial questions (0.385).  
 In general, these classifications are somewhat informative but the overall model does not 
quite provide the level of gradation and clear direction as the factor analysis and originally 
proposed resistance indices. 
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Table C-3. Latent class models on survey resistance indicators by wave 
 2-class model  3-class model 
Wave 1 Class 1 Class 2   Class 1 Class 2 Class 3 
How long (Never asked) 0.906 0.578  0.913 0.627 0.454 
Why need (Never asked) 0.974 0.663  0.987 0.758 0.411 
Confidentiality (Never) 0.941 0.667  0.952 0.767 0.429 
Very attentive 0.982 0.659  0.976 0.509 0.934 
Excellent cooperation 0.944 0.294  0.936 0.123 0.622 
Enjoy (Very much/Quite a bit) 0.864 0.350  0.856 0.221 0.612 
Truth financial (Completely/Mainly) 0.902 0.442  0.894 0.340 0.664 
Estimated class size 0.771 0.229  0.770 0.138 0.092 
       
 2-class model  3-class model 
Wave 2 Class 1 Class 2   Class 1 Class 2 Class 3 
How long (Never asked) 0.932 0.566  0.931 0.721 0.352 
Why need (Never asked) 0.986 0.735  0.982 1.000 0.189 
Confidentiality (Never) 0.976 0.820  0.973 0.941 0.614 
Very attentive 0.973 0.583  0.983 0.611 0.613 
Excellent cooperation 0.846 0.636  0.851 0.659 0.626 
Enjoy (Very much/Quite a bit) 0.755 0.245  0.779 0.232 0.303 
Truth financial (Completely/Mainly) 0.888 0.378  0.904 0.415 0.385 
Estimated class size 0.764 0.236  0.726 0.199 0.075 
 
C.1.4 Comparison of consent models with all resistance variables versus resistance indices 
 There is evidence of multicollinearity between the seven survey resistance variables 
examined. The preliminary factor analysis and latent class analysis offer differing degrees of 
support for the indices used by Sakshaug et al. (2012). Given the previous establishment of these 
two indices from Sakshaug et al. (2012) and the similar pattern seen in the factor analysis, a final 
comparison of the consent model by using the adapted indices mentioned at the beginning of this 
appendix is considered.  
By using an index instead of individual indicators, this reduces the number of estimated 
survey resistance coefficients in the consent models considered in Chapter 3 from 10 to 3 (call 
attempts, uncooperative index, and confidentiality index) for W1 and W2 for a total of 14 less 
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coefficients estimated. The models presented here were preliminary models to those presented in 
Chapter 3. The models presented here were part of the early model building process and include 
both consenters and non-consenters in a single model. Model 1 includes measures only from the 
previous telephone wave (W2) while Model 2 includes measures from the previous E-FTF wave 
(W1). Only the relevant survey resistance indicators for W1 and W2 are presented in the 
corresponding tables. 
Predicting consent to physical measurements (PM) in Model 1, only one W2 indicator is 
significant: asked about why information was needed. When replacing the individual W2 factors 
with the two resistance indices, both indices are significant with each value increase on the 
confidentiality index having 0.767 times the odds of PM consent (which includes the significant 
indicator from the original model) and each increase on the uncooperative index having 0.911 
times the odds of PM consent. Introducing the W1 indicators in Model 2, the one significant 
effect for W2 is weakened but four W1 indicators appear as significant: asked why information 
was needed, untruthful on financial questions, poor cooperation, and did not enjoy – the first two 
corresponding to the confidentiality index and the latter to the uncooperative index. Replacing 
the individual indicators in Model 2, the W2 confidentiality index is still significant, but the odds 
ratio is not as large. Both W1 indices are significant each with odds ratios around 0.74.  
For the dried blood spot (DBS) consent model, similar patterns are observed, but more 
individual indicators appear as significant predictors. In Model 1, asking about confidentiality is 
significant (corresponding to the W2 confidentiality index) while being rated as uncooperative, 
asking how long, and inattentiveness are significant indicators (corresponding to the W2 
uncooperative index). However, being rated as inattentive actually results in an odds ratio greater 
than one meaning less attentive respondents are more likely to consent to DBS collection. 
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Transitioning to Model 1 with the indices, both W2 survey resistance indices are significant. The 
inclusion of W1 resistance indicators in Model 2 maintained by lessened the effects seen in the 
W2 indicators in Model 1. Five indicators from W1 were significant. Model 2 with the indices 
sees both W1 indices as significant predictors, but only the W2 confidentiality index remains 
significant though greatly reduced.  
Further investigation discovered that the inattentive measure for W2 when not included 
with the other survey resistance indicators resulted in an odds ratio less than one for both the PM 
and DBS consent models, though not always as a statistically significant predictor. This is a key 
example of how multicollinearity can impact the interpretation of such models. 
C.1.5 Discussion 
 Overall, the statistical evidence supports the hypothesis that these post-survey interviewer 
observations are in fact correlated and can be summarized into two factors (or indices). The use 
of these two indices over the use of seven individual indicators did not substantively change the 
conclusions of the analysis while simultaneously freeing up 14 degrees of freedom for analysis. 
While interpretation of individual indicators is no longer possible, any interpretation may be 
subject to scrutiny given the moderate correlations between indicators as evidenced by the 
inattentiveness indicator. Given the benefits of summarizing survey resistance this way, the pair 
of survey resistance indices for uncooperativeness and confidentiality were used in the final 
models in Chapter 3.
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Table C-4. Comparison of individual survey resistance indicators and survey resistance indices in the physical measurement consent 
model 
 Model 1  Model 2 
 Indicators Indices  Indicators Indices 
  Odds Ratio (SE) Odds Ratio (SE)   Odds Ratio (SE) Odds Ratio (SE) 
Survey resistance (W2)      
Nonrespondent in W2 0.612 (0.436) 0.592 (0.419)  0.473 (0.352) 0.450 (0.334) 
No. of contact attempts 0.994 (0.006) 0.994 (0.006)  0.998 (0.006) 0.999 (0.006) 
Asked about confidentiality 0.849 (0.145)   0.948 (0.169)  
Asked why information was needed 0.637 (0.102)**   0.668 (0.110)*  
Untruthful on financial questions 0.845 (0.095)   0.974 (0.113)  
Confidentiality Index  0.767 (0.053)****   0.850 (0.062)* 
Rated uncooperative 0.794 (0.095)   0.870 (0.107)  
Asked how long interview would last 0.813 (0.100)   0.861 (0.110)  
Rated as not enjoying interview 0.967 (0.100)   1.078 (0.114)  
Rated as inattentive 1.129 (0.158)   1.192 (0.172)  
Uncooperative Index  0.911 (0.040)*   0.988 (0.045) 
Survey resistance (W1)      
No. of contact attempts    1.008 (0.010) 1.008 (0.010) 
Asked about confidentiality    0.872 (0.119)  
Asked why information was needed    0.725 (0.104)*  
Untruthful on financial questions    0.636 (0.070)****  
Confidentiality Index     0.729 (0.045)**** 
Rated cooperation (ref: Excellent)    0.562 (0.066)****  
Asked how long interview would last    1.062 (0.129)  
Rated as not enjoying interview    0.588 (0.065)****  
Rated as inattentive    1.215 (0.178)  
Uncooperative Index     0.749 (0.033)**** 
Note. W1 = Wave 1, or HRS 2006 and HRS 2008 enhanced face-to-face (E-FTF) interviews. W2 = Wave 2, or HRS 2008 and HRS 2010 computer-assisted 
telephone interviews (CATI). 




Table C-5. Comparison of individual survey resistance indicators and survey resistance indices in the dried blood spot consent model 
 Model 1  Model 2 
 Indicators Indices  Indicators Indices 
  Odds Ratio (SE) Odds Ratio (SE)   Odds Ratio (SE) Odds Ratio (SE) 
Survey resistance (W2)      
Nonrespondent in W2 0.497 (0.264) 0.471 (0.249)  0.424 (0.232) 0.401 (0.220) 
No. of contact attempts 0.998 (0.004) 0.998 (0.004)  1.002 (0.005) 1.002 (0.005) 
Asked about confidentiality 0.676 (0.081)***   0.752 (0.092)*  
Asked why information was needed 0.817 (0.097)   0.872 (0.106)  
Untruthful on financial questions 0.863 (0.070)   0.936 (0.078)  
Confidentiality Index  0.776 (0.039)****   0.841 (0.044)*** 
Rated uncooperative 0.694 (0.059)****   0.762 (0.066)**  
Asked how long interview would last 0.749 (0.065)***   0.800 (0.071)*  
Rated as not enjoying interview 0.927 (0.067)   1.006 (0.075)  
Rated as inattentive 1.246 (0.129)*   1.275 (0.135)*  
Uncooperative Index  0.874 (0.027)****   0.941 (0.030) 
Survey resistance (W1)      
No. of contact attempts    1.006 (0.007) 1.006 (0.007) 
Asked about confidentiality    0.670 (0.062)****  
Asked why information was needed    0.744 (0.077)**  
Untruthful on financial questions    0.847 (0.070)*  
Confidentiality Index     0.734 (0.033)**** 
Rated cooperation (ref: Excellent)    0.537 (0.046)****  
Asked how long interview would last    1.011 (0.087)  
Rated as not enjoying interview    0.764 (0.060)***  
Rated as inattentive    1.001 (0.107)  
Uncooperative Index     0.779 (0.025)**** 
Note. W1 = Wave 1, or HRS 2006 and HRS 2008 enhanced face-to-face (E-FTF) interviews. W2 = Wave 2, or HRS 2008 and HRS 2010 computer-assisted 
telephone interviews (CATI). 




C.2 Systematic differences in post-survey observations across survey modes 
 One study assumption in Chapter 3 is that interviewer observations related to survey 
resistance differ depending on the survey mode, because of the inherent differences of each 
mode and the timing of a particular wave (e.g., last E-FTF wave) relative to the wave of interest. 
Unfortunately, there seems to be no literature related to this phenomenon and if it should be 
accounted for. In order to further explore and justify this assumption, two investigations were 
completed: (1) examine distributions of survey resistance variables across the two interview 
modes and (2) compare tetrachoric correlations of the resistance indicators between W1 and W2 
for the analytic sample. 
C.2.1 Survey resistance distributions by survey mode 
 Table C-6 summarizes the weighted distributions for each of the seven previously 
discussed survey resistance variables for the entire HRS sample from 2006 through 2012. The 
Rao-Scott Chi-Square statistic for each comparison is reported to best account for the sample 
design and weighting (Heeringa, West, & Berglund, 2010). Two indicators (truth on financial 
questions and if the respondent ever asked why this information was needed) are excluded from 
HRS 2012 as they were removed from the post-survey assessment.  
Focusing on the differences across modes, the only variables that consistently exhibit a 
difference by mode are if the respondent asked why this information was needed, if the 
respondent expressed concern over confidentiality, and interviewer-rated respondent enjoyment. 
Questions why this information is needed is more likely to occur in the E-FTF interview 
primarily due to an increase in the “seldom” category. Expressing concerns about keeping 
responses confidential is also more likely to occur in the E-FTF interview with increases in both 
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the “seldom” and “often” categories. Enjoyment is also more likely to be rated higher in the E-
FTF interview. The E-FTF assessment of enjoyment can be anywhere from 8 to 14 percentage 
point higher for the combined “great deal” and “quite a bit” categories.  
Table C-6. Differences in survey resistance variables by mode for four waves of the Health 
and Retirement Study 
  2006 2008 2010 2012 
Survey resistance variable E-FTF CATI E-FTF CATI E-FTF CATI E-FTF CATI 
How Long Never 84.5 82.2 82.8 83.5 78.1 79.6 80.6 80.3 
 Seldom 12.5 14.5 13.6 13.2 18.4 17.2 16.5 16.1 
 Often 3.0 3.3 3.6 3.3 3.5 3.2 2.9 3.6 
Rao-Scott Chi-square 8.21 * 0.90 n.s. 3.60 n.s. 4.34 n.s. 
Why Need Never 91.0 93.6 89.4 93.5 87.6 90.8 - - 
  Seldom 7.8 5.5 9.3 5.5 11.2 8.1 - - 
  Often 1.2 0.9 1.2 1.0 1.2 1.1 - - 
Rao-Scott Chi-square 21.34 **** 56.38 **** 24.91 **** - - 
Confidentiality Never 88.6 92.9 87.2 93.1 82.8 92.6 89.0 93.3 
  Seldom 10.1 6.3 11.3 6.2 15.7 6.7 9.9 6.0 
  Often 1.2 0.8 1.5 0.7 1.5 0.7 1.1 0.7 
Rao-Scott Chi-square 52.71 **** 83.89 **** 196.08 **** 58.50 **** 
Attentiveness Not at all 0.6 0.5 0.6 0.4 0.6 0.5 0.7 0.7 
 Somewhat 9.7 8.8 10.3 9.7 13.4 13.1 13.5 14.7 
 Very 89.7 90.8 89.1 89.9 86.0 86.4 85.8 84.5 
Rao-Scott Chi-square 3.67 n.s. 2.61 n.s. 0.29 n.s. 2.16 n.s. 
Cooperation Excellent 77.8 76.6 77.2 76.8 73.8 71.8 71.0 71.1 
  Good 19.2 21.0 20.0 20.7 22.5 24.0 25.2 24.8 
  Fair 2.8 2.1 2.5 2.3 3.2 3.8 3.5 3.3 
  Poor 0.2 0.3 0.4 0.2 0.4 0.5 0.4 0.8 
Rao-Scott Chi-square 11.17 * 2.64 n.s. 4.55 n.s. 5.86 n.s. 
Enjoy Great deal 37.9 28.1 38.9 33.6 26.7 22.3 23.0 15.4 
 Quite a bit 34.1 33.1 34.1 32.0 35.8 32.0 37.8 30.9 
 Some 20.6 28.0 21.5 27.3 28.5 32.1 30.1 37.1 
 A little 5.9 8.2 4.0 5.4 7.0 9.9 7.1 13.1 
 Not at all 1.5 2.5 1.5 1.8 2.0 3.7 2.0 3.5 
Rao-Scott Chi-square 106.91 **** 38.85 **** 64.57 **** 167.94 **** 
Truth  Completely 79.1 79.2 77.9 80.0 72.6 72.8 - - 
financial  Mainly truthful 18.1 17.9 18.7 16.8 24.0 23.0 - - 
  Half and half 2.3 2.5 3.0 2.6 2.9 3.6 - - 
  Mainly untruthful 0.5 0.4 0.4 0.6 0.5 0.6 - - 
Rao-Scott Chi-square 1.01 n.s. 7.82 * 4.61 n.s. - - 
Note. Percentages are weighted. Rao-Scott Chi-square statistics adjust for survey design (Heeringa, West, & Berglund, 
2010). Base sample: 2006 - 17,106; 2008 - 15,840; 2010 - 20,337; 2012 - 18,851. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
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While it is not the focus of this analysis, it is interesting to note the change in these 
distributions over time from wave to wave. Many of the “best” or “positive” categories for each 
resistance indicator greatly reduce from 2006 to 2012. It is unclear if this is due to the growing 
trend of resistance to surveys generally, if this is evidence of panel fatigue, or a change in 
interviewer training regarding post-survey observations. 
C.2.2 Between wave correlations of survey resistance indicators and indices  
The second analysis revisits the tetrachoric correlations between the seven dichotomous 
survey resistance indicators from W1 with those from W2. Table C-1 already displayed the 
tetrachoric correlation values both within and between each wave. Figure C-1 reproduces this 
data visually showing the corresponding correlations highlighting the differences between the 
W1 and W2 correlations. Variables from the same wave have a higher correlation (on average) 
than with any variable from the alternative wave. The only real exception is the same variable 
from the other wave where its correlation is (on average) in the same range as the lowest of the 
variables from the current wave. 
To verify these findings also applied to the proposed resistance indices, a standard 
Pearson correlation and a polychoric correlation on the two indices within and between waves 
was conducted. Similar to the individual indicators, within wave correlations are much higher 
than between wave correlations even for the same index. For W1, the two indices have a 
moderate correlation with each other (𝑁𝑁𝑃𝑃𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 = 0.47;𝑁𝑁𝑝𝑝𝑐𝑐𝑖𝑖𝑝𝑝𝑑𝑑ℎ𝑐𝑐𝑠𝑠𝑠𝑠𝑑𝑑 = 0.58). This correlation is 
not as strong in W2 (𝑁𝑁𝑃𝑃𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 = 0.35;𝑁𝑁𝑝𝑝𝑐𝑐𝑖𝑖𝑝𝑝𝑑𝑑ℎ𝑐𝑐𝑠𝑠𝑠𝑠𝑑𝑑 = 0.46). The between wave Pearson 
correlations have a range of 0.18 and 0.25 while the polychoric correlations have a range of 0.24 
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to 0.31. The uncooperativeness index between W1 and W2 is the strongest of the between wave 
correlations (𝑁𝑁𝑃𝑃𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 = 0.25;𝑁𝑁𝑝𝑝𝑐𝑐𝑖𝑖𝑝𝑝𝑑𝑑ℎ𝑐𝑐𝑠𝑠𝑠𝑠𝑑𝑑 = 0.31).    
C.2.3 Discussion 
Overall these results suggest that within wave resistance variables have a stronger 
association with each other than with between wave resistance variables most likely due to 
interviewer continuity. While this does support the hypothesis that there are potential mode 
differences in resistance variables, these could also be differences related to at least two other 
 




phenomenon. First, there is only a small proportion of panelists that have the same interviewer 
from W1 to W2 suggesting that some of the observation changes may related to the perception of 
a new interviewer. Second, the passage of time can lead to changes in attitude. This could 
include an increasing resistance to participate as part of the panel as well as temporary changes 







Model 4 Results from Multilevel Logistic Regressions on Wave 1 Non-consenters 
Below are the full two-level random effects logistic regression model results for physical 
measurement and dried blood spot non-consenters including the interaction term of interviewer 




Table D-1. Predictors of wave 3 biomeasure consent for wave 1 non-consenters (physical 
measurements and dried blood spot) including the interaction term of interviewer 
continuity and reason for wave 1 consent refusal (Model 4) 
 Physical measurements  Dried blood spot 
  Odds Ratio   Odds Ratio 
Respondent Characteristics    
Age (years) 0.98 (0.94, 1.01)   1.01 (0.99, 1.02)  
Female 1.29 (0.84, 1.97)   0.92 (0.72, 1.18)  
Education (ref: less than HS) 
   
High school  1.17 (0.61, 2.25)   1.19 (0.83, 1.72)  
Some college 1.61 (0.70, 3.73)   0.90 (0.60, 1.35)  
College graduate 1.09 (0.45, 2.68)   0.90 (0.57, 1.42)  
Race/ethnicity (ref: Non-Hispanic other) 
   
Non-Hispanic black 0.78 (0.40, 1.49)   1.03 (0.70, 1.53)  
Hispanic (English interview) 1.29 (0.37, 4.57)   1.30 (0.69, 2.48)  
Hispanic (Spanish interview) 10.05 (0.84, 120.37)   2.70 (1.10, 6.60)* 
Attends religious services at least 1/wk 1.35 (0.82, 2.22)   1.01 (0.78, 1.32)  
Another eligible HH member 0.73 (0.46, 1.17)   1.06 (0.83, 1.36)  
Health status indicators (W1)    
Self-rated health (ref: Excellent)    
     Very good 1.02 (0.35, 2.95)   1.04 (0.65, 1.64)  
     Good 1.21 (0.42, 3.51)   1.12 (0.69, 1.80)  
     Fair/Poor 1.14 (0.36, 3.65)   1.07 (0.62, 1.86)  
BMI (ref: Underweight/Normal) 
   
     Overweight 0.80 (0.38, 1.67)   1.11 (0.81, 1.51)  
     Obese 0.73 (0.37, 1.46)   1.34 (1.03, 1.73)* 
     Did not report 0.59 (0.13, 2.64)   1.56 (0.75, 3.22)  
Diabetes 0.89 (0.44, 1.82)   1.19 (0.95, 1.49)  
Mildly vigorous activity (ref: At least 1/wk)   
 
     1-3 times/month 0.58 (0.23, 1.47)   0.74 (0.49, 1.12)  
     Hardly ever/never 0.84 (0.28, 2.54)   1.11 (0.65, 1.90)  
No. of functional limitations 0.91 (0.84, 0.99)*  0.97 (0.93, 1.01)  
Ever visited doctor in last 2 years (W1) 1.52 (0.59, 3.92)   0.95 (0.57, 1.59)  
Change in health status    
Self-rated health (ref: No change)    
     Declined 1.05 (0.59, 1.88)   0.86 (0.64, 1.15)  
     Improved 1.54 (0.62, 3.84)   1.12 (0.78, 1.60)  
BMI (ref: No change)    
     Declined 1.55 (0.53, 4.53)  1.38 (0.92, 2.08)  
     Improved 2.52 (1.19, 5.33)*  0.78 (0.57, 1.08)  
Developed diabetes 1.86 (0.67, 5.18)   1.19 (0.72, 1.97)  
Mildly vigorous activity (ref: No change)   
 
     Declined 0.82 (0.48, 1.40)   1.18 (0.87, 1.59)  
     Improved 0.79 (0.26, 2.36)   0.90 (0.54, 1.52)  
Change in no. functional limitations 0.95 (0.88, 1.04)   1.00 (0.96, 1.04)  




Table D-1. Predictors of wave 3 biomeasure consent for wave 1 non-consenters (physical 
measurements and dried blood spot) including the interaction term of interviewer 
continuity and reason for wave 1 consent refusal (Model 4) (continued) 
 Physical measurements  Dried blood spot 
  Odds Ratio   Odds Ratio 
Cognition indices    
Word recall score (W1) 0.90 (0.81, 0.99)*  0.96 (0.92, 1.00)  
Mental status score (W1) 1.10 (0.97, 1.24)   0.98 (0.92, 1.05)  
Change in word recall score 0.99 (0.88, 1.12)   1.00 (0.96, 1.04)  
Change in mental status score 1.08 (0.93, 1.25)   0.99 (0.90, 1.08)  
Survey resistance (W1)    
No. of contact attempts 1.02 (0.98, 1.06)   1.01 (0.99, 1.03)  
Uncooperative Index 0.96 (0.80, 1.15)   1.01 (0.91, 1.13)  
Confidentiality Index 0.66 (0.52, 0.84)***  0.80 (0.70, 0.91)** 
Survey resistance (W2)    
Nonrespondent in W2 0.22 (0.01, 5.13)   0.65 (0.14, 3.08)  
No. of contact attempts 1.01 (0.98, 1.04)   1.00 (0.99, 1.01)  
Uncooperative Index 1.13 (0.92, 1.39)   0.98 (0.89, 1.08)  
Confidentiality Index 0.73 (0.54, 1.00)*  0.81 (0.68, 0.98)* 
Survey resistance (W3)    
No. of contact attempts 0.99 (0.95, 1.02)   0.99 (0.97, 1.01)  
Panel status    
Ever a nonrespondent before W1 0.66 (0.33, 1.32)   0.84 (0.59, 1.20)  
Interviewer continuity    
E-FTF interviewer continuity 1.01 (0.14, 7.08)  1.39 (0.49, 3.93)  
Previous biomeasure consent    
Straight refusal to PM sample (W1) 0.69 (0.36, 1.30)    
    Straight refusal to DBS sample (W1)   0.56 (0.40, 0.80)** 
Continuity and consent interactions    
    Interviewer continuity * PM refusal 0.53 (0.07, 4.09)   
    Interviewer continuity * DBS refusal   0.45 (0.16, 1.26) 
Interviewer attributes    
Age (years) 0.99 (0.97, 1.02)   0.98 (0.97, 1.00)** 
Female 0.53 (0.28, 1.01)   1.29 (0.93, 1.79)  
Race (ref: Non-Hispanic other)    
     Non-Hispanic black 0.46 (0.22, 0.96)*  0.72 (0.54, 0.96)* 
     Hispanic 0.26 (0.08, 0.87)*  0.95 (0.62, 1.46)  
Education (ref: HS graduate)    
     Some college 0.87 (0.39, 1.96)   0.79 (0.52, 1.22)  
     College graduate 0.83 (0.37, 1.83)   0.91 (0.60, 1.36)  
     Advanced degree 0.63 (0.29, 1.35)   0.83 (0.53, 1.29)  
New hire 1.21 (0.66, 2.19)   0.68 (0.53, 0.89)** 
Interviewer variance 1.81 (0.38, 8.47)   1.16 (0.87, 1.56) 
Note. Odd ratios 95% confidence intervals are based on jackknife standard errors from a two-level random effects 
logistic regression model. CI = confidence interval. PM = physical measurements. DBS = dried blood spot. W1 = 
Wave 1. W2 = Wave 2. W3 = Wave 3. HS = high school. 
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Table E-1. Observed and imputed means and standard errors of C-reactive protein (back-transformed from natural log transform) by 
year and imputation approach 
 Biomeasure weighted  Base weighted 
CRP (ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 5,817 4.473 0.1141 0.0255 6.2%  5,874 4.448 0.1155 0.0260 26.2% 
Cross-sectional 6,203 4.483 0.1157 0.0258 8.5%  7,954 4.523 0.1210 0.0268 18.9% 
Sequential 6,203 4.494 0.1145 0.0255 6.8%  7,954 4.539 0.1126 0.0248 13.2% 
Wide 6,203 4.476 0.1155 0.0258 6.5%  7,954 4.457 0.1185 0.0266 31.6% 
2010            
Observed 5,053 3.761 0.1363 0.0362 3.3%  5,053 3.717 0.1306 0.0351 23.8% 
Cross-sectional 5,228 3.747 0.1336 0.0357 0.8%  6,631 3.724 0.1138 0.0305 12.3% 
Sequential 5,228 3.754 0.1344 0.0358 1.5%  6,631 3.711 0.1251 0.0337 20.3% 
Wide 5,228 3.746 0.1346 0.0359 0.5%  6,631 3.722 0.1223 0.0329 12.0% 
2014            
Observed 4,335 3.641 0.1486 0.0408 1.8%  4,335 3.679 0.1667 0.0453 19.8% 
Cross-sectional 4,413 3.649 0.1495 0.0410 2.7%  5,406 3.683 0.1727 0.0469 27.1% 
Sequential 4,413 3.633 0.1466 0.0404 0.5%  5,406 3.676 0.1533 0.0417 10.4% 
Wide 4,413 3.653 0.1547 0.0423 2.9%   5,406 3.699 0.1533 0.0414 9.9% 




Table E-2. Observed and imputed percentiles of CRP (back-transformed from natural log transform) by year and imputation approach 
 Biomeasure weighted  Base weighted 
CRP (ug/mL) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.251 0.905 1.964 4.813 15.922  0.255 0.914 1.968 4.757 15.908 
(SE) (0.013) (0.030) (0.061) (0.138) (0.705)  (0.013) (0.032) (0.061) (0.141) (0.723) 
Cross-sectional 0.254 0.905 1.967 4.844 16.002  0.263 0.918 2.048 4.850 16.262 
(SE) (0.013) (0.030) (0.063) (0.138) (0.682)  (0.011) (0.027) (0.066) (0.138) (0.673) 
Sequential 0.255 0.904 1.967 4.836 16.038  0.263 0.915 2.048 4.852 16.313 
(SE) (0.013) (0.030) (0.063) (0.140) (0.692)  (0.012) (0.033) (0.066) (0.142) (0.685) 
Wide 0.253 0.901 1.966 4.818 15.950  0.261 0.906 2.016 4.760 16.053 
(SE) (0.013) (0.029) (0.064) (0.141) (0.724)  (0.012) (0.029) (0.070) (0.163) (0.664) 
2010            
Observed 0.247 0.792 1.745 3.786 12.443  0.249 0.790 1.725 3.765 12.378 
(SE) (0.009) (0.022) (0.046) (0.094) (0.349)  (0.009) (0.022) (0.048) (0.096) (0.401) 
Cross-sectional 0.248 0.790 1.742 3.786 12.431  0.256 0.801 1.745 3.826 12.577 
(SE) (0.009) (0.022) (0.046) (0.093) (0.366)  (0.007) (0.022) (0.041) (0.101) (0.399) 
Sequential 0.247 0.793 1.742 3.789 12.456  0.252 0.794 1.749 3.814 12.497 
(SE) (0.009) (0.023) (0.046) (0.094) (0.369)  (0.009) (0.025) (0.043) (0.097) (0.430) 
Wide 0.247 0.790 1.742 3.791 12.458  0.253 0.804 1.758 3.855 12.533 
(SE) (0.009) (0.022) (0.044) (0.095) (0.364)  (0.008) (0.025) (0.043) (0.101) (0.376) 
2014            
Observed 0.111 0.483 1.284 3.496 13.800  0.112 0.484 1.281 3.507 13.845 
(SE) (0.006) (0.149) (0.046) (0.103) (0.735)  (0.008) (0.015) (0.047) (0.100) (0.782) 
Cross-sectional 0.111 0.483 1.284 3.499 13.784  0.118 0.487 1.281 3.469 13.809 
(SE) (0.007) (0.015) (0.046) (0.101) (0.719)  (0.008) (0.014) (0.047) (0.110) (0.767) 
Sequential 0.112 0.484 1.284 3.495 13.781  0.118 0.489 1.288 3.506 14.051 
(SE) (0.007) (0.015) (0.047) (0.103) (0.713)  (0.008) (0.016) (0.045) (0.107) (0.736) 
Wide 0.111 0.483 1.286 3.497 13.813  0.117 0.491 1.306 3.555 14.042 




Figure E-1. Distribution of CRP (back-transformed from natural log transform) by year, analysis weight, and imputation approach. 






Cross-sectional Multivariate Models for 2010 and 2014 
Table F-1. Logistic regression logit coefficients and standard errors for predicting cardiovascular 
disease in HRS 2010 using biomeasure weights 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.050 (0.006)****  0.049 (0.006)****  0.049 (0.006)****  0.049 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.312 (0.088)*** -0.310 (0.086)*** -0.314 (0.086)*** -0.315 (0.086)*** 
Age x Female -0.019 (0.007)** -0.018 (0.006)** -0.018 (0.006)** -0.018 (0.006)** 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.517 (0.156)** -0.530 (0.167)** -0.528 (0.167)** -0.529 (0.167)** 
Non-Hispanic black -0.306 (0.124)* -0.305 (0.116)** -0.301 (0.116)** -0.304 (0.115)** 
Health conditions     
Hypertension  0.681 (0.094)****  0.694 (0.091)****  0.693 (0.091)****  0.693 (0.092)**** 
Diabetes  0.605 (0.094)****  0.602 (0.087)****  0.601 (0.087)****  0.597 (0.087)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.079 (0.117)  -0.093 (0.088)  -0.096 (0.086)  -0.084 (0.084)  
Obese (BMI > 30)                  -0.041 (0.089)  -0.046 (0.112)  -0.049 (0.112)  -0.042 (0.112)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.029 (0.165)   0.036 (0.167)   0.038 (0.166)   0.033 (0.167)  
Hardly ever/never   0.230 (0.123)   0.270 (0.113)*  0.271 (0.113)*  0.265 (0.113)* 
Smoking status (ref: never smoked)    
Current smoker           0.203 (0.147)   0.223 (0.147)   0.222 (0.146)   0.218 (0.147)  
Former smoker            0.297 (0.092)**  0.317 (0.089)***  0.318 (0.089)***  0.315 (0.088)*** 
Biomeasures     
ln(CRP)  0.037 (0.032)   0.031 (0.031)   0.033 (0.032)   0.038 (0.032)  
Cystatin C  0.441 (0.098)****  0.426 (0.094)****  0.421 (0.092)****  0.426 (0.094)**** 
Intercept                           -2.013 (0.158)**** -2.001 (0.148)**** -1.992 (0.147)**** -2.001 (0.148)**** 
Note. Sample sizes: observed n = 4,958; imputed n = 5,228.  
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.  
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Table F-2. Logistic regression logit coefficients and standard errors for predicting cardiovascular 
disease in HRS 2010 using base weights 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.051 (0.006)****  0.051 (0.006)****  0.052 (0.006)****  0.053 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.321 (0.091)*** -0.305 (0.075)**** -0.310 (0.075)**** -0.310 (0.075)**** 
Age x Female -0.018 (0.007)** -0.017 (0.006)** -0.017 (0.006)** -0.017 (0.006)** 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.483 (0.154)** -0.521 (0.149)*** -0.526 (0.148)*** -0.526 (0.149)*** 
Non-Hispanic black -0.317 (0.125)* -0.358 (0.106)*** -0.358 (0.106)*** -0.358 (0.105)*** 
Health conditions     
Hypertension  0.658 (0.093)****  0.660 (0.081)****  0.655 (0.082)****  0.656 (0.082)**** 
Diabetes  0.611 (0.092)****  0.571 (0.078)****  0.566 (0.078)****  0.562 (0.078)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.102 (0.119)  -0.083 (0.078)  -0.088 (0.076)  -0.081 (0.075)  
Obese (BMI > 30)                  -0.057 (0.092)  -0.055 (0.105)  -0.053 (0.103)  -0.053 (0.103)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.003 (0.166)   0.077 (0.130)   0.078 (0.129)   0.072 (0.130)  
Hardly ever/never   0.201 (0.126)   0.257 (0.111)*  0.256 (0.112)*  0.253 (0.112)* 
Smoking status (ref: never smoked)    
Current smoker           0.218 (0.145)   0.233 (0.126)   0.231 (0.127)   0.223 (0.128)  
Former smoker            0.324 (0.090)***  0.298 (0.079)***  0.297 (0.079)***  0.294 (0.079)*** 
Biomeasures     
ln(CRP)  0.041 (0.033)   0.036 (0.032)   0.043 (0.034)   0.054 (0.032)  
Cystatin C  0.457 (0.096)****  0.364 (0.075)****  0.344 (0.073)****  0.338 (0.066)**** 
Intercept                           -1.987 (0.154)**** -1.902 (0.142)**** -1.873 (0.141)**** -1.873 (0.139)**** 
Note. Sample sizes: observed n = 4,958; imputed n = 6,631.  





Figure F-1. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2010 by imputation approach and analysis weight. 
Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) and 0.50 
for Cystatin C. 95% confidence interval of the odds ratio included.
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Table F-3. Logistic regression logit coefficients and standard errors for predicting cardiovascular 
disease in HRS 2014 using biomeasure weights 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.051 (0.008)****  0.050 (0.008)****  0.050 (0.008)****  0.050 (0.008)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.373 (0.078)**** -0.342 (0.075)**** -0.345 (0.075)**** -0.344 (0.075)**** 
Age x Female -0.022 (0.010)* -0.018 (0.010)  -0.018 (0.010)  -0.017 (0.010)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.482 (0.181)* -0.500 (0.180)** -0.502 (0.180)** -0.500 (0.180)** 
Non-Hispanic black -0.134 (0.102)  -0.164 (0.119)  -0.166 (0.119)  -0.164 (0.119)  
Health conditions     
Hypertension  0.579 (0.116)****  0.592 (0.108)****  0.587 (0.108)****  0.587 (0.108)**** 
Diabetes  0.496 (0.101)****  0.503 (0.101)****  0.504 (0.101)****  0.504 (0.101)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.089 (0.111)  -0.106 (0.109)  -0.111 (0.108)  -0.111 (0.109)  
Obese (BMI > 30)                  -0.094 (0.112)  -0.094 (0.106)  -0.096 (0.105)  -0.097 (0.106)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.189 (0.138)   0.182 (0.133)   0.181 (0.133)   0.185 (0.133)  
Hardly ever/never   0.334 (0.124)**  0.331 (0.119)**  0.330 (0.120)**  0.329 (0.119)** 
Smoking status (ref: never smoked)    
Current smoker           0.200 (0.129)   0.207 (0.124)   0.211 (0.124)   0.206 (0.123)  
Former smoker            0.260 (0.078)**  0.270 (0.076)***  0.270 (0.076)***  0.269 (0.076)*** 
Biomeasures     
ln(CRP)  0.012 (0.032)   0.011 (0.032)   0.010 (0.031)   0.014 (0.031)  
Cystatin C  0.483 (0.093)****  0.447 (0.081)****  0.453 (0.081)****  0.447 (0.081)**** 
Intercept                           -1.797 (0.163)**** -1.763 (0.159)**** -1.763 (0.158)**** -1.757 (0.159)**** 
Note. Sample sizes: observed n = 4,256; imputed n = 4,413.  





Table F-4. Logistic regression logit coefficients and standard errors for predicting cardiovascular 
disease in HRS 2014 using base weights 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.052 (0.008)****  0.053 (0.008)****  0.053 (0.008)****  0.054 (0.008)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.358 (0.079)**** -0.357 (0.062)**** -0.356 (0.061)**** -0.352 (0.061)**** 
Age x Female -0.022 (0.010)* -0.022 (0.009)* -0.021 (0.009)* -0.021 (0.009)* 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.466 (0.181)* -0.528 (0.146)*** -0.522 (0.145)*** -0.518 (0.145)*** 
Non-Hispanic black -0.115 (0.103)  -0.272 (0.100)** -0.268 (0.101)** -0.269 (0.101)** 
Health conditions     
Hypertension  0.551 (0.117)****  0.585 (0.096)****  0.569 (0.097)****  0.569 (0.097)**** 
Diabetes  0.526 (0.101)****  0.511 (0.082)****  0.516 (0.081)****  0.517 (0.080)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.104 (0.108)  -0.156 (0.092)  -0.164 (0.091)  -0.161 (0.090)  
Obese (BMI > 30)                  -0.120 (0.112)  -0.097 (0.092)  -0.102 (0.089)  -0.098 (0.089)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.175 (0.135)   0.277 (0.116)*  0.277 (0.116)*  0.281 (0.116)* 
Hardly ever/never   0.318 (0.131)*  0.280 (0.107)**  0.290 (0.107)**  0.287 (0.108)** 
Smoking status (ref: never smoked)    
Current smoker           0.175 (0.131)   0.280 (0.120)*  0.280 (0.120)*  0.283 (0.120)* 
Former smoker            0.279 (0.079)***  0.275 (0.072)***  0.277 (0.073)***  0.279 (0.073)*** 
Biomeasures     
ln(CRP)  0.017 (0.034)   0.013 (0.031)   0.016 (0.033)   0.013 (0.030)  
Cystatin C  0.488 (0.095)****  0.389 (0.071)****  0.397 (0.076)****  0.399 (0.072)**** 
Intercept                           -1.793 (0.166)**** -1.633 (0.150)**** -1.634 (0.152)**** -1.642 (0.151)**** 
Note. Sample sizes: observed n = 4,256; imputed n = 5,406.  






Figure F-2. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2014 by imputation approach and analysis weight. 
Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) and 0.50 






Gender Subgroup Analyses 
The following sections include tables and figures to show the results of the subgroup analyses by 
gender in conjunction with Section 4.3.6. Section G.1 reviews the univariate characteristics for 
males and females like Sections 4.3.1 and 4.3.2. Section G.2 includes the cross-sectional 
multivariate models covering Section 4.3.4 and Appendix F. Section G.3 covers the longitudinal 
multivariate models like Section 4.3.5.
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G.1 Univariate characteristics by gender 
Table G1-1. Observed and imputed means and standard errors of Cystatin C by year and imputation approach (males) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 2,399 1.064 0.0083 0.0078 7.8%  2,422 1.061 0.0078 0.0074 28.0% 
Cross-sectional 2,601 1.068 0.0090 0.0085 12.7%  3,365 1.069 0.0097 0.0091 27.6% 
Sequential 2,601 1.067 0.0086 0.0080 6.5%  3,365 1.070 0.0092 0.0086 14.6% 
Wide 2,601 1.068 0.0087 0.0082 10.2%  3,365 1.073 0.0086 0.0081 14.1% 
2010            
Observed 2,070 1.125 0.0100 0.0089 4.1%  2,070 1.122 0.0103 0.0091 24.4% 
Cross-sectional 2,159 1.126 0.0102 0.0091 1.2%  2,737 1.125 0.0118 0.0105 24.8% 
Sequential 2,159 1.126 0.0104 0.0093 6.2%  2,737 1.131 0.0123 0.0109 32.9% 
Wide 2,159 1.125 0.0105 0.0093 4.1%  2,737 1.137 0.0109 0.0096 18.5% 
2014            
Observed 1,745 1.168 0.0148 0.0127 1.6%  1,745 1.167 0.0150 0.0128 19.1% 
Cross-sectional 1,774 1.169 0.0147 0.0126 0.9%  2,158 1.177 0.0143 0.0122 19.5% 
Sequential 1,774 1.168 0.0148 0.0127 1.0%  2,158 1.184 0.0163 0.0138 26.2% 
Wide 1,774 1.168 0.0147 0.0126 0.6%   2,158 1.190 0.0149 0.0125 10.0% 





Table G1-2. Observed and imputed means and standard errors of Cystatin C by year and imputation approach (females) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 3,325 1.095 0.0097 0.0089 7.7%  3,356 1.084 0.0088 0.0081 26.9% 
Cross-sectional 3,602 1.100 0.0986 0.0896 4.9%  4,589 1.108 0.0088 0.0079 17.9% 
Sequential 3,602 1.101 0.0101 0.0091 7.8%  4,589 1.111 0.0088 0.0079 6.5% 
Wide 3,602 1.097 0.0099 0.0090 4.4%  4,589 1.095 0.0093 0.0085 23.9% 
2010            
Observed 2,992 1.140 0.0132 0.0116 2.5%  2,992 1.136 0.0124 0.0109 23.2% 
Cross-sectional 3,069 1.141 0.0131 0.0115 1.4%  3,894 1.147 0.0114 0.0100 13.6% 
Sequential 3,069 1.141 0.0130 0.0114 0.8%  3,894 1.151 0.0124 0.0108 27.6% 
Wide 3,069 1.140 0.0132 0.0116 1.0%  3,894 1.152 0.0122 0.0106 26.0% 
2014            
Observed 2,597 1.205 0.0130 0.0108 1.6%  2,597 1.204 0.0127 0.0105 20.0% 
Cross-sectional 2,639 1.205 0.0131 0.0109 3.6%  3,248 1.213 0.0127 0.0105 17.0% 
Sequential 2,639 1.205 0.0131 0.0108 0.7%  3,248 1.218 0.0118 0.0097 5.6% 
Wide 2,639 1.205 0.0131 0.0108 1.3%   3,248 1.218 0.0137 0.0112 26.3% 




Table G1-3. Observed and imputed at proportion at risk for Cystatin C by year and imputation approach (males) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 2,399 0.078 0.0061 0.0781 7.8%  2,422 0.075 0.0057 0.0759 28.0% 
Cross-sectional 2,601 0.087 0.0069 0.0784 18.6%  3,365 0.106 0.0071 0.0674 30.0% 
Sequential 2,601 0.086 0.0063 0.0728 7.6%  3,365 0.105 0.0067 0.0637 18.5% 
Wide 2,601 0.085 0.0060 0.0711 6.7%  3,365 0.099 0.0066 0.0666 34.8% 
2010            
Observed 2,070 0.112 0.0082 0.0731 4.1%  2,070 0.110 0.0082 0.0745 24.4% 
Cross-sectional 2,159 0.117 0.0085 0.0725 2.3%  2,737 0.134 0.0096 0.0718 31.2% 
Sequential 2,159 0.116 0.0084 0.0727 3.7%  2,737 0.138 0.0096 0.0695 27.6% 
Wide 2,159 0.115 0.0085 0.0743 3.5%  2,737 0.136 0.0087 0.0643 16.0% 
2014            
Observed 1,745 0.143 0.0105 0.0732 1.6%  1,745 0.143 0.0107 0.0746 19.1% 
Cross-sectional 1,774 0.146 0.0105 0.0720 1.8%  2,158 0.167 0.0102 0.0614 12.2% 
Sequential 1,774 0.145 0.0104 0.0716 1.3%  2,158 0.170 0.0116 0.0679 29.5% 
Wide 1,774 0.145 0.0103 0.0708 0.7%   2,158 0.174 0.0109 0.0628 15.6% 
Note. FMI for observed is the missing rate. 
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Table G1-4. Observed and imputed at proportion at risk for Cystatin C by year and imputation approach (females) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 3,325 0.102 0.0050 0.0486 7.7%  3,356 0.096 0.0047 0.0493 26.9% 
Cross-sectional 3,602 0.111 0.0054 0.0482 9.5%  4,589 0.133 0.0061 0.0455 32.1% 
Sequential 3,602 0.112 0.0057 0.0507 19.6%  4,589 0.134 0.0061 0.0452 20.8% 
Wide 3,602 0.107 0.0052 0.0492 10.0%  4,589 0.118 0.0072 0.0609 54.6% 
2010            
Observed 2,992 0.136 0.0089 0.0652 2.5%  2,992 0.135 0.0087 0.0645 23.2% 
Cross-sectional 3,069 0.138 0.0088 0.0636 1.2%  3,894 0.157 0.0088 0.0558 25.9% 
Sequential 3,069 0.139 0.0087 0.0630 0.6%  3,894 0.160 0.0083 0.0514 19.5% 
Wide 3,069 0.137 0.0088 0.0645 1.7%  3,894 0.157 0.0086 0.0549 25.9% 
2014            
Observed 2,597 0.147 0.0075 0.0511 1.6%  2,597 0.146 0.0075 0.0515 20.0% 
Cross-sectional 2,639 0.149 0.0077 0.0517 4.7%  3,248 0.175 0.0083 0.0475 17.9% 
Sequential 2,639 0.149 0.0076 0.0511 1.1%  3,248 0.175 0.0083 0.0470 10.3% 
Wide 2,639 0.148 0.0076 0.0515 1.4%   3,248 0.175 0.0082 0.0470 13.7% 






Figure G1-1. Proportion at risk for Cystatin C by year, gender, analysis weight, and imputation approach. 95% confidence interval of 




Table G1-5. Observed and imputed percentiles of Cystatin C by year and imputation approach (males) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.659 0.814 0.946 1.137 1.663  0.660 0.815 0.949 1.137 1.641 
(SE) (0.010) (0.006) (0.007) (0.011) (0.035)  (0.009) (0.006) (0.007) (0.011) (0.034) 
Cross-sectional 0.649 0.835 0.967 1.168 1.744  0.557 0.839 0.974 1.239 1.813 
(SE) (0.019) (0.014) (0.014) (0.015) (0.051)  (0.033) (0.015) (0.020) (0.017) (0.031) 
Sequential 0.649 0.837 0.967 1.168 1.736  0.562 0.839 0.976 1.239 1.808 
(SE) (0.019) (0.014) (0.015) (0.014) (0.044)  (0.030) (0.015) (0.018) (0.017) (0.036) 
Wide 0.669 0.837 0.967 1.168 1.739  0.601 0.839 0.981 1.238 1.782 
(SE) (0.028) (0.014) (0.015) (0.015) (0.045)  (0.030) (0.015) (0.021) (0.017) (0.038) 
2010            
Observed 0.656 0.853 1.028 1.257 1.888  0.655 0.852 1.029 1.256 1.881 
(SE) (0.012) (0.008) (0.009) (0.016) (0.042)  (0.014) (0.009) (0.009) (0.016) (0.041) 
Cross-sectional 0.655 0.853 1.033 1.267 1.900  0.582 0.844 1.047 1.319 1.916 
(SE) (0.013) (0.009) (0.009) (0.018) (0.043)  (0.025) (0.011) (0.009) (0.021) (0.038) 
Sequential 0.654 0.852 1.032 1.267 1.891  0.590 0.847 1.049 1.323 1.934 
(SE) (0.013) (0.009) (0.009) (0.017) (0.043)  (0.024) (0.010) (0.010) (0.021) (0.039) 
Wide 0.653 0.853 1.031 1.265 1.893  0.607 0.854 1.050 1.326 1.940 
(SE) (0.014) (0.009) (0.009) (0.018) (0.042)  (0.020) (0.010) (0.009) (0.018) (0.040) 
2014            
Observed 0.663 0.880 1.061 1.313 1.959  0.661 0.879 1.061 1.314 1.951 
(SE) (0.015) (0.011) (0.014) (0.017) (0.052)  (0.016) (0.012) (0.014) (0.018) (0.051) 
Cross-sectional 0.660 0.881 1.063 1.319 1.964  0.609 0.877 1.086 1.376 2.002 
(SE) (0.017) (0.011) (0.014) (0.017) (0.052)  (0.026) (0.012) (0.012) (0.024) (0.043) 
Sequential 0.660 0.881 1.063 1.316 1.961  0.613 0.881 1.086 1.383 2.026 
(SE) (0.017) (0.012) (0.014) (0.017) (0.053)  (0.025) (0.012) (0.012) (0.029) (0.049) 
Wide 0.662 0.881 1.063 1.317 1.962  0.626 0.882 1.088 1.386 2.046 




Table G1-6. Observed and imputed percentiles of Cystatin C by year and imputation approach (females) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.625 0.797 0.946 1.169 1.809  0.629 0.797 0.944 1.161 1.780 
(SE) (0.010) (0.005) (0.007) (0.011) (0.031)  (0.010) (0.005) (0.007) (0.012) (0.030) 
Cross-sectional 0.641 0.838 0.969 1.237 1.867  0.580 0.839 0.987 1.277 1.916 
(SE) (0.016) (0.015) (0.014) (0.017) (0.039)  (0.014) (0.015) (0.025) (0.025) (0.030) 
Sequential 0.648 0.834 0.969 1.238 1.875  0.582 0.839 1.007 1.289 1.924 
(SE) (0.018) (0.015) (0.014) (0.017) (0.039)  (0.016) (0.015) (0.023) (0.022) (0.032) 
Wide 0.647 0.836 0.969 1.235 1.853  0.583 0.839 0.970 1.240 1.874 
(SE) (0.017) (0.015) (0.014) (0.017) (0.038)  (0.017) (0.015) (0.015) (0.017) (0.035) 
2010            
Observed 0.642 0.847 1.024 1.280 1.978  0.640 0.846 1.022 1.276 1.967 
(SE) (0.009) (0.006) (0.007) (0.012) (0.035)  (0.010) (0.007) (0.009) (0.015) (0.053) 
Cross-sectional 0.640 0.848 1.027 1.289 1.978  0.583 0.848 1.048 1.344 1.987 
(SE) (0.010) (0.007) (0.009) (0.015) (0.051)  (0.017) (0.008) (0.008) (0.016) (0.038) 
Sequential 0.640 0.847 1.026 1.288 1.979  0.589 0.849 1.049 1.348 2.004 
(SE) (0.010) (0.007) (0.009) (0.015) (0.050)  (0.021) (0.009) (0.010) (0.018) (0.039) 
Wide 0.640 0.847 1.027 1.288 1.977  0.601 0.849 1.048 1.341 2.008 
(SE) (0.011) (0.007) (0.009) (0.015) (0.052)  (0.018) (0.008) (0.009) (0.019) (0.039) 
2014            
Observed 0.673 0.897 1.079 1.355 2.012  0.672 0.896 1.079 1.355 2.012 
(SE) (0.010) (0.006) (0.008) (0.016) (0.063)  (0.011) (0.006) (0.008) (0.015) (0.061) 
Cross-sectional 0.669 0.898 1.084 1.359 2.013  0.627 0.896 1.102 1.409 2.085 
(SE) (0.010) (0.007) (0.010) (0.016) (0.061)  (0.021) (0.006) (0.010) (0.016) (0.047) 
Sequential 0.670 0.898 1.081 1.359 2.015  0.633 0.903 1.104 1.414 2.088 
(SE) (0.011) (0.006) (0.009) (0.015) (0.061)  (0.019) (0.007) (0.009) (0.017) (0.049) 
Wide 0.668 0.899 1.081 1.360 2.013  0.631 0.899 1.104 1.409 2.115 





Figure G1-2. Distribution of Cystatin C comparing gender by year, analysis weight, and imputation approach. Ends of whisker plot 
represent 5th and 95th percentiles corresponding with values in Table G1-5 and G1-6. Black squares represent means. 
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Table G1-7. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach (males) 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 2,436 0.559 0.0303 0.0542 6.3%  2,460 0.567 0.0309 0.0546 26.9% 
Cross-sectional 2,601 0.559 0.0290 0.0519 3.9%  3,365 0.579 0.0316 0.0546 26.5% 
Sequential 2,601 0.562 0.0287 0.0510 6.0%  3,365 0.582 0.0305 0.0525 23.7% 
Wide 2,601 0.567 0.0292 0.0515 3.5%  3,365 0.602 0.0300 0.0498 25.0% 
2010            
Observed 2,066 0.496 0.0351 0.0708 4.3%  2,066 0.490 0.0365 0.0746 24.5% 
Cross-sectional 2,159 0.496 0.0347 0.0699 4.6%  2,737 0.514 0.0323 0.0629 14.2% 
Sequential 2,159 0.495 0.0337 0.0681 1.6%  2,737 0.502 0.0335 0.0668 16.5% 
Wide 2,159 0.490 0.0341 0.0695 1.1%  2,737 0.508 0.0355 0.0699 15.6% 
2014            
Observed 1,743 0.134 0.0399 0.2971 1.7%  1,743 0.137 0.0412 0.3019 19.2% 
Cross-sectional 1,774 0.141 0.0398 0.2832 0.8%  2,158 0.168 0.0405 0.2402 22.3% 
Sequential 1,774 0.133 0.0397 0.2973 0.4%  2,158 0.164 0.0418 0.2558 16.7% 
Wide 1,774 0.136 0.0396 0.2923 1.1%   2,158 0.174 0.0397 0.2281 12.0% 




Table G1-8. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach (females) 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 3,381 0.852 0.0242 0.0284 6.1%  3,414 0.848 0.0247 0.0291 25.6% 
Cross-sectional 3,602 0.854 0.0232 0.0272 4.9%  4,589 0.860 0.0216 0.0252 7.6% 
Sequential 3,602 0.854 0.0235 0.0276 1.7%  4,589 0.858 0.0243 0.0283 19.2% 
Wide 3,602 0.844 0.0229 0.0272 3.8%  4,589 0.823 0.0215 0.0262 11.8% 
2010            
Observed 2,987 0.614 0.0226 0.0368 2.7%  2,987 0.607 0.0224 0.0369 23.3% 
Cross-sectional 3,069 0.611 0.0226 0.0370 0.9%  3,894 0.609 0.0221 0.0363 17.6% 
Sequential 3,069 0.613 0.0228 0.0372 1.4%  3,894 0.610 0.0228 0.0373 24.6% 
Wide 3,069 0.615 0.0226 0.0368 0.8%  3,894 0.621 0.0238 0.0383 39.7% 
2014            
Observed 2,592 0.346 0.0328 0.0949 1.8%  2,592 0.350 0.0342 0.0978 20.2% 
Cross-sectional 2,639 0.341 0.0331 0.0970 1.2%  3,248 0.326 0.0351 0.1075 27.7% 
Sequential 2,639 0.345 0.0330 0.0956 0.6%  3,248 0.338 0.0324 0.0961 13.1% 
Wide 2,639 0.345 0.0335 0.0973 2.4%   3,248 0.341 0.0333 0.0976 17.6% 




Table G1-9. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach (males) 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 2,436 0.314 0.0127 0.0403 6.3%  2,460 0.314 0.0129 0.0411 26.9% 
Cross-sectional 2,601 0.315 0.0122 0.0385 2.7%  3,365 0.324 0.0124 0.0382 23.8% 
Sequential 2,601 0.316 0.0125 0.0395 12.8%  3,365 0.323 0.0126 0.0390 26.0% 
Wide 2,601 0.318 0.0122 0.0384 4.8%  3,365 0.329 0.0120 0.0365 23.1% 
2010            
Observed 2,066 0.280 0.0109 0.0390 4.3%  2,066 0.276 0.0112 0.0406 24.5% 
Cross-sectional 2,159 0.282 0.0107 0.0382 4.0%  2,737 0.290 0.0103 0.0355 8.5% 
Sequential 2,159 0.281 0.0107 0.0380 1.7%  2,737 0.286 0.0110 0.0386 24.2% 
Wide 2,159 0.280 0.0107 0.0381 2.0%  2,737 0.288 0.0118 0.0410 26.9% 
2014            
Observed 1,743 0.257 0.0131 0.0509 1.7%  1,743 0.257 0.0134 0.0520 19.2% 
Cross-sectional 1,774 0.258 0.0132 0.0510 2.8%  2,158 0.262 0.0133 0.0507 24.1% 
Sequential 1,774 0.256 0.0130 0.0509 0.2%  2,158 0.261 0.0131 0.0503 13.3% 
Wide 1,774 0.257 0.0129 0.0502 0.6%   2,158 0.264 0.0134 0.0505 17.7% 




Table G1-10. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach (females) 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 3,381 0.437 0.0105 0.0241 6.1%  3,414 0.436 0.0108 0.0248 25.6% 
Cross-sectional 3,602 0.437 0.0101 0.0231 4.9%  4,589 0.436 0.0094 0.0215 7.4% 
Sequential 3,602 0.437 0.0100 0.0230 1.6%  4,589 0.436 0.0106 0.0242 21.5% 
Wide 3,602 0.434 0.0100 0.0231 3.1%  4,589 0.425 0.0093 0.0220 9.0% 
2010            
Observed 2,987 0.348 0.0086 0.0247 2.7%  2,987 0.345 0.0088 0.0255 23.3% 
Cross-sectional 3,069 0.346 0.0086 0.0248 1.8%  3,894 0.342 0.0098 0.0286 32.4% 
Sequential 3,069 0.347 0.0085 0.0246 1.5%  3,894 0.343 0.0089 0.0258 23.7% 
Wide 3,069 0.348 0.0086 0.0248 2.3%  3,894 0.349 0.0091 0.0260 32.0% 
2014            
Observed 2,592 0.305 0.0097 0.0319 1.8%  2,592 0.307 0.0100 0.0326 20.2% 
Cross-sectional 2,639 0.304 0.0098 0.0323 2.0%  3,248 0.299 0.0107 0.0358 30.4% 
Sequential 2,639 0.305 0.0098 0.0322 1.4%  3,248 0.302 0.0097 0.0323 13.7% 
Wide 2,639 0.305 0.0099 0.0324 2.1%   3,248 0.304 0.0104 0.0342 24.6% 






Figure G1-3. Proportion at risk for C-reactive protein by year, gender, analysis weight, and imputation approach. 95% confidence 




Table G1-11. Observed and imputed percentiles of CRP (natural log transform) by year and imputation approach (males) 
 Biomeasure weighted  Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.444 -0.227 0.478 1.338 2.612  -1.418 -0.221 0.483 1.327 2.615 
(SE) (0.057) (0.034) (0.039) (0.061) (0.075)  (0.049) (0.032) (0.039) (0.058) (0.072) 
Cross-sectional -1.449 -0.228 0.479 1.344 2.615  -1.411 -0.218 0.528 1.371 2.642 
(SE) (0.057) (0.034) (0.041) (0.058) (0.070)  (0.056) (0.036) (0.041) (0.053) (0.075) 
Sequential -1.437 -0.228 0.480 1.343 2.617  -1.400 -0.217 0.530 1.368 2.628 
(SE) (0.057) (0.034) (0.040) (0.057) (0.070)  (0.053) (0.038) (0.040) (0.049) (0.064) 
Wide -1.436 -0.223 0.483 1.356 2.618  -1.389 -0.193 0.544 1.393 2.661 
(SE) (0.053) (0.031) (0.039) (0.058) (0.069)  (0.052) (0.034) (0.044) (0.050) (0.063) 
2010            
Observed -1.358 -0.320 0.431 1.217 2.564  -1.354 -0.312 0.421 1.194 2.564 
(SE) (0.033) (0.047) (0.044) (0.043) (0.064)  (0.031) (0.046) (0.042) (0.045) (0.065) 
Cross-sectional -1.359 -0.318 0.434 1.220 2.564  -1.348 -0.289 0.449 1.253 2.573 
(SE) (0.033) (0.048) (0.041) (0.041) (0.063)  (0.040) (0.044) (0.038) (0.040) (0.068) 
Sequential -1.361 -0.318 0.433 1.218 2.562  -1.357 -0.301 0.449 1.234 2.555 
(SE) (0.035) (0.047) (0.041) (0.041) (0.063)  (0.043) (0.047) (0.040) (0.041) (0.063) 
Wide -1.366 -0.328 0.429 1.216 2.562  -1.351 -0.286 0.447 1.244 2.562 
(SE) (0.033) (0.047) (0.042) (0.042) (0.064)  (0.040) (0.046) (0.041) (0.046) (0.063) 
2014            
Observed -2.287 -0.886 0.096 1.134 2.584  -1.354 -0.312 0.421 1.194 2.564 
(SE) (0.132) (0.060) (0.046) (0.066) (0.098)  (0.031) (0.046) (0.042) (0.045) (0.065) 
Cross-sectional -2.284 -0.880 0.100 1.148 2.588  -1.348 -0.289 0.449 1.253 2.573 
(SE) (0.132) (0.059) (0.046) (0.066) (0.093)  (0.040) (0.044) (0.038) (0.040) (0.068) 
Sequential -2.283 -0.884 0.094 1.133 2.584  -1.357 -0.301 0.449 1.234 2.555 
(SE) (0.130) (0.059) (0.045) (0.065) (0.090)  (0.043) (0.047) (0.040) (0.041) (0.063) 
Wide -2.287 -0.885 0.098 1.137 2.586  -1.351 -0.286 0.447 1.244 2.562 




Table G1-12. Observed and imputed percentiles of CRP (natural log transform) by year and imputation approach (females) 
 Biomeasure weighted  Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.268 0.051 0.869 1.741 2.876  -1.267 0.050 0.869 1.722 2.869 
(SE) (0.067) (0.039) (0.034) (0.029) (0.035)  (0.067) (0.039) (0.034) (0.034) (0.041) 
Cross-sectional -1.257 0.051 0.868 1.738 2.878  -1.234 0.052 0.876 1.728 2.887 
(SE) (0.063) (0.039) (0.037) (0.031) (0.033)  (0.054) (0.039) (0.035) (0.028) (0.037) 
Sequential -1.258 0.050 0.867 1.734 2.879  -1.240 0.044 0.870 1.729 2.888 
(SE) (0.065) (0.040) (0.036) (0.030) (0.032)  (0.060) (0.042) (0.040) (0.032) (0.039) 
Wide -1.276 0.042 0.846 1.729 2.877  -1.283 0.005 0.835 1.703 2.859 
(SE) (0.067) (0.040) (0.038) (0.034) (0.036)  (0.068) (0.037) (0.031) (0.032) (0.039) 
2010            
Observed -1.460 -0.158 0.655 1.408 2.489  -1.462 -0.160 0.650 1.398 2.476 
(SE) (0.050) (0.036) (0.027) (0.034) (0.040)  (0.049) (0.036) (0.025) (0.034) (0.040) 
Cross-sectional -1.458 -0.160 0.653 1.405 2.484  -1.412 -0.166 0.645 1.403 2.493 
(SE) (0.053) (0.035) (0.027) (0.034) (0.037)  (0.057) (0.037) (0.026) (0.035) (0.040) 
Sequential -1.456 -0.160 0.655 1.407 2.489  -1.428 -0.174 0.646 1.409 2.500 
(SE) (0.051) (0.036) (0.027) (0.034) (0.039)  (0.052) (0.036) (0.026) (0.033) (0.042) 
Wide -1.458 -0.156 0.655 1.411 2.490  -1.415 -0.158 0.653 1.422 2.495 
(SE) (0.050) (0.036) (0.027) (0.034) (0.040)  (0.049) (0.039) (0.025) (0.034) (0.045) 
2014            
Observed -2.137 -0.590 0.389 1.327 2.649  -2.134 -0.586 0.388 1.333 2.658 
(SE) (0.069) (0.049) (0.041) (0.040) (0.071)  (0.074) (0.050) (0.043) (0.040) (0.058) 
Cross-sectional -2.135 -0.596 0.380 1.323 2.643  -2.113 -0.609 0.352 1.309 2.637 
(SE) (0.068) (0.050) (0.043) (0.038) (0.069)  (0.070) (0.049) (0.047) (0.042) (0.066) 
Sequential -2.132 -0.591 0.385 1.326 2.647  -2.093 -0.604 0.361 1.320 2.661 
(SE) (0.069) (0.050) (0.041) (0.039) (0.067)  (0.072) (0.048) (0.044) (0.038) (0.069) 
Wide -2.140 -0.593 0.386 1.326 2.652  -2.117 -0.597 0.372 1.329 2.658 




Figure G1-4. Distribution of C-reactive protein (natural log transform) comparing gender by year, analysis weight, and imputation 
approach. Ends of whisker plot represent 5th and 95th percentiles corresponding with values in Table G1-11 and G1-12. Black squares 
represent means.  
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G.2 Cross-sectional multivariate model by gender 
Table G2-1. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.051 (0.008)****  0.053 (0.007)****  0.053 (0.007)****  0.053 (0.007)**** 
Age (squared) -0.001 (0.001)  -0.001 (0.000)  -0.001 (0.000)  -0.001 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.614 (0.229)** -0.649 (0.223)** -0.649 (0.223)** -0.646 (0.223)** 
Non-Hispanic black -0.351 (0.192)  -0.386 (0.177)* -0.386 (0.176)* -0.380 (0.176)* 
Health conditions     
Hypertension  0.666 (0.116)****  0.661 (0.107)****  0.662 (0.107)****  0.660 (0.108)**** 
Diabetes  0.581 (0.140)***  0.572 (0.130)****  0.570 (0.131)****  0.565 (0.130)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.113 (0.152)  -0.125 (0.143)  -0.127 (0.142)  -0.128 (0.143)  
Obese (BMI > 30)                  -0.183 (0.170)  -0.079 (0.166)  -0.081 (0.164)  -0.082 (0.165)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.070 (0.238)   0.030 (0.225)   0.032 (0.225)   0.029 (0.226)  
Hardly ever/never   0.244 (0.178)   0.247 (0.166)   0.242 (0.166)   0.248 (0.168)  
Smoking status (ref: never smoked)    
Current smoker           0.298 (0.212)   0.287 (0.202)   0.287 (0.202)   0.283 (0.201)  
Former smoker            0.140 (0.151)   0.145 (0.147)   0.146 (0.147)   0.146 (0.147)  
Biomeasures     
ln(CRP)  0.036 (0.041)   0.024 (0.041)   0.025 (0.041)   0.024 (0.044)  
Cystatin C  0.482 (0.148)**  0.442 (0.138)**  0.441 (0.140)**  0.463 (0.145)** 
Intercept                           -2.013 (0.290)**** -1.989 (0.273)**** -1.986 (0.274)**** -2.009 (0.280)**** 
Note. Sample sizes: observed n = 2,384; imputed n = 2,601.  




Table G2-2. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.028 (0.006)****  0.031 (0.005)****  0.031 (0.005)****  0.031 (0.005)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.213 (0.195)  -0.262 (0.187)  -0.262 (0.187)  -0.260 (0.187)  
Non-Hispanic black -0.048 (0.147)  -0.061 (0.130)  -0.062 (0.129)  -0.058 (0.129)  
Health conditions     
Hypertension  0.794 (0.119)****  0.800 (0.111)****  0.798 (0.111)****  0.802 (0.111)**** 
Diabetes  0.585 (0.123)****  0.627 (0.108)****  0.624 (0.109)****  0.623 (0.110)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.223 (0.115)  -0.230 (0.106)* -0.230 (0.104)* -0.227 (0.107)* 
Obese (BMI > 30)                  -0.304 (0.153)  -0.298 (0.145)* -0.293 (0.144)* -0.286 (0.142)* 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.203 (0.254)   0.188 (0.219)   0.188 (0.219)   0.197 (0.220)  
Hardly ever/never   0.552 (0.186)**  0.556 (0.161)***  0.551 (0.161)***  0.556 (0.161)*** 
Smoking status (ref: never smoked)    
Current smoker           0.292 (0.177)   0.317 (0.167)   0.314 (0.166)   0.321 (0.166)  
Former smoker            0.230 (0.119)   0.259 (0.121)*  0.258 (0.121)*  0.259 (0.121)* 
Biomeasures     
ln(CRP)  0.031 (0.042)   0.019 (0.038)   0.024 (0.039)   0.016 (0.037)  
Cystatin C  0.404 (0.110)***  0.372 (0.103)***  0.370 (0.100)***  0.342 (0.103)*** 
Intercept                           -2.439 (0.149)**** -2.440 (0.141)**** -2.439 (0.139)**** -2.408 (0.143)**** 
Note. Sample sizes: observed n = 3,230; imputed n = 3,602.  




Table G2-3. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.050 (0.008)****  0.056 (0.006)****  0.056 (0.006)****  0.057 (0.006)**** 
Age (squared) -0.001 (0.001)  -0.001 (0.000)* -0.001 (0.000)* -0.001 (0.000)* 
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.804 (0.210)*** -0.820 (0.193)**** -0.825 (0.193)**** -0.814 (0.192)**** 
Non-Hispanic black -0.440 (0.193)* -0.417 (0.170)* -0.411 (0.168)* -0.398 (0.169)* 
Health conditions     
Hypertension  0.681 (0.120)****  0.659 (0.093)****  0.657 (0.093)****  0.658 (0.093)**** 
Diabetes  0.578 (0.137)****  0.505 (0.123)****  0.503 (0.123)****  0.495 (0.122)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.150 (0.152)  -0.166 (0.104)  -0.172 (0.105)  -0.156 (0.102)  
Obese (BMI > 30)                  -0.190 (0.171)  -0.144 (0.132)  -0.148 (0.129)  -0.125 (0.127)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.050 (0.237)   0.022 (0.212)   0.020 (0.210)   0.021 (0.212)  
Hardly ever/never   0.172 (0.188)   0.202 (0.141)   0.196 (0.143)   0.214 (0.142)  
Smoking status (ref: never smoked)    
Current smoker           0.243 (0.211)   0.167 (0.165)   0.172 (0.165)   0.182 (0.164)  
Former smoker            0.079 (0.142)   0.161 (0.106)   0.167 (0.106)   0.165 (0.106)  
Biomeasures     
ln(CRP)  0.044 (0.046)   0.042 (0.048)   0.033 (0.040)   0.026 (0.042)  
Cystatin C  0.552 (0.159)**  0.386 (0.132)**  0.442 (0.139)**  0.421 (0.129)** 
Intercept                           -2.054 (0.282)**** -1.803 (0.221)**** -1.857 (0.224)**** -1.848 (0.216)**** 
Note. Sample sizes: observed n = 2,406; imputed n = 3,365.  




Table G2-4. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.027 (0.006)****  0.036 (0.006)****  0.036 (0.006)****  0.037 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.274 (0.196)  -0.436 (0.156)** -0.436 (0.155)** -0.429 (0.156)** 
Non-Hispanic black -0.044 (0.147)  -0.155 (0.130)  -0.155 (0.130)  -0.149 (0.130)  
Health conditions     
Hypertension  0.766 (0.120)****  0.785 (0.092)****  0.784 (0.092)****  0.784 (0.092)**** 
Diabetes  0.529 (0.123)****  0.567 (0.096)****  0.565 (0.097)****  0.556 (0.096)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.168 (0.112)  -0.112 (0.083)  -0.115 (0.082)  -0.111 (0.084)  
Obese (BMI > 30)                  -0.259 (0.155)  -0.147 (0.116)  -0.150 (0.115)  -0.137 (0.115)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.123 (0.261)   0.139 (0.180)   0.140 (0.179)   0.154 (0.181)  
Hardly ever/never   0.575 (0.176)**  0.487 (0.151)**  0.486 (0.151)**  0.500 (0.151)*** 
Smoking status (ref: never smoked)    
Current smoker           0.279 (0.175)   0.310 (0.118)**  0.307 (0.117)**  0.315 (0.117)** 
Former smoker            0.224 (0.118)   0.224 (0.099)*  0.223 (0.098)*  0.223 (0.099)* 
Biomeasures     
ln(CRP)  0.024 (0.041)   0.016 (0.038)   0.029 (0.036)   0.019 (0.033)  
Cystatin C  0.373 (0.104)***  0.319 (0.095)**  0.303 (0.079)***  0.304 (0.082)*** 
Intercept                           -2.395 (0.144)**** -2.386 (0.134)**** -2.377 (0.123)**** -2.371 (0.125)**** 
Note. Sample sizes: observed n = 3,261; imputed n = 4,589.  






Figure G2-1. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2006 by imputation approach, analysis weight, and 
gender. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) 
and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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Table G2-5. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using biomeasure weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)   0.054 (0.007)****  0.052 (0.007)****  0.053 (0.007)****  0.052 (0.007)**** 
Age (squared)  -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.785 (0.284)** -0.885 (0.293)** -0.883 (0.292)** -0.884 (0.292)** 
Non-Hispanic black -0.788 (0.191)*** -0.760 (0.182)**** -0.746 (0.182)**** -0.749 (0.182)**** 
Health conditions     
Hypertension  0.502 (0.123)***  0.506 (0.122)****  0.504 (0.122)****  0.508 (0.122)**** 
Diabetes  0.655 (0.130)****  0.648 (0.126)****  0.650 (0.125)****  0.647 (0.126)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.037 (0.158)  -0.061 (0.151)  -0.057 (0.151)  -0.060 (0.150)  
Obese (BMI > 30)                   0.049 (0.171)   0.039 (0.166)   0.036 (0.165)   0.031 (0.166)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.100 (0.173)  -0.054 (0.180)  -0.055 (0.179)  -0.057 (0.180)  
Hardly ever/never   0.120 (0.193)   0.186 (0.187)   0.195 (0.186)   0.191 (0.186)  
Smoking status (ref: never smoked)    
Current smoker           0.147 (0.243)   0.099 (0.240)   0.098 (0.239)   0.090 (0.239)  
Former smoker            0.251 (0.123)*  0.251 (0.118)*  0.252 (0.117)*  0.249 (0.117)* 
Biomeasures     
ln(CRP)  0.026 (0.052)   0.021 (0.053)   0.024 (0.053)   0.030 (0.054)  
Cystatin C  0.428 (0.164)*  0.413 (0.159)**  0.406 (0.159)*  0.409 (0.161)* 
Intercept                           -1.769 (0.265)**** -1.744 (0.257)**** -1.738 (0.258)**** -1.738 (0.261)**** 
Note. Sample sizes: observed n = 2,049; imputed n = 2,159.  




Table G2-6. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using biomeasure weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.026 (0.006)****  0.028 (0.006)****  0.028 (0.006)****  0.028 (0.006)**** 
Age (squared)  0.000 (0.001)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.273 (0.222)  -0.239 (0.180)  -0.241 (0.179)  -0.241 (0.179)  
Non-Hispanic black -0.037 (0.138)  -0.037 (0.139)  -0.038 (0.138)  -0.042 (0.137)  
Health conditions     
Hypertension  0.865 (0.153)****  0.886 (0.149)****  0.884 (0.149)****  0.881 (0.149)**** 
Diabetes  0.565 (0.118)****  0.569 (0.113)****  0.567 (0.113)****  0.562 (0.112)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.129 (0.112)  -0.130 (0.113)  -0.139 (0.115)  -0.114 (0.109)  
Obese (BMI > 30)                  -0.159 (0.153)  -0.159 (0.153)  -0.158 (0.151)  -0.141 (0.151)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.235 (0.286)   0.172 (0.280)   0.180 (0.278)   0.170 (0.279)  
Hardly ever/never   0.380 (0.156)*  0.391 (0.149)**  0.383 (0.151)*  0.373 (0.150)* 
Smoking status (ref: never smoked)    
Current smoker           0.270 (0.206)   0.350 (0.202)   0.348 (0.202)   0.347 (0.202)  
Former smoker            0.345 (0.127)**  0.379 (0.124)**  0.381 (0.123)**  0.377 (0.123)** 
Biomeasures     
ln(CRP)  0.054 (0.041)   0.047 (0.039)   0.047 (0.040)   0.049 (0.040)  
Cystatin C  0.444 (0.129)**  0.429 (0.123)***  0.424 (0.122)***  0.431 (0.123)*** 
Intercept                           -2.567 (0.225)**** -2.561 (0.214)**** -2.553 (0.213)**** -2.568 (0.214)**** 
Note. Sample sizes: observed n = 2,909; imputed n = 3,069.  




Table G2-7. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using base weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.055 (0.007)****  0.055 (0.007)****  0.057 (0.007)****  0.057 (0.006)**** 
Age (squared)  -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.738 (0.300)* -0.763 (0.249)** -0.766 (0.250)** -0.763 (0.250)** 
Non-Hispanic black -0.810 (0.191)**** -0.739 (0.173)**** -0.731 (0.173)**** -0.726 (0.173)**** 
Health conditions     
Hypertension  0.518 (0.123)****  0.448 (0.116)***  0.447 (0.116)***  0.450 (0.117)*** 
Diabetes  0.662 (0.129)****  0.653 (0.116)****  0.652 (0.116)****  0.649 (0.117)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.084 (0.161)  -0.063 (0.138)  -0.063 (0.137)  -0.061 (0.136)  
Obese (BMI > 30)                   0.002 (0.176)   0.004 (0.169)  -0.001 (0.169)  -0.003 (0.168)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.134 (0.172)  -0.015 (0.157)  -0.013 (0.156)  -0.016 (0.156)  
Hardly ever/never   0.096 (0.195)   0.150 (0.174)   0.155 (0.175)   0.153 (0.174)  
Smoking status (ref: never smoked)    
Current smoker           0.182 (0.242)   0.149 (0.223)   0.144 (0.224)   0.141 (0.227)  
Former smoker            0.283 (0.123)*  0.270 (0.127)*  0.266 (0.127)*  0.267 (0.127)* 
Biomeasures     
ln(CRP)  0.025 (0.055)   0.026 (0.050)   0.041 (0.050)   0.040 (0.050)  
Cystatin C  0.422 (0.167)*  0.342 (0.133)*  0.279 (0.133)*  0.279 (0.127)* 
Intercept                           -1.722 (0.270)**** -1.632 (0.242)**** -1.560 (0.238)**** -1.561 (0.236)**** 
Note. Sample sizes: observed n = 2,049; imputed n = 2,737.  




Table G2-8. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using base weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.029 (0.006)****  0.030 (0.006)****  0.031 (0.005)****  0.031 (0.005)**** 
Age (squared)  0.000 (0.001)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.254 (0.229)  -0.309 (0.159)  -0.317 (0.159)* -0.322 (0.158)* 
Non-Hispanic black -0.056 (0.140)  -0.131 (0.126)  -0.136 (0.125)  -0.144 (0.124)  
Health conditions     
Hypertension  0.800 (0.152)****  0.867 (0.121)****  0.857 (0.121)****  0.858 (0.121)**** 
Diabetes  0.571 (0.117)****  0.503 (0.104)****  0.495 (0.104)****  0.490 (0.103)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.138 (0.111)  -0.117 (0.093)  -0.123 (0.096)  -0.117 (0.091)  
Obese (BMI > 30)                  -0.147 (0.151)  -0.141 (0.129)  -0.128 (0.126)  -0.131 (0.122)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.207 (0.290)   0.192 (0.210)   0.195 (0.209)   0.184 (0.211)  
Hardly ever/never   0.341 (0.155)*  0.384 (0.126)**  0.375 (0.128)**  0.375 (0.129)** 
Smoking status (ref: never smoked)    
Current smoker           0.266 (0.206)   0.349 (0.169)*  0.349 (0.169)*  0.340 (0.168)* 
Former smoker            0.366 (0.123)**  0.330 (0.098)***  0.330 (0.097)***  0.325 (0.097)*** 
Biomeasures     
ln(CRP)  0.060 (0.042)   0.050 (0.044)   0.047 (0.046)   0.069 (0.042)  
Cystatin C  0.475 (0.124)***  0.376 (0.103)***  0.387 (0.104)***  0.377 (0.097)*** 
Intercept                           -2.547 (0.215)**** -2.461 (0.170)**** -2.469 (0.170)**** -2.467 (0.163)**** 
Note. Sample sizes: observed n = 2,909; imputed n = 3,894.  






Figure G2-2. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2010 by imputation approach, analysis weight, and 
gender. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) 
and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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Table G2-9. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using biomeasure weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)   0.053 (0.009)****  0.051 (0.009)****  0.051 (0.009)****  0.051 (0.009)**** 
Age (squared)  -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.959 (0.270)*** -0.952 (0.263)*** -0.955 (0.263)*** -0.951 (0.263)*** 
Non-Hispanic black -0.495 (0.200)* -0.558 (0.206)** -0.559 (0.206)** -0.560 (0.206)** 
Health conditions     
Hypertension  0.431 (0.153)**  0.432 (0.151)**  0.435 (0.151)**  0.434 (0.151)** 
Diabetes  0.458 (0.170)**  0.478 (0.167)**  0.479 (0.167)**  0.480 (0.167)** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.262 (0.155)  -0.263 (0.151)  -0.272 (0.151)  -0.270 (0.151)  
Obese (BMI > 30)                  -0.139 (0.188)  -0.134 (0.189)  -0.140 (0.188)  -0.142 (0.189)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.035 (0.194)  -0.046 (0.190)  -0.045 (0.190)  -0.044 (0.190)  
Hardly ever/never   0.281 (0.181)   0.281 (0.179)   0.284 (0.179)   0.281 (0.179)  
Smoking status (ref: never smoked)    
Current smoker          -0.027 (0.230)  -0.022 (0.231)  -0.023 (0.230)  -0.026 (0.231)  
Former smoker            0.155 (0.132)   0.151 (0.130)   0.154 (0.130)   0.151 (0.130)  
Biomeasures     
ln(CRP)  0.010 (0.050)   0.011 (0.050)   0.009 (0.050)   0.015 (0.050)  
Cystatin C  0.345 (0.185)   0.362 (0.187)   0.362 (0.187)   0.357 (0.185)  
Intercept                           -1.184 (0.239)**** -1.203 (0.242)**** -1.199 (0.241)**** -1.193 (0.240)**** 
Note. Sample sizes: observed n = 1,726; imputed n = 1,774.  




Table G2-10. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using biomeasure weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.026 (0.007)***  0.030 (0.006)****  0.030 (0.006)****  0.030 (0.006)**** 
Age (squared)  0.001 (0.001)   0.001 (0.001)   0.001 (0.001)   0.001 (0.001)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.094 (0.241)  -0.133 (0.240)  -0.134 (0.240)  -0.134 (0.240)  
Non-Hispanic black  0.064 (0.123)   0.054 (0.149)   0.052 (0.150)   0.055 (0.150)  
Health conditions     
Hypertension  0.759 (0.143)****  0.768 (0.136)****  0.758 (0.134)****  0.758 (0.134)**** 
Diabetes  0.529 (0.113)****  0.528 (0.110)****  0.527 (0.109)****  0.527 (0.109)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.117 (0.137)   0.019 (0.135)   0.014 (0.137)   0.013 (0.138)  
Obese (BMI > 30)                   0.046 (0.137)  -0.116 (0.136)  -0.114 (0.133)  -0.114 (0.135)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.640 (0.184)**  0.606 (0.164)***  0.603 (0.165)***  0.612 (0.163)*** 
Hardly ever/never   0.399 (0.217)   0.388 (0.206)   0.385 (0.206)   0.384 (0.206)  
Smoking status (ref: never smoked)    
Current smoker           0.431 (0.228)   0.428 (0.221)   0.435 (0.220)*  0.427 (0.219)  
Former smoker            0.368 (0.115)**  0.386 (0.110)***  0.382 (0.110)***  0.382 (0.109)*** 
Biomeasures     
ln(CRP)  0.021 (0.046)   0.018 (0.045)   0.018 (0.044)   0.020 (0.045)  
Cystatin C  0.566 (0.113)****  0.498 (0.097)****  0.506 (0.099)****  0.501 (0.099)**** 
Intercept                           -2.701 (0.178)**** -2.581 (0.170)**** -2.583 (0.167)**** -2.575 (0.167)**** 
Note. Sample sizes: observed n = 2,530; imputed n = 2,639.  




Table G2-11. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using base weights (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.053 (0.009)****  0.054 (0.008)****  0.053 (0.008)****  0.054 (0.008)**** 
Age (squared)  -0.001 (0.001)  -0.001 (0.001)  -0.001 (0.001)  -0.001 (0.001)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.925 (0.256)*** -0.851 (0.205)**** -0.839 (0.205)**** -0.835 (0.206)**** 
Non-Hispanic black -0.505 (0.205)* -0.573 (0.172)*** -0.571 (0.172)*** -0.573 (0.173)*** 
Health conditions     
Hypertension  0.406 (0.154)*  0.367 (0.134)**  0.357 (0.135)**  0.355 (0.134)** 
Diabetes  0.489 (0.171)**  0.497 (0.142)***  0.501 (0.143)***  0.499 (0.142)*** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.272 (0.154)  -0.271 (0.120)* -0.286 (0.122)* -0.280 (0.121)* 
Obese (BMI > 30)                  -0.164 (0.189)  -0.160 (0.167)  -0.186 (0.168)  -0.168 (0.167)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.047 (0.189)   0.060 (0.166)   0.064 (0.165)   0.067 (0.165)  
Hardly ever/never   0.252 (0.187)   0.279 (0.152)   0.279 (0.151)   0.277 (0.152)  
Smoking status (ref: never smoked)    
Current smoker          -0.040 (0.227)   0.251 (0.235)   0.242 (0.233)   0.256 (0.233)  
Former smoker            0.192 (0.137)   0.279 (0.128)*  0.282 (0.127)*  0.286 (0.127)* 
Biomeasures     
ln(CRP)  0.010 (0.052)   0.002 (0.049)   0.018 (0.049)   0.007 (0.050)  
Cystatin C  0.357 (0.188)   0.319 (0.163)   0.318 (0.160)*  0.329 (0.152)* 
Intercept                           -1.192 (0.237)**** -1.179 (0.240)**** -1.161 (0.235)**** -1.185 (0.232)**** 
Note. Sample sizes: observed n = 1,726; imputed n = 2,158.  




Table G2-12. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using base weights (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.028 (0.006)****  0.029 (0.006)****  0.029 (0.006)****  0.029 (0.006)**** 
Age (squared)  0.001 (0.001)*  0.001 (0.000)   0.001 (0.000)   0.001 (0.000)  
Race/ethnicity (ref: non-Hispanic other)    
Hispanic -0.094 (0.239)  -0.263 (0.207)  -0.266 (0.206)  -0.262 (0.206)  
Non-Hispanic black  0.095 (0.123)  -0.117 (0.126)  -0.113 (0.127)  -0.114 (0.127)  
Health conditions     
Hypertension  0.722 (0.147)****  0.791 (0.116)****  0.769 (0.117)****  0.772 (0.117)**** 
Diabetes  0.555 (0.117)****  0.518 (0.091)****  0.529 (0.091)****  0.532 (0.090)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30)  0.024 (0.138)  -0.081 (0.119)  -0.082 (0.118)  -0.084 (0.118)  
Obese (BMI > 30)                  -0.142 (0.134)  -0.101 (0.116)  -0.089 (0.114)  -0.101 (0.113)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.617 (0.184)**  0.667 (0.171)****  0.661 (0.173)***  0.668 (0.171)**** 
Hardly ever/never   0.415 (0.218)   0.276 (0.181)   0.296 (0.180)   0.295 (0.180)  
Smoking status (ref: never smoked)    
Current smoker           0.402 (0.226)   0.339 (0.174)   0.343 (0.172)*  0.337 (0.174)  
Former smoker            0.369 (0.117)**  0.300 (0.092)**  0.299 (0.092)**  0.299 (0.092)** 
Biomeasures     
ln(CRP)  0.029 (0.049)   0.024 (0.046)   0.013 (0.046)   0.018 (0.042)  
Cystatin C  0.571 (0.119)****  0.437 (0.093)****  0.450 (0.095)****  0.448 (0.095)**** 
Intercept                           -2.669 (0.186)**** -2.393 (0.167)**** -2.398 (0.163)**** -2.394 (0.163)**** 
Note. Sample sizes: observed n = 2,530; imputed n = 3,248.  






Figure G2-3. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2014 by imputation approach, analysis weight, and 
gender. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) 
and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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G.3 Longitudinal multivariate model by gender 
Table G3-1. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (biomeasure weight) (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.057 (0.017)**  0.058 (0.013)****  0.058 (0.013)****  0.058 (0.013)**** 
Age (squared) -0.002 (0.001)  0.000 (0.001)  0.000 (0.001)  0.000 (0.001) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.852 (0.520) -0.716 (0.405) -0.713 (0.402) -0.711 (0.405) 
Non-Hispanic black -0.691 (0.424) -0.410 (0.329) -0.409 (0.327) -0.404 (0.330) 
Health conditions     
High blood pressure (2006)  0.167 (0.242)  0.185 (0.226)  0.187 (0.224)  0.185 (0.228) 
Recent HBP diagnosis -0.117 (0.253)  0.022 (0.237)  0.022 (0.236)  0.015 (0.236) 
Diabetes (2006)  0.735 (0.266)**  0.777 (0.228)***  0.775 (0.228)***  0.778 (0.227)*** 
Recent diagnosis diabetes  0.028 (0.298)  0.149 (0.262)  0.150 (0.262)  0.148 (0.263) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.043 (0.308)  0.125 (0.232)  0.125 (0.232)  0.117 (0.231) 
Obese (2006)  0.101 (0.269)  0.168 (0.265)  0.158 (0.265)  0.142 (0.265) 
Decreased BMI category -0.193 (0.349)  0.070 (0.286)  0.056 (0.286)  0.049 (0.290) 
Increased BMI category  0.387 (0.266)  0.354 (0.274)  0.364 (0.273)  0.352 (0.275) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.336 (0.372) -0.649 (0.350) -0.649 (0.352) -0.646 (0.351) 
Hardly ever/never (2006) -0.219 (0.518) -0.547 (0.564) -0.545 (0.565) -0.555 (0.560) 
Decreased daily activity  0.265 (0.470)  0.475 (0.384)  0.472 (0.384)  0.483 (0.380) 
Increased daily activity -0.086 (0.238) -0.236 (0.216) -0.239 (0.215) -0.241 (0.213) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.127 (0.347)  0.256 (0.315)  0.252 (0.317)  0.240 (0.314) 
Former smoker (2006)  0.376 (0.198)  0.270 (0.190)  0.274 (0.190)  0.272 (0.190) 
Recently quit smoking  0.929 (0.476)  0.849 (0.387)*  0.851 (0.387)*  0.863 (0.390)* 
Recently started smoking  0.057 (1.016) -0.249 (1.038) -0.241 (1.034) -0.231 (1.032) 
Biomeasures     
ln(CRP) (2006)  0.041 (0.109)  0.053 (0.099)  0.057 (0.101)  0.083 (0.098) 
ln(CRP) change -0.094 (0.082) -0.051 (0.076) -0.053 (0.074) -0.068 (0.078) 
Cystatin C (2006)  0.511 (0.447)  0.401 (0.376)  0.441 (0.388)  0.394 (0.382) 
Cystatin C change  0.241 (0.246)  0.327 (0.224)  0.312 (0.220)  0.305 (0.241) 
Intercept -2.391 (0.502)**** -2.468 (0.445)**** -2.503 (0.457)**** -2.464 (0.426)**** 
Note. Sample sizes: 1,062 for observed, 1,355 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  
* = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001. 
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Table G3-2. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (biomeasure weight) (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.035 (0.012)**  0.036 (0.009)****  0.036 (0.009)****  0.037 (0.009)**** 
Age (squared)  0.002 (0.001)  0.001 (0.001)  0.001 (0.001)  0.001 (0.001) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.219 (0.304) -0.085 (0.272) -0.077 (0.272) -0.081 (0.274) 
Non-Hispanic black  0.302 (0.217)  0.050 (0.229)  0.047 (0.229)  0.055 (0.229) 
Health conditions     
High blood pressure (2006)  0.696 (0.300)*  0.744 (0.220)***  0.726 (0.219)***  0.726 (0.214)*** 
Recent HBP diagnosis  0.521 (0.310)  0.649 (0.255)*  0.621 (0.258)*  0.621 (0.256)* 
Diabetes (2006)  0.605 (0.238)*  0.444 (0.194)*  0.445 (0.196)*  0.433 (0.195)* 
Recent diagnosis diabetes  0.377 (0.284)  0.405 (0.217)  0.407 (0.218)  0.408 (0.215) 
BMI (ref: Under/normal weight)    
Overweight (2006) -0.027 (0.226) -0.075 (0.187) -0.076 (0.188) -0.062 (0.192) 
Obese (2006) -0.114 (0.213)  0.017 (0.213) -0.006 (0.216)  0.044 (0.223) 
Decreased BMI category -0.125 (0.304)  0.014 (0.252) -0.031 (0.257) -0.059 (0.271) 
Increased BMI category  0.017 (0.226) -0.027 (0.191) -0.043 (0.189) -0.001 (0.189) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006)  0.589 (0.558)  0.438 (0.509)  0.437 (0.502)  0.395 (0.501) 
Hardly ever/never (2006)  0.525 (0.572)  0.270 (0.454)  0.286 (0.457)  0.264 (0.458) 
Decreased daily activity -1.503 (0.644)* -0.949 (0.525) -0.978 (0.520) -0.918 (0.521) 
Increased daily activity  0.098 (0.285)  0.259 (0.275)  0.264 (0.276)  0.260 (0.277) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.319 (0.363)  0.349 (0.287)  0.373 (0.283)  0.358 (0.284) 
Former smoker (2006)  0.270 (0.161)  0.305 (0.132)*  0.302 (0.133)*  0.302 (0.131)* 
Recently quit smoking  0.436 (0.431)  0.557 (0.310)  0.512 (0.321)  0.547 (0.318) 
Recently started smoking -0.485 (0.876) -0.875 (0.797) -0.866 (0.800) -0.855 (0.796) 
Biomeasures     
log(CRP) (2006) -0.009 (0.085)  0.017 (0.071)  0.018 (0.080)  0.015 (0.069) 
log(CRP) change -0.035 (0.073) -0.013 (0.053) -0.010 (0.055)  0.000 (0.056) 
Cystatin C (2006)  0.834 (0.246)**  0.576 (0.213)**  0.627 (0.202)**  0.548 (0.184)** 
Cystatin C change  0.467 (0.170)**  0.380 (0.116)**  0.390 (0.118)**  0.365 (0.132)** 
Intercept -3.626 (0.329)**** -3.331 (0.269)**** -3.359 (0.258)**** -3.282 (0.231)**** 
Note. Sample sizes: 1,666 for observed, 2,190 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  




Table G3-3. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) (males) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.055 (0.018)**  0.055 (0.012)****  0.056 (0.012)****  0.056 (0.012)**** 
Age (squared) -0.002 (0.001) -0.001 (0.001) -0.001 (0.001) -0.001 (0.001) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.811 (0.504) -0.431 (0.308) -0.425 (0.307) -0.424 (0.312) 
Non-Hispanic black -0.670 (0.439) -0.397 (0.277) -0.400 (0.277) -0.397 (0.279) 
Health conditions     
High blood pressure (2006)  0.159 (0.248)  0.186 (0.210)  0.185 (0.206)  0.186 (0.207) 
Recent HBP diagnosis -0.146 (0.260)  0.016 (0.189) -0.007 (0.187) -0.015 (0.187) 
Diabetes (2006)  0.727 (0.270)**  0.687 (0.215)**  0.692 (0.214)**  0.688 (0.214)** 
Recent diagnosis diabetes  0.021 (0.293)  0.107 (0.258)  0.113 (0.258)  0.107 (0.260) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.021 (0.300)  0.036 (0.223)  0.025 (0.226)  0.025 (0.224) 
Obese (2006)  0.106 (0.261) -0.017 (0.242) -0.047 (0.241) -0.038 (0.238) 
Decreased BMI category -0.222 (0.349)  0.076 (0.289)  0.073 (0.287)  0.079 (0.289) 
Increased BMI category  0.380 (0.258)  0.506 (0.256)*  0.544 (0.254)*  0.521 (0.255)* 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.275 (0.379) -0.577 (0.306) -0.575 (0.310) -0.577 (0.310) 
Hardly ever/never (2006) -0.204 (0.528) -0.509 (0.472) -0.502 (0.472) -0.513 (0.472) 
Decreased daily activity  0.257 (0.474)  0.429 (0.322)  0.414 (0.320)  0.426 (0.320) 
Increased daily activity -0.120 (0.240) -0.032 (0.199) -0.026 (0.198) -0.029 (0.198) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.114 (0.351)  0.551 (0.339)  0.545 (0.337)  0.555 (0.338) 
Former smoker (2006)  0.395 (0.204)  0.359 (0.184)  0.362 (0.184)*  0.365 (0.183)* 
Recently quit smoking  0.909 (0.474)  0.576 (0.365)  0.579 (0.363)  0.587 (0.367) 
Recently started smoking  0.074 (1.011) -0.643 (1.035) -0.653 (1.040) -0.626 (1.033) 
Biomeasures     
ln(CRP) (2006)  0.050 (0.109)  0.020 (0.108)  0.054 (0.095)  0.056 (0.093) 
ln(CRP) change -0.113 (0.085) -0.042 (0.077) -0.033 (0.076) -0.058 (0.078) 
Cystatin C (2006)  0.471 (0.456)  0.489 (0.333)  0.383 (0.358)  0.337 (0.313) 
Cystatin C change  0.271 (0.252)  0.275 (0.199)  0.262 (0.199)  0.289 (0.228) 
Intercept -2.371 (0.501)**** -2.470 (0.401)**** -2.359 (0.421)**** -2.333 (0.359)**** 
Note. Sample sizes: 1,062 for observed, 1,656 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  




Table G3-4. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) (females) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.036 (0.011)**  0.033 (0.007)****  0.034 (0.007)****  0.035 (0.007)**** 
Age (squared)  0.002 (0.001)*  0.000 (0.001)  0.000 (0.001)  0.000 (0.001) 
Race/ethnicity (ref: Non-Hispanic other)    
Hispanic -0.223 (0.310) -0.252 (0.235) -0.244 (0.236) -0.245 (0.237) 
Non-Hispanic black  0.272 (0.221) -0.193 (0.209) -0.185 (0.209) -0.185 (0.208) 
Health conditions     
High blood pressure (2006)  0.680 (0.308)*  0.809 (0.182)****  0.790 (0.182)****  0.794 (0.181)**** 
Recent HBP diagnosis  0.469 (0.308)  0.868 (0.224)***  0.832 (0.228)***  0.836 (0.227)*** 
Diabetes (2006)  0.595 (0.242)*  0.410 (0.181)*  0.411 (0.184)*  0.409 (0.182)* 
Recent diagnosis diabetes  0.451 (0.298)  0.472 (0.195)*  0.482 (0.194)*  0.486 (0.189)* 
BMI (ref: Under/normal weight)    
Overweight (2006) -0.028 (0.225) -0.199 (0.155) -0.167 (0.155) -0.192 (0.155) 
Obese (2006) -0.105 (0.212) -0.081 (0.191) -0.063 (0.195) -0.052 (0.195) 
Decreased BMI category -0.155 (0.298) -0.022 (0.220) -0.049 (0.222) -0.067 (0.233) 
Increased BMI category  0.008 (0.223)  0.149 (0.184)  0.131 (0.177)  0.170 (0.179) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006)  0.633 (0.579)  0.042 (0.447)  0.022 (0.443) -0.008 (0.437) 
Hardly ever/never (2006)  0.544 (0.583)  0.126 (0.420)  0.134 (0.427)  0.143 (0.422) 
Decreased daily activity -1.589 (0.665)* -0.870 (0.493) -0.877 (0.495) -0.837 (0.488) 
Increased daily activity  0.126 (0.289)  0.326 (0.222)  0.337 (0.219)  0.333 (0.222) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.306 (0.352)  0.250 (0.191)  0.270 (0.189)  0.269 (0.189) 
Former smoker (2006)  0.260 (0.160)  0.184 (0.125)  0.183 (0.125)  0.185 (0.124) 
Recently quit smoking  0.585 (0.455)  0.610 (0.269)*  0.596 (0.276)*  0.613 (0.270)* 
Recently started smoking -0.377 (0.880) -0.774 (0.782) -0.746 (0.783) -0.744 (0.778) 
Biomeasures     
log(CRP) (2006)  0.014 (0.087)  0.058 (0.077)  0.044 (0.079)  0.056 (0.067) 
log(CRP) change -0.035 (0.074) -0.008 (0.062) -0.028 (0.060) -0.019 (0.060) 
Cystatin C (2006)  0.832 (0.247)**  0.583 (0.201)**  0.571 (0.204)**  0.495 (0.158)** 
Cystatin C change  0.479 (0.174)**  0.343 (0.130)**  0.384 (0.135)**  0.335 (0.139)* 
Intercept -3.615 (0.336)**** -3.252 (0.265)**** -3.248 (0.266)**** -3.155 (0.221)**** 
Note. Sample sizes: 1,666 for observed, 2,701 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.   




Figure G3-1. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting the 
development of cardiovascular disease by 2014 by imputation approach, analysis weight, and 
gender.  Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for ln(CRP) 





Figure G3-2. Odds ratios of change in Cystatin C and change in ln(CRP) in logistic regression 
model predicting the development of cardiovascular disease by 2014 by imputation approach, 
analysis weight, and gender. Odds ratio is based on 1 standard deviation change in each 







Race/ethnicity Subgroup Analyses 
The following sections include tables and figures to show the results of the subgroup analyses by 
race/ethnicity in conjunction with Section 4.3.6. Section H.1 reviews the univariate 
characteristics for Hispanics, non-Hispanic blacks, and non-Hispanic others like Sections 4.3.1 
and 4.3.2. Section H.2 includes the cross-sectional multivariate models covering Section 4.3.4 




H.1 Univariate characteristics by race/ethnicity 
Table H1-1. Observed and imputed means and standard errors of Cystatin C by year and imputation approach (non-Hispanic other) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 4,556 1.073 0.0079 0.0074 7.5%  4,603 1.068 0.0074 0.0070 25.5% 
Cross-sectional 4,926 1.078 0.0083 0.0077 4.5%  6,180 1.085 0.0079 0.0073 23.9% 
Sequential 4,926 1.078 0.0080 0.0074 3.7%  6,180 1.087 0.0078 0.0072 17.1% 
Wide 4,926 1.077 0.0081 0.0075 2.7%  6,180 1.082 0.0080 0.0073 20.4% 
2010            
Observed 4,011 1.126 0.0099 0.0088 2.8%  4,011 1.123 0.0094 0.0084 22.1% 
Cross-sectional 4,126 1.127 0.0098 0.0087 1.4%  5,152 1.131 0.0094 0.0083 16.7% 
Sequential 4,126 1.127 0.0098 0.0087 1.5%  5,152 1.135 0.0096 0.0085 17.9% 
Wide 4,126 1.126 0.0097 0.0087 1.8%  5,152 1.139 0.0095 0.0083 23.3% 
2014            
Observed 3,387 1.178 0.0107 0.0091 1.7%  3,387 1.177 0.0108 0.0091 19.1% 
Cross-sectional 3,446 1.179 0.0109 0.0092 3.9%  4,185 1.186 0.0113 0.0095 25.5% 
Sequential 3,446 1.178 0.0107 0.0091 0.9%  4,185 1.194 0.0109 0.0091 19.4% 
Wide 3,446 1.179 0.0107 0.0091 1.2%   4,185 1.197 0.0110 0.0092 18.6% 





Table H1-2. Observed and imputed means and standard errors of Cystatin C by year and imputation approach (non-Hispanic black) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 688 1.178 0.0298 0.0253 11.8%  692 1.155 0.0291 0.0252 38.9% 
Cross-sectional 780 1.172 0.0277 0.0236 5.4%  1,133 1.150 0.0255 0.0222 21.9% 
Sequential 780 1.170 0.0283 0.0242 10.7%  1,133 1.147 0.0249 0.0217 21.1% 
Wide 780 1.162 0.0268 0.0231 3.1%  1,133 1.125 0.0217 0.0193 13.6% 
2010            
Observed 668 1.229 0.0339 0.0276 5.4%  668 1.228 0.0351 0.0286 28.7% 
Cross-sectional 706 1.224 0.0337 0.0275 3.3%  937 1.216 0.0299 0.0246 9.7% 
Sequential 706 1.232 0.0333 0.0270 5.0%  937 1.229 0.0318 0.0259 25.7% 
Wide 706 1.231 0.0332 0.0270 3.4%  937 1.227 0.0313 0.0255 12.1% 
2014            
Observed 582 1.255 0.0356 0.0284 1.5%  582 1.260 0.0353 0.0280 23.8% 
Cross-sectional 591 1.254 0.0357 0.0285 2.4%  764 1.272 0.0324 0.0255 17.5% 
Sequential 591 1.257 0.0356 0.0283 1.5%  764 1.265 0.0331 0.0261 17.9% 
Wide 591 1.254 0.0355 0.0284 1.1%   764 1.269 0.0324 0.0255 6.2% 




Table H1-3. Observed and imputed means and standard errors of Cystatin C by year and imputation approach (Hispanic) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 480 1.058 0.0221 0.0209 3.4%  483 1.049 0.0181 0.0172 24.6% 
Cross-sectional 497 1.060 0.0229 0.0216 5.6%  641 1.071 0.0215 0.0200 19.2% 
Sequential 497 1.060 0.0228 0.0215 4.9%  641 1.080 0.0242 0.0224 36.3% 
Wide 497 1.056 0.0215 0.0203 3.6%  641 1.058 0.0214 0.0202 15.9% 
2010            
Observed 383 1.120 0.0311 0.0278 3.3%  383 1.111 0.0314 0.0282 29.3% 
Cross-sectional 396 1.121 0.0324 0.0289 8.4%  542 1.125 0.0323 0.0287 29.6% 
Sequential 396 1.119 0.0312 0.0279 5.8%  542 1.137 0.0316 0.0278 24.4% 
Wide 396 1.119 0.0304 0.0271 2.4%  542 1.135 0.0306 0.0269 21.5% 
2014            
Observed 373 1.268 0.0471 0.0372 0.8%  373 1.264 0.0442 0.0350 18.4% 
Cross-sectional 376 1.268 0.0468 0.0369 0.2%  457 1.270 0.0405 0.0319 9.2% 
Sequential 376 1.268 0.0468 0.0369 0.2%  457 1.263 0.0400 0.0316 7.5% 
Wide 376 1.266 0.0468 0.0370 0.1%   457 1.254 0.0387 0.0309 6.0% 
Note. FMI for observed is the missing rate. 
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Table H1-4. Observed and imputed at proportion at risk for Cystatin C by year and imputation approach (non-Hispanic other) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 4,556 0.088 0.0047 0.0541 7.5%  4,603 0.084 0.0046 0.0550 25.5% 
Cross-sectional 4,926 0.097 0.0051 0.0525 9.0%  6,180 0.117 0.0058 0.0494 37.8% 
Sequential 4,926 0.097 0.0050 0.0519 11.5%  6,180 0.117 0.0055 0.0466 20.0% 
Wide 4,926 0.094 0.0047 0.0499 4.7%  6,180 0.107 0.0054 0.0502 36.4% 
2010            
Observed 4,011 0.122 0.0065 0.0535 2.8%  4,011 0.120 0.0063 0.0524 22.1% 
Cross-sectional 4,126 0.125 0.0066 0.0527 2.6%  5,152 0.143 0.0065 0.0457 23.5% 
Sequential 4,126 0.124 0.0065 0.0526 1.7%  5,152 0.145 0.0070 0.0481 25.4% 
Wide 4,126 0.122 0.0065 0.0529 2.7%  5,152 0.144 0.0066 0.0457 21.0% 
2014            
Observed 3,387 0.140 0.0072 0.0518 1.7%  3,387 0.139 0.0074 0.0529 19.1% 
Cross-sectional 3,446 0.142 0.0073 0.0514 3.7%  4,185 0.164 0.0073 0.0445 12.6% 
Sequential 3,446 0.141 0.0072 0.0511 1.2%  4,185 0.168 0.0075 0.0447 14.8% 
Wide 3,446 0.141 0.0072 0.0513 0.9%   4,185 0.169 0.0075 0.0445 15.4% 




Table H1-5. Observed and imputed at proportion at risk for Cystatin C by year and imputation approach (non-Hispanic black) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 688 0.138 0.0175 0.1269 11.8%  692 0.126 0.0152 0.1208 38.9% 
Cross-sectional 780 0.147 0.0174 0.1180 10.5%  1,133 0.162 0.0166 0.1024 27.5% 
Sequential 780 0.142 0.0165 0.1158 6.6%  1,133 0.157 0.0158 0.1005 30.8% 
Wide 780 0.138 0.0170 0.1238 13.1%  1,133 0.138 0.0150 0.1082 38.8% 
2010            
Observed 668 0.186 0.0199 0.1068 5.4%  668 0.186 0.0214 0.1148 28.7% 
Cross-sectional 706 0.188 0.0207 0.1103 7.9%  937 0.201 0.0202 0.1005 19.3% 
Sequential 706 0.193 0.0203 0.1050 13.3%  937 0.211 0.0227 0.1075 40.2% 
Wide 706 0.193 0.0203 0.1050 8.5%  937 0.204 0.0204 0.0997 18.6% 
2014            
Observed 582 0.193 0.0197 0.1020 1.5%  582 0.197 0.0205 0.1043 23.8% 
Cross-sectional 591 0.193 0.0197 0.1021 1.8%  764 0.230 0.0194 0.0844 12.6% 
Sequential 591 0.196 0.0204 0.1042 5.9%  764 0.224 0.0213 0.0952 19.7% 
Wide 591 0.194 0.0201 0.1040 4.5%   764 0.227 0.0239 0.1053 27.6% 




Table H1-6. Observed and imputed at proportion at risk for Cystatin C by year and imputation approach (Hispanic) 
 Biomeasure weighted  Base weighted 
Proportion at risk (> 1.55 mg/L) n Prop. SE CV FMI   n Prop. SE CV FMI 
2006            
Observed 480 0.077 0.0125 0.1615 3.4%  483 0.075 0.0101 0.1350 24.6% 
Cross-sectional 497 0.082 0.0140 0.1708 15.9%  641 0.109 0.0139 0.1271 38.4% 
Sequential 497 0.081 0.0134 0.1654 8.8%  641 0.112 0.0129 0.1154 35.7% 
Wide 497 0.078 0.0125 0.1604 6.1%  641 0.093 0.0126 0.1358 13.5% 
2010            
Observed 383 0.111 0.0188 0.1695 3.3%  383 0.107 0.0198 0.1844 29.3% 
Cross-sectional 396 0.117 0.0201 0.1720 11.2%  542 0.142 0.0217 0.1530 45.5% 
Sequential 396 0.114 0.0196 0.1721 13.4%  542 0.149 0.0237 0.1584 30.6% 
Wide 396 0.111 0.0186 0.1677 4.2%  542 0.138 0.0216 0.1567 25.9% 
2014            
Observed 373 0.174 0.0189 0.1085 0.8%  373 0.170 0.0178 0.1043 18.4% 
Cross-sectional 376 0.175 0.0189 0.1078 1.1%  457 0.200 0.0218 0.1094 26.6% 
Sequential 376 0.174 0.0189 0.1085 1.1%  457 0.186 0.0207 0.1110 29.0% 
Wide 376 0.174 0.0189 0.1088 0.6%   457 0.185 0.0186 0.1003 17.2% 






Figure H1-1. Proportion at risk for Cystatin C by year, race/ethnicity, analysis weight, and imputation approach. 95% confidence 




Table H1-7. Observed and imputed percentiles of Cystatin C by year and imputation approach (non-Hispanic other) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.650 0.810 0.949 1.154 1.723  0.651 0.810 0.949 1.151 1.700 
(SE) (0.008) (0.005) (0.006) (0.009) (0.033)  (0.008) (0.005) (0.006) (0.009) (0.033) 
Cross-sectional 0.647 0.837 0.969 1.221 1.794  0.579 0.839 0.982 1.240 1.853 
(SE) (0.016) (0.014) (0.014) (0.026) (0.037)  (0.015) (0.015) (0.027) (0.017) (0.032) 
Sequential 0.649 0.837 0.969 1.223 1.794  0.580 0.840 0.996 1.240 1.855 
(SE) (0.018) (0.014) (0.014) (0.026) (0.038)  (0.015) (0.015) (0.026) (0.017) (0.034) 
Wide 0.649 0.838 0.969 1.178 1.770  0.599 0.840 0.974 1.240 1.820 
(SE) (0.017) (0.015) (0.014) (0.021) (0.039)  (0.023) (0.015) (0.017) (0.016) (0.022) 
2010            
Observed 0.651 0.851 1.023 1.262 1.924  0.648 0.850 1.023 1.260 1.906 
(SE) (0.009) (0.006) (0.007) (0.013) (0.038)  (0.012) (0.007) (0.007) (0.011) (0.038) 
Cross-sectional 0.647 0.853 1.027 1.270 1.931  0.588 0.848 1.044 1.324 1.945 
(SE) (0.011) (0.007) (0.008) (0.013) (0.038)  (0.017) (0.008) (0.009) (0.015) (0.029) 
Sequential 0.647 0.851 1.026 1.269 1.925  0.593 0.850 1.047 1.325 1.960 
(SE) (0.011) (0.007) (0.008) (0.013) (0.037)  (0.016) (0.008) (0.008) (0.016) (0.031) 
Wide 0.647 0.853 1.027 1.267 1.921  0.609 0.852 1.048 1.324 1.966 
(SE) (0.011) (0.008) (0.008) (0.013) (0.038)  (0.017) (0.008) (0.008) (0.013) (0.031) 
2014            
Observed 0.673 0.890 1.070 1.330 1.928  0.671 0.889 1.069 1.331 1.924 
(SE) (0.009) (0.007) (0.008) (0.014) (0.039)  (0.009) (0.007) (0.008) (0.014) (0.038) 
Cross-sectional 0.670 0.891 1.073 1.337 1.935  0.623 0.890 1.090 1.384 2.004 
(SE) (0.009) (0.007) (0.009) (0.014) (0.039)  (0.021) (0.010) (0.010) (0.015) (0.040) 
Sequential 0.670 0.891 1.073 1.334 1.932  0.631 0.894 1.091 1.390 2.024 
(SE) (0.009) (0.007) (0.009) (0.014) (0.039)  (0.017) (0.009) (0.010) (0.014) (0.039) 
Wide 0.670 0.891 1.073 1.336 1.934  0.633 0.894 1.093 1.390 2.050 




Table H1-8. Observed and imputed percentiles of Cystatin C by year and imputation approach (non-Hispanic black) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.609 0.789 0.965 1.213 1.988  0.613 0.792 0.962 1.203 1.907 
(SE) (0.023) (0.011) (0.016) (0.027) (0.183)  (0.019) (0.011) (0.014) (0.025) (0.129) 
Cross-sectional 0.596 0.814 0.988 1.248 1.998  0.515 0.812 1.036 1.328 1.970 
(SE) (0.039) (0.026) (0.029) (0.030) (0.125)  (0.048) (0.031) (0.019) (0.046) (0.063) 
Sequential 0.623 0.811 1.010 1.238 1.980  0.507 0.815 1.038 1.318 1.965 
(SE) (0.035) (0.020) (0.032) (0.021) (0.126)  (0.059) (0.028) (0.017) (0.041) (0.057) 
Wide 0.607 0.793 0.970 1.235 1.955  0.515 0.789 1.028 1.281 1.909 
(SE) (0.044) (0.027) (0.016) (0.020) (0.120)  (0.056) (0.023) (0.020) (0.034) (0.061) 
2010            
Observed 0.646 0.840 1.067 1.414 2.148  0.649 0.840 1.066 1.415 2.146 
(SE) (0.024) (0.018) (0.024) (0.046) (0.170)  (0.024) (0.018) (0.025) (0.048) (0.189) 
Cross-sectional 0.629 0.840 1.071 1.415 2.145  0.566 0.840 1.089 1.451 2.113 
(SE) (0.031) (0.018) (0.025) (0.046) (0.162)  (0.039) (0.020) (0.023) (0.043) (0.093) 
Sequential 0.633 0.842 1.073 1.429 2.153  0.576 0.844 1.101 1.484 2.155 
(SE) (0.029) (0.017) (0.024) (0.045) (0.135)  (0.042) (0.021) (0.025) (0.050) (0.092) 
Wide 0.629 0.841 1.071 1.423 2.160  0.574 0.841 1.090 1.469 2.158 
(SE) (0.028) (0.017) (0.025) (0.044) (0.133)  (0.045) (0.022) (0.025) (0.040) (0.098) 
2014            
Observed 0.618 0.861 1.075 1.409 2.256  0.619 0.860 1.079 1.415 2.268 
(SE) (0.027) (0.014) (0.020) (0.035) (0.147)  (0.027) (0.014) (0.025) (0.036) (0.149) 
Cross-sectional 0.615 0.862 1.079 1.413 2.253  0.579 0.872 1.129 1.498 2.265 
(SE) (0.028) (0.017) (0.024) (0.036) (0.110)  (0.043) (0.019) (0.032) (0.052) (0.085) 
Sequential 0.617 0.864 1.078 1.419 2.257  0.579 0.867 1.124 1.490 2.262 
(SE) (0.027) (0.015) (0.022) (0.041) (0.122)  (0.030) (0.020) (0.035) (0.051) (0.093) 
Wide 0.616 0.862 1.077 1.411 2.253  0.578 0.864 1.124 1.492 2.287 




Table H1-9. Observed and imputed percentiles of Cystatin C by year and imputation approach (Hispanic) 
 Biomeasure weighted  Base weighted 
Cystatin C (mg/L) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed 0.621 0.770 0.895 1.060 1.804  0.625 0.769 0.897 1.058 1.730 
(SE) (0.021) (0.012) (0.011) (0.018) (0.126)  (0.020) (0.011) (0.011) (0.016) (0.104) 
Cross-sectional 0.624 0.771 0.902 1.085 1.837  0.590 0.778 0.945 1.167 1.916 
(SE) (0.025) (0.013) (0.014) (0.027) (0.124)  (0.048) (0.017) (0.027) (0.015) (0.108) 
Sequential 0.621 0.772 0.899 1.085 1.821  0.616 0.788 0.962 1.167 1.947 
(SE) (0.024) (0.015) (0.011) (0.023) (0.126)  (0.052) (0.025) (0.016) (0.016) (0.118) 
Wide 0.624 0.773 0.901 1.083 1.789  0.611 0.780 0.946 1.144 1.822 
(SE) (0.022) (0.015) (0.014) (0.027) (0.121)  (0.050) (0.016) (0.028) (0.031) (0.108) 
2010            
Observed 0.612 0.837 1.024 1.241 1.786  0.609 0.835 1.019 1.227 1.769 
(SE) (0.020) (0.017) (0.025) (0.033) (0.139)  (0.018) (0.018) (0.026) (0.031) (0.077) 
Cross-sectional 0.603 0.836 1.025 1.250 1.817  0.541 0.831 1.044 1.316 1.887 
(SE) (0.027) (0.018) (0.027) (0.038) (0.130)  (0.062) (0.026) (0.032) (0.046) (0.081) 
Sequential 0.603 0.835 1.024 1.249 1.797  0.558 0.833 1.044 1.317 1.948 
(SE) (0.029) (0.017) (0.026) (0.036) (0.132)  (0.040) (0.022) (0.029) (0.044) (0.130) 
Wide 0.610 0.836 1.026 1.249 1.787  0.575 0.838 1.041 1.308 1.919 
(SE) (0.021) (0.016) (0.025) (0.034) (0.126)  (0.025) (0.021) (0.028) (0.047) (0.140) 
2014            
Observed 0.688 0.929 1.092 1.399 2.147  0.689 0.932 1.097 1.392 2.148 
(SE) (0.025) (0.021) (0.017) (0.032) (0.459)  (0.026) (0.021) (0.018) (0.031) (0.269) 
Cross-sectional 0.686 0.929 1.094 1.401 2.145  0.650 0.930 1.123 1.440 2.206 
(SE) (0.024) (0.022) (0.019) (0.033) (0.451)  (0.035) (0.023) (0.024) (0.041) (0.170) 
Sequential 0.686 0.929 1.096 1.403 2.145  0.647 0.928 1.114 1.429 2.221 
(SE) (0.025) (0.021) (0.019) (0.034) (0.452)  (0.037) (0.023) (0.021) (0.033) (0.204) 
Wide 0.683 0.928 1.093 1.399 2.145  0.631 0.923 1.112 1.420 2.181 





Figure H1-2. Distribution of Cystatin C comparing race/ethnicity by year, analysis weight, and imputation approach. Ends of whisker 
plot represent 5th and 95th percentiles corresponding with values in Table H1-7, H1-8, and H1-9. Black squares represent means. 
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Table H1-10. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach (non-Hispanic other) 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 4,633 0.667 0.0204 0.0306 5.9%  4,682 0.675 0.0216 0.0319 24.2% 
Cross-sectional 4,926 0.670 0.0197 0.0294 4.1%  6,180 0.691 0.0202 0.0293 11.7% 
Sequential 4,926 0.671 0.0199 0.0297 2.1%  6,180 0.690 0.0213 0.0309 16.5% 
Wide 4,926 0.667 0.0200 0.0300 6.8%  6,180 0.678 0.0219 0.0323 35.9% 
2010            
Observed 4,005 0.527 0.0221 0.0418 2.9%  4,005 0.523 0.0226 0.0432 22.3% 
Cross-sectional 4,126 0.525 0.0221 0.0421 1.8%  5,152 0.537 0.0214 0.0398 20.9% 
Sequential 4,126 0.526 0.0219 0.0415 1.9%  5,152 0.530 0.0239 0.0451 32.3% 
Wide 4,126 0.525 0.0218 0.0415 0.4%  5,152 0.538 0.0234 0.0434 22.9% 
2014            
Observed 3,382 0.211 0.0257 0.1215 1.9%  3,382 0.217 0.0273 0.1259 19.2% 
Cross-sectional 3,446 0.212 0.0263 0.1239 1.9%  4,185 0.224 0.0271 0.1213 20.8% 
Sequential 3,446 0.212 0.0257 0.1214 0.7%  4,185 0.225 0.0249 0.1106 3.1% 
Wide 3,446 0.212 0.0260 0.1226 2.4%   4,185 0.232 0.0268 0.1155 20.3% 




Table H1-11. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach (non-Hispanic black) 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 699 1.096 0.0696 0.0635 10.4%  704 1.084 0.0649 0.0599 37.9% 
Cross-sectional 780 1.063 0.0634 0.0597 2.0%  1,133 1.008 0.0577 0.0573 24.2% 
Sequential 780 1.075 0.0676 0.0629 8.1%  1,133 1.012 0.0593 0.0586 34.8% 
Wide 780 1.073 0.0643 0.0599 8.7%  1,133 1.007 0.0525 0.0521 21.0% 
2010            
Observed 665 0.874 0.0533 0.0610 5.8%  665 0.869 0.0519 0.0597 29.0% 
Cross-sectional 706 0.859 0.0541 0.0630 6.8%  937 0.818 0.0500 0.0611 19.7% 
Sequential 706 0.856 0.0539 0.0629 7.6%  937 0.827 0.0502 0.0608 22.1% 
Wide 706 0.860 0.0536 0.0624 4.5%  937 0.844 0.0545 0.0646 26.7% 
2014            
Observed 580 0.639 0.0742 0.1161 1.9%  580 0.634 0.0746 0.1177 24.1% 
Cross-sectional 591 0.628 0.0734 0.1168 2.3%  764 0.569 0.0742 0.1304 19.9% 
Sequential 591 0.626 0.0720 0.1151 1.8%  764 0.602 0.0684 0.1136 12.9% 
Wide 591 0.627 0.0739 0.1179 4.3%   764 0.613 0.0720 0.1173 11.9% 




Table H1-12. Observed and imputed means and standard errors of C-reactive protein (natural log transform) by year and imputation 
approach (Hispanic) 
 Biomeasure weighted  Base weighted 
ln(CRP) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 485 0.870 0.0372 0.0428 2.4%  488 0.880 0.0406 0.0461 23.9% 
Cross-sectional 497 0.867 0.0385 0.0444 7.0%  641 0.851 0.0453 0.0532 31.0% 
Sequential 497 0.861 0.0373 0.0433 3.9%  641 0.857 0.0484 0.0564 26.2% 
Wide 497 0.868 0.0372 0.0428 3.8%  641 0.866 0.0440 0.0508 18.2% 
2010            
Observed 383 0.713 0.0438 0.0614 3.3%  383 0.702 0.0486 0.0692 29.3% 
Cross-sectional 396 0.716 0.0535 0.0747 15.4%  542 0.694 0.0661 0.0952 39.0% 
Sequential 396 0.709 0.0490 0.0692 8.4%  542 0.706 0.0628 0.0889 50.0% 
Wide 396 0.706 0.0506 0.0717 7.4%  542 0.723 0.0582 0.0805 36.0% 
2014            
Observed 373 0.416 0.0757 0.1819 0.8%  373 0.406 0.0768 0.1892 18.4% 
Cross-sectional 376 0.419 0.0756 0.1806 0.5%  457 0.388 0.0764 0.1971 20.4% 
Sequential 376 0.420 0.0757 0.1801 0.6%  457 0.399 0.0726 0.1819 17.7% 
Wide 376 0.420 0.0756 0.1802 0.5%   457 0.394 0.0728 0.1850 22.0% 





Table H1-13. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach (non-Hispanic other) 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 4,633 0.363 0.0095 0.0261 5.9%  4,682 0.366 0.0098 0.0268 24.2% 
Cross-sectional 4,926 0.364 0.0091 0.0250 3.3%  6,180 0.372 0.0087 0.0235 11.5% 
Sequential 4,926 0.365 0.0093 0.0254 5.2%  6,180 0.371 0.0094 0.0253 16.6% 
Wide 4,926 0.364 0.0092 0.0252 4.4%  6,180 0.366 0.0086 0.0234 17.6% 
2010            
Observed 4,005 0.304 0.0073 0.0240 2.9%  4,005 0.302 0.0076 0.0252 22.3% 
Cross-sectional 4,126 0.303 0.0073 0.0241 2.1%  5,152 0.308 0.0083 0.0270 33.4% 
Sequential 4,126 0.304 0.0073 0.0242 3.5%  5,152 0.306 0.0081 0.0263 29.0% 
Wide 4,126 0.304 0.0073 0.0240 1.6%  5,152 0.309 0.0082 0.0264 30.2% 
2014            
Observed 3,382 0.274 0.0082 0.0299 1.9%  3,382 0.276 0.0085 0.0309 19.2% 
Cross-sectional 3,446 0.275 0.0083 0.0303 2.6%  4,185 0.275 0.0084 0.0304 19.2% 
Sequential 3,446 0.274 0.0083 0.0303 1.1%  4,185 0.275 0.0084 0.0303 9.0% 
Wide 3,446 0.274 0.0083 0.0301 1.8%   4,185 0.278 0.0088 0.0318 27.5% 




Table H1-14. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach (non-Hispanic black) 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 699 0.520 0.0235 0.0451 10.4%  704 0.515 0.0210 0.0408 37.9% 
Cross-sectional 780 0.510 0.0212 0.0416 3.3%  1,133 0.480 0.0182 0.0379 15.9% 
Sequential 780 0.512 0.0228 0.0445 11.0%  1,133 0.486 0.0232 0.0477 48.0% 
Wide 780 0.512 0.0229 0.0448 16.7%  1,133 0.488 0.0184 0.0377 18.0% 
2010            
Observed 665 0.467 0.0188 0.0403 5.8%  665 0.462 0.0188 0.0406 29.0% 
Cross-sectional 706 0.461 0.0189 0.0410 6.2%  937 0.432 0.0180 0.0416 12.9% 
Sequential 706 0.460 0.0194 0.0423 8.6%  937 0.437 0.0181 0.0413 10.9% 
Wide 706 0.459 0.0188 0.0409 4.6%  937 0.445 0.0217 0.0488 41.7% 
2014            
Observed 580 0.391 0.0227 0.0581 1.9%  580 0.391 0.0228 0.0585 24.1% 
Cross-sectional 591 0.388 0.0228 0.0587 2.6%  764 0.368 0.0217 0.0591 11.0% 
Sequential 591 0.388 0.0223 0.0576 2.4%  764 0.379 0.0219 0.0579 15.2% 
Wide 591 0.388 0.0226 0.0582 2.8%   764 0.381 0.0226 0.0594 17.3% 




Table H1-15. Observed and imputed proportion at risk for C-reactive protein by year and imputation approach (Hispanic) 
 Biomeasure weighted  Base weighted 
Proportion at risk (>= 3.0 ug/mL) n Mean SE CV FMI   n Mean SE CV FMI 
2006            
Observed 485 0.419 0.0166 0.0396 2.4%  488 0.416 0.0163 0.0391 23.9% 
Cross-sectional 497 0.419 0.0171 0.0409 4.3%  641 0.409 0.0190 0.0463 27.7% 
Sequential 497 0.417 0.0162 0.0389 2.4%  641 0.411 0.0201 0.0490 40.7% 
Wide 497 0.418 0.0168 0.0401 3.2%  641 0.417 0.0212 0.0507 25.3% 
2010            
Observed 383 0.349 0.0204 0.0584 3.3%  383 0.344 0.0200 0.0581 29.3% 
Cross-sectional 396 0.351 0.0229 0.0653 13.1%  542 0.347 0.0250 0.0721 37.9% 
Sequential 396 0.348 0.0213 0.0613 6.8%  542 0.352 0.0250 0.0710 41.7% 
Wide 396 0.350 0.0224 0.0638 7.8%  542 0.361 0.0232 0.0644 24.0% 
2014            
Observed 373 0.301 0.0304 0.1013 0.8%  373 0.301 0.0305 0.1012 18.4% 
Cross-sectional 376 0.302 0.0304 0.1007 0.3%  457 0.299 0.0287 0.0960 9.8% 
Sequential 376 0.301 0.0305 0.1010 0.8%  457 0.300 0.0281 0.0936 13.4% 
Wide 376 0.303 0.0305 0.1007 0.5%   457 0.302 0.0281 0.0930 17.3% 







Figure H1-3. Proportion at risk for C-reactive protein by year, race/ethnicity, analysis weight, and imputation approach. 95% 




Table H1-16. Observed and imputed percentiles of CRP (natural log transform) by year and imputation approach (non-Hispanic 
other) 
 Biomeasure weighted  Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.401 -0.169 0.623 1.489 2.700  -1.388 -0.157 0.630 1.488 2.707 
(SE) (0.047) (0.029) (0.033) (0.030) (0.051)  (0.046) (0.032) (0.033) (0.029) (0.051) 
Cross-sectional -1.397 -0.162 0.630 1.499 2.719  -1.365 -0.142 0.673 1.525 2.748 
(SE) (0.046) (0.028) (0.030) (0.031) (0.052)  (0.042) (0.029) (0.029) (0.030) (0.049) 
Sequential -1.389 -0.163 0.632 1.498 2.721  -1.361 -0.146 0.667 1.523 2.749 
(SE) (0.050) (0.028) (0.029) (0.032) (0.054)  (0.045) (0.035) (0.034) (0.032) (0.051) 
Wide -1.401 -0.170 0.626 1.495 2.713  -1.370 -0.154 0.649 1.501 2.731 
(SE) (0.048) (0.025) (0.030) (0.031) (0.053)  (0.048) (0.028) (0.032) (0.031) (0.053) 
2010            
Observed -1.426 -0.272 0.513 1.285 2.490  -1.412 -0.268 0.502 1.278 2.480 
(SE) (0.040) (0.031) (0.030) (0.028) (0.042)  (0.041) (0.031) (0.030) (0.027) (0.043) 
Cross-sectional -1.426 -0.274 0.510 1.282 2.486  -1.385 -0.254 0.524 1.298 2.492 
(SE) (0.041) (0.031) (0.031) (0.027) (0.043)  (0.042) (0.029) (0.030) (0.030) (0.040) 
Sequential -1.425 -0.271 0.513 1.284 2.488  -1.406 -0.259 0.522 1.292 2.483 
(SE) (0.042) (0.031) (0.030) (0.028) (0.042)  (0.045) (0.034) (0.032) (0.029) (0.047) 
Wide -1.430 -0.276 0.512 1.285 2.486  -1.396 -0.246 0.527 1.303 2.491 
(SE) (0.039) (0.031) (0.030) (0.028) (0.042)  (0.043) (0.037) (0.033) (0.029) (0.040) 
2014            
Observed -2.243 -0.753 0.195 1.220 2.567  -2.229 -0.745 0.195 1.227 2.587 
(SE) (0.064) (0.036) (0.040) (0.036) (0.066)  (0.068) (0.037) (0.041) (0.039) (0.070) 
Cross-sectional -2.241 -0.752 0.198 1.221 2.565  -2.172 -0.736 0.205 1.220 2.577 
(SE) (0.062) (0.036) (0.040) (0.037) (0.065)  (0.070) (0.033) (0.039) (0.035) (0.072) 
Sequential -2.237 -0.751 0.197 1.218 2.568  -2.178 -0.741 0.206 1.225 2.597 
(SE) (0.063) (0.036) (0.041) (0.035) (0.065)  (0.069) (0.037) (0.038) (0.038) (0.066) 
Wide -2.240 -0.751 0.200 1.220 2.568  -2.189 -0.735 0.220 1.231 2.596 
(SE) (0.061) (0.036) (0.041) (0.036) (0.068)   (0.066) (0.036) (0.038) (0.037) (0.066) 
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Table H1-17. Observed and imputed percentiles of CRP (natural log transform) by year and imputation approach (non-Hispanic 
black) 
 Biomeasure weighted  Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.389 0.256 1.182 2.009 3.231  -1.386 0.256 1.167 1.997 3.154 
(SE) (0.222) (0.049) (0.095) (0.059) (0.093)  (0.191) (0.044) (0.085) (0.056) (0.096) 
Cross-sectional -1.386 0.240 1.147 1.983 3.185  -1.260 0.182 1.015 1.922 3.132 
(SE) (0.206) (0.050) (0.082) (0.056) (0.103)  (0.160) (0.059) (0.071) (0.055) (0.093) 
Sequential -1.379 0.244 1.155 1.987 3.182  -1.269 0.187 1.038 1.924 3.123 
(SE) (0.212) (0.054) (0.092) (0.059) (0.115)  (0.149) (0.052) (0.085) (0.052) (0.090) 
Wide -1.339 0.245 1.148 1.987 3.163  -1.289 0.185 1.043 1.926 3.119 
(SE) (0.199) (0.048) (0.094) (0.058) (0.099)  (0.148) (0.053) (0.069) (0.054) (0.081) 
2010            
Observed -1.392 -0.101 0.982 1.754 2.842  -1.392 -0.107 0.970 1.757 2.842 
(SE) (0.157) (0.076) (0.069) (0.052) (0.084)  (0.157) (0.078) (0.070) (0.053) (0.085) 
Cross-sectional -1.367 -0.097 0.961 1.737 2.812  -1.298 -0.088 0.886 1.702 2.782 
(SE) (0.166) (0.080) (0.070) (0.057) (0.094)  (0.168) (0.072) (0.071) (0.065) (0.099) 
Sequential -1.390 -0.101 0.958 1.745 2.814  -1.352 -0.111 0.901 1.718 2.826 
(SE) (0.167) (0.075) (0.072) (0.060) (0.095)  (0.157) (0.077) (0.069) (0.059) (0.096) 
Wide -1.379 -0.101 0.959 1.740 2.814  -1.300 -0.086 0.923 1.723 2.831 
(SE) (0.158) (0.081) (0.069) (0.056) (0.096)  (0.132) (0.077) (0.073) (0.063) (0.128) 
2014            
Observed -1.917 -0.398 0.653 1.700 3.224  -1.929 -0.400 0.650 1.699 3.226 
(SE) (0.181) (0.085) (0.108) (0.107) (0.131)  (0.197) (0.093) (0.107) (0.112) (0.120) 
Cross-sectional -1.912 -0.391 0.647 1.698 3.216  -1.944 -0.439 0.583 1.592 3.122 
(SE) (0.173) (0.086) (0.108) (0.108) (0.133)  (0.185) (0.094) (0.098) (0.109) (0.123) 
Sequential -1.936 -0.402 0.644 1.699 3.215  -1.916 -0.407 0.621 1.651 3.133 
(SE) (0.176) (0.088) (0.106) (0.109) (0.132)  (0.208) (0.086) (0.100) (0.105) (0.124) 
Wide -1.946 -0.400 0.645 1.700 3.219  -1.897 -0.395 0.634 1.655 3.146 
(SE) (0.186) (0.091) (0.107) (0.113) (0.131)   (0.182) (0.087) (0.106) (0.107) (0.123) 
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Table H1-18. Observed and imputed percentiles of CRP (natural log transform) by year and imputation approach (Hispanic) 
 Biomeasure weighted  Base weighted 
ln(CRP) 5th 25th (Q1) Median 75th (Q3) 95th   5th 25th (Q1) Median 75th (Q3) 95th 
2006            
Observed -1.017 0.130 0.777 1.639 2.717  -0.955 0.141 0.774 1.632 2.709 
(SE) (0.072) (0.060) (0.067) (0.048) (0.121)  (0.087) (0.061) (0.063) (0.060) (0.117) 
Cross-sectional -1.027 0.131 0.776 1.636 2.724  -1.019 0.110 0.783 1.618 2.748 
(SE) (0.090) (0.064) (0.070) (0.049) (0.127)  (0.119) (0.059) (0.067) (0.060) (0.118) 
Sequential -1.039 0.122 0.767 1.636 2.734  -1.056 0.124 0.787 1.623 2.756 
(SE) (0.083) (0.065) (0.068) (0.048) (0.131)  (0.112) (0.073) (0.069) (0.062) (0.121) 
Wide -1.017 0.132 0.776 1.636 2.721  -1.022 0.132 0.803 1.627 2.719 
(SE) (0.074) (0.061) (0.068) (0.049) (0.127)  (0.085) (0.063) (0.068) (0.073) (0.104) 
2010            
Observed -0.987 -0.058 0.681 1.423 2.508  -1.046 -0.058 0.646 1.420 2.508 
(SE) (0.161) (0.082) (0.063) (0.057) (0.136)  (0.398) (0.099) (0.065) (0.058) (0.138) 
Cross-sectional -0.997 -0.053 0.689 1.425 2.526  -1.129 -0.060 0.662 1.415 2.604 
(SE) (0.252) (0.083) (0.073) (0.064) (0.128)  (0.220) (0.092) (0.076) (0.070) (0.172) 
Sequential -0.995 -0.062 0.672 1.416 2.537  -1.130 -0.066 0.682 1.433 2.593 
(SE) (0.196) (0.077) (0.070) (0.063) (0.158)  (0.192) (0.085) (0.079) (0.086) (0.156) 
Wide -1.020 -0.060 0.674 1.415 2.522  -1.077 -0.048 0.685 1.445 2.582 
(SE) (0.333) (0.086) (0.071) (0.068) (0.148)  (0.196) (0.095) (0.069) (0.078) (0.156) 
2014            
Observed -1.720 -0.594 0.515 1.333 2.548  -1.732 -0.596 0.507 1.332 2.550 
(SE) (0.079) (0.099) (0.146) (0.134) (0.231)  (0.089) (0.098) (0.153) (0.135) (0.187) 
Cross-sectional -1.718 -0.593 0.517 1.336 2.547  -1.785 -0.598 0.469 1.328 2.574 
(SE) (0.079) (0.099) (0.144) (0.131) (0.230)  (0.143) (0.092) (0.137) (0.124) (0.186) 
Sequential -1.722 -0.593 0.520 1.337 2.549  -1.800 -0.599 0.504 1.325 2.559 
(SE) (0.080) (0.098) (0.144) (0.133) (0.206)  (0.127) (0.093) (0.123) (0.126) (0.179) 
Wide -1.722 -0.593 0.520 1.338 2.548  -1.820 -0.602 0.502 1.339 2.553 
(SE) (0.080) (0.098) (0.144) (0.132) (0.224)   (0.115) (0.092) (0.128) (0.122) (0.161) 
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Figure H1-4. Distribution of C-reactive protein (natural log transform) comparing race/ethnicity by year, analysis weight, and 
imputation approach. Ends of whisker plot represent 5th and 95th percentiles corresponding with values in Table H1-16, H1-17, and 
H1-18. Black squares represent means.  
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H.2 Cross-sectional multivariate model by race/ethnicity 
Table H2-1. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.043 (0.006)****  0.046 (0.006)****  0.046 (0.006)****  0.046 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.338 (0.091)*** -0.352 (0.083)**** -0.355 (0.083)**** -0.350 (0.083)**** 
Health conditions     
Hypertension  0.609 (0.082)****  0.617 (0.080)****  0.617 (0.080)****  0.618 (0.081)**** 
Diabetes  0.615 (0.084)****  0.627 (0.080)****  0.625 (0.081)****  0.620 (0.081)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.215 (0.127)  -0.152 (0.109)  -0.155 (0.108)  -0.157 (0.111)  
Obese (BMI > 30)                  -0.146 (0.115)  -0.155 (0.121)  -0.154 (0.120)  -0.154 (0.121)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.005 (0.164)  -0.021 (0.150)  -0.019 (0.150)  -0.017 (0.151)  
Hardly ever/never   0.426 (0.142)**  0.417 (0.127)**  0.412 (0.126)**  0.420 (0.126)*** 
Smoking status (ref: never smoked)    
Current smoker           0.351 (0.149)*  0.353 (0.142)*  0.352 (0.142)*  0.353 (0.140)* 
Former smoker            0.134 (0.113)   0.149 (0.114)   0.149 (0.114)   0.148 (0.114)  
Biomeasures     
ln(CRP)  0.042 (0.035)   0.031 (0.034)   0.034 (0.035)   0.030 (0.034)  
Cystatin C  0.449 (0.111)***  0.414 (0.101)****  0.410 (0.098)****  0.398 (0.102)**** 
Intercept                           -2.000 (0.196)**** -1.994 (0.192)**** -1.988 (0.190)**** -1.974 (0.190)**** 
Note. Sample sizes: observed n = 4,489; imputed n = 4,926.  




Table H2-2. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.012 (0.013)   0.018 (0.012)   0.018 (0.012)   0.018 (0.012)  
Age (squared)  0.000 (0.001)   -0.001 (0.001)   -0.001 (0.001)   -0.001 (0.001)  
Female  0.085 (0.240)   0.103 (0.225)   0.103 (0.224)   0.102 (0.222)  
Health conditions     
Hypertension  1.449 (0.273)****  1.374 (0.264)****  1.373 (0.263)****  1.373 (0.262)**** 
Diabetes  0.433 (0.217)   0.452 (0.193)*  0.445 (0.193)*  0.459 (0.192)* 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.605 (0.278)* -0.462 (0.267)  -0.443 (0.267)  -0.425 (0.269)  
Obese (BMI > 30)                  -0.451 (0.326)  -0.460 (0.259)  -0.446 (0.252)  -0.436 (0.247)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.076 (0.521)   0.110 (0.481)   0.112 (0.480)   0.120 (0.481)  
Hardly ever/never   0.847 (0.293)**  0.787 (0.252)**  0.786 (0.254)**  0.779 (0.255)** 
Smoking status (ref: never smoked)    
Current smoker          -0.174 (0.360)  -0.032 (0.325)  -0.030 (0.323)  -0.020 (0.324)  
Former smoker            0.405 (0.216)   0.452 (0.214)*  0.453 (0.214)*  0.455 (0.213)* 
Biomeasures     
ln(CRP)  0.045 (0.082)   0.037 (0.077)   0.034 (0.080)   0.029 (0.075)  
Cystatin C  0.224 (0.127)   0.211 (0.116)   0.211 (0.119)   0.207 (0.114)  
Intercept                           -2.615 (0.527)**** -2.651 (0.482)**** -2.657 (0.485)**** -2.664 (0.483)**** 
Note. Sample sizes: observed n = 671; imputed n = 780.  




Table H2-3. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using biomeasure weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.023 (0.015)   0.017 (0.012)   0.017 (0.012)   0.017 (0.012)  
Age (squared)  0.001 (0.001)   0.000 (0.001)   0.000 (0.001)   0.000 (0.001)  
Female  0.330 (0.344)   0.262 (0.331)   0.264 (0.331)   0.271 (0.332)  
Health conditions     
Hypertension  1.970 (0.422)****  1.925 (0.390)****  1.926 (0.392)****  1.920 (0.393)**** 
Diabetes  0.293 (0.238)   0.292 (0.224)   0.285 (0.224)   0.273 (0.224)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.224 (0.362)  -0.118 (0.323)  -0.100 (0.318)  -0.046 (0.336)  
Obese (BMI > 30)                   0.074 (0.347)  -0.448 (0.324)  -0.428 (0.327)  -0.379 (0.337)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           1.086 (0.487)*  0.867 (0.408)*  0.867 (0.408)*  0.883 (0.413)* 
Hardly ever/never  -0.294 (0.373)  -0.154 (0.335)  -0.155 (0.333)  -0.161 (0.334)  
Smoking status (ref: never smoked)    
Current smoker           0.452 (0.573)   0.357 (0.549)   0.358 (0.548)   0.360 (0.550)  
Former smoker            0.788 (0.380)*  0.816 (0.354)*  0.816 (0.352)*  0.818 (0.354)* 
Biomeasures     
ln(CRP) -0.043 (0.132)  -0.052 (0.119) -0.051 (0.120)  -0.045 (0.121)  
Cystatin C  0.810 (0.343)* 0.670 (0.266)*  0.675 (0.269)*  0.685 (0.270)* 
Intercept                           -4.554 (0.691)**** -4.185 (0.608)**** -4.204 (0.609)**** -4.259 (0.612)**** 
Note. Sample sizes: observed n = 454; imputed n = 497.  





Table H2-4. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.041 (0.006)****  0.051 (0.005)****  0.051 (0.005)****  0.051 (0.005)**** 
Age (squared)  0.000 (0.000)   -0.001 (0.000)   -0.001 (0.000)   -0.001 (0.000)  
Female -0.335 (0.087)*** -0.370 (0.067)**** -0.372 (0.067)**** -0.360 (0.066)**** 
Health conditions     
Hypertension  0.617 (0.086)****  0.654 (0.071)****  0.653 (0.070)****  0.653 (0.071)**** 
Diabetes  0.602 (0.084)****  0.564 (0.078)****  0.562 (0.078)****  0.548 (0.078)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.202 (0.128)  -0.113 (0.083)  -0.118 (0.082)  -0.106 (0.083)  
Obese (BMI > 30)                  -0.146 (0.113)  -0.126 (0.098)  -0.129 (0.096)  -0.107 (0.095)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.049 (0.171)   0.008 (0.157)   0.008 (0.156)   0.011 (0.157)  
Hardly ever/never   0.383 (0.149)*  0.340 (0.107)**  0.338 (0.109)**  0.355 (0.107)*** 
Smoking status (ref: never smoked)    
Current smoker           0.318 (0.146)*  0.278 (0.106)**  0.276 (0.106)**  0.289 (0.104)** 
Former smoker            0.107 (0.109)   0.131 (0.085)   0.133 (0.085)   0.133 (0.085)  
Biomeasures     
ln(CRP)  0.046 (0.035)   0.038 (0.034)   0.037 (0.031)   0.027 (0.030)  
Cystatin C  0.448 (0.110)***  0.334 (0.102)**  0.350 (0.084)****  0.348 (0.081)**** 
Intercept                           -1.996 (0.191)**** -1.857 (0.161)**** -1.871 (0.147)**** -1.878 (0.147)**** 
Note. Sample sizes: observed n = 4,535; imputed n = 6,180.  




Table H2-5. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.015 (0.012)   0.022 (0.009)*  0.022 (0.009)*  0.022 (0.009)* 
Age (squared)  0.000 (0.001)   0.000 (0.001)   0.000 (0.001)   0.000 (0.001)  
Female  0.178 (0.242)   0.059 (0.197)   0.045 (0.198)   0.049 (0.196)  
Health conditions     
Hypertension  1.436 (0.254)****  1.001 (0.205)****  1.003 (0.206)****  1.013 (0.207)**** 
Diabetes  0.353 (0.205)   0.417 (0.157)**  0.418 (0.158)**  0.433 (0.157)** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.511 (0.279)  -0.336 (0.179)  -0.315 (0.181)  -0.335 (0.178)  
Obese (BMI > 30)                  -0.367 (0.309)  -0.108 (0.222)  -0.107 (0.222)  -0.148 (0.218)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.161 (0.494)  -0.030 (0.322)  -0.030 (0.324)  -0.014 (0.323)  
Hardly ever/never   0.839 (0.315)**  0.598 (0.162)***  0.589 (0.159)***  0.595 (0.158)*** 
Smoking status (ref: never smoked)    
Current smoker          -0.183 (0.357)   0.223 (0.243)   0.218 (0.241)   0.213 (0.240)  
Former smoker            0.428 (0.229)   0.634 (0.167)***  0.627 (0.166)***  0.626 (0.166)*** 
Biomeasures     
ln(CRP)  -0.001 (0.084)   0.002 (0.083)   0.028 (0.079)   0.041 (0.075)  
Cystatin C  0.231 (0.137)   0.259 (0.134)   0.245 (0.131)   0.225 (0.118)  
Intercept                           -2.758 (0.493)**** -2.733 (0.374)**** -2.738 (0.375)**** -2.711 (0.370)**** 
Note. Sample sizes: observed n = 675; imputed n = 1,133.  




Table H2-6. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2006 using base weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.023 (0.016)   0.015 (0.014)   0.015 (0.014)   0.017 (0.014)  
Age (squared)  0.001 (0.001)   0.000 (0.001)   0.000 (0.001)   0.000 (0.001)  
Female  0.431 (0.311)   0.261 (0.253)   0.249 (0.257)   0.274 (0.258)  
Health conditions     
Hypertension  1.885 (0.432)****  1.588 (0.310)****  1.587 (0.311)****  1.576 (0.311)**** 
Diabetes  0.131 (0.245)   0.079 (0.225)   0.074 (0.227)   0.064 (0.224)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.241 (0.369)  -0.014 (0.293)  -0.047 (0.286)   0.007 (0.306)  
Obese (BMI > 30)                   0.062 (0.338)  -0.390 (0.288)  -0.420 (0.290)  -0.341 (0.299)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           1.041 (0.431)*  0.776 (0.397)   0.784 (0.397)*  0.780 (0.397)* 
Hardly ever/never  -0.222 (0.343)   0.368 (0.369)   0.351 (0.364)   0.361 (0.371)  
Smoking status (ref: never smoked)    
Current smoker           0.194 (0.496)  -0.345 (0.462)  -0.345 (0.451)  -0.387 (0.490)  
Former smoker            0.758 (0.404)   0.805 (0.316)*  0.812 (0.312)**  0.802 (0.320)* 
Biomeasures     
ln(CRP) -0.011 (0.129)  -0.008 (0.107)   0.018 (0.113)  -0.013 (0.124)  
Cystatin C  0.854 (0.335)*  0.601 (0.205)**  0.610 (0.225)**  0.597 (0.224)** 
Intercept                           -4.633 (0.698)**** -3.935 (0.530)**** -3.947 (0.545)**** -3.941 (0.540)**** 
Note. Sample sizes: observed n = 457; imputed n = 641.  







Figure H2-1. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2006 by imputation approach, analysis weight, and 
race/ethnicity. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for 
ln(CRP) and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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Table H2-7. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using biomeasure weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.041 (0.006)****  0.041 (0.006)****  0.042 (0.006)****  0.042 (0.006)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.399 (0.096)*** -0.408 (0.095)**** -0.411 (0.095)**** -0.411 (0.095)**** 
Health conditions     
Hypertension  0.639 (0.096)****  0.632 (0.092)****  0.629 (0.092)****  0.630 (0.092)**** 
Diabetes  0.612 (0.100)****  0.631 (0.095)****  0.628 (0.095)****  0.624 (0.095)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.063 (0.133)  -0.139 (0.095)  -0.139 (0.095)  -0.134 (0.093)  
Obese (BMI > 30)                  -0.123 (0.096)  -0.082 (0.127)  -0.076 (0.126)  -0.070 (0.127)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.007 (0.178)   0.019 (0.179)   0.021 (0.177)   0.015 (0.178)  
Hardly ever/never   0.223 (0.138)   0.258 (0.131)*  0.255 (0.131)   0.250 (0.131)  
Smoking status (ref: never smoked)    
Current smoker           0.171 (0.157)   0.169 (0.156)   0.172 (0.156)   0.167 (0.156)  
Former smoker            0.256 (0.091)**  0.277 (0.087)**  0.277 (0.087)**  0.274 (0.086)** 
Biomeasures     
ln(CRP)  0.038 (0.037)   0.034 (0.036)   0.036 (0.037)   0.041 (0.037)  
Cystatin C  0.503 (0.118)****  0.487 (0.114)****  0.476 (0.112)****  0.476 (0.112)**** 
Intercept                           -1.977 (0.184)**** -1.939 (0.172)**** -1.927 (0.170)**** -1.927 (0.171)**** 
Note. Sample sizes: observed n = 3,946; imputed n = 4,126.  




Table H2-8. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using biomeasure weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.024 (0.013)   0.025 (0.011)*  0.023 (0.012)*  0.023 (0.011)* 
Age (squared)  0.001 (0.001)   0.001 (0.001)   0.001 (0.001)   0.001 (0.001)  
Female  0.487 (0.221)*  0.449 (0.224)*  0.447 (0.222)*  0.439 (0.222)* 
Health conditions     
Hypertension  1.113 (0.293)***  1.215 (0.257)****  1.227 (0.258)****  1.219 (0.259)**** 
Diabetes  0.653 (0.188)**  0.599 (0.183)**  0.600 (0.182)**  0.591 (0.185)** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30)  0.166 (0.351)  -0.178 (0.257)  -0.169 (0.259)  -0.174 (0.256)  
Obese (BMI > 30)                  -0.124 (0.262)   0.213 (0.317)   0.204 (0.312)   0.198 (0.310)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.039 (0.450)  -0.089 (0.450)  -0.089 (0.448)  -0.091 (0.447)  
Hardly ever/never   0.401 (0.242)   0.518 (0.224)*  0.558 (0.223)*  0.544 (0.222)* 
Smoking status (ref: never smoked)    
Current smoker           0.398 (0.314)   0.467 (0.300)   0.456 (0.298)   0.446 (0.295)  
Former smoker            0.743 (0.246)**  0.800 (0.247)**  0.805 (0.249)**  0.802 (0.247)** 
Biomeasures     
ln(CRP)  0.061 (0.099)   0.048 (0.092)   0.025 (0.093)   0.037 (0.092)  
Cystatin C  0.167 (0.135)   0.174 (0.127)   0.184 (0.127)   0.211 (0.129)  
Intercept                           -3.413 (0.356)**** -3.502 (0.316)**** -3.504 (0.309)**** -3.523 (0.306)**** 
Note. Sample sizes: observed n = 655; imputed n = 706.  




Table H2-9. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using biomeasure weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.007 (0.025)  -0.002 (0.020)  -0.002 (0.020)  -0.002 (0.020)  
Age (squared) -0.004 (0.002)* -0.002 (0.002)  -0.002 (0.002)  -0.002 (0.002)  
Female  0.583 (0.364)   0.717 (0.258)**  0.701 (0.261)**  0.725 (0.260)** 
Health conditions     
Hypertension  0.907 (0.434)*  1.231 (0.342)***  1.230 (0.347)***  1.227 (0.344)*** 
Diabetes  0.425 (0.454)   0.289 (0.382)   0.303 (0.390)   0.292 (0.391)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.347 (0.395)   0.807 (0.439)   0.681 (0.394)   0.855 (0.400)* 
Obese (BMI > 30)                   0.691 (0.524)  -0.143 (0.428)  -0.338 (0.359)  -0.235 (0.342)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.896 (0.383)*  0.899 (0.300)**  0.892 (0.301)**  0.895 (0.299)** 
Hardly ever/never   0.472 (0.361)   0.530 (0.341)   0.533 (0.345)   0.537 (0.343)  
Smoking status (ref: never smoked)    
Current smoker           0.660 (0.619)   0.916 (0.670)   0.911 (0.660)   0.862 (0.640)  
Former smoker            0.798 (0.409)   0.720 (0.333)*  0.726 (0.335)*  0.724 (0.337)* 
Biomeasures     
ln(CRP)  0.066 (0.154)   0.030 (0.122)   0.058 (0.128)   0.068 (0.132)  
Cystatin C  0.518 (0.307)   0.423 (0.256)   0.422 (0.259)   0.444 (0.251)  
Intercept                           -3.800 (0.859)**** -4.179 (0.669)**** -4.060 (0.676)**** -4.217 (0.673)**** 
Note. Sample sizes: observed n = 357; imputed n = 396.  





Table H2-10. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using base weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.043 (0.006)****  0.045 (0.005)****  0.046 (0.005)****  0.046 (0.005)**** 
Age (squared)  0.000 (0.000)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.402 (0.099)*** -0.382 (0.083)**** -0.385 (0.083)**** -0.385 (0.083)**** 
Health conditions     
Hypertension  0.616 (0.096)****  0.616 (0.085)****  0.609 (0.085)****  0.611 (0.086)**** 
Diabetes  0.614 (0.097)****  0.583 (0.088)****  0.577 (0.087)****  0.573 (0.087)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.077 (0.134)  -0.130 (0.084)  -0.128 (0.084)  -0.126 (0.082)  
Obese (BMI > 30)                  -0.148 (0.099)  -0.069 (0.119)  -0.055 (0.118)  -0.058 (0.118)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.028 (0.177)   0.085 (0.139)   0.087 (0.138)   0.080 (0.139)  
Hardly ever/never   0.188 (0.142)   0.285 (0.132)*  0.283 (0.133)*  0.281 (0.132)* 
Smoking status (ref: never smoked)    
Current smoker           0.187 (0.156)   0.232 (0.133)   0.233 (0.134)   0.223 (0.135)  
Former smoker            0.287 (0.090)**  0.268 (0.082)**  0.267 (0.082)**  0.264 (0.082)** 
Biomeasures     
ln(CRP)  0.042 (0.037)   0.038 (0.036)   0.045 (0.037)   0.058 (0.035)  
Cystatin C  0.522 (0.111)****  0.398 (0.087)****  0.366 (0.082)****  0.359 (0.072)**** 
Intercept                           -1.957 (0.174)**** -1.856 (0.157)**** -1.820 (0.156)**** -1.815 (0.151)**** 
Note. Sample sizes: observed n = 3,946; imputed n = 5,152.  




Table H2-11. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using base weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.026 (0.013)   0.028 (0.012)*  0.027 (0.012)*  0.027 (0.012)* 
Age (squared)  0.001 (0.001)   0.000 (0.001)   0.000 (0.001)   0.000 (0.001)  
Female  0.470 (0.218)*  0.277 (0.216)   0.261 (0.216)   0.259 (0.218)  
Health conditions     
Hypertension  1.131 (0.293)***  1.073 (0.278)***  1.076 (0.279)***  1.069 (0.279)*** 
Diabetes  0.659 (0.192)**  0.560 (0.199)**  0.552 (0.199)**  0.558 (0.200)** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30)  0.168 (0.358)  -0.186 (0.238)  -0.202 (0.242)  -0.199 (0.238)  
Obese (BMI > 30)                  -0.114 (0.268)   0.116 (0.297)   0.074 (0.289)   0.087 (0.291)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -0.025 (0.442)  -0.166 (0.349)  -0.181 (0.349)  -0.177 (0.346)  
Hardly ever/never   0.399 (0.248)   0.225 (0.199)   0.242 (0.198)   0.238 (0.199)  
Smoking status (ref: never smoked)    
Current smoker           0.345 (0.300)   0.281 (0.325)   0.257 (0.323)   0.251 (0.319)  
Former smoker            0.712 (0.244)**  0.565 (0.221)*  0.566 (0.221)*  0.565 (0.218)** 
Biomeasures     
ln(CRP)  0.058 (0.101)   0.082 (0.089)   0.079 (0.091)   0.072 (0.094)  
Cystatin C  0.172 (0.137)   0.164 (0.128)   0.211 (0.138)   0.218 (0.128)  
Intercept                           -3.406 (0.359)**** -2.972 (0.418)**** -2.995 (0.419)**** -2.995 (0.408)**** 
Note. Sample sizes: observed n = 655; imputed n = 937.  




Table H2-12. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2010 using base weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.011 (0.025)  -0.007 (0.017)  -0.005 (0.016)  -0.005 (0.016)  
Age (squared) -0.004 (0.002)* -0.001 (0.001)  -0.001 (0.001)   -0.001 (0.001)  
Female  0.549 (0.380)   0.481 (0.235)*  0.449 (0.240)   0.454 (0.235)  
Health conditions     
Hypertension  0.906 (0.467)   1.118 (0.351)**  1.115 (0.366)**  1.109 (0.365)** 
Diabetes  0.482 (0.467)   0.257 (0.302)   0.254 (0.306)   0.230 (0.312)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.349 (0.424)   0.840 (0.371)*  0.707 (0.307)*  0.813 (0.337)* 
Obese (BMI > 30)                   0.675 (0.540)  -0.383 (0.446)  -0.547 (0.389)  -0.493 (0.383)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.907 (0.397)*  0.456 (0.299)   0.454 (0.297)   0.471 (0.294)  
Hardly ever/never   0.476 (0.354)   0.276 (0.336)   0.263 (0.339)   0.254 (0.343)  
Smoking status (ref: never smoked)    
Current smoker           0.777 (0.655)   0.623 (0.607)   0.590 (0.595)   0.566 (0.578)  
Former smoker            0.879 (0.424)*  0.839 (0.289)**  0.844 (0.287)**  0.838 (0.289)** 
Biomeasures     
ln(CRP)  0.075 (0.164)   -0.001 (0.135)   0.032 (0.140)   0.048 (0.147)  
Cystatin C  0.515 (0.302)   0.493 (0.252)   0.407 (0.256)   0.435 (0.265)  
Intercept                           -3.824 (0.864)**** -3.942 (0.572)**** -3.708 (0.498)**** -3.812 (0.538)**** 
Note. Sample sizes: observed n = 357; imputed n = 542.  







Figure H2-2. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2010 by imputation approach, analysis weight, and 
race/ethnicity. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for 
ln(CRP) and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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Table H2-13. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using biomeasure weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.042 (0.005)****  0.044 (0.005)****  0.044 (0.005)****  0.044 (0.005)**** 
Age (squared)  0.000 (0.001)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.419 (0.088)**** -0.400 (0.086)**** -0.402 (0.086)**** -0.402 (0.086)**** 
Health conditions     
Hypertension  0.577 (0.124)****  0.571 (0.120)****  0.567 (0.120)****  0.567 (0.120)**** 
Diabetes  0.526 (0.110)****  0.539 (0.109)****  0.538 (0.108)****  0.539 (0.108)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.102 (0.121)  -0.142 (0.115)  -0.138 (0.115)  -0.142 (0.116)  
Obese (BMI > 30)                  -0.136 (0.118)  -0.089 (0.116)  -0.083 (0.116)  -0.088 (0.116)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.253 (0.152)   0.240 (0.147)   0.239 (0.146)   0.243 (0.146)  
Hardly ever/never   0.346 (0.134)*  0.354 (0.131)**  0.351 (0.132)**  0.349 (0.131)** 
Smoking status (ref: never smoked)    
Current smoker           0.198 (0.144)   0.215 (0.135)   0.221 (0.135)   0.215 (0.135)  
Former smoker            0.243 (0.086)**  0.261 (0.082)**  0.261 (0.082)**  0.259 (0.082)** 
Biomeasures     
ln(CRP)  -0.001 (0.036)   0.000 (0.036)   0.000 (0.035)   0.005 (0.036)  
Cystatin C  0.474 (0.111)****  0.465 (0.107)****  0.474 (0.107)****  0.466 (0.107)**** 
Intercept                           -1.768 (0.182)**** -1.759 (0.182)**** -1.768 (0.180)**** -1.758 (0.181)**** 
Note. Sample sizes: observed n = 3,336; imputed n = 3,446.  




Table H2-14. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using biomeasure weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.027 (0.018)   0.027 (0.016)   0.027 (0.016)   0.026 (0.016)  
Age (squared)  0.000 (0.002)   0.000 (0.002)   0.000 (0.002)   0.000 (0.002)  
Female  0.187 (0.299)   0.242 (0.304)   0.243 (0.303)   0.248 (0.304)  
Health conditions     
Hypertension  0.923 (0.387)*  1.204 (0.384)**  1.209 (0.386)**  1.212 (0.386)** 
Diabetes  0.561 (0.247)*  0.530 (0.245)*  0.535 (0.243)*  0.531 (0.243)* 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30)  0.059 (0.316)  -0.134 (0.324)  -0.294 (0.310)  -0.242 (0.323)  
Obese (BMI > 30)                   0.009 (0.312)  -0.084 (0.345)  -0.178 (0.334)  -0.146 (0.333)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.148 (0.361)   0.109 (0.339)   0.118 (0.343)   0.119 (0.340)  
Hardly ever/never   0.459 (0.455)   0.415 (0.435)   0.439 (0.433)   0.440 (0.433)  
Smoking status (ref: never smoked)    
Current smoker           0.226 (0.267)   0.188 (0.277)   0.160 (0.283)   0.169 (0.281)  
Former smoker            0.330 (0.248)   0.279 (0.228)   0.270 (0.229)   0.273 (0.229)  
Biomeasures     
ln(CRP)  0.133 (0.076)   0.116 (0.081)   0.110 (0.077)   0.105 (0.077)  
Cystatin C  0.663 (0.217)**  0.396 (0.160)*  0.387 (0.153)*  0.386 (0.153)* 
Intercept                           -3.159 (0.561)**** -2.899 (0.529)**** -2.793 (0.541)**** -2.827 (0.533)**** 
Note. Sample sizes: observed n = 569; imputed n = 591.  




Table H2-15. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using biomeasure weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.044 (0.025)  -0.035 (0.025)  -0.035 (0.025)  -0.035 (0.025)  
Age (squared) -0.005 (0.002)* -0.005 (0.002)* -0.005 (0.002)* -0.005 (0.002)* 
Female  0.366 (0.356)   0.347 (0.275)   0.347 (0.276)   0.341 (0.277)  
Health conditions     
Hypertension  0.467 (0.470)   0.504 (0.424)   0.502 (0.426)   0.500 (0.426)  
Diabetes  0.057 (0.370)   0.000 (0.299)   0.001 (0.299)  -0.001 (0.300)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.593 (0.497)   0.053 (0.393)   0.063 (0.389)   0.058 (0.389)  
Obese (BMI > 30)                   0.064 (0.465)  -0.605 (0.440)  -0.619 (0.433)  -0.615 (0.431)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -1.313 (0.724)  -1.268 (0.694)  -1.266 (0.695)  -1.270 (0.696)  
Hardly ever/never   0.195 (0.358)   0.163 (0.246)   0.163 (0.247)   0.158 (0.247)  
Smoking status (ref: never smoked)    
Current smoker           0.558 (0.622)   0.493 (0.568)   0.477 (0.572)   0.475 (0.571)  
Former smoker            0.885 (0.387)*  0.792 (0.332)*  0.790 (0.330)*  0.788 (0.330)* 
Biomeasures     
ln(CRP)  0.046 (0.106)   0.023 (0.095)   0.020 (0.095)   0.021 (0.095)  
Cystatin C  0.506 (0.220)*  0.496 (0.198)*  0.502 (0.199)*  0.506 (0.199)* 
Intercept                           -2.594 (0.679)**** -2.505 (0.539)**** -2.511 (0.542)**** -2.507 (0.540)**** 
Note. Sample sizes: observed n = 351; imputed n = 376.  





Table H2-16. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using base weights (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.043 (0.005)****  0.044 (0.005)****  0.044 (0.005)****  0.044 (0.005)**** 
Age (squared)  0.000 (0.001)   0.000 (0.000)   0.000 (0.000)   0.000 (0.000)  
Female -0.401 (0.089)**** -0.378 (0.075)**** -0.379 (0.075)**** -0.375 (0.074)**** 
Health conditions     
Hypertension  0.553 (0.127)****  0.574 (0.106)****  0.560 (0.107)****  0.561 (0.107)**** 
Diabetes  0.550 (0.110)****  0.516 (0.092)****  0.518 (0.091)****  0.521 (0.091)**** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.129 (0.116)  -0.190 (0.098)  -0.193 (0.097)* -0.193 (0.097)* 
Obese (BMI > 30)                  -0.146 (0.118)  -0.097 (0.102)  -0.098 (0.101)  -0.094 (0.100)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.244 (0.148)   0.350 (0.130)**  0.350 (0.130)**  0.355 (0.130)** 
Hardly ever/never   0.319 (0.137)*  0.270 (0.123)*  0.274 (0.124)*  0.272 (0.124)* 
Smoking status (ref: never smoked)    
Current smoker           0.170 (0.145)   0.282 (0.125)*  0.283 (0.125)*  0.287 (0.125)* 
Former smoker            0.260 (0.086)**  0.260 (0.079)**  0.261 (0.080)**  0.263 (0.079)*** 
Biomeasures     
ln(CRP)  0.003 (0.038)   0.002 (0.035)   0.009 (0.037)   0.005 (0.034)  
Cystatin C  0.487 (0.112)****  0.398 (0.091)****  0.412 (0.093)****  0.410 (0.086)**** 
Intercept                           -1.771 (0.184)**** -1.627 (0.170)**** -1.637 (0.168)**** -1.641 (0.166)**** 
Note. Sample sizes: observed n = 3,336; imputed n = 4,185.  




Table H2-17. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using base weights (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.032 (0.019)   0.030 (0.014)*  0.029 (0.014)*  0.029 (0.014)* 
Age (squared)  0.000 (0.002)   0.000 (0.001)   0.000 (0.001)   0.000 (0.001)  
Female  0.221 (0.299)   0.075 (0.249)   0.085 (0.250)   0.091 (0.249)  
Health conditions     
Hypertension  0.812 (0.386)*  0.982 (0.380)**  0.990 (0.381)**  0.990 (0.382)** 
Diabetes  0.591 (0.249)*  0.643 (0.211)**  0.661 (0.210)**  0.653 (0.211)** 
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30)  0.079 (0.329)  -0.127 (0.323)  -0.262 (0.315)  -0.217 (0.319)  
Obese (BMI > 30)                  -0.020 (0.305)   0.072 (0.370)  -0.028 (0.368)   -0.001 (0.368)  
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month           0.145 (0.357)   0.130 (0.246)   0.139 (0.252)   0.137 (0.249)  
Hardly ever/never   0.467 (0.448)   0.381 (0.353)   0.410 (0.351)   0.400 (0.357)  
Smoking status (ref: never smoked)    
Current smoker           0.248 (0.274)   0.407 (0.278)   0.375 (0.276)   0.398 (0.276)  
Former smoker            0.296 (0.246)   0.272 (0.225)   0.277 (0.226)   0.271 (0.227)  
Biomeasures     
ln(CRP)  0.159 (0.076)*  0.121 (0.079)   0.106 (0.072)   0.110 (0.073)  
Cystatin C  0.632 (0.215)**  0.364 (0.151)*  0.359 (0.149)*  0.376 (0.152)* 
Intercept                           -3.048 (0.559)**** -2.786 (0.527)**** -2.707 (0.537)**** -2.758 (0.520)**** 
Note. Sample sizes: observed n = 569; imputed n = 764.  




Table H2-18. Logistic regression logit coefficients and standard errors for predicting 
cardiovascular disease in HRS 2014 using base weights (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.036 (0.024)  -0.016 (0.019)  -0.015 (0.019)  -0.015 (0.019)  
Age (squared) -0.004 (0.002)  -0.002 (0.002)  -0.002 (0.002)  -0.002 (0.002)  
Female  0.402 (0.360)   0.253 (0.272)   0.264 (0.263)   0.261 (0.264)  
Health conditions     
Hypertension  0.441 (0.487)   0.540 (0.419)   0.466 (0.431)   0.456 (0.433)  
Diabetes  0.115 (0.372)   0.095 (0.267)   0.135 (0.264)   0.136 (0.264)  
BMI (ref: under/normal weight)     
Overweight (25 ≤ BMI < 30) -0.601 (0.504)  -0.007 (0.316)   0.031 (0.307)   0.029 (0.308)  
Obese (BMI > 30)                   0.097 (0.460)  -0.780 (0.402)  -0.750 (0.384)  -0.775 (0.381)* 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3/month          -1.317 (0.714)  -1.428 (0.661)* -1.383 (0.644)* -1.391 (0.639)* 
Hardly ever/never   0.181 (0.387)   0.354 (0.259)   0.396 (0.253)   0.388 (0.251)  
Smoking status (ref: never smoked)    
Current smoker           0.563 (0.625)   0.482 (0.486)   0.490 (0.491)   0.452 (0.487)  
Former smoker            0.985 (0.392)*  0.924 (0.303)**  0.930 (0.297)**  0.910 (0.294)** 
Biomeasures     
ln(CRP)  0.029 (0.108)   0.048 (0.109)   0.005 (0.092)   0.010 (0.094)  
Cystatin C  0.501 (0.225)*  0.468 (0.216)*  0.447 (0.183)*  0.472 (0.167)** 
Intercept                           -2.695 (0.703)**** -2.585 (0.539)**** -2.537 (0.539)**** -2.535 (0.542)**** 
Note. Sample sizes: observed n = 351; imputed n = 457.  







Figure H2-3. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting 
prevalence of cardiovascular disease in HRS 2014 by imputation approach, analysis weight, and 
race/ethnicity. Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for 
ln(CRP) and 0.50 for Cystatin C. 95% confidence interval of the odds ratio included. 
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H.3 Longitudinal multivariate model by race/ethnicity 
Table H3-1. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (biomeasure weight) (non-Hispanic other) 
  Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.049 (0.010)****  0.052 (0.007)****  0.051 (0.007)****  0.053 (0.007)**** 
Age (squared)  0.000 (0.001)  0.001 (0.001)  0.001 (0.001)  0.001 (0.001) 
Female -0.403 (0.149)** -0.298 (0.130)* -0.305 (0.132)* -0.300 (0.130)* 
Health conditions     
High blood pressure (2006)  0.429 (0.256)  0.490 (0.207)*  0.478 (0.206)*  0.480 (0.206)* 
Recent HBP diagnosis  0.248 (0.235)  0.373 (0.211)  0.353 (0.212)  0.348 (0.211) 
Diabetes (2006)  0.675 (0.171)***  0.635 (0.149)****  0.633 (0.150)****  0.628 (0.150)**** 
Recent diagnosis diabetes  0.194 (0.199)  0.271 (0.168)  0.269 (0.170)  0.269 (0.170) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.041 (0.184)  0.014 (0.187)  0.009 (0.187)  0.008 (0.189) 
Obese (2006) -0.026 (0.210)  0.114 (0.169)  0.106 (0.164)  0.113 (0.168) 
Decreased BMI category -0.096 (0.222)  0.045 (0.193)  0.059 (0.191)  0.041 (0.194) 
Increased BMI category  0.199 (0.175)  0.149 (0.160)  0.153 (0.155)  0.163 (0.154) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.049 (0.345) -0.239 (0.268) -0.251 (0.269) -0.250 (0.267) 
Hardly ever/never (2006) -0.090 (0.392) -0.164 (0.392) -0.172 (0.391) -0.172 (0.390) 
Decreased daily activity -0.208 (0.396)  0.008 (0.276)  0.013 (0.275)  0.017 (0.276) 
Increased daily activity -0.069 (0.190) -0.042 (0.194) -0.048 (0.194) -0.045 (0.194) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.289 (0.252)  0.349 (0.203)  0.365 (0.204)  0.358 (0.203) 
Former smoker (2006)  0.314 (0.131)*  0.301 (0.123)*  0.302 (0.124)*  0.300 (0.121)* 
Recently quit smoking  0.571 (0.391)  0.654 (0.324)*  0.609 (0.324)  0.642 (0.326)* 
Recently started smoking -0.249 (0.843) -0.530 (0.794) -0.520 (0.796) -0.518 (0.795) 
Biomeasures     
ln(CRP) (2006)  0.012 (0.065)  0.026 (0.059)  0.029 (0.060)  0.047 (0.055) 
ln(CRP) change -0.105 (0.060) -0.058 (0.048) -0.060 (0.047) -0.067 (0.051) 
Cystatin C (2006)  0.663 (0.241)**  0.552 (0.220)*  0.598 (0.231)*  0.513 (0.187)** 
Cystatin C change  0.405 (0.149)**  0.372 (0.108)***  0.377 (0.110)***  0.356 (0.124)** 
Intercept -2.731 (0.273)**** -2.795 (0.270)**** -2.828 (0.284)**** -2.751 (0.244)**** 
Note. Sample sizes: 2,194 for observed, 3,337 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  




Table H3-2. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (biomeasure weight) (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.024 (0.020)  0.035 (0.017)*  0.032 (0.016)*  0.034 (0.016)* 
Age (squared)  0.001 (0.002)  0.001 (0.002)  0.001 (0.002)  0.001 (0.002) 
Female  0.673 (0.533)  0.283 (0.469)  0.314 (0.477)  0.315 (0.460) 
Health conditions     
High blood pressure (2006)  0.391 (0.661)  0.690 (0.486)  0.675 (0.491)  0.692 (0.486) 
Recent HBP diagnosis  0.094 (0.830)  0.915 (0.584)  0.895 (0.610)  0.947 (0.619) 
Diabetes (2006)  0.555 (0.404)  0.596 (0.286)*  0.638 (0.286)*  0.605 (0.281)* 
Recent diagnosis diabetes  0.465 (0.616)  0.645 (0.506)  0.656 (0.500)  0.665 (0.504) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.054 (0.487) -0.126 (0.420) -0.135 (0.476) -0.162 (0.491) 
Obese (2006)  0.165 (0.472) -0.116 (0.436) -0.238 (0.498) -0.207 (0.519) 
Decreased BMI category -0.163 (0.593)  0.284 (0.563) -0.129 (0.678) -0.297 (0.743) 
Increased BMI category -0.650 (0.536) -0.508 (0.316) -0.599 (0.329) -0.563 (0.321) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.073 (0.902) -0.656 (0.888) -0.662 (0.890) -0.769 (0.889) 
Hardly ever/never (2006)  1.839 (0.741)* -0.327 (0.866) -0.284 (0.852) -0.279 (0.811) 
Decreased daily activity -0.717 (0.882)  0.685 (0.659)  0.625 (0.629)  0.732 (0.645) 
Increased daily activity  0.631 (0.532)  0.601 (0.481)  0.621 (0.485)  0.623 (0.483) 
Smoking status (ref: never smoked)    
Current smoker (2006) -0.596 (0.706)  0.068 (0.459)  0.051 (0.465)  0.072 (0.464) 
Former smoker (2006) -0.152 (0.343) -0.112 (0.263) -0.129 (0.259) -0.132 (0.247) 
Recently quit smoking  1.181 (0.789)  0.550 (0.606)  0.643 (0.609)  0.619 (0.621) 
Recently started smoking -14.22 (0.716)**** -13.35 (0.847)**** -13.42 (0.807)**** -13.62 (0.689) 
Biomeasures     
log(CRP) (2006) -0.073 (0.169)  0.032 (0.169)  0.053 (0.165)  0.012 (0.149) 
log(CRP) change  0.008 (0.135)  0.037 (0.106)  0.037 (0.110)  0.076 (0.118) 
Cystatin C (2006)  1.464 (0.468)**  0.223 (0.316)  0.212 (0.298)  0.078 (0.278) 
Cystatin C change  0.560 (0.312)  0.180 (0.286)  0.183 (0.288)  0.305 (0.321) 
Intercept -4.243 (1.096)*** -2.980 (0.877)*** -2.896 (0.878)** -2.739 (0.865)** 
Note. Sample sizes: 297 for observed, 623 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  




Table H3-3. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (biomeasure weight) (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.039 (0.036)  0.035 (0.017)*  0.032 (0.016)*  0.034 (0.016)* 
Age (squared) -0.002 (0.003)  0.001 (0.002)  0.001 (0.002)  0.001 (0.002) 
Female  0.156 (0.613)  0.283 (0.469)  0.314 (0.477)  0.315 (0.460) 
Health conditions     
High blood pressure (2006)  0.407 (0.646)  0.690 (0.486)  0.675 (0.491)  0.692 (0.486) 
Recent HBP diagnosis -0.945 (0.977)  0.915 (0.584)  0.895 (0.610)  0.947 (0.619) 
Diabetes (2006)  0.580 (0.546)  0.596 (0.286)*  0.638 (0.286)*  0.605 (0.281)* 
Recent diagnosis diabetes -0.340 (0.802)  0.645 (0.506)  0.656 (0.500)  0.665 (0.504) 
BMI (ref: Under/normal weight)    
Overweight (2006) -0.751 (0.653) -0.126 (0.420) -0.135 (0.476) -0.162 (0.491) 
Obese (2006)  0.288 (0.680) -0.116 (0.436) -0.238 (0.498) -0.207 (0.519) 
Decreased BMI category -0.720 (0.887)  0.284 (0.563) -0.129 (0.678) -0.297 (0.743) 
Increased BMI category  0.754 (0.521) -0.508 (0.316) -0.599 (0.329) -0.563 (0.321) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -11.41 (1.282)**** -0.656 (0.888) -0.662 (0.890) -0.769 (0.889) 
Hardly ever/never (2006)  0.381 (0.740) -0.327 (0.866) -0.284 (0.852) -0.279 (0.811) 
Decreased daily activity -1.123 (1.216)  0.685 (0.659)  0.625 (0.629)  0.732 (0.645) 
Increased daily activity -0.671 (0.866)  0.601 (0.481)  0.621 (0.485)  0.623 (0.483) 
Smoking status (ref: never smoked)    
Current smoker (2006) -10.29 (0.693)****  0.068 (0.459)  0.051 (0.465)  0.072 (0.464) 
Former smoker (2006)  1.058 (0.580) -0.112 (0.263) -0.129 (0.259) -0.132 (0.247) 
Recently quit smoking  12.60 (0.870)****  0.550 (0.606)  0.643 (0.609)  0.619 (0.621) 
Recently started smoking  19.76 (1.281)**** -13.35 (0.847)**** -13.42 (0.807)**** -13.62 (0.689)**** 
Biomeasures     
log(CRP) (2006) -0.343 (0.224)  0.032 (0.169)  0.053 (0.165)  0.012 (0.149) 
log(CRP) change  0.401 (0.233)  0.037 (0.106)  0.037 (0.110)  0.076 (0.118) 
Cystatin C (2006)  1.227 (1.035)  0.223 (0.316)  0.212 (0.298)  0.078 (0.278) 
Cystatin C change -0.045 (0.495)  0.180 (0.286)  0.183 (0.288)  0.305 (0.321) 
Intercept -3.875 (1.272)** -2.980 (0.877)*** -2.896 (0.878)** -2.739 (0.865)** 
Note. Sample sizes: 237 for observed, 397 for imputed. Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  





Table H3-4. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) (non-Hispanic other) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.049 (0.010)****  0.048 (0.007)****  0.049 (0.007)****  0.051 (0.007)**** 
Age (squared)  0.000 (0.001)  0.000 (0.000)  0.000 (0.000)  0.000 (0.000) 
Female -0.376 (0.152)* -0.299 (0.117)* -0.307 (0.118)** -0.298 (0.116)* 
Health conditions     
High blood pressure (2006)  0.429 (0.263)  0.554 (0.167)***  0.546 (0.166)**  0.550 (0.167)** 
Recent HBP diagnosis  0.212 (0.236)  0.455 (0.180)*  0.432 (0.180)*  0.427 (0.181)* 
Diabetes (2006)  0.667 (0.171)***  0.545 (0.134)****  0.541 (0.136)****  0.541 (0.135)**** 
Recent diagnosis diabetes  0.235 (0.206)  0.270 (0.175)  0.270 (0.176)  0.276 (0.176) 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.033 (0.180) -0.100 (0.160) -0.099 (0.161) -0.114 (0.158) 
Obese (2006) -0.010 (0.213) -0.032 (0.164) -0.036 (0.161) -0.036 (0.157) 
Decreased BMI category -0.123 (0.219)  0.031 (0.172)  0.045 (0.169)  0.033 (0.171) 
Increased BMI category  0.181 (0.173)  0.285 (0.182)  0.292 (0.177)  0.297 (0.179) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006)  0.010 (0.344) -0.341 (0.255) -0.360 (0.260) -0.365 (0.257) 
Hardly ever/never (2006) -0.056 (0.395) -0.223 (0.341) -0.227 (0.341) -0.224 (0.336) 
Decreased daily activity -0.236 (0.392) -0.038 (0.269) -0.045 (0.268) -0.036 (0.267) 
Increased daily activity -0.084 (0.188)  0.101 (0.163)  0.103 (0.163)  0.103 (0.164) 
Smoking status (ref: never smoked)    
Current smoker (2006)  0.262 (0.256)  0.394 (0.175)*  0.404 (0.174)*  0.411 (0.172)* 
Former smoker (2006)  0.310 (0.134)*  0.257 (0.120)*  0.258 (0.120)*  0.260 (0.119)* 
Recently quit smoking  0.673 (0.404)  0.501 (0.277)  0.478 (0.277)  0.500 (0.277) 
Recently started smoking -0.201 (0.830) -0.733 (0.796) -0.730 (0.796) -0.723 (0.795) 
Biomeasures     
ln(CRP) (2006)  0.026 (0.066)  0.036 (0.068)  0.050 (0.063)  0.064 (0.055) 
ln(CRP) change -0.111 (0.062) -0.045 (0.051) -0.048 (0.051) -0.062 (0.050) 
Cystatin C (2006)  0.654 (0.246)*  0.580 (0.211)**  0.536 (0.242)*  0.452 (0.177)* 
Cystatin C change  0.427 (0.150)**  0.317 (0.106)**  0.349 (0.114)**  0.325 (0.116)** 
Intercept -2.749 (0.275)**** -2.690 (0.263)**** -2.651 (0.291)**** -2.569 (0.235)**** 
Note. Sample sizes: 2,194 for observed, 2,740 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.  




Table H3-5. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) (non-Hispanic black) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered)  0.027 (0.021)  0.025 (0.016)  0.023 (0.016)  0.026 (0.016) 
Age (squared)  0.000 (0.003)  0.000 (0.001)  0.000 (0.001)  0.000 (0.001) 
Female  0.653 (0.557)  0.014 (0.392)  0.034 (0.395)  0.058 (0.384) 
Health conditions     
High blood pressure (2006)  0.187 (0.628)  0.324 (0.448)  0.342 (0.445)  0.297 (0.448) 
Recent HBP diagnosis  0.020 (0.796)  0.638 (0.560)  0.641 (0.583)  0.639 (0.587) 
Diabetes (2006)  0.496 (0.394)  0.610 (0.263)*  0.628 (0.262)*  0.622 (0.260)* 
Recent diagnosis diabetes  0.522 (0.590)  0.697 (0.371)  0.703 (0.370)  0.725 (0.366)* 
BMI (ref: Under/normal weight)    
Overweight (2006)  0.087 (0.468)  0.094 (0.438)  0.109 (0.488)  0.108 (0.498) 
Obese (2006)  0.052 (0.470)  0.309 (0.447)  0.233 (0.509)  0.288 (0.530) 
Decreased BMI category -0.484 (0.611)  0.293 (0.538) -0.083 (0.658) -0.217 (0.694) 
Increased BMI category -0.552 (0.519) -0.086 (0.333) -0.090 (0.335) -0.062 (0.322) 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -0.250 (0.880) -0.804 (0.630) -0.857 (0.638) -0.945 (0.661) 
Hardly ever/never (2006)  1.513 (0.758)  0.052 (0.695)  0.088 (0.685)  0.102 (0.673) 
Decreased daily activity -0.347 (0.853)  0.607 (0.642)  0.592 (0.620)  0.695 (0.667) 
Increased daily activity  0.715 (0.527)  0.681 (0.394)  0.697 (0.395)  0.711 (0.396) 
Smoking status (ref: never smoked)    
Current smoker (2006) -0.468 (0.718)  0.477 (0.448)  0.482 (0.448)  0.497 (0.447) 
Former smoker (2006) -0.136 (0.339) -0.115 (0.240) -0.107 (0.237) -0.123 (0.232) 
Recently quit smoking  0.891 (0.841)  0.296 (0.624)  0.330 (0.635)  0.312 (0.636) 
Recently started smoking -14.22 (0.717)**** -12.68 (0.606)**** -12.66 (0.616)**** -12.70 (0.608)**** 
Biomeasures     
log(CRP) (2006) -0.031 (0.165)  0.083 (0.160)  0.092 (0.148)  0.033 (0.137) 
log(CRP) change -0.003 (0.131)  0.040 (0.100)  0.012 (0.104)  0.010 (0.110) 
Cystatin C (2006)  1.449 (0.450)**  0.264 (0.328)  0.237 (0.336)  0.080 (0.292) 
Cystatin C change  0.563 (0.329)  0.141 (0.259)  0.136 (0.298)  0.299 (0.322) 
Intercept -4.013 (1.073)*** -3.074 (0.767)**** -3.048 (0.778)**** -2.850 (0.781)*** 
Note. Sample sizes: 297 for observed, 480 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.   




Table H3-6. Logistic regression logit coefficients and standard errors predicting development of 
cardiovascular disease by 2014 (base weight) (Hispanic) 
 
 Imputation approach 
  Observed Cross-sectional Sequential Wide 
Demographics     
Age (centered) -0.034 (0.035) -0.014 (0.021) -0.014 (0.019) -0.013 (0.018) 
Age (squared) -0.001 (0.003) -0.003 (0.001)* -0.003 (0.001)* -0.003 (0.001)* 
Female  0.138 (0.614) -0.076 (0.308) -0.026 (0.287) -0.008 (0.295) 
Health conditions     
High blood pressure (2006)  0.400 (0.649)  0.108 (0.477)  0.105 (0.474)  0.071 (0.466) 
Recent HBP diagnosis -0.908 (0.980)  0.363 (0.431)  0.237 (0.425)  0.277 (0.429) 
Diabetes (2006)  0.588 (0.540)  0.175 (0.339)  0.169 (0.332)  0.207 (0.332) 
Recent diagnosis diabetes -0.303 (0.794) -0.110 (0.442) -0.044 (0.460)  0.044 (0.457) 
BMI (ref: Under/normal weight)    
Overweight (2006) -0.847 (0.638)  0.022 (0.417)  0.039 (0.425)  0.035 (0.373) 
Obese (2006)  0.276 (0.657) -0.348 (0.598) -0.348 (0.581) -0.401 (0.532) 
Decreased BMI category -0.702 (0.886) -0.043 (0.573) -0.221 (0.583) -0.228 (0.585) 
Increased BMI category  0.832 (0.525)  0.821 (0.366)*  0.789 (0.331)*  0.794 (0.330)* 
Health behaviors     
Mildly vigorous activity (ref: weekly)    
1-3 times/month (2006) -11.57 (1.314)**** -0.747 (0.911) -0.574 (0.919) -0.604 (0.938) 
Hardly ever/never (2006)  0.354 (0.764) -0.248 (0.720) -0.127 (0.672) -0.212 (0.647) 
Decreased daily activity -1.006 (1.189)  0.130 (0.790)  0.133 (0.796)  0.206 (0.794) 
Increased daily activity -0.704 (0.863) -0.395 (0.318) -0.315 (0.322) -0.300 (0.324) 
Smoking status (ref: never smoked)    
Current smoker (2006) -10.34 (0.706)**** -0.601 (0.733) -0.590 (0.735) -0.620 (0.723) 
Former smoker (2006)  1.094 (0.582)  0.716 (0.335)*  0.707 (0.313)*  0.645 (0.321)* 
Recently quit smoking  12.64 (0.890)****  2.556 (1.088)*  2.794 (1.120)*  2.666 (1.091)* 
Recently started smoking  19.79 (1.260)**** -0.013 (1.614)  0.055 (1.610)  0.168 (1.616) 
Biomeasures     
log(CRP) (2006) -0.361 (0.229) -0.064 (0.159) -0.145 (0.137) -0.158 (0.142) 
log(CRP) change  0.373 (0.237)  0.177 (0.161)  0.117 (0.128)  0.210 (0.145) 
Cystatin C (2006)  1.230 (1.062)  0.457 (0.882)  0.604 (0.721)  0.747 (0.657) 
Cystatin C change  0.044 (0.498)  0.584 (0.318)  0.425 (0.349)  0.293 (0.460) 
Intercept -3.918 (1.267)** -2.753 (1.028)** -2.841 (0.909)** -2.844 (0.770)*** 
Note. Sample sizes: 237 for observed, 325 for imputed.  Only includes 2006 respondents who had not been 
diagnosed with cardiovascular disease.   




Figure H3-1. Odds ratios of Cystatin C and ln(CRP) in logistic regression model predicting the 
development of cardiovascular disease by 2014 by imputation approach, analysis weight, and 
race/ethnicity.  Odds ratio is based on 1 standard deviation change in each biomarker: 1.25 for 




Figure H3-2. Odds ratios of change in Cystatin C and change in ln(CRP) in logistic regression 
model predicting the development of cardiovascular disease by 2014 by imputation approach, 
analysis weight, and race/ethnicity. Odds ratio is based on 1 standard deviation change in each 
biomarker: 1.25 for ln(CRP) and 0.50 for Cystatin C. 95% confidence interval of the odds ratio 
included. 
